

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2011204405 B2**

(54) Title
Methods for use of a specific anti-angiogenic adenoviral agent

(51) International Patent Classification(s)
A61K 48/00 (2006.01) **C12N 15/00** (2006.01)

(21) Application No: **2011204405** (22) Date of Filing: **2011.01.05**

(87) WIPO No: **WO11/083464**

(30) Priority Data

(31) Number	(32) Date	(33) Country
61/282,247	2010.01.07	US
61/282,228	2010.01.05	US

(43) Publication Date: **2011.07.14**

(44) Accepted Journal Date: **2015.06.18**

(71) Applicant(s)
Vascular Biogenics Ltd.

(72) Inventor(s)
Cohen, Yael;Sher, Naamit;Feige, Erez;Bangio, Livnat;Breitbart, Eyal

(74) Agent / Attorney
Cullens Patent and Trade Mark Attorneys, Level 32 239 George Street, Brisbane, QLD, 4000

(56) Related Art
Greenberger S et al, The Journal of Clinical Investigation, 2004, 113(7):1017-1024
Peled m et al, Cancer Gene Therapy, 2008, 15:535-542
WO 2008/132729 A2 (VASCULAR BIOGENICS LTD) 06 November 2008

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 July 2011 (14.07.2011)

(10) International Publication Number
WO 2011/083464 A3

PCT

(51) International Patent Classification:
C12N 15/00 (2006.01)

(21) International Application Number:
PCT/IL2011/000007

(22) International Filing Date:
5 January 2011 (05.01.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/282,228 5 January 2010 (05.01.2010) US
61/282,247 7 January 2010 (07.01.2010) US

(71) Applicant (for all designated States except US): **VASCULAR BIOGENICS LTD.** [IL/IL]; 6 Yoni Netanyahu Street, 60376 Or Yehuda (IL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **COHEN, Yael** [IL/IL]; 100 Stern Street, 55602 Kiryat-Ono (IL). **SHER, Naamit** [IL/IL]; 3 Paldi Street, 76248 Rechovot (IL). **FEIGE, Erez** [IL/IL]; P.O. Box 170, 50295 Hemed (IL). **BANGIO, Livnat** [IL/IL]; 1 Daniel Lifshitz Street, 49776 Petach-Tikva (IL). **BREITBART, Eyal** [IL/IL]; 27 HaYitzhar Street, 73127 Hashmonaim (IL).

(74) Agents: **G.E. EHRLICH (1995) LTD.** et al.; 11 Menachem Begin Road, 52681 Ramat Gan (IL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PF, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

— with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

10 November 2011

(54) Title: METHODS FOR USE OF A SPECIFIC ANTI-ANGIOGENIC ADENOVIRAL AGENT

(57) Abstract: Anti-angiogenic adenovirus vectors, and therapeutic use thereof are provided, and more particularly, but not exclusively, clinical protocols for treatment of solid tumors in patients with an Ad5-PPE-1-3X-fas-chimera adenovirus vector.



WO 2011/083464 A3

METHODS FOR USE OF A SPECIFIC ANTI-ANGIOGENIC ADENOVIRAL
AGENT5 FIELD AND BACKGROUND OF THE INVENTION

The present invention, in some embodiments thereof, relates to anti-angiogenic adenovirus vectors, and therapeutic use thereof, and more particularly, but not exclusively, to clinical protocols for treatment of solid tumors in patients with an Ad5-PPE-1-3X-fas-chimera adenovirus vector.

10 Angiogenesis is a process of new blood vessel formation by sprouting from pre-existing neighboring vessels. This process is common and major feature of several pathologies. Among these are diseases in which excessive angiogenesis is a part of the pathology and thus is a target of therapy, most significantly, cancer. Angiogenesis occurs in tumors and permits their growth, invasion and metastatic proliferation. In
15 1971, Folkman proposed that tumor growth and metastases are angiogenesis dependent, and suggested that inhibiting angiogenesis may be a strategy to arrest tumor growth.

There are several molecules involved in angiogenesis, from cell surface molecules to transcription factors to growth factors. Hypoxia is an important environmental factor that leads to neovascularization, inducing release of several pro-
20 angiogenic cytokines, including vascular endothelial growth factors (VEGF) and their receptors, members of the angiopoietin family, basic fibroblast growth factor, and endothelin-1 (ET-1). These factors mediate induction of angiogenesis through control of activation, proliferation and migration of endothelial cells.

Recombinant forms of endogenous inhibitors of angiogenesis have been tested
25 for the treatment of cancer, however the potential pharmacokinetic, biotechnological and economic drawbacks of chronic delivery of these recombinant inhibitors have led scientists to develop other approaches. The development of the anti-VEGF monoclonal antibody bevacizumab has validated anti-angiogenic targeting as a complementary therapeutic modality to chemotherapy. Several small molecule inhibitors, including
30 second-generation multi-targeted tyrosine kinase inhibitors, have also shown promise as antiangiogenic agents for cancer.

The drawbacks of chronic delivery of recombinant inhibitors, antibodies, and small molecules, as well as the limited activity manifested when these drugs are administered as monotherapy have led to the development of anti-angiogenic gene

therapies. Gene therapy is an emerging modality for treating inherited and acquired human diseases. However, a number of obstacles have impeded development of successful gene therapy, including duration of expression, induction of the immune response, cytotoxicity of the vectors and tissue specificity.

5 Two general strategies for anti-cancer gene therapy have proposed: tumor directed or systemic gene therapy. The lack of success in targeting gene therapy products to cancerous cells or their environment by systemic treatments, and the danger of significant anti-drug or anti-vector immunity has caused most therapies to be administered to the tumor itself, despite the advantages of systemic administration.

10 "Adenoviral vaccines", designed to induce immunity to a recombinant antigen or epitope expressed in the patient's body, have been tried but produce mostly disappointing results. Thus, elaborate, potentially dangerous and costly strategies for eluding pathological host immune responses to systemic and repeated administration of therapeutic recombinant adenoviral vectors have been proposed, including

15 immunosuppression, oral tolerization to vector antigens and genetic modification of the vectors (see Bangari et al, Current Gene Therapy 2006;6: 215-226).

United States Patent 5,747,340 teaches use of a murine endothelial cell-specific promoter which shows selectivity towards angiogenic cells, and therapeutic applications thereof.

20 International Application WO/2008/132729 discloses a non-replicating adenovirus vector (Ad5, E1 deleted), containing a modified murine pre-proendothelin promoter (PPE-1-3X) and a fas-chimera transgene [Fas and human tumor necrosis factor (TNF) receptor] which has been developed, in which the modified murine promoter (PPE-1-3X), is able to restrict expression of the fas chimera transgene to

25 angiogenic blood vessels, leading to targeted apoptosis of these vessels.

Endothelial-specific gene therapy with the PPE-1-3X promoter does not increase the specificity of viral interactions with the host (e.g. transfection) but restricts the expression of the transgene to those tissues that endogenously recognize the modified promoter – angiogenic endothelial cells. The chimeric receptor can trigger the Fas

30 pathway by binding TNF α , which is less toxic in non-tumoral tissues than using the Fas/Fas ligand mechanism, which is highly expressed in non-tumoral normal tissues such as the liver. Further, TNF α was found to be abundant in the microenvironment of

tumors adding to the specificity of the transgene activity in the tumor and its surroundings.

Preliminary studies have shown that a single systemic injection of a PPE-1-3X-fas chimera results in transgene expression restricted to the tumor-bearing organ, causing tumor growth retardation, necrosis of the blood vessels in the metastatic tumor mass and reduction in tumor burden in B16 melanoma and Lewis lung carcinoma mice models.

However, an effective procedure for administration of a therapeutic amount of a recombinant anti-angiogenic adenovirus vector in the clinical setting is still lacking. As such, there is a great need for defining the parameters of clinically viable protocols for anti-angiogenic-adenoviral treatment of conditions associated with neovascularization, such as cancer, without the disadvantages of the current methods as described herein.

SUMMARY OF THE INVENTION

According to an aspect of some embodiments of the present invention there is provided a method of treating a solid tumor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a non-replicating adenovirus vector, the vector comprises a polynucleotide which comprises a fas-chimera transgene transcriptionally linked to a murine pre-proendothelin promoter, wherein the therapeutically effective amount is at least 1×10^8 virus particles.

According to an aspect of some embodiments of the present invention there is provided a method of treating a solid tumor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a non-replicating adenovirus vector which comprises a polynucleotide comprising a fas-chimera transgene transcriptionally linked to a murine pre-proendothelin promoter, the adenovirus vector comprising a nucleic acid sequence as set forth in SEQ ID NOs: 9 or 10.

According to an aspect of some embodiments of the present invention there is provided a method of treating a solid tumor in a subject in need thereof, the method comprising administering to the subject, in at least two separate doses, a therapeutically effective amount of a non-replicating adenovirus vector which comprises a polynucleotide comprising a fas-chimera transgene transcriptionally linked to a murine pre-proendothelin promoter, wherein the time between administration of the first dose

and the at least a second dose is sufficient for anti-Ad5 antibody formation in the subject.

According to an aspect of some embodiments of the present invention there is provided a method of treating a solid tumor in a subject in need thereof, the method comprising administering to the subject a single intravenous dose of 3×10^{12} or 1×10^{13} virus particles of a non-replicating adenovirus vector comprising a polynucleotide having a nucleotide sequence as set forth in SEQ ID NOs: 9 or 10.

According to an aspect of some embodiments of the present invention there is provided a method of treating a thyroid cancer in a subject in need thereof, the method comprising administering to the subject a single intravenous dose of 3×10^{12} or 1×10^{13} virus particles of a non-replicating adenovirus vector comprising a polynucleotide having a nucleotide sequence as set forth in SEQ ID NOs: 9 or 10.

According to an aspect of some embodiments of the present invention there is provided a method of treating a neuroendocrine cancer in a subject in need thereof, the method comprising administering to the subject a single intravenous dose of 3×10^{12} or 1×10^{12} virus particles of a non-replicating adenovirus vector comprising a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 9 or 10.

According to some embodiments of the present invention administering the dose of adenovirus vector inhibits angiogenesis of the tumor.

According to some embodiments of the present invention administering the dose of adenovirus inhibits growth of the tumor.

According to an aspect of some embodiments of the present invention there is provided a method for administering a therapeutically effective amount of a therapeutic composition comprising an adenoviral vector to a subject in need thereof comprising administering the composition to the subject at least twice, wherein the administration does not induce a dose-dependent increase in antibodies against the adenoviral vector in the subject.

According to an aspect of some embodiments of the present invention there is provided a kit for treating a solid tumor in a subject in need thereof, comprising a unit dosage of virus particles of a non-replicating adenovirus vector comprising a polynucleotide having a nucleotide sequence as set forth in SEQ ID NOs: 9 or 10,

wherein the non-replicating adenovirus vector is formulated for intravenous administration, and instructions for administration of the adenovirus.

According to some embodiments of the present invention the unit dosage comprises about 3×10^{12} virus particles, at least about 1×10^8 to about 1×10^{16} virus particles, at least about 1×10^{11} to about 1×10^{13} virus particles, optionally at least about 3×10^{12} virus particles.

According to some embodiments of the present invention the fas-chimera transgene comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 3.

According to yet other embodiments of the present invention the fas-chimera transgene comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 2.

According to still other embodiments of the present invention the fas-chimera transgene comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 4.

According to some embodiments of the present invention the murine pre-pro endothelin promoter comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 6.

According to some embodiments of the present invention the murine pre-pro endothelin promoter comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 7.

According to yet other embodiments of the present invention the murine pre-pro endothelin promoter comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 8.

According to yet other embodiments of the present invention the murine pre-pro endothelin promoter comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 5.

According to still other embodiments of the present invention the murine prepro-endothelin promoter comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 12.

According to some embodiments of the present invention the murine pre-pro endothelin promoter comprises a polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 13.

According to some embodiments of the present invention the non-replicating
5 adenovirus vector is an adenovirus 5 vector.

According to yet other embodiments of the present invention the adenovirus 5 vector comprises a nucleic acid sequence as set forth in SEQ ID NOs: 9 or 10.

According to some embodiments of the present invention the solid tumor is a cancerous tumor.

10 According to still other embodiments of the present invention the solid tumor is a primary tumor.

According to yet other embodiments of the present invention the solid tumor is a metastatic tumor.

According to some embodiments the solid tumor is a thyroid tumor.

15 According to some embodiments the solid tumor is a neuroendocrine tumor.

According to some embodiments administering the dose of adenovirus vector inhibits angiogenesis of the tumor.

According to some embodiments administering the dose of the adenovirus vector inhibits growth of the tumor.

20 According to some embodiments the adenovirus is detected in the blood of the subject at least about 4 days post administration.

According to some embodiments an amount of serum anti-adenovirus antibodies is increased following the administering, and the adenovirus is detected in the blood of the subject at least about 21 days post administration.

25 According to some embodiments of the present invention the adenovirus vector is administered systemically.

According to still other embodiments of the present invention the vector is administered systemically by a route selected from the group consisting of intra-articular administration, intravenous administration, intraperitoneal administration, subcutaneous
30 administration, infusion, oral administration, rectal administration, nasal administration and inhalation.

According to still other embodiments of the present invention administering the adenovirus vector is in at least two separate systemic doses.

According to some embodiments of the present invention the administering of the adenovirus vector is in a first dose and at least a second additional dose, wherein the first dose is sufficient to induce anti-Ad5 antibodies in the subject, and wherein the time between administration of the first dose and the at least a second dose is sufficient for anti-Ad5 antibody formation in the subject.

According to some embodiments of the present invention the subject is further receiving a chemotherapeutic agent as well as treatment with the virus particles of said non-replicating adenovirus vector.

According to some embodiments of the present invention the chemotherapeutic agent is administered prior to, concomitantly with, or following treatment with said virus particles.

According to some embodiments of the present invention the chemotherapeutic agent is sunitinib.

Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.

A definition of the specific embodiment of the invention claimed herein follows.

In a broad format, the invention provides a method of treating a solid tumor in a human subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a virus particle comprising an adenoviral nucleic acid, which comprises a fas-chimera transgene transcriptionally linked to a PPE-1-3X promoter, wherein said therapeutically effective amount is about 3×10^{12} to about 1×10^{13} virus particles.

BRIEF DESCRIPTION OF THE DRAWINGS

Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings and images. With specific reference now to the drawings and images in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.

In the drawings:

FIG. 1A-1D is a graph with photos illustrating inhibition of metastatic disease by systemic administration of Ad5-PPE-1-3X fas-chimera adenovirus vector in the Lewis Lung Cancer model. FIGs. 1A-1C are photos of exemplary lungs from control (saline) and Ad5-PPE-1-3X fas-chimera adenovirus vector treated mice. Note the strong, dose dependent inhibition of metastatic development by the Ad5-PPE-1-3X fas-chimera adenovirus vector, as reflected in both the gross morphology and weight of the excised lungs (FIG. 1C);

FIG. 2 is a histogram showing the pre-treatment titer of pre-treatment neutralizing anti-Ad5 antibodies in the serum of patients in cohort 6 (3×10^{12} vp), as a function of their disease progression at day 28 post administration of Ad5-PPE-1-3X fas-chimera adenovirus vector. Note the lack of correlation between progressive disease (blue), stable disease (red) and antibody titer (Y-axis);

FIGs. 3A and 3B are histograms showing the pre-treatment titer of neutralizing anti-Ad5 antibodies in the serum of patients, as a function of their disease progression at day 56 post administration of Ad5-PPE-1-3X fas-chimera adenovirus vector. Figure 3A represents values for cohort 6. Figure 3B represents the values for cohorts 6 and 7. Note the lack of correlation between progressive disease (blue), stable disease (red) and the baseline titer of neutralizing antibodies;

FIG. 4 is a baseline (pre-dose) cervical CT scan of a subject with advanced papillary thyroid cancer who received a single dose (3×10^{12} virus particles) of Ad5-PPE-1-3X fas-chimera adenovirus vector, demonstrating a paratracheal metastasis causing partial obstruction of the trachea (red arrows);

FIG. 5 is a follow-up cervical CT of the same subject as described in FIG. 4, 6 months post-administration of Ad5-PPE-1-3X fas-chimera adenovirus vector, demonstrating regression of the metastatic lesion (red arrows) with central liquefaction (blue arrow);

FIGs. 6A-6C are abdominal CT scans illustrating regression of a metastatic lesion following administration of a single dose of Ad5-PPE-1-3X fas-chimera adenovirus vector (3×10^{12} virus particles) in a subject with advanced neuroendocrine cancer. FIG. 6A is an abdominal CT scan showing the metastatic lesion (circled) in the liver at 21 days post-administration. FIG. 6B is an abdominal CT scan showing

significant regression of the lesion (circled) in the liver at 50 days post-administration. FIG. 6C is an abdominal CT scan showing even greater regression of the lesion (circled) in the liver at 112 days post-administration;

FIGs. 7A-7C are abdominal CT scans illustrating regression of a metastatic lesion following administration of a single dose of Ad5-PPE-1-3X fas-chimera adenovirus vector (3×10^{12} virus particles) as described in FIGs. 6A-6C. FIGs. 7A-7C are CT scans from the same series, same subject as in FIGs. 6A-6C, showing the same lesion from a different orientation (CT slice at a different level);

FIG. 8 is a graph illustrating the disease response of individual patients in cohorts 1-5, measured at days 0, 28 and 56, and expressed as percent change in RECIST scores, relative to those observed on day 0. Greater increase in RECIST scores is typically indicative of progressive disease (solid line = stable disease, dotted line = progressive disease);

FIG. 9 is a graph illustrating the disease response of individual patients in cohorts 6 and 7, measured at days 0, 28 and 56, and expressed as percent change in RECIST scores, relative to those observed on day 0. Greater increase in RECIST scores is typically indicative of progressive disease (solid line = stable disease, dotted line = progressive disease). Note the trend to lesser change in RECIST scores among cohorts 6 and 7;

FIGs. 10A and 10B is a timeline showing the effects of administration of a single dose of Ad5-PPE-1-3X fas-chimera adenovirus vector (3×10^{12} virus particles) on disease progression in two thyroid cancer patients (see Example II herein). Figure 10A depicts the survival of a patient with refractory metastatic papillary thyroid cancer, receiving two doses the Ad5-PPE-1-3X fas-chimera adenovirus vector nearly two years apart, and has remained progression-free for most of that time. Figure 10B shows the progression free survival of a patient with medullary thyroid cancer, who remained stable and progression free when monitored at 120 days after receiving a single dose of the Ad5-PPE-1-3X fas-chimera adenovirus vector. SD=stable disease. PD= progressive disease. PR= partial response;

FIG. 11 is a graph illustrating the humoral immune response to a single administration of the Ad5-PPE-1-3X fas-chimera adenovirus, in cohorts 1 to 7 (cohort 1=diamond ♦; cohort 2= square ■; cohort 3= triangle ▲; cohort 4= "X"; cohort 5= star;

.10

cohort 6= circle ●; cohort 7= vertical line |). Individual patients' anti-Adenovirus 5 IgG levels were assayed (as detailed in Example II) at day 0 (administration), and days 7, 14, 21 and 28 post infusion. Note the plateau of the immune response as early as day 7 in some cohorts (e.g. 1, 3, 4) and later in others (e.g. cohorts 2, 5, 6, 7);

5 FIGs. 12A and 12B show the pharmacokinetics of the Ad5-PPE-1-3X fas-chimera adenovirus vector, following intravenous administration. FIG. 12A is a graph depicting the pharmacokinetics of the Ad5-PPE-1-3X fas-chimera adenovirus vector in blood, from administration to day 56, post-infusion. Whole blood samples of patients receiving 10^{10} (♦, solid black line), 3×10^{10} (■, dotted black line), 10^{11} (▲, dashed black line), 3×10^{11} (X, solid grey line), 10^{12} (■, dotted grey line) and 3×10^{12} (●, dashed grey line) Ad5-PPE-1-3X fas-chimera adenovirus particles were analyzed by RT-PCR at
10 indicated timepoints for adenovirus 5 DNA. Adenovirus levels were reduced by at least two orders of magnitude, or undetectable by day 56. FIG 12B represents the average levels of adenovirus particles, analyzed by RT-PCR, in whole blood sampled at the end
15 of the infusion with the virus vector;

FIGs. 13A and 13B illustrate the effects of combined Ad5-PPE-1-3X fas-chimera adenovirus vector and sunitinib on the Lewis Lung metastatic cancer model. Mice with induced lung metastases received either the Ad5-PPE-1-3X fas-chimera adenovirus vector or oral sunitinib, in the indicated dosages, or a combination of the two therapies.
20 Control mice received empty (sham) virus vehicles. Lung metastases were evaluated according to the tumor mass in grams (tumor burden) at 22 days post- primary tumor removal. Figure 13 A is a histogram of the values in Figure 13B. Note the enhanced effect of the combination therapy at 80 mg/kg sunitinib, and 10^9 Ad5-PPE-1-3X fas-chimera virus particles.

25 Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent
30 specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.

DESCRIPTION OF SPECIFIC EMBODIMENTS OF THE INVENTION

The present invention, in some embodiments thereof, relates to anti-angiogenic adenovirus vectors, and therapeutic use thereof, and more particularly, but not exclusively, to clinical protocols for treatment of solid tumors in patients with an Ad5-
5 PPE-1-3X-fas-chimera adenovirus vector.

Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.

10 Angiogenesis is required for the development of neoplastic and hyperproliferative growths. Gene therapy for anti-angiogenic therapy in conditions associated with neovascularization, such as cancer, has been investigated, however, despite promising results in *in-vitro* experiments and in animal models, there has been little success with anti-angiogenic gene therapy in the clinical setting, likely due to
15 obstacles including duration of expression of the transferred gene, induction of host immune response, cytotoxicity of the vectors and tissue specificity of expression.

The present inventors have developed a clinically safe and effective procedure for administration of a therapeutic recombinant adenovirus vector comprising a cytotoxic fas-chimera effector sequence under transcriptional control of an angiogenic
20 endothelial-specific modified murine pre-pro endothelin promoter, which can be used for treatment of a variety of cancers and other hyperproliferative, neovascular-dependent diseases, for example, for solid tumors.

Thus, according to one aspect of the present invention, there is provided a method of treating a solid tumor in a subject in need thereof, the method comprising
25 administering to the subject a therapeutically effective amount of a non-replicating adenovirus vector, said vector comprises a polynucleotide which comprises a fas-chimera transgene transcriptionally linked to a murine pre-proendothelin promoter, wherein said therapeutically effective amount is at least 1×10^8 virus particles, thereby treating the solid tumor.

30 As used herein, the phrases "cancer", "malignancy", "solid tumor" or "hyperproliferative disorder" are used as synonymous terms and refer to any of a number of diseases that are characterized by uncontrolled, abnormal proliferation of

cells, the ability of affected cells to spread locally or through the bloodstream and lymphatic system to other parts of the body (i.e., metastasize) as well as any of a number of characteristic structural and/or molecular features. A "cancerous" or "malignant cell" or "solid tumor cell" is understood as a cell having specific structural properties, lacking differentiation and being capable of invasion and metastasis. "Cancer" refers to all types of cancer or neoplasm or malignant tumors found in mammals, including carcinomas and sarcomas. Examples are cancers of the breast, lung, non-small cell lung, stomach, brain, head and neck, medulloblastoma, bone, liver, colon, genitourinary, bladder, urinary, kidney, testes, uterus, ovary, cervix, prostate, melanoma, mesothelioma, sarcoma, (see DeVita, et al., (eds.), 2001, Cancer Principles and Practice of Oncology, 6th. Ed., Lippincott Williams & Wilkins, Philadelphia, Pa.; this reference is herein incorporated by reference in its entirety for all purposes).

"Cancer-associated" refers to the relationship of a nucleic acid and its expression, or lack thereof, or a protein and its level or activity, or lack thereof, to the onset of malignancy in a subject cell. For example, cancer can be associated with expression of a particular gene that is not expressed, or is expressed at a lower level, in a normal healthy cell. Conversely, a cancer-associated gene can be one that is not expressed in a malignant cell (or in a cell undergoing transformation), or is expressed at a lower level in the malignant cell than it is expressed in a normal healthy cell.

"Hyperproliferative disease" refers to any disease or disorder in which the cells proliferate more rapidly than normal tissue growth. Thus, a hyperproliferating cell is a cell that is proliferating more rapidly than normal cells.

"Neovascularization" and "angiogenesis" refer to the growth of new blood vessels. Pathological angiogenesis or neovascularization refers to unbalanced new blood vessel growth, including non-self-limiting endothelial and periendothelial cell-proliferation. "Angiogenic diseases" are conditions of unregulated angiogenesis, for example, cancer, ocular neovascularization, arthritis, diabetes, skin diseases, chronic inflammatory diseases such as rheumatoid arthritis, psoriasis and synovitis.

"Advanced cancer" means cancer that is no longer localized to the primary tumor site, or a cancer that is Stage III or IV according to the American Joint Committee on Cancer (AJCC).

"Well tolerated" refers to the absence of adverse changes in health status that occur as a result of the treatment and would affect treatment decisions.

"Metastatic" refers to tumor cells, e.g., human solid tumor or thyroid malignancy, that are able to establish secondary tumor lesions in the lungs, liver, bone or brain of immune deficient mice upon injection into the mammary fat pad and/or the circulation of the immune deficient mouse.

A "solid tumor" includes, but is not limited to, sarcoma, melanoma, carcinoma, or other solid tumor cancer. "Sarcoma" refers to a tumor which is made up of a substance like the embryonic connective tissue and is generally composed of closely packed cells embedded in a fibrillar or homogeneous substance. Sarcomas include, but are not limited to, chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy's sarcoma, adipose sarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastic sarcoma, botryoid sarcoma, chloroma sarcoma, chorio carcinoma, embryonal sarcoma, Wilms' tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial sarcoma, fibroblastic sarcoma, giant cell sarcoma, granulocytic sarcoma, Hodgkin's sarcoma, idiopathic multiple pigmented hemorrhagic sarcoma, immunoblastic sarcoma of B cells, lymphoma, immunoblastic sarcoma of T-cells, Jensen's sarcoma, Kaposi's sarcoma, Kupffer cell sarcoma, angiosarcoma, leukosarcoma, malignant mesenchymoma sarcoma, parosteal sarcoma, reticulocytic sarcoma, Rous sarcoma, serocystic sarcoma, synovial sarcoma, and telangiectaltic sarcoma.

"Melanoma" refers to a tumor arising from the melanocytic system of the skin and other organs. Melanomas include, for example, acral-lentiginous melanoma, amelanotic melanoma, benign juvenile melanoma, Cloudman's melanoma, S91 melanoma, Harding-Passey melanoma, juvenile melanoma, lentigo maligna melanoma, malignant melanoma, metastatic melanoma, nodular melanoma, subungal melanoma, and superficial spreading melanoma.

"Carcinoma" refers to a malignant new growth made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. Exemplary carcinomas include, for example, acinar carcinoma, acinous carcinoma, adenocystic carcinoma, adenoid cystic carcinoma, carcinoma adenomatosum, carcinoma of adrenal cortex, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, carcinoma

basocellulare, basaloid carcinoma, basosquamous cell carcinoma, bronchioalveolar carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, cerebriform carcinoma, cholangiocellular carcinoma, chorionic carcinoma, colloid carcinoma, comedo carcinoma, corpus carcinoma, cribriform carcinoma, carcinoma en cuirasse, carcinoma
 5 cutaneum, cylindrical carcinoma, cylindrical cell carcinoma, duct carcinoma, carcinoma durum, embryonal carcinoma, encephaloid carcinoma, epiermoid carcinoma, carcinoma epitheliale adenoides, exophytic carcinoma, carcinoma ex ulcere, carcinoma fibrosum, gelatiniform carcinoma, gelatinous carcinoma, giant cell carcinoma, carcinoma gigantocellulare, glandular carcinoma, granulosa cell carcinoma, hair-matrix carcinoma,
 10 hematoid carcinoma, hepatocellular carcinoma, Hurthle cell carcinoma, hyaline carcinoma, hypemephrroid carcinoma, infantile embryonal carcinoma, carcinoma in situ, intraepidermal carcinoma, intraepithelial carcinoma, Krompecher's carcinoma, Kulchitzky-cell carcinoma, large-cell carcinoma, lenticular carcinoma, carcinoma lenticulare, lipomatous carcinoma, lymphoepithelial carcinoma, carcinoma medullare,
 15 medullary carcinoma, melanotic carcinoma, carcinoma molle, mucinous carcinoma, carcinoma muciparum, carcinoma mucocellulare, mucoepidermoid carcinoma, carcinoma mucosum, mucous carcinoma, carcinoma myxomatodes, nasopharyngeal carcinoma, oat cell carcinoma, carcinoma ossificans, osteoid carcinoma, papillary carcinoma, periportal carcinoma, preinvasive carcinoma, prickle cell carcinoma,
 20 pultaceous carcinoma, renal cell carcinoma of kidney, reserve cell carcinoma, carcinoma sarcomatodes, schneiderian carcinoma, scirrhus carcinoma, carcinoma scroti, signet-ring cell carcinoma, carcinoma simplex, small-cell carcinoma, solanoid carcinoma, spheroidal cell carcinoma, spindle cell carcinoma, carcinoma spongiosum, squamous carcinoma, squamous cell carcinoma, string carcinoma, carcinoma
 25 telangiectaticum, carcinoma telangiectodes, transitional cell carcinoma, carcinoma tuberosum, tuberosus carcinoma, verrucous carcinoma, and carcinoma villosum.

Additional cancers include, for example, Leukemia, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, breast cancer, ovarian cancer, lung cancer, rhabdomyosarcoma, primary thrombocytosis, primary
 30 macroglobulinemia, small-cell lung tumors, primary brain tumors, stomach cancer, colon cancer, malignant pancreatic insulinoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer,

papillary thyroid cancer, neuroblastoma, neuroendocrine cancer, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, cervical cancer, endometrial cancer, adrenal cortical cancer, and prostate cancer.

The present inventors have shown that systemic administration of the Ad5-PPE-1-3X-fas-c adenoviral vector was correlated with a reduction in tumor mass and prolonged stable disease in a patient suffering from metastatic papillary thyroid cancer (see Example II and FIGs. 4 and 5 that follow). Thus, according to one aspect of some embodiments of the present invention there is provided a method for treating a thyroid cancer in a patient in need thereof, the method comprising administering to the subject a single or multiple intravenous dose(s) of 3×10^{12} or 10^{13} virus particles of a non-replicating adenovirus vector comprising a polynucleotide having a nucleotide sequence as set forth in SEQ ID NOs: 9 or 10. Disease progression in thyroid cancer can be assessed or monitored by methods including, but not limited to, radiographic analysis of tumor mass and density (e.g. RECIST criteria), measurement of thyroid and thyroid-associated hormone levels, thyroglobulin levels, and the like.

The present inventors have shown that systemic administration of the Ad5-PPE-1-3X-fas-c adenoviral vector was correlated with a reduction in a metastatic hepatic lesion and prolonged stable disease in a patient suffering from metastatic neuroendocrine cancer (see Example II and FIGs. 6A-6C, 7A- 7C that follow). Thus, according to one aspect of some embodiments of the present invention there is provided a method for treating a neuroendocrine cancer in a patient in need thereof, the method comprising administering to the subject a single or multiple intravenous dose(s) of 3×10^{12} or 10^{13} virus particles of a non-replicating adenovirus vector comprising a polynucleotide having a nucleotide sequence as set forth in SEQ ID NOs: 9 or 10. Methods for assessing or monitoring disease progression in neuroendocrine cancer include radiographic analysis of tumor mass and density (e.g. RECIST criteria), measurement of liver enzyme levels (where the tumor is a liver metastasis), and the like.

The method of the present invention as claimed has been indicated effective in treating other cancers. Thus, according to further aspects of some embodiments of the present invention there is provided a method for treating an ovarian cancer, a non small cell lung cancer and/or a renal cell carcinoma in a patient in need thereof, the method comprising administering to the subject a single or multiple intravenous dose(s) of

3X10¹² or 10¹³ virus particles of a non-replicating adenovirus vector comprising a polynucleotide having a nucleotide sequence as set forth in SEQ ID NOs: 9 or 10. Methods for assessing or monitoring disease progression in these cancers include radiographic analysis of tumor mass and density (e.g. RECIST criteria), measurement of organ function (e.g. kidney function in renal cell carcinoma), measurement of specific biomarkers, endocrine function, and the like.

Contemplated subjects to be treated include mammals – e.g. humans. According to one embodiment the subject has received a prior treatment for the solid tumor (e.g. radiotherapy and/or chemotherapy) and the malignant tumor has relapsed. According to another embodiment, the subject has not received a prior treatment for the malignant tumor.

The phrase "viral vector" refers to a replication-competent or replication-deficient viral particle which is capable of transferring nucleic acid molecules into a host.

The present inventors contemplate use of Replication Defective Vectors and Replication Defective Vector-Producing Packaging Cells. Examples of such vectors are adenoviral vectors, AAV vectors and retroviral vectors and others described in Shir et al, Cellular and Molecular Neurobiology, Vol. 21, No. 6, December 2001, the contents of which are incorporated herein by reference.

The term "virus" refers to any of the obligate intracellular parasites having no protein-synthesizing or energy-generating mechanism. The viral genome may be RNA or DNA contained within a coated structure of protein or a lipid membrane. Examples of viruses useful in the practice of the present invention include baculoviridae, parvoviridae, picornaviridae, herpesviridae, poxviridae, adenoviridae, picotnaviridae. The term recombinant virus includes chimeric (or even multimeric) viruses, i.e. vectors constructed using complementary coding sequences from more than one viral subtype. (See, e.g. Feng, et al. Nature Biotechnology 15:866-870) The term "adenovirus" is synonymous with the term "adenoviral vector" and refers to viruses of the genus adenoviridae. The term adenoviridae refers collectively to animal adenoviruses of the genus mastadenovirus including but not limited to human, bovine, ovine, equine, canine, porcine, murine and simian adenovirus subgenera. In particular, human adenoviruses includes the A-F subgenera as well as the individual serotypes

thereof the individual serotypes and A-F subgenera including but not limited to human adenovirus types 1, 2, 3, 4, 4a, 5, 6, 7, 8, 9, 10, 11 (Ad11A and Ad 11P), 12, 13, 14, 15, 16, 17, 18, 19, 19a, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 34a, 35, 35p, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, and 91. The term bovine adenoviruses includes but is not limited to bovine adenovirus types 1, 2, 3, 4, 7, and 10. The term canine adenoviruses includes but is not limited to canine types 1 (strains CLL, Glaxo, RI261, Utrecht, Toronto 26-61) and 2. The term equine adenoviruses includes but is not limited to equine types 1 and 2. The term porcine adenoviruses includes but is not limited to porcine types 3 and 4. In one embodiment of the invention, the adenovirus is derived from the human adenovirus serotypes 2 or 5. For purposes of this invention, adenovirus vectors can be replication-competent or replication deficient in a target cell. In some embodiments, the adenovirus vectors are conditionally or selectively replicating adenoviruses, wherein a gene[s] required for viral replication is [are] operatively linked to a cell and/or context-specific promoter. Examples of selectively replicating or conditionally replicating viral vectors are known in the art (see, for example, US 7,691,370). In one embodiment, the adenovirus vector is a conditionally replicating adenovirus wherein the E1 gene is under transcriptional control of the pre-proendothelin promoter PPE-1 (PPE-1, SEQ ID NO: 13). In another embodiment, the adenovirus vector is a conditionally replicating or selectively replicating adenovirus wherein the E1 gene is under transcriptional control of the modified pre-proendothelin promoter PPE-1-3X (PPE-1-3X, SEQ ID NO: 12). In some embodiments, adenovirus vectors suitable for use with the present invention include all adenovirus serotypes having hexon protein structure. Viral vectors suitable for therapeutic use include adenoviral vectors, retroviral vectors, AAV, herpesvirus vectors and the like. Engineering and production of viral vectors is well known in the art, as described in detail in, for example, US Patent No: 7,732,129 or 6,649,158, which are incorporated herein by reference, in their entirety. In specific embodiments, the adenovirus is a C-type adenovirus (Ad5, Ad2), a B-type adenovirus (Ad3, Ad16, Ad21, Ad35, Ad50), an E-type adenovirus (Ad4) or an F-type adenovirus (Ad41).

As used herein, the phrase adenoviral vector refers to a vector in which, among the nucleic acid molecules in the viral particle, sequences necessary to function as a viral vector are based on the adenoviral genome.

According to one embodiment the adenoviral vector is a non-replicating serotype 5 (Ad5) adenoviral vector.

According to another embodiment, the adenoviral vector comprises a sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 11.

5 It will be appreciated that the present invention also contemplates use of oncolytic viruses which reproduce themselves in cancer cells and subsequently kill the initially infected cells by lysis. Such viruses proceed to infect adjacent cells thus repeating the cycle. Contemplated examples of oncolytic viruses include, but are not limited to Herpes Simplex Virus, conditionally replicative Ads (CRAds) and reoviruses.

10 Two major strategies for development of CRAd vectors have been developed, mainly focusing on the genetic engineering of the early 1 (E1) genes to restrict virus replication to target cells and to spare normal tissue. Genetic complementation-type (type 1) CRAds, such as Ad524, have a mutation in the immediately early (E1A) or early (E1B) adenoviral region, which is complemented in tumor cells but not in normal
15 cells. In trans complementation-type (type 2) CRAds, virus replication is controlled via a tumor/tissue-specific promoter.

Reovirus is a naturally occurring oncolytic virus that requires activated Ras signaling pathways of tumor cells for its replication. Ras pathways are activated in most malignant tumors via upstream signaling by receptor tyrosine kinases.

20 As mentioned the viral vectors of this aspect of the present invention comprise a cytotoxic fas-chimera effector sequence under transcriptional control of an angiogenic endothelial-specific modified murine pre-pro endothelin promoter.

Typically, such viral vectors are constructed using genetic recombination technology – i.e. recombinant viral vectors.

25 The Fas-chimera (Fas-c) polypeptide, is a previously described fusion of two "death receptors", constructed from the extracellular region of TNFR1 (SEQ ID NO: 2) and the trans-membrane and intracellular regions of Fas (SEQ ID NO: 3) [Boldin MP et al. J Biol Chem (1995) 270(14):7795-8; the contents of which are incorporated herein by reference].

30 According to one embodiment the Fas-c is encoded by a polynucleotide as set forth in SEQ ID NO: 4.

It will be appreciated that the present invention also contemplates use of a viral construct (e.g. an adenoviral construct) comprising an endothelial/periendothelial cell-specific promoter operatively linked to other cytotoxic polypeptides for the treatment of solid tumors.

5 Such polypeptides, include but are not limited to suicide polypeptides such as p53 and egr-1-TNF-alpha, cytotoxic pro-drug/enzymes for drug susceptibility therapy such as ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase, and antimetastatic polypeptides such as 5 E1A.

10 The term "promoter" as used herein refers to a DNA sequence which directs transcription of a polynucleotide sequence operatively linked thereto in the cell in a constitutive or inducible manner. The promoter may also comprise enhancer elements which stimulate transcription from the linked promoter.

15 The pre-pro endothelial promoter as used herein refers to the preproendothelin-1 (PPE-1) promoter, of mammalian origin. In one embodiment, the pre-proendothelin 1 promoter is a murine pre-pro endothelin 1 promoter (PPE-1, SEQ ID NO: 13) and modifications thereof. It will be appreciated that other endothelial specific promoters can be used with the present invention, for example, the TIE-1 promoter, the TIE-2 promoter, the Endoglin promoter, the von Willerband promoter, the KDR/flk-1 promoter, The FLT-1 promoter, the Egr-1 promoter, the ICAM-1 promoter, the VCAM-1 promoter, the PECAM-1 promoter and the aortic carboxypeptidase-like protein (ACLP) promoter.

25 According to one embodiment the promoter comprises at least one copy of an enhancer element that confers endothelial cell specific transcriptional activity. According to one embodiment the enhancer element is naturally found positioned between the -364 bp and -320 bp of the murine PPE-1 promoter (as set forth in SEQ ID NO: 6). In one embodiment, the promoter comprises at least two and more preferably three of the above described enhancer elements. According to a specific embodiment, the promoter comprises two of the above described enhancer elements on one strand of the promoter DNA and one of the above described enhancer element on the complementary strand of the promoter DNA.

30 In yet another embodiment, the promoter comprises a modified enhancer element as set forth in SEQ ID NO: 8, optionally in combination with other enhancer

elements. Thus, according to this embodiment, the promoter comprises a sequence as set forth in SEQ ID NO: 7.

According to another embodiment, the promoter further comprises at least one hypoxia response element – e.g. comprising a sequence as set forth in SEQ ID NO: 5.

5 An exemplary promoter which can be used in the context of the present invention comprises a sequence as set forth in SEQ ID NO: 12. This sequence comprises SEQ ID NO: 5 and SEQ ID NO: 7 (which itself comprises two copies of SEQ ID NO: 6 either side of one copy of SEQ ID NO: 8).

10 According to a particular embodiment of this aspect of the present invention, the viral vector consists of a sequence as set forth in SEQ ID NOs: 9 or 10.

The Ad5-PPE-1-3X-fas-c sequence, as set forth in SEQ ID NO: 9 or 10 comprises a sequence which is an anti-sense copy of SEQ ID NO: 7, located at nucleic acid coordinates 894- 1036, a sequence which is a single antisense copy of SEQ ID NO: 8 located at nucleotide coordinates 951-997; a sequence which is a first antisense copy
15 of SEQ ID NO: 6 located at nucleotide coordinates 907-950; a sequence which is a second antisense copy of SEQ ID NO: 6 located at nucleotide coordinates 993-1036; and a third copy of SEQ ID NO: 6 in the sense orientation at position 823-866.

In some embodiments of the invention, the viral vector comprises additional polynucleotide sequences capable of enhancing or inhibiting transcriptional activity of
20 an endothelial specific promoter. According to an aspect of some embodiments of the invention, the additional polynucleotide sequence includes an isolated polynucleotide comprising at least 6 nucleotides of element X of a pre-proendothelin (PPE-1) promoter, the element X having a wild type sequence as set forth by SEQ ID NO:6, wherein the at least 6 nucleotides comprise at least 2 consecutive sequences derived from SEQ ID
25 NO:6, each of the at least 2 consecutive sequences comprises at least 3 nucleotides, at least one of the at least 3 nucleotide being positioned next to at least one nucleotide position in SEQ ID NO:6, the at least one nucleotide position in SEQ ID NO:6 is selected from the group consisting of:

- (i) at least one nucleotide of wild type M4 sequence set forth by SEQ ID
30 NO: 15 (CATTC);
- (ii) at least one nucleotide of wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG);

(iii) at least one nucleotide of wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC);

(iv) at least one nucleotide of wild type M6 sequence set forth by SEQ ID NO: 17 (GGGTG);

5 (v) at least one nucleotide of wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT);

(vi) at least one nucleotide of wild type M1 sequence set forth by SEQ ID NO: 20 (GTACT); and

(v) at least one nucleotide of wild type M3 sequence set forth by SEQ ID
10 NO: 21 (CTTTT);

wherein the at least one nucleotide position is mutated as compared to SEQ ID NO:6 by at least one nucleotide substitution, at least one nucleotide deletion and/or at least one nucleotide insertion, with the proviso that a mutation of the at least one nucleotide position does not result in nucleotides GGTA at position 21-24 of SEQ ID
15 NO:6 and/or in nucleotides CATG at position 29-32 of SEQ ID NO:6, such that when the isolated polynucleotide is integrated into the PPE-1 promoter and placed upstream of a reporter gene (e.g., luciferase coding sequence) the expression level of the reporter gene is upregulated or downregulated as compared to when SEQ ID NO:6 is similarly integrated into the PPE-1 promoter and placed upstream of the reporter gene coding
20 sequence.

According to some embodiments of the invention, the isolated polynucleotide is not naturally occurring in a genome or a whole chromosome sequence of an organism.

As used herein the phrase "naturally occurring" refers to as found in nature, without any man-made modifications.

25 As described above, the at least 6 nucleotides of element X comprise at least 2 consecutive sequences derived from SEQ ID NO:6.

As used herein the phrase "consecutive sequence derived from SEQ ID NO:6" refers to a nucleic acid sequence (a polynucleotide) in which the nucleotides appear in the same order as in the nucleic acid sequence of SEQ ID NO:6 from which they are
30 derived. It should be noted that the order of nucleotides is determined by the chemical bond (phosphodiester bond) formed between a 3'-OH of a preceding nucleotide and the 5'-phosphate of the following nucleotide.

According to some embodiments of the invention, each of the at least 2 consecutive sequences comprises at least 3 nucleotides, e.g., 3 nucleotides, 4 nucleotides, 5 nucleotides, 6 nucleotides, 7 nucleotides, 8 nucleotides, 9 nucleotides, 10 nucleotides, 11 nucleotides, 12 nucleotides, 13 nucleotides, 14 nucleotides, 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, 30 nucleotide, 31 nucleotides, 32 nucleotides, 33 nucleotides, 34 nucleotides, 35 nucleotides, 36 nucleotides, 37 nucleotides, 38 nucleotides, 39 nucleotides, 40 nucleotides, 41 nucleotides of SEQ ID NO:6.

As described, the isolated polynucleotide comprises at least 2 consecutive sequences derived from SEQ ID NO:6. According to some embodiments of the invention, the isolated polynucleotide comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 consecutive sequences derived from SEQ ID NO:6.

As used herein the phrase "wild type" with respect to a nucleotide sequence refers to the nucleic acid sequence as appears in SEQ ID NO:6. Examples include, but are not limited to wild type M4 sequence (SEQ ID NO: 15), wild type M5 sequence (SEQ ID NO: 16), wild type M8 (SEQ ID NO:19), wild type M6 sequence (SEQ ID NO:17), wild type M7 sequence (SEQ ID NO:18), wild type M1 (SEQ ID NO:20) and wild type M3 sequence (SEQ ID NO:21).

According to some embodiments of the invention, the mutation is an insertion of at least one nucleotide in a nucleotide position with respect to SEQ ID NO:6. According to some embodiments of the invention, the insertion includes at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 nucleotides, e.g., at least about 15, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 55, at least about 60, at least about 65, at least about 70, at least about 75, at least about 80, at least about 85, at least about 90, at least about 95, at least about 100, at least about 200, at least about 300, or more nucleotides.

It should be noted that the sequence which is inserted by the mutation can be derived from any source (e.g., species, tissue or cell type), and is not limited to the source of the sequence of element X.

According to some embodiments of the invention, the mutation is a combination of any of the mutation types described above, *i.e.*, substitution, insertion and deletion. For example, while one nucleotide position in SEQ ID NO:6 can be subject to a substitution mutation, another nucleotide position in SEQ ID NO:6 can be subject to a deletion or insertion. Additionally or alternatively, while one nucleotide position in SEQ ID NO:6 can be subject to a deletion mutation, another nucleotide position in SEQ ID NO:6 can be subject to a substitution or insertion. Additionally or alternatively, while one nucleotide position in SEQ ID NO:6 can be subject to an insertion mutation, another nucleotide position in SEQ ID NO:6 can be subject to a substitution or deletion. It should be noted that various other combinations are possible.

According to specific embodiments of the invention, the mutation in the isolated polynucleotide of the invention does not result in nucleotides GGTA at position 21-24 of SEQ ID NO:6 and/or in nucleotides CATG at position 29-32 of SEQ ID NO:6.

As used herein the phrase "integrated into the PPE-1 promoter" refers to a nucleotide sequence (the isolated polynucleotide) which is covalently conjugated within the PPE-1 promoter sequence.

According to some embodiments of the invention, the isolated polynucleotide further comprises at least one copy of a nucleic acid sequence selected from the group consisting of:

- (i) wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC),
- (ii) wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG),
- (iii) wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC),
- (iv) wild type M6 sequence set forth by SEQ ID NO: 17 (GGGTG),
- (v) wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT);
- (vi) wild type M1 sequence set forth by SEQ ID NO: 20 (GTACT), and
- (vii) wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT).

According to some embodiments of the invention, the isolated polynucleotide is integrated into (within), downstream of, or upstream of any known (or unknown) promoter sequence to thereby regulate (e.g., increase, decrease, modulate tissue-specificity, modulate inductive or constitutive expression) the transcriptional promoting activity of the promoter.

According to some embodiments of the invention, the isolated polynucleotide is for increasing expression of a heterologous polynucleotide operably linked thereto in endothelial cells. Such a polynucleotide can include wild type sequences of M4 and/or M5 in the presence or absence of additional sequences from element X, and/or in the presence of other mutated sequences from element X.

According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC).

According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG).

According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC) and at least one copy of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG).

According to some embodiments of the invention, the at least one nucleotide position which is mutated as compared to SEQ ID NO:6 is at least one nucleotide of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC). It should be noted that such an isolated polynucleotide may further include a wild type M6 sequence (SEQ ID NO:17) and/or a wild type M7 sequence (SEQ ID NO:18).

Non-limiting examples of isolated polynucleotides which include at least one copy of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC) and a mutation in at least one nucleotide of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs:55-62.

Non-limiting examples of isolated polynucleotides which include at least one copy of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG) and a mutation in at least one nucleotide of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs: 63-66.

Non-limiting examples of isolated polynucleotides which include at least one copy of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), at least one copy of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG) and a

mutation in at least one nucleotide of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs: 67-70.

According to some embodiments of the invention, the isolated polynucleotide further comprising at least one copy of wild type M1 sequence set forth by SEQ ID NO: 20 (GTACT).

Non-limiting examples of isolated polynucleotides which include at least one copy of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), at least one copy of the wild type M1 sequence set forth by SEQ ID NO: 20 (GTACT), and a mutation in at least one nucleotide of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs: 71-105.

Non-limiting examples of isolated polynucleotides which include at least one copy of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), at least one copy of the wild type M1 sequence set forth by SEQ ID NO: 20 (GTACT) and a mutation in at least one nucleotide of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs: 106-136.

Non-limiting examples of isolated polynucleotides which include at least one copy of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), at least one copy of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), at least one copy of the wild type M1 sequence set forth by SEQ ID NO: 20 (GTACT) and a mutation in at least one nucleotide of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs: 137-152.

According to some embodiments of the invention, the isolated polynucleotide reduces expression of a heterologous polynucleotide operably linked thereto in endothelial cells. Such a polynucleotide can include mutations in M4 and/or M5 in the presence or absence of additional sequences from element X, and/or in the presence of other mutated sequences from element X.

According to some embodiments of the invention, the at least one nucleotide position which is mutated as compared to SEQ ID NO: 6 is at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC).

Non-limiting examples of isolated polynucleotides which includes a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 46 (CATTC) are provided in SEQ ID NOs: 153-162.

According to some embodiments of the invention, the at least one nucleotide position which is mutated as compared to SEQ ID NO:6 is at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG).

Non-limiting examples of isolated polynucleotides which include a mutation in
5 at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG) are provided in SEQ ID NOs:163-171.

According to some embodiments of the invention, the at least one nucleotide position which is mutated as compared to SEQ ID NO:6 is at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC) and at least one
10 nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG).

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC) and a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG) are provided in SEQ ID NOs:172-180.

15 According to some embodiments of the invention, the isolated polynucleotide is for increasing expression of a heterologous polynucleotide operably linked thereto in cells other than endothelial cells. Such a polynucleotide can include mutations in M4 and/or M5 and wild type sequences of M6 and/or M7, in the presence or absence of additional sequences from element X, and/or in the presence of other mutated sequences
20 from element X.

According to some embodiments of the invention, the isolated polynucleotide comprises a mutation in M4 (SEQ ID NO: 15) and/or in M5 (SEQ ID NO: 16) and at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and/or at least one copy of wild type M7 set forth by SEQ ID NO:18.

25 Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC) and at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) are provided in SEQ ID NOs:181-182.

Non-limiting examples of isolated polynucleotides which include a mutation in
30 at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG) and at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) are provided in SEQ ID NOs:183-189.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG) and at least one copy of the wild type M6 set forth by
5 SEQ ID NO: 17 (GGGTG) are provided in SEQ ID NOs:190-191.

According to some embodiments of the invention, the isolated polynucleotide further comprises at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT).

Non-limiting examples of isolated polynucleotides which include a mutation in
10 at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC) and at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT) are provided in SEQ ID NOs:192-195.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG) and at least one copy of the wild type M7 sequence set forth by SEQ ID NO:
15 18 (ACTTT) are provided in SEQ ID NOs:196-198.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth
20 by SEQ ID NO: 16 (CAATG) and at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT) are provided in SEQ ID NOs:199-202.

According to some embodiments of the invention, the isolated polynucleotide further comprises at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and at least one copy of the wild type M7 sequence set forth by SEQ ID NO:
25 18 (ACTTT).

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT) are provided in SEQ ID NOs:203-205.
30

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16

(CAATG), at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT) are provided in SEQ ID NOs:206-207.

Non-limiting examples of isolated polynucleotides which include a mutation in
5 at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT) are provided in SEQ ID NOs:208-209.

10 According to some embodiments of the invention, the isolated polynucleotide reduces expression in cells of a heterologous polynucleotide operably linked thereto. Such a polynucleotide can include mutations in M4, M5, M6 and/or M7, in the presence or absence of additional sequences from element X, and/or in the presence of other mutated sequences from element X.

15 According to some embodiments of the invention, the isolated polynucleotide comprises at least one mutation in wild type M4 (SEQ ID NO: 15) and/or in wild type M5 (SEQ ID NO:47) and in wild type M6 set forth by SEQ ID NO: 17 (GGGTG).

Non-limiting examples of isolated polynucleotides which include a mutation in
at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15
20 (CATTC) and a mutation in at least one nucleotide position of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) are provided in SEQ ID NOs:210-213.

Non-limiting examples of isolated polynucleotides which include a mutation in
at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16
(CAATG) and a mutation in at least one nucleotide position of the wild type M6 set
25 forth by SEQ ID NO: 17 (GGGTG) are provided in SEQ ID NOs:214-222.

Non-limiting examples of isolated polynucleotides which include a mutation in
at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15
(CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth
by SEQ ID NO: 16 (CAATG), and a mutation in at least one nucleotide position of the
30 wild type M6 set forth by SEQ ID NO: 17 (GGGTG) are provided in SEQ ID NOs:223-231.

According to some embodiments of the invention, the isolated polynucleotide further comprises at least one mutation in wild type M7 set forth by SEQ ID NO: 18 (ACTTT).

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC) and a mutation in at least one nucleotide position of the wild type M7 set forth by SEQ ID NO: 18 (ACTTT) are provided in SEQ ID NOs:232-236.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG) and a mutation in at least one nucleotide position of the wild type M7 set forth by SEQ ID NO: 18 (ACTTT) are provided in SEQ ID NOs:237-240.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), and a mutation in at least one nucleotide position of the wild type M7 set forth by SEQ ID NO: 18 (ACTTT) are provided in SEQ ID NOs:241-248.

According to some embodiments of the invention, the isolated polynucleotide further comprises at least one mutation in wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and at least one mutation in wild type M7 set forth by SEQ ID NO: 18 (ACTTT).

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide position of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and a mutation in at least one nucleotide position of the wild type M7 set forth by SEQ ID NO: 18 (ACTTT) are provided in SEQ ID NOs:249-258.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), a mutation in at least one nucleotide position of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and a mutation in at least one nucleotide position of the wild type M7 set forth by SEQ ID NO: 18 (ACTTT) are provided in SEQ ID NOs:259-264.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), a mutation in at least one nucleotide position of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and a mutation in at least one nucleotide position of the wild type M7 set forth by SEQ ID NO: 18 (ACTTT) are provided in SEQ ID NOs:265-270.

According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) with additional wild type or mutated sequences derived from element X (SEQ ID NO:6).

Non-limiting examples of isolated polynucleotides which includes a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC) and at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs:271-279.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG) and at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs:280-287.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG) and at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs:288-291.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs:294-298.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG)

and at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs:299-301.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs:302-303.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT) and at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs:304-308.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT) and at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs:309-311.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT) and at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs:312-315.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG), at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT) and at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NO:316.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16

(CAATG), at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG), at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT) and at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NO:317.

5 Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG), at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT) and at least one copy of the wild type M8 sequence set forth by
10 SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NO:318.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide position of the wild type M6 set forth by
15 SEQ ID NO: 17 (GGGTG) and at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs:319-327.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), a mutation in at least one nucleotide position of the wild type M6 set forth by
20 SEQ ID NO: 17 (GGGTG) and at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs:328-333.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth
25 by SEQ ID NO: 16 (CAATG), a mutation in at least one nucleotide position of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs:334-337.

Non-limiting examples of isolated polynucleotides which include a mutation in
30 at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide position of the wild type M7 set forth by

SEQ ID NO: 18 (ACTTT) and at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs:338-344.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), a mutation in at least one nucleotide position of the wild type M7 set forth by SEQ ID NO: 18 (ACTTT) and at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs:345-348.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), a mutation in at least one nucleotide position of the wild type M7 set forth by SEQ ID NO: 18 (ACTTT) and at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs:349-354.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide position of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG), a mutation in at least one nucleotide position of the wild type M7 set forth by SEQ ID NO: 18 (ACTTT) and at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs:355-361.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), a mutation in at least one nucleotide position of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG), a mutation in at least one nucleotide position of the wild type M7 set forth by SEQ ID NO: 18 (ACTTT) and at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs:362-365.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), a mutation in at least one nucleotide position of the wild

type M6 set forth by SEQ ID NO: 17 (GGGTG), a mutation in at least one nucleotide position of the wild type M7 set forth by SEQ ID NO: 18 (ACTTT) and at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) are provided in SEQ ID NOs:366-369.

- 5 According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) with additional wild type or mutated sequences derived from element X (SEQ ID NO:6).

- 10 Non-limiting examples of isolated polynucleotides which includes a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:378-384.

- 15 Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:628-634.

- 20 Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:370-377.

- 25 Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:385-390.

- 30 Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:391-396.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:397-401.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:402-409.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:410-417.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:418-423.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG), at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:424-425.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG), at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT)

and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:538-540.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG), at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NO:426.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide position of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:427-435.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), a mutation in at least one nucleotide position of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:436-444.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), a mutation in at least one nucleotide position of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:445-451.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide position of the wild type M7 set forth by SEQ ID NO: 18 (ACTTT) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:452-458.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), a mutation in at least one nucleotide position of the wild type M7 set forth by SEQ ID NO: 18 (ACTTT) and at least one copy of the wild type M3 sequence set forth
5 by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:459-465.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), a mutation in at least one nucleotide position of the wild
10 type M7 set forth by SEQ ID NO: 18 (ACTTT) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NO:466.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide position of the wild type M6 set forth by
15 SEQ ID NO: 17 (GGGTG), a mutation in at least one nucleotide position of the wild type M7 set forth by SEQ ID NO: 18 (ACTTT) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:467-471.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), a mutation in at least one nucleotide position of the wild type M6 set forth by
20 SEQ ID NO: 17 (GGGTG), a mutation in at least one nucleotide position of the wild type M7 set forth by SEQ ID NO: 18 (ACTTT) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:472-
25 477.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), a mutation in at least one nucleotide position of the wild
30 type M6 set forth by SEQ ID NO: 17 (GGGTG), a mutation in at least one nucleotide position of the wild type M7 set forth by SEQ ID NO: 18 (ACTTT) and at least one

copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:478-483.

According to some embodiments of the invention, the isolated polynucleotide further comprises at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) with additional wild type or mutated sequences derived from element X (SEQ ID NO:6).

Non-limiting examples of isolated polynucleotides which includes a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:484-495.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:496-507.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:508-515.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG), at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:516-519.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG),

at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:520-523.

Non-limiting examples of isolated polynucleotides which include a mutation in
5 at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG), at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of the wild type M3 sequence set forth by
10 SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:524-525.

Non-limiting examples of isolated polynucleotides which include a mutation in
at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT), at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO:
15 21 (CTTTT) are provided in SEQ ID NOs:526-529.

Non-limiting examples of isolated polynucleotides which include a mutation in
at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT), at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO:
20 21 (CTTTT) are provided in SEQ ID NOs:530-533.

Non-limiting examples of isolated polynucleotides which include a mutation in
at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth
25 by SEQ ID NO: 16 (CAATG), at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT), at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:534-535.

30 Non-limiting examples of isolated polynucleotides which include a mutation in
at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG),

at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT), at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:536-537.

5 Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG), at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT) at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and
10 at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:538-539.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth
15 by SEQ ID NO: 16 (CAATG), at least one copy of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG), at least one copy of the wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT), at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NO:540.

20 Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide position of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG), at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of the wild type M3 sequence set forth
25 by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:541-547.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), a mutation in at least one nucleotide position of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG), at least one copy of the wild type M8 sequence set forth by
30 SEQ ID NO: 19 (GCTTC) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:548-554.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), a mutation in at least one nucleotide position of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG), at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:555-559.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide position of the wild type M7 set forth by SEQ ID NO: 18 (ACTTT), at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:560-566.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), a mutation in at least one nucleotide position of the wild type M7 set forth by SEQ ID NO: 18 (ACTTT), at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:567-573.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), a mutation in at least one nucleotide position of the wild type M7 set forth by SEQ ID NO: 18 (ACTTT), at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:574-578.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC), a mutation in at least one nucleotide position of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG), a mutation in at least one nucleotide position of the wild

type M7 set forth by SEQ ID NO: 18 (ACTTT), at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:579-583.

5 Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), a mutation in at least one nucleotide position of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG), a mutation in at least one nucleotide position of the wild type M7 set forth by SEQ ID NO: 18 (ACTTT), at least one copy of the wild type M8
10 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:584-588.

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of the wild type M4 sequence set forth by SEQ ID NO: 15
15 (CATTC), a mutation in at least one nucleotide of the wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG), a mutation in at least one nucleotide position of the wild type M6 set forth by SEQ ID NO: 17 (GGGTG), a mutation in at least one nucleotide position of the wild type M7 set forth by SEQ ID NO: 18 (ACTTT), at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy
20 of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) are provided in SEQ ID NOs:589-592.

According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of wild type M3 sequence (SEQ ID NO: 21) and at least one copy of wild type M8 sequence (SEQ ID NO: 19), with at least one mutation in wild
25 type M6 (SEQ ID NO: 17) and/or in wild type M7 (SEQ ID NO: 18).

Non-limiting examples of isolated polynucleotides which include at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT), with a mutation in at least one nucleotide of the wild type M6 sequence (SEQ ID NO: 17),
30 and/or a mutation in at least one nucleotide of the wild type M7 (SEQ ID NO: 18) are provided in SEQ ID NOs:593-600.

The present inventors have envisaged that an isolated polynucleotide which includes the wild type M8 sequence (SEQ ID NO: 19) and/or the wild type M3 (SEQ ID NO: 21) sequence in addition to tissue specific enhancers (e.g., wild type M4 and/or wild type M5), and/or induced enhancers (e.g., developmentally related- or stress related-enhancers) is expected to exert a more specific regulatory effect by suppressing
5 expression in non-target cells or under non-induced conditions.

According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and an endothelial specific enhancer sequence.

10 According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of wild type M4 sequence set forth by SEQ ID NO: 15.

According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of wild type M5 sequence set forth by SEQ ID NO:16.
15

According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC), at least one copy of wild type M4 sequence set forth by SEQ ID NO: 15 and at least one copy of wild type M5 sequence set forth by SEQ ID NO:16.

20 According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) and an endothelial specific enhancer sequence.

According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) and at least one copy of wild type M4 sequence set forth by SEQ ID NO: 15.
25

According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT) and at least one copy of wild type M5 sequence set forth by SEQ ID NO:16.

According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT), at least one copy of wild type M4 sequence set forth by SEQ ID NO: 15 and at least one copy of wild type M5 sequence set forth by SEQ ID NO:16.
30

According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT), at least one copy of wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and an endothelial specific enhancer sequence.

5 According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT), at least one copy of wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of wild type M4 sequence set forth by SEQ ID NO: 15.

 According to some embodiments of the invention, the isolated polynucleotide
10 comprises at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT), at least one copy of wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one copy of wild type M5 sequence set forth by SEQ ID NO: 16.

 According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21
15 (CTTTT), at least one copy of wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC), at least one copy of wild type M4 sequence set forth by SEQ ID NO: 15 and at least one copy of wild type M5 sequence set forth by SEQ ID NO: 16.

 According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of the wild type M3 sequence set forth by SEQ ID NO: 21
20 (CTTTT), at least one copy of wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC) and at least one enhancer element such as wild type M6 (SEQ ID NO: 17) and/or wild type M7 sequence (SEQ ID NO:18).

 According to some embodiments of the invention, the isolated polynucleotide includes at least one copy of wild type M8 with additional flanking sequences such as at
25 least one copy of a wild type M8 sequence (SEQ ID NO:19), at least one copy of wild type M7 (SEQ ID NO: 18) and/or wild type M9 sequence (SEQ ID NO: 14, CTGGA); and/or the isolated polynucleotide includes at least one copy of wild type M8 and at least one mutation in M7, with or without M9 (SEQ ID NO: 22). Such polynucleotides can be used as a non-specific repressor.

30 According to some embodiments of the invention, the isolated polynucleotide is for increasing expression of a heterologous polynucleotide operably linked thereto in cells/tissues.

According to some embodiments of the invention, the isolated polynucleotide comprises at least one copy of wild type M6 sequence set forth by SEQ ID NO: 17 (GGGTG) and/or at least one copy of wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT).

5 According to some embodiments of the invention, the isolated polynucleotide includes at least one copy of wild type M6 (SEQ ID NO: 17) and a mutation in at least one nucleotide of wild type M8 (SEQ ID NO: 19) .

Non-limiting examples of isolated polynucleotide which include at least one copy of wild type M6 (SEQ ID NO: 17) and a mutation in at least one nucleotide of the wild type M8 (SEQ ID NO: 19) are provided in SEQ ID NOs:23-26.

According to some embodiments of the invention, the isolated polynucleotide includes at least one copy of wild type M7 (SEQ ID NO: 18) and a mutation in at least one nucleotide of wild type M8 (SEQ ID NO: 19) .

Non-limiting examples of isolated polynucleotide which include at least one copy of wild type M7 (SEQ ID NO: 18) and a mutation in at least one nucleotide of the wild type M8 (SEQ ID NO: 19) are provided in SEQ ID NOs:27-28.

According to some embodiments of the invention, the isolated polynucleotide includes at least one copy of wild type M6 (SEQ ID NO: 17) , at least one copy of wild type M7 (SEQ ID NO: 18) and a mutation in at least one nucleotide of wild type M8 (SEQ ID NO: 19) .

According to some embodiments of the invention, the isolated polynucleotide includes at least one copy of wild type M1 (SEQ ID NO: 20) and a mutation in at least one nucleotide of wild type M8 (SEQ ID NO: 19) .

Non-limiting examples of isolated polynucleotide which include at least one copy of wild type M1 (SEQ ID NO: 20) and a mutation in at least one nucleotide of the wild type M8 (SEQ ID NO: 19) are provided in SEQ ID NOs:43-54 and 601-632.

According to some embodiments of the invention, the isolated polynucleotide includes at least one copy of wild type M1 (SEQ ID NO: 20) , at least one copy of wild type M6 (SEQ ID NO: 17) and/or at least one copy of wild type M7 (SEQ ID NO: 18) and a mutation in at least one nucleotide of wild type M8 (SEQ ID NO: 19) .

Non-limiting examples of isolated polynucleotides which include a mutation in at least one nucleotide of wild type M8 (SEQ ID NO: 19) and at least one copy of wild

type M1 (SEQ ID NO: 20) , wild type M6 (SEQ ID NO: 17) and/or wild type M7 (SEQ ID NO: 18) are provided in SEQ ID NOs:29-42.

Additional examples of regulatory isolated polynucleotides which can be used according to some embodiments of the invention are provided (; SEQ ID NOs: 633-644)

5 in the Examples section which follows.

According to an aspect of some embodiments of the invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence which comprises a first polynucleotide comprising the pre-proendothelin (PPE-1) promoter set forth by SEQ ID NO:13 and a second polynucleotide comprising at least one copy of a nucleic acid
10 sequence selected from the group consisting of:

- (i) wild type M4 sequence set forth by SEQ ID NO: 15 (CATTC),
- (ii) wild type M5 sequence set forth by SEQ ID NO: 16 (CAATG),
- (iii) wild type M8 sequence set forth by SEQ ID NO: 19 (GCTTC),
- (iv) wild type M6 sequence set forth by SEQ ID NO: 17 (GGGTG),
- 15 (v) wild type M7 sequence set forth by SEQ ID NO: 18 (ACTTT);
- (vi) wild type M1 sequence set forth by SEQ ID NO: 20 (GTACT), and
- (vii) wild type M3 sequence set forth by SEQ ID NO: 21 (CTTTT);

with the proviso that the second polynucleotide is not SEQ ID NO:6 (element X), and wherein the isolated polynucleotide is not SEQ ID NO:12 (PPE-1-3X).

20 According to some embodiments of the invention, each of the wild type M4, M5, M8, M6, M7 and/or M1 sequences is placed in a head to tail (5'→3') orientation with respect to the PPE-1 promoter set forth by SEQ ID NO:13.

According to some embodiments of the invention, each of the wild type M4, M5, M8, M6, M7 and/or M1 sequences is placed in a tail to head (3'→5') orientation with
25 respect to the PPE-1 promoter set forth by SEQ ID NO:13.

According to some embodiments of the invention, the wild type M4, M5, M8, M6, M7 and/or M1 sequences are placed in various orientations (head to tail or tail to head) and/or sequential order with respect the other wild type M4, M5, M8, M6, M7 and/or M1 sequences, and/or with respect to the orientation of SEQ ID NO:13.

30 Construction of such viral vectors may be effected using known molecular biology techniques such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Springs Harbor Laboratory, New York (1989, 1992), in

Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, Md. (1989), Chang et al., Somatic Gene Therapy, CRC Press, Ann Arbor, Mich. (1995), Vega et al., Gene Targeting, CRC Press, Ann Arbor Mich. (1995), Vectors: A Survey of Molecular Cloning Vectors and Their Uses, Butterworths, Boston
5 Mass. (1988) and Gilboa et al. [Biotechniques 4 (6): 504-512, 1986].

Construction of the viral vector of SEQ ID NO: 9 is described in International Application WO/2008/132729, the contents of which are incorporated herein by reference.

As used herein, the term "administration" refers to providing or giving a subject
10 an agent, such as an anti-angiogenic viral composition, by any effective route.

The viral vector of this aspect of the present invention may be administered per se or as part of a pharmaceutical composition which also includes a physiologically acceptable carrier. The purpose of a pharmaceutical composition is to facilitate administration of the active ingredient to an organism.

15 As used herein a "pharmaceutical composition" refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.

Herein the term "active ingredient" refers to the viral vector of the present
20 invention accountable for the biological effect.

Hereinafter, the phrases "physiologically acceptable carrier" and "pharmaceutically acceptable carrier" which may be interchangeably used refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound. An
25 adjuvant is included under these phrases.

Herein the term "excipient" refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable
30 oils and polyethylene glycols.

Techniques for formulation and administration of drugs may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, latest edition, which is incorporated herein by reference.

Suitable routes of administration may, for example, include oral, rectal, 5 transmucosal, especially transnasal, intestinal or parenteral delivery, including intramuscular, intradermal, intraperitoneal, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intracardiac, e.g., into the right or left ventricular cavity, into the common coronary artery, intravenous, intraperitoneal, intranasal, or intraocular injections, sublingual, rectal, transdermal, intranasal, vaginal 10 and inhalation routes. Injection of the viral vectors into a spinal fluid can also be used as a mode of administration.

The viral vectors or compositions thereof can be administered in an in-patient or out-patient setting. In one particular embodiment, the viral vectors or compositions thereof are administered in an injection or in an intravenous drip.

15 The present invention also contemplates engineering of the viral vectors in order to avoid, suppress or manipulate the immune response, ideally resulting in sustained expression and immune tolerance to the transgene product – such methods are described for example in Nayak et al., *Gene Therapy* (12 November 2009), incorporated herein by reference.

20 Alternately, one may administer the pharmaceutical composition in a local rather than systemic manner, for example, via injection of the pharmaceutical composition directly into the tissue or tumor mass of a patient and even more directly into the tumor cells themselves.

Pharmaceutical compositions of the present invention may be manufactured by 25 processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically 30 acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which, can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

For injection, the active ingredients of the pharmaceutical composition may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological salt buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

For administration by nasal inhalation, the active ingredients for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in a dispenser may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The pharmaceutical composition described herein may be formulated for parenteral administration, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative. The compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

Pharmaceutical compositions for parenteral administration include aqueous solutions of the active preparation in water-soluble form. Additionally, suspensions of the active ingredients may be prepared as appropriate oily or water based injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acids esters such as ethyl oleate, triglycerides or liposomes. Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the active ingredients to allow for the preparation of highly concentrated solutions.

Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water based solution, before use.

The pharmaceutical composition of the present invention may also be formulated in rectal compositions such as suppositories or retention enemas, using, e.g.,
5 conventional suppository bases such as cocoa butter or other glycerides.

Pharmaceutical compositions suitable for use in context of the present invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a therapeutically effective amount means an amount of active ingredients (i.e. viral particles) effective to prevent,
10 alleviate or ameliorate symptoms of a disorder (e.g., thyroid cancer, neuroendocrine cancer) or prolong the survival of the subject being treated.

Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein. Therapeutic efficacy of administration of the adenoviral vector of the present invention
15 can be assessed according to a variety of criteria, including clinical presentation, biochemical parameters, radiological evaluation and the like. In some embodiments, efficacy is evaluated according to one or more of the following exemplary parameters:

Biodistribution: for example, levels of virus DNA in blood and urine samples, expression of the fas-c transgene (mRNA) in blood;

20 Antibodies: for example, levels of total anti-Ad-5 Ig, IgG and neutralizing anti-Ad5 antibodies in serum;

Angiogenic biomarkers: for example, von Willebrand Factor, TNF α , VEGFR1 and VEGFR2 levels in the blood;

25 Cytokine levels: for example, peripheral blood cytokine levels (e.g. IL-6, IL-8-see Table 6);

Tumor response: Tumor dimensions can be measured on CT (or MRI) scans, or other radiographic means. Tumor response can then be evaluated according to accepted criteria, such as Response Evaluation Criteria in Solid Tumors (RECIST).

The criteria can be evaluated at any time following administration, and can also
30 be compared to pre-dosing values. In one embodiment, the evaluation criteria are assessed prior to administration of the adenovirus vector, and then on days 4 $\pm$ 1, 7 $\pm$ 1, 14 $\pm$ 1, 28 $\pm$ 2, day 56 $\pm$ 3, day 112 $\pm$ 4, about 3 months, about 4 months, about 5 months,

about 6 months, about 1 year or more post dosing. In some embodiments, the evaluation criteria are assessed at day 7 ± 1 , 14 ± 1 , 28 ± 2 , day 56 ± 3 , day 112 ± 4 , about 3 months, about 6 months, about 9 months, about 1 year and about every 3 months thereafter for up to 2, up to 3, up to 4 or more years post dosing.

5 Determination of safety of dosing or dosing regimen is well within the ability of one skilled in the art. Safety can be assessed according to a variety of criteria, including, but not limited to, clinical presentation, tissue and organ pathology, presence of abnormal vital signs (e.g. pyrexia, fatigue, chills, tachycardia, hypertension, constipation and the like), hematology values (e.g. hemoglobin, hematocrit, RCV and
10 the like), chemistry or urinalysis abnormalities (elevated enzymes such as alkaline phosphatase ALT, AST, bilirubin and the like) and ECG, EEG, etc.

As used herein, the term "antibody" refers to a molecule including an antigen binding site which specifically binds (immunoreacts with) an antigen. The term "antibody" includes intact molecules as well as functional fragments thereof, such as
15 Fab, F(ab')₂, and Fv that are capable of binding to macrophages. These functional antibody fragments are defined as follows: (1) Fab, the fragment which contains a monovalent antigen-binding fragment of an antibody molecule, can be produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain; (2) Fab', the fragment of an antibody molecule that can be
20 obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab' fragments are obtained per antibody molecule; (3) (Fab')₂, the fragment of the antibody that can be obtained by treating whole antibody with the enzyme pepsin without subsequent reduction; F(ab')₂ is a dimer of two Fab' fragments held together by two disulfide bonds; (4) Fv, defined
25 as a genetically engineered fragment containing the variable region of the light chain and the variable region of the heavy chain expressed as two chains; and (5) Single chain antibody ("SCA"), a genetically engineered molecule containing the variable region of the light chain and the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule.

30 Methods of producing polyclonal and monoclonal antibodies as well as fragments thereof are well known in the art (See for example, Harlow and Lane,

Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1988, incorporated herein by reference).

As used herein, the term "antigen" refers to a substance that can stimulate the production of antibodies or a T-cell response in a mammal, including compositions that are injected or absorbed into a mammal. An antigen reacts with the products of specific humoral or cellular immunity, including those induced by heterologous immunogens. The term "antigen" includes all related antigenic epitopes. In one example, an antigen is a cancer antigen. A target antigen is an antigen against which an immune response is desired, for example to achieve a therapeutic effect, such as tumor regression.

For any preparation used in the methods of the invention, the therapeutically effective amount or dose can be estimated initially from in vitro and cell culture assays. For example, a dose can be formulated in animal models to achieve a desired concentration or titer. Such information can be used to more accurately determine useful doses in humans.

The therapeutically effective amount of the active ingredient can be formulated in a unit dose. As used herein "unit dose" refers to a physically discrete unit containing a predetermined quantity of an active material calculated to individually or collectively produce a desired effect such as an anti-cancer effect. A single unit dose or a plurality of unit doses can be used to provide the desired effect, such as an anti-cancer therapeutic effect. In some embodiments, the unit dosage is 1×10^8 to about 1×10^{16} virus particles, at least about 1×10^{11} to about 1×10^{13} virus particles, and optionally about 1×10^{11} , about 3×10^{11} , about 5×10^{11} , about 1×10^{12} , about 3×10^{12} , about 5×10^{12} , about 1×10^{13} , about 3×10^{13} or more virus particles.

Toxicity and therapeutic efficacy of the active ingredients described herein can be determined by standard pharmaceutical procedures in vitro, in cell cultures or experimental animals. The data obtained from these in vitro and cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl, et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p.1).

Dosage amount and interval may be adjusted individually to provide levels of the active ingredient sufficient to induce or suppress the biological effect (minimal effective concentration, MEC). The MEC will vary for each preparation, but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. Detection assays can be used to determine plasma concentrations.

Depending on the severity and responsiveness of the condition to be treated, dosing can be of a single or a plurality of administrations, with course of treatment lasting from several days to several weeks or until cure is effected or diminution of the disease state is achieved.

The amount of a composition to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.

According to one embodiment, about 10^3 to about 10^{16} virus particles are administered to the subject.

According to another embodiment, about 10^5 to about 10^{13} virus particles are administered to the subject.

According to one embodiment, about 10^7 to about 10^{12} virus particles are administered to the subject.

According to one embodiment, about 1×10^{12} to about 5×10^{12} virus particles are administered to the subject.

According to yet another embodiment, about 1×10^9 to about 1×10^{16} virus particles, at least about 1×10^{11} to about 1×10^{13} virus particles are administered to the subject.

According to yet another embodiment the subject is administered intravenously with 1×10^{12} - 1×10^{13} viral particles of SEQ ID NO: 9. or SEQ ID NO: 10.

According to yet another embodiment the subject is administered intravenously with at least two doses of 1×10^{12} - 1×10^{13} viral particles of SEQ ID NO: 9. or SEQ ID NO: 10. According to yet another embodiment the subject is administered intravenously with at least three or more doses of 1×10^{12} - 1×10^{13} viral particles of SEQ ID NO: 9. or SEQ ID NO: 10. In a particular embodiment, the at least two doses are administered at least about 1 day, at least about 3 days, at least about 5 days, at least

about 7 days, at least about 2 weeks, at least about 3 weeks, at least about 4 weeks, at least about 2 months, at least about 6 months, at least about 9 months, at least about 1 year, at least about 1.25 years, at least about 1.5 years, at least about 1.75 years, at least about 2 years, at least about 2.5 years, at least about 3 years or more apart.

5 Compositions of the present invention may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredient. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be
10 accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration. Such notice, for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product
15 insert. Compositions comprising a preparation of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition, as is further detailed above.

 Thus, according to some aspects of some embodiments of the present invention
20 there is provided a kit for treating a solid tumor in a subject in need thereof, comprising a unit dosage of virus particles of a non-replicating adenovirus vector comprising a polynucleotide having a nucleotide sequence as set forth in SEQ ID NOs: 9 or 10, wherein the non-replicating adenovirus vector is formulated for intravenous administration, and instructions for administration of the adenovirus.

25 The adenovirus vector can be used in combination with other treatments. For example, the uptake of adenoviral vectors into EC cells can be enhanced by treating the vectors with engineered antibodies or small peptides. Such "adenobody" treatment, was shown effective in directing adenovirus constructs to EGF receptors on cells (Watkins et al 1997, Gene Therapy 4:1004-1012). In addition, Nicklin et al have shown that a
30 small peptide, isolated via phage display, increased specificity and efficiency of vectors in endothelial cells and decreased the expression in liver cells in culture (Nicklin et al

2000, *Circulation* 102:231-237). In a recent study, an FGF retargeted adenoviral vector reduced the toxicity of tk in mice (Printz et al 2000, *Human Gene Therapy* 11:191-204).

Low dose radiation has been shown to cause breaks in DNA strands primarily in the G2/M phase, cell membrane damage enhancing the bystander effect, and thus may potentiate other cytotoxic and anti-neoplastic therapies, when administered in combination. Vascular endothelial cells may be particularly suitable to such combination, or adjunct, therapies, since it has been demonstrated that low dose radiation specifically targets the apoptotic system of the microvascular endothelial cells (Kolesnick et al., *Oncogene* 2003; 22:5897-906). Angiostatin has been shown to potentiate the therapeutic effects of low dose radiation (Gorski et al. *Can Res* 1998;58:5686-89). However, the effects of radiation are still poorly understood, since irradiation has also been shown to increase pro-angiogenic "tissue repair factors" (Itasaka et al., *Am Assoc Canc Res*, 2003; abstract 115). Similarly, certain chemotherapeutic agents have been shown to activate specific cytotoxic and apoptotic pathways [doxorubicin, cisplatin and mitomycin C induce accumulation of Fas receptor, FADD, and other proapoptotic signals in the FADD/MORT-1 pathway (Micheau et al., *BBRC* 1999 256:603-07)].

For example International Application WO/2008/132729 teaches combined doxorubicin and AdPPE-1 (3x)-Fas-c chimera construct administration in endothelial cells (BAEC). Thus, the viral vectors and the pharmaceutical compositions comprising same of the present invention can be used to treat solid tumors alone or in combination with one or more other established or experimental therapeutic regimen for such disorders. Therapeutic regimen for treatment of solid tumors suitable for combination with the viral vectors of the present invention include, but are not limited to chemotherapy, radiotherapy, phototherapy and photodynamic therapy, surgery, nutritional therapy, ablative therapy, combined radiotherapy and chemotherapy, brachiotherapy, proton beam therapy, immunotherapy, cellular therapy and photon beam radiosurgical therapy. The vectors of the present invention may be administered with additional ingredients which may improve the uptake of the nucleic acid construct by the cells, expression of the chimeric polypeptide by the nucleic acid construct in the cells, the activity of the expressed chimeric polypeptide or the efficacy of the treatment on any aspects of the disease. Protocols for use of recombinant anti-angiogenic

adenovirus vectors for cancer treatment are known in the art. Many clinical trials of adenovirus-based anti-angiogenic gene therapy are currently being conducted, mostly involving a recombinant anti-angiogenic adenovirus in combination with other cancer therapies, and administered intra-tumorally, such as an adenovirus-p53 vaccine with
 5 chemotherapy for small cell lung cancer (NCT0049218), adenovirus-suicide gene with chemotherapy for small cell lung cancer (NCT00964756), an adenovirus-endostatin construct with chemotherapy for head and neck cancer (NCT00634595), an adenovirus-suicide gene with chemotherapy for malignant melanoma (NCT00005057) and an adenovirus-tk construct with chemotherapy for hepatocellular carcinoma
 10 (NCT00844623).

Anti-cancer drugs that can be co-administered with the compounds of the invention include, but are not limited to Acivicin; Aclarubicin; Acodazole Hydrochloride; Acronine; Adriamycin; Adozelesin; Aldesleukin; Altretamine; Ambomycin; Ametantrone Acetate; Aminoglutethimide; Amsacrine; Anastrozole;
 15 Anthramycin; Asparaginase; Asperlin; Azacitidine; Azetepa; Azotomycin; Batimastat; Benzodepa; Bicalutamide; Bisantrene Hydrochloride; Bisnafide Dimesylate; Bevacizumab; Bizelesin; Bleomycin Sulfate; Brequinar Sodium; Bropiramine; Busulfan; Cactinomycin; Calusterone; Caracemide; Carbetimer; Carboplatin; Carmustine; Carubicin Hydrochloride; Carzelesin; Cedefingol; Chlorambucil; Cirolemycin;
 20 Cisplatin; Cladribine; Crisnatol Mesylate; Cyclophosphamide; Cytarabine; Dacarbazine; Dactinomycin; Daunorubicin Hydrochloride; Decitabine; Dexormaplatin; Dezaguanine; Dezaguanine Mesylate; Diaziquone; Docetaxel; Doxorubicin; Doxorubicin Hydrochloride; Droloxifene; Droloxifene Citrate; Dromostanolone Propionate; Duazomycin; Edatrexate; Eflornithine Hydrochloride; Elsamitrucin;
 25 Enloplatin; Enpromate; Epiropidine; Epirubicin Hydrochloride; Erbulozole; Esorubicin Hydrochloride; Estramustine; Estramustine Phosphate Sodium; Etanidazole; Etoposide; Etoposide Phosphate; Etoprine; Fadrozole Hydrochloride; Fazarabine; Fenretinide; Floxuridine; Fludarabine Phosphate; Fluorouracil; Flurocitabine; Fosquidone; Fostriecin Sodium; Gemcitabine; Gemcitabine Hydrochloride;
 30 Hydroxyurea; Idarubicin Hydrochloride; Ifosfamide; Ilmofosine; Interferon Alfa-2a; Interferon Alfa-2b; Interferon Alfa-n1; Interferon Alfa-n3; Interferon Beta- I a; Interferon Gamma- I b; Iproplatin; Irinotecan Hydrochloride; Lanreotide Acetate;

Letrozole; Leuprolide Acetate; Liarozole Hydrochloride; Lometrexol Sodium; Lomustine; Losoxantrone Hydrochloride; Masoprocol; Maytansine; Mechlorethamine Hydrochloride; Megestrol Acetate; Melengestrol Acetate; Melfalan; Menogaril; Mercaptopurine; Methotrexate; Methotrexate Sodium; Metoprine; Meturedopa; 5 Mitindomide; Mitocarcin; Mitocromin; Mitogillin; Mitomalcin; Mitomycin; Mitosper; Mitotane; Mitoxantrone Hydrochloride; Mycophenolic Acid; Nocodazole; Nogalamycin; Ormaplatin; Oxisuran; pazotinib; Paclitaxel; Pegaspargase; Peliomycin; Pentamustine; Peplomycin Sulfate; Perfosfamide; Pipobroman; Pipsulfan; Piroxantrone Hydrochloride; Plicamycin; Plomestane; Porfimer Sodium; Porfiromycin; 10 Prednimustine; Procarbazine Hydrochloride; Puromycin; Puromycin Hydrochloride; Pyrazofurin; Riboprine; Rogletimide; Safingol; Safingol Hydrochloride; Semustine; Simtrazene; Sorafinib; Sparfosate Sodium; Sparsomycin; Spirogermanium Hydrochloride; Spiromustine; Spiroplatin; Streptonigrin; Streptozocin; Sulofenur; Sunitinib; Talisomycin; Taxol; Tecogalan Sodium; Tegafur; Teloxantrone 15 Hydrochloride; Temoporfin; Teniposide; Teroxirone; Testolactone; Thiamiprine; Thioguanine; Thiotepa; Tiazofuirin; Tirapazamine; Topotecan Hydrochloride; Toremifene Citrate; Trestolone Acetate; Triciribine Phosphate; Trimetrexate; Trimetrexate Glucuronate; Triptorelin; Tubulozole Hydrochloride; Uracil Mustard; Uredea; Vapreotide; Verteporfin; Vinblastine Sulfate; Vincristine Sulfate; Vindesine; 20 Vindesine Sulfate; Vinepidine Sulfate; Vinglycinat Sulfate; Vinleurosine Sulfate; Vinorelbine Tartrate; Vinrosidine Sulfate; Vinzolidine Sulfate; Vorozole; Zeniplatin; Zinostatin; Zorubicin Hydrochloride. Additional antineoplastic agents include those disclosed in Chapter 52, Antineoplastic Agents (Paul Calabresi and Bruce A. Chabner), and the introduction thereto, 1202-1263, of Goodman and Gilman's "The 25 Pharmacological Basis of Therapeutics", Eighth Edition, 1990, McGraw-Hill, Inc. (Health Professions Division).

The present inventors have shown that administering a single dose of the viral vectors of the present invention (e.g. Ad5PPE-1-3X fas-chimera) in combination with the chemotherapeutic drug sunitinib (Sutent), can improve the efficacy of the 30 chemotherapy treatment, or of the viral vector's effect on a metastatic cancer, in the Lewis Lung Carcinoma model (see Example VI below). Thus, in some embodiments

the viral vectors of the present invention are administered in combination with one or more of the chemotherapeutic drugs, such as sunitinib (Sutent).

Chemotherapeutic agents can be administered along with the viral vectors of the invention, prior to treatment with the viral vectors of the present invention, or following
5 treatment with the viral vectors of the present invention. In a particular embodiment, the chemotherapeutic agent is administered at least about 1 day, at least about 3 days, at least about 5 days, at least about 7 days, at least about 2 weeks, at least about 3 weeks, at least about 4 weeks, at least about 2 months, at least about 6 months, at least about 9 months, at least about 1 year prior to initiation of treatment with the viral vector of the
10 present invention. In another particular embodiment, the chemotherapeutic agent is administered at least about 1 day, at least about 3 days, at least about 5 days, at least about 7 days, at least about 2 weeks, at least about 3 weeks, at least about 4 weeks, at least about 2 months, at least about 6 months, at least about 9 months, at least about 1 year following initiation of treatment with the viral vector of the present invention. In
15 another particular embodiment, the chemotherapeutic agent is administered during, or alongside with initiation of treatment with the viral vector of the present invention.

The viral vectors of the present invention may also be administered with an agent that enhances expression of transgenes in adenoviral-mediated transient expression. For example International Application WO/2008/132729 teaches
20 administration of a corticosteroid (e.g. dexamethasone and/or N-Acetyl Cysteine (NAC) prior to AdPPE-1 (3x)-Fas-c chimera construct administration, or concomitant treatment with an endothelin inhibitor such as bosentan.

In addition, the viral vectors of the present invention may also be administered with an agent that brings about transient immunosuppression, such as for example
25 deoxyspergualin (DSG) or cyclophosphamide (see for example Smith et al., Gene Ther. 1996 Jun;3(6):496-502) in order to allow for repetitive dosing.

Adenovirus-based gene therapy protocols have commonly been limited to single doses, for reasons pertaining to safety and efficacy of the drug, particularly concerning patient anti-adenovirus immune response, as most populations are repeatedly exposed
30 and sensitized to various adenoviral antigens. The present inventors have surprisingly found no correlation between levels of anti-adenovirus antibodies in serum of patients following administration of the adenovirus of the invention, and the dose of adenovirus

administered. Evaluation of antibody titers, including anti-Ad5 neutralizing antibodies, IgG and total anti-Ad5 antibodies in the patients (see Example II, and FIGs. 2 and 3A-3B) revealed no effect of the baseline levels of neutralizing anti-adenovirus antibody on disease progression following dosing. Evaluation of total anti-adenovirus Ad5 antibody titers, and specific anti-Ad5 IgG in serum of patients prior to, and following administration of the Ad5-PPE-1-3X-fas-c adenoviral vectors revealed increased antibody titers following adenovirus vector administration, but indicated no correlation with the doses administered (see Table 4 in Example II that follows), suggesting that repeated doses of the adenovirus as described herein may not lead to an immune response limiting the clinical utility of the adenovirus in the host. Further, it was found that administration of Ad5PPE-1-3X-fas chimera was effective in reducing disease progression even in subjects with high levels of neutralizing anti-Ad5 antibodies and total anti-Ad5 antibodies detected prior to first injection of the construct (see FIGs. 2 and 3). Yet further, assays of blood and urine Ad5-PPE-1-3X-fas-c levels (biodistribution) following administration revealed high levels of the adenovirus constructs of the invention 28 days post-administration, even in the presence of elevated total or IgG anti-Ad5 antibody levels (see Tables 4 and 7 of Example II that follows, specifically, see subjects 2, 9 and 10). In one subject [036], for example, significant levels of transgene expression were detected in an aspirate from a metastatic lesion as many as 28 days following adenovirus vector administration, despite a massive fold increase (X3125) in anti-Ad5 antibody titer (see Tables 4 and 9 in Example II that follows).

Thus, in some embodiments, administering the dose of the adenovirus vector of the present invention inhibits growth of a tumor. In other embodiments, administering the adenovirus vector inhibits angiogenesis of the tumor.

Thus, the adenovirus vectors of the present invention can be administered in one, at least two, three or more doses, with intervals therebetween sufficient for antibody formation, without causing a dose-dependent antiviral antibody response. Such intervals are typically 21-28 days, but may be as few as 1 or 2 days, or as many as 7 days, 10 days, 2 weeks, three weeks, four, six, eight ten or more weeks. Thus, according to another aspect of some embodiments of the present invention there is provided a method for administering a therapeutically effective amount of a therapeutic

composition comprising an adenoviral vector to a subject in need thereof comprising administering the composition to the subject at least twice, wherein the administration does not induce a dose-dependent increase in antibodies against the adenoviral vector in the subject. According to another aspect of one embodiment of the present invention,
5 the time between administration between a first dose and an at least second dose is sufficient for anti-Ad5 antibody formation.

In yet another embodiment, the adenovirus vectors of the present invention are effective when administered to subjects having elevated levels of serum anti Ad5 antibodies. In some particular embodiments the anti-Ad5 antibody levels are elevated
10 compared to the subjects pre-dosing baseline anti-Ad5 levels. In yet other embodiments, the adenovirus vectors of the present invention are detected in the blood of the subjects having elevated anti-Ad5 antibody levels are compared to the subjects pre-dosing baseline anti-Ad5 levels, at day 4 post-administration, day 7 post-administration, day 15 post-administration, day 21 post-administration, day 28 post-administration, day 37 post-administration, day 56 post-administration or day 112 post-administration or more. Such anti-Ad5 antibodies can be neutralizing antibodies, total
15 anti-Ad5 antibodies, or a specific anti-Ad5 antibody subtype, such as anti-Ad5 IgG.

Thus, in some embodiments, the adenovirus is detected in the blood of the subject at least about 4 days post administration. According to other embodiments an
20 amount of serum anti-adenovirus antibodies is increased following the administering, and the adenovirus is detected in the blood of the subject at least about 21 days post administration.

It is expected that during the life of a patent maturing from this application many relevant chemotherapeutic agents will be developed and the scope of the term
25 chemotherapeutic agent is intended to include all such new technologies *a priori*.

As used herein the term "about" refers to $\pm 10\%$.

The terms "comprises", "comprising", "includes", "including", "having" and their conjugates mean "including but not limited to".

The term "consisting of" means "including and limited to".

30 The term "consisting essentially of" means that the composition, method or structure may include additional ingredients, steps and/or parts, but only if the

additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.

As used herein, the singular form "a", "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a compound" or
5 "at least one compound" may include a plurality of compounds, including mixtures thereof.

Throughout this application, various embodiments of this invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible
10 limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well
15 as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.

Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases "ranging/ranges between" a first indicate number and a second indicate number and "ranging/ranges
20 from" a first indicate number "to" a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.

As used herein the term "method" refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners,
25 means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.

As used herein, the term "treating" includes abrogating, substantially inhibiting, slowing or reversing the progression of a condition, substantially ameliorating clinical or
30 aesthetical symptoms of a condition or substantially preventing the appearance of clinical or aesthetical symptoms of a condition.

It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided
5 separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.

Various embodiments and aspects of the present invention as delineated
10 hereinabove and as claimed in the claims section below find experimental support in the following examples.

EXAMPLES

Reference is now made to the following examples, which together with the above
15 descriptions illustrate some embodiments of the invention in a non limiting fashion.

Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, "Molecular Cloning: A laboratory Manual" Sambrook et al., (1989); "Current Protocols in Molecular Biology" Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., "Current Protocols in Molecular Biology", John Wiley and Sons, Baltimore, Maryland (1989); Perbal, "A Practical Guide to Molecular Cloning", John Wiley & Sons, New York (1988); Watson et al., "Recombinant DNA", Scientific American Books, New York; Birren et al. (eds) "Genome Analysis: A Laboratory
20 Manual Series", Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998); methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; "Cell Biology: A Laboratory Handbook", Volumes I-III Cellis, J. E., ed. (1994); "Culture of Animal Cells - A Manual of Basic Technique" by Freshney, Wiley-Liss, N. Y. (1994), Third Edition; "Current Protocols in Immunology" Volumes I-III
30 Coligan J. E., ed. (1994); Stites et al. (eds), "Basic and Clinical Immunology" (8th Edition), Appleton & Lange, Norwalk, CT (1994); Mishell and Shiigi (eds), "Selected Methods in Cellular Immunology", W. H. Freeman and Co., New York (1980);

available immunoassays are extensively described in the patent and scientific literature, see, for example, U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521; "Oligonucleotide
5 Synthesis" Gait, M. J., ed. (1984); "Nucleic Acid Hybridization" Hames, B. D., and Higgins S. J., eds. (1985); "Transcription and Translation" Hames, B. D., and Higgins S. J., eds. (1984); "Animal Cell Culture" Freshney, R. I., ed. (1986); "Immobilized Cells and Enzymes" IRL Press, (1986); "A Practical Guide to Molecular Cloning" Perbal, B., (1984) and "Methods in Enzymology" Vol. 1-317, Academic Press; "PCR
10 Protocols: A Guide To Methods And Applications", Academic Press, San Diego, CA (1990); Marshak et al., "Strategies for Protein Purification and Characterization - A Laboratory Course Manual" CSHL Press (1996); all of which are incorporated by reference as if fully set forth herein. Other general references are provided throughout this document. The procedures therein are believed to be well known in the art and are
15 provided for the convenience of the reader. All the information contained therein is incorporated herein by reference.

Example I

Efficacy of Ad5PPE-1-3X-fas chimera in Lewis Lung Carcinoma Model

In order to evaluate effective dosage ranges Ad5PPE-1-3X-fas chimera
20 adenovirus for treatment of solid tumors, metastatic tumors were induced in the mouse Lewis Lung Carcinoma model, and a range of doses of Ad5PPE-1-3X-fas chimera adenovirus (SEQ ID NO: 10) administered systemically.

MATERIALS AND EXPERIMENTAL METHODS

Construction and cloning of the viral vector:

25 The vector was constructed using a backbone containing most of the genome of adenovirus type 5, as well as partial homology to an adaptor plasmid, which enables recombination.

The E1 early transcriptional unit was deleted from the backbone plasmid, and further modified by deleting the pWE25 and the Amp resistance selection marker site.

30 The adaptor plasmid, containing sequences of the Ad5, CMV promoter, MCS, and SV40 polyA was modified to delete deleting the CMV promoter, and the PPE-1 promoter and Fas-c fragment were inserted by restriction digestion.

The modified PPE-1 promoter (PPE-1-3X, SEQ ID NO: 12) and the Fas-chimera transgene (Fas-c, SEQ ID NO: 4) were utilized for construction of the adenoviral vector. The PPE-1- (3X)-Fas-c element (2115bp) was constructed from the PPE-1- (3X)-luc element. This element contains the 1.4kb of the murine preproendothelin PPE-1-(3X) promoter, the Luciferase gene, the SV40 polyA site and the first intron of the murine ET-1 gene, originated from the pEL8 plasmid (8848bp) used by Harats et al (Harats D. et al., JCI, 1995). The PPE-3-Luc cassette was extracted from the pEL8 plasmid using the BamHI restriction enzyme. The Luciferase gene was substituted by the Fas-c gene [composed of the extra cellular and intra membranal domains of the human TNF-R1 (Tumor Necrosis Factor Receptor 1, SEQ ID NO: 2) and of the Fas (p55) intracellular domain (SEQ ID NO: 3) (Boldin et al, JBC, 1995)] to obtain the PPE-1-3x-Fas-c cassette.

PPE-1(3x)-Fas-c Plasmid - The cassette was further introduced into the backbone plasmid by restriction digestion, resulting with the PPE-1(3x)-Fas-c plasmid.

Adaptor-PPE-1(3x)-Fas-c Plasmid - The PPE-1-3x-Fas-c element was extracted from the first generation construct PPE-1-3x-Fas-c plasmid, and was amplified with designated PCR primers introducing SnaB1 and EcoR1 restriction sites at the 5'-and-3'-end respectively. These sites were used to clone the PPE-Fas-c fragment into the adaptor plasmid digested with SnaB1 and EcoR1, resulting in the adaptor-PPE-1-3x-Fas-c used for transfection of the host cells (for example, PER.C6 cells).

Lewis Lung Carcinoma model

Freshly harvested D122 Lewis Lung Carcinoma (LLC) cells (5×10^5 per mouse) were administered to C57BL/6 mice (3 months old), by subcutaneous injection into the foot pad. Primary tumors developed in the feet in about 14 days. When tumors reached a diameter of at least 7 mm, the mice were anesthetized and the distal segment of the limb was amputated. Five days after limb amputation, mice were randomized to one of the following groups:

	Treatment	Dose- virus particles (vp/mouse)
Group 1	Ad5PPE-1-3X-fas chimera adenovirus	10^{11}
Group 2	Ad5PPE-1-3X-fas chimera adenovirus	10^{10}
Group 3	Ad5PPE-1-3X-fas chimera adenovirus	10^9

	65	
Group 4	Ad5PPE-1-3X-fas chimera adenovirus	10^8
Group 5	Ad5PPE-1-3X-fas chimera adenovirus	10^7
Group 6	Ad5PPE-1-3X-fas chimera adenovirus	10^6
Group 7	Vehicle	0

5

Vehicle = PBS, 10% glycerol

Viruses were intravenously injected to the mouse tail. Mice were sacrificed upon death of 5 control (vehicle injected) mice (approximately 24 days after virus/control administration). Mice in which the primary tumor re-emerged after treatment, were withdrawn from the study. Upon sacrifice, animal's lungs were removed, washed and weighed, and blood was collected for liver function testing.

Liver and tumor tissues were cut and frozen in 4% formaldehyde or in OCT compound for histological analysis by hematoxylin-eosin staining or anti PECAM1 (anti- CD31) staining, respectively. Tumor weight differences were evaluated using the Mann-Whitney U-test.

The purpose of this study was to evaluate the dose dependent efficacy of Ad5PPE-1-3X-fas chimera adenovirus and to assess the minimal effective dose.

Results

Clinically significant doses (10^6 to 10^{11} vp/mouse) of Ad5PPE-1-3X-fas chimera adenovirus do not cause non-specific systemic effects

Mortality was observed in all groups prior to scheduled sacrifice with no dose response trend. Clinical signs of surviving mice did not reveal any abnormalities. No dose response trend was observed in mice weights.

No statistical significant differences were observed in the kidney function in all groups, except for an increase in uric acid observed at the lowest dose cohort on day 5 post dosing. No statistical significant differences were observed in the SGOP and SGPT levels of treated vs. non treated mice.

Macroscopic examination at necropsy (brain, liver heart, spleen, gonads, kidneys, small intestine, lungs), did not reveal any abnormalities except for metastases found in the lungs. No statistical differences were found in the weight of organs between groups (liver, spleen, small intestine, heart, kidney, lung, and brain), except for the heart and spleen where an increase (not dose dependent) in the weight was observed in mice treated with adenovirus compared to the untreated mice.

Microscopic observations (on the lung, liver and heart) showed mild to moderate inflammation and regenerative changes of the liver following treatment with 10^8 - 10^{11} vp/mouse.

5 ***Ad5PPE-1-3X-fas chimera adenovirus (10^8 to 10^{11} vp/mouse) suppresses metastatic tumor growth***

FIGs. 1A-1C show exemplary lungs of treatment and control groups, at the completion of the study. In the lung, large metastases were found in mice treated with vehicle (FIG. 1A). These metastases were reduced in a dose dependent fashion in Ad5PPE-1-3X-fas chimera adenovirus-treated mice (FIGs. 1B-1C), with the strongest
10 effect in the highest dose (10^{11} vp/mouse) cohort (FIG. 1C), in which most of the lungs appeared to be normal or with only small metastases. This effect decreased to non observable levels at low titers of the virus (10^7 vp/mouse and 10^6 vp/mouse). The protective, anti-tumor effect of the Ad5PPE-1-3X-fas chimera adenovirus was confirmed by the difference in weight of the lungs of the Ad5PPE-1-3X-fas chimera
15 adenovirus-treated mice, which was significantly reduced when compared to control mice but diminished to non observable level at low virus titers (FIG. 1D).

Thus, a single, systemic injection of a clinically significant amount of Ad5PPE-1-3X-fas chimera adenovirus was highly effective in reducing the tumor burden in Lewis Lung Carcinoma model in a dose dependent fashion. 10^{11} vp/mouse resulted in a
20 70% decrease in tumor burden. No efficacy of treatment was observed at the lowest doses (10^6 vp/mouse- 10^7 vp/mouse).

Example II

Administration of Ad5PPE-1-3X-fas chimera in the clinical setting

In order to determine the safety and efficacy of administration of AD5PPE-1-3X-fas-chimera in the clinical setting, outcomes such as toxicity, adverse effects,
25 antibody titer, biodistribution, disease progression and disease recurrence and survival were monitored in subjects with solid primary and metastatic tumors receiving intravenous infusion of a range of doses of the Ad5PPE-1-3X-fas chimera adenovirus vector.

MATERIALS AND EXPERIMENTAL METHODS

Subject population:

Subjects with advanced and/or metastatic solid organ cancer 18 years of age and older, without remaining options for standard curative or palliative measures are
5 enrolled.

Criteria for subject's inclusion in the treatment group are:

1. Subjects at least 18 years of age;
2. Histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer
10 effective;
3. Karnofsky performance status of $\geq 70\%$;
4. Adequate haematological profile: ANC $>1500/\mu\text{l}$, hemoglobin $\geq 10\text{g/dl}$, platelets $>100,000/\mu\text{l}$, and INR within normal limits;
5. Adequate renal function (CCT $>60\text{ mL/min/1.73 m}^2$);
- 15 6. Adequate hepatic function: (ALT and AST $<2.5 \times \text{ULN}$) and total bilirubin within normal limits.

Criteria for subject's exclusion from the treatment group are:

1. Recent cardiac event (within 12 months) or active cardiac/vascular disease;
2. Recent surgery (within 4 weeks);
- 20 3. Proliferative retinopathy;
4. Liver disease;
5. CNS metastasis;
6. Recent anti-angiogenic therapy (within 6 weeks);
7. Current/recent (within 4 weeks) immunosuppressive therapy;
- 25 8. Recent chemo/radiotherapy or investigational agent (within 4 weeks);
9. Uncontrolled co-morbidity.

Composition: Ad5-PPE-1-3X-fas-chimera

Ad5-PPE-1-3X-fas-chimera (SEQ ID NO: 10) is a vascular disruptive gene therapeutic, consisting of a non-replicating adenovirus vector (Ad5, E1 deleted, SEQ ID
30 NO: 1) which contains a modified murine pre-proendothelin promoter (PPE-1-3x, SEQ ID NO: 12) and a fas-chimera transgene [Fas and human tumor necrosis factor (TNF) receptor](SEQ ID NO: 4). It is formulated as a sterile vector solution and supplied

68

frozen (below -65°C), in single use vials. Each vial contains 0.5 mL of vector solution at a specific viral titer.

Dosage

Dose escalation is done by cohort as follows:

5	Dose (virus particles)	Subjects per Cohort
	Cohort 1	1x10 ¹⁰
	Cohort 2	3x10 ¹⁰
	Cohort 3	1x10 ¹¹
	Cohort 4	3x10 ¹¹
10	Cohort 5	1x10 ¹²
	Cohort 6	3x10 ¹²
	Cohort 7	1x10 ¹³

Since no dose limiting toxicity was observed after dosing 3 subjects in each of the first 6 cohorts, 9 additional subjects were enrolled into cohort 6 according to the protocol and after approval of the Institutional Review Boards. 27 subjects (3 in each of cohorts 1-5 [total of 15 subjects] and 12 in Cohort 6) were treated. Since no dose limiting toxicity was observed, 6 more patients were enrolled to cohort 7. A total of 33 subjects were treated. One case of NCI Grade 3 fever, shortly following administration of the highest dose (cohort 7), was observed.

The Ad5-PPE-1-3X-fas-chimera is administered as an intravenous infusion. The same drug volume and saline volume were used for each subject within each cohort, and each subject was infused with the same volume of the drug. The infusion duration was between 3 and 5 minutes in cohorts 1-5 and 15 minutes in cohort 6 and 50 minutes for cohort 7. In general, these numbers reflect the instructions specified in the pharmacy manual provided with the study.

Subject evaluation criteria

Biodistribution: Blood and urine samples were collected prior to dosing, at the end of the infusion (blood samples only), 3 hours, 6 hours, and on days 4(±1), 7(±1), 14(±1), 28(±2) and at day 56(±3) for evaluation of levels of virus DNA (in blood and urine) and the expression of the transgene (messenger RNA in blood). Only samples with detectable viral DNA are tested for transgene expression.

Antibodies: Serum samples were collected prior to dosing for analysis of total anti-Ad-5 Ig, IgG and neutralizing anti-Ad5 antibody levels, and on day 28 and day 56 for analysis of total anti-Ad-5 Ig, IgG anti-Ad5 antibody levels.

Ad-5-IgG assay: Serum samples were diluted and analyzed for adenovirus-specific immunoglobulin G (IgG) by ELISA. For the ELISA, 96 well flat bottomed, high-binding Immulon-IV plates were coated with 50 ul Ad5-antigen (Upenn Vector Core) at (5×10^8 particles/well) in pH 9.5 carbonate buffer (coating buffer) overnight at 4°C, washed two times in PBS/0.05% Tween, blocked in PBS/1% HSA for 1 hour at 24°C, and then washed two times in PBS/0.05 Tween. Appropriately diluted (3-fold) samples were added to antigen-coated plates and incubated for 4 hours at room temperature. Plates were washed three times with PBS/0.05% Tween and incubated with peroxidase conjugated goat anti-human Ig (1:5000 dilution, Jackson ImmunoResearch Laboratories, Inc.) for 1 hour at room temperature. Plates were washed three times as above and TMB substrate (Sigma Chemical Co., St Louis, MO) is added at 100 ul/well for 30 minutes. Reaction was stopped when 100 ul 2N H₂SO₄ was added, and optical densities were read at 450nm on a VersaMAX tunable microplate reader (Molecular Devices). Titer is the dilution achieving 0.5 maximum OD.

Neutralizing anti-Ad5 antibodies assay: The ability of serum to block adenovirus infection of Hela cells (ATCC) in vitro was analyzed utilizing adenovirus expressing green fluorescent protein (GFP) as a reporter (Upenn Vector Core). Various dilutions of test sera and, as a control/standard, pooled AB sera (Sigma), pre-incubated with moi of 1000 of reporter viruses for 1 hour at 37°C were added to 90% confluent cell cultures. Cells were incubated for 16 hours and expression of GFP quantified by fluorimaging using the Victor² (Wallace/PerkinElmer) and visually. The neutralizing titer of the sera was calculated as the reciprocal dilution of serum with 50% of the maximum fluorescence at 1000 MOI.

Angiogenic biomarkers: Blood samples were collected prior to dosing, and at the following visits thereafter, for evaluation of von Willebrand Factor levels and TNFα levels, on days 4±1, 7±1, 14±1, 28 ± 2 and at day 56 ±3 post dosing.

Cytokine levels: Peripheral blood cytokine (see Table 6 below) levels were measured in cohort 6 patients at baseline, and at the following times after dosing with Ad5-PPE-1-3X-fas-chimera, at 6 hours, 4 days, 7 days, 14 days, 28 days, and 56 days

post dosing.

Tumor response: The possible effect of the drug treatment on tumor response was evaluated by measuring the tumor dimensions on CT (or MRI) scans according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria at screening and at week 4 and 8 post dosing, or according to RECIST criteria at screening, baseline day - 1/0 and at day 7 ± 1 , week 4 (day 28 ± 2) and week 8 (day 56 ± 3) post dosing.

RECIST criteria:

Evaluation of target lesions

Complete Response (CR): Disappearance of all target lesions.

10 *Partial Response (PR):* At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD.

Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.

15 *Progressive Disease (PD):* At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions

Evaluation of non-target lesions

20 *Complete Response (CR):* Disappearance of all non-target lesions and normalization of tumor marker level

Incomplete Response/ Stable Disease (SD): Persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits

Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions

25 **Evaluation of best overall response**

The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). In general, the patient's best response assignment will depend on the achievement of both measurement and confirmation criteria

30 Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be

classified as having "symptomatic deterioration". Every effort should be made to document the objective progression even after discontinuation of treatment.

In some circumstances it may be difficult to distinguish residual disease from normal tissue. When the evaluation of complete response depends on this determination, it is recommended that the residual lesion be investigated (fine needle aspirate/biopsy) to confirm the complete response status.

RESULTS:

Patient Disposition

Disposition of patients is summarized herein: 26 subjects in 6 cohorts were enrolled between November 2007 and August 2009, and a total of 33 subjects had enrolled by December 2010. Each of the 3 subjects in cohorts 1-4 discontinued the study prematurely: 2 subjects due to death, 8 due to voluntary subject drop out, and 2 to pursue other treatment protocols. Of the 2 deaths, patient no. 1 was reported as a serious adverse effect, whereas patient no.9 died 88 days post dosing and therefore, as defined in the protocol, was not reported as an SAE. In cohort 5, one subject completed the study (up to day 56), one withdrew prior to day 56 and one designated as "Other" withdrew due to disease progression. Five cohort 6 patients completed the study, 5 withdrew due to disease progression (2 had brain metastases), and one died approximately 2 months after receiving study treatment. Four cohort 7 patients completed the study; two withdrew due to disease progression.

Among the initial 33 patients enrolled, 31 attended the day 28 visit, and 19 attended the day 56 visit. Subjects were contacted for follow-up every 2-3 months thereafter for a period of up to 3 years or more post dosing for monitoring.

Patient Population Profile

Demographics

Demographics and baseline characteristics are summarized in Table 1 that follows. Overall, 54 % of the subjects were male and 46% female. All but five of the subjects (4-Hispanic and 1-Asian) enrolled were Caucasian. The mean age of the subjects enrolled was 58.5 years, with the youngest 35.1 years old and the oldest 74.1 years. The mean Karnofsky score at entry was 85.4; the lowest score at entry was 70 (the minimum permitted by the protocol inclusion criteria) and the highest 100.

Table 1: Demographics/Baseline Characteristics Summary

Demographic/Baseline Characteristic	Number	%
Gender		
Male	14	53.8
Female	12	46.2
Race		
Caucasian	21	80.8
Asian	1	3.8
Hispanic	4	15.4
Age, mean (years)	58.5	-
Karnofsky score (mean)	85.4	-

Medical History

5 Medical history is summarized herewith: As expected in a patient population with a mean age of 58.5 years, all subjects had other medical conditions at baseline. The most common medical conditions (defined as those present in at least three subjects) were: hypertension (13 subjects); fatigue (10 subjects); constipation (6 subjects); diarrhea and anemia (5 subjects each); nausea, GERD, hypercholesterolemia, 10 hyperlipidemia, seasonal allergy, and cholecystectomy (4 subjects each); abdominal pain, cough, hypothyroidism, low back pain, and pneumonia (3 subjects each).

Primary Diagnosis

The frequency of tumor type at baseline is summarized in Table 2 that follows. The most frequent tumor types were colorectal adenocarcinoma, non-small cell lung 15 cancer, melanoma, sarcoma, and carcinoid/neuroendocrine. One subject each had the following tumor types: transitional cell carcinoma of the bladder, cancer of the distal esophagus, Merkle cell carcinoma, lung small cell carcinoma, renal cell carcinoma, gastro-intestinal stromal tumor, testicular sex cord tumor, and papillary thyroid carcinoma.

Table 2: Primary Tumor Diagnoses (cohorts 1-7)

Tumor Type	Total number	Number at cohort 6-7
Colorectal Adenocarcinoma	11	5
Carcinoid/Neuroendocrine	4	4
Non-small cell lung cancer	3	1
Renal Cell Carcinoma	3	3
Melanoma	2	1
Sarcoma	2	0
Thyroid cancer	2	2
Esophageal Adenocarcinoma	1	1
Merkle cell carcinoma	1	1
Bladder/Transitional Cell	1	0
Lung small cell carcinoma	1	0
G-I stromal tumor	1	0
Testicular/ sex cord tumor	1	0

Prior Chemotherapy

5 Prior chemotherapy is summarized by the number and frequency of chemotherapy herewith: All subjects enrolled in the trial had previous chemotherapy with multiple agents, with 3.7 (range 1-8) mean previous chemotherapy lines. The most frequently utilized medications were: 5-FU (10.9%), Bevacizumab (10.9%), Capecitabine (8.6%), Leucovorin (8.0%), Irinotecan (8.0%), Cetuximab (5.2%),
 10 Oxaliplatin (4.6%), Temozolomide (3.4%), Cisplatin (3.4%), Folfox (3.4%), Sunitinib (2.9%), Dacarbazine (2.3%), and Docetaxel (2.3%). Most subjects (16/26, 61.5%), received at least one prior anti-angiogenic agent: Bevacizumab (12 patients), Sunitinib (4 patients), and Sorafenib (2 patients). The use of these chemotherapeutic agents reflects the types of tumors occurring in this patient population.

Other Anti-tumor Interventions

15 Essentially all subjects had previous surgery for their tumor. The details of the surgery and of other anti-tumor interventions, excluding chemotherapy, are summarized herewith: The average number of previous surgical procedures related to the tumor was >2/subject, with a few subjects having had 4 surgical procedures. Also, 12 of the

subjects had previous radiation therapy. All of the courses of radiation therapy occurred at least 8 months prior to study treatment except for subject no. 13, whose last course of radiotherapy ended about 4.5 months previously. The protocol required no radiotherapy for at least 4 weeks prior to enrolment.

5 Tumor Evaluation at Baseline

All subjects had CT evaluations of tumor target lesions with measurement of tumor size at baseline for subsequent comparison post-treatment. For these measurements, the longest diameter of each target lesion was utilized.

Summary of Patient Population

10 Most subjects enrolled in this study were Caucasian with an almost equal gender distribution and a mean age of 58.5 years. The mean entry Karnofsky score was 85.4, and all subjects had concurrent medical conditions. The most frequent tumor types were colorectal adenocarcinoma, non-small cell lung cancer, melanoma, sarcoma and carcinoid/neuroendocrine. All subjects enrolled in the trial had previous cancer-related
15 surgery and chemotherapy with multiple agents, the most common of which were 5-FU, Bevacizumab, Capecitabine, Leucovorin, Irinotecan, Cetuximab, Oxaliplatin, Temozolomide, Cisplatin, Folflox, Sunitinib, Dacarbazine, and Docetaxel; the majority also had previous anti-angiogenic therapy and radiation therapy.

SAFETY EVALUATIONS

20 Adverse Events

The incidence and frequency of adverse events are summarized in Table 3 that follows: Overall, events experienced by at least 4 (15.4%) subjects included: pyrexia (50%); fatigue (46.2%); prolonged aPTT (38.5%); chills, hyponatremia and decreased hemoglobin (26.9% each); constipation (23.1%); nausea, vomiting, anorexia, and
25 dyspnoea (19.2% each); lymphopenia, elevated aspartate aminotransferase, hyperglycemia, myalgia, and hyperhidrosis (15.4% each). Pyrexia and chills occurred at higher doses only (cohorts 4-6). In cohort 6, 9 of 11 subjects experienced pyrexia and 6 of 11 also had chills. In cohort 7, one subject experienced a grade 3 fever. In all patients, the pyrexia and chills occurred on the day of study treatment (post-infusion),
30 were transient, and resolved within 24 hours.

Table 3: Most Frequent Adverse Events (cohort 1-6)

Adverse Event	Number Patients	%
Pyrexia	13	50.0
Fatigue	12	46.2
aPTT Prolonged	10	38.5
Chills	7	26.9
Hyponatremia	7	26.9
Hemoglobin decreased	7	26.9
Constipation	6	23.1
Nausea	5	19.2
Vomiting	5	19.2
Anorexia	5	19.2
Dyspnea	5	19.2
Lymphopenia	4	15.4
AST Increased	4	15.4
Hyperglycemia	4	15.4
Myalgia	4	15.4
Hyperhidrosis	4	15.4

Most of the events of pyrexia (11 of 14) and chills (7 of 8) that occurred in the higher dose groups were considered possibly, probably or definitely related to study drug. The only other events considered definitely related to study drug included two events of nausea and one event each of anemia, vomiting, fatigue, hyperhidrosis, anorexia, and headache. None of these events were classified as NCI Grade 3 or higher. Thus, no dose limiting toxicities had occurred. Most of the other adverse events were considered unrelated or unlikely related to study drug.

Of the most common adverse events, fatigue was considered unrelated in 9/12 subjects and unlikely in one subject; prolonged aPTT unrelated in 7/10 subjects; decreased hemoglobin was considered unrelated in all 7 subjects; and constipation unrelated in all occurrences. Note: The local investigator commented that the aPTT local lab test is highly sensitive (as used for screening for lupus anti-coagulant); indeed, all aPTT elevation adverse events occurred in patients of that clinic.

The following Grade 3 or higher adverse events were reported; all were considered unrelated or unlikely related to the investigational drug: Subject no.001 (cohort 1): Grade 3 disease progression; subject no.007 (cohort 3): Grade 3 hyponatremia and hyperkalemia; subject no.008 (cohort 3): Grade 3 hemoglobin decreased; subject no.009 (cohort 3): Grade 3 fatigue; subject no.013 (cohort 4): Grade 3 hypokalemia, hyponatremia, hypochloremia, and fatigue; subject no.025 (cohort 6): Grade 4 suicidal ideation; subject no.027 (cohort 6): Grade 3 weakness; subject no.033 (cohort 6): Grade 4 abdominal pain and Grade 3 hyperglycemia; subject no.035 (cohort 6): Grade 3 elevated total bilirubin, elevated AST, elevated ALT, and elevated alkaline phosphatase; and subject no.036 (cohort 6): Grade 3 hyponatremia. Disease progression in subject no.1 was a serious adverse event; all of the other events were not serious. All of the subjects with Grade 3 hyponatremia (no.007, no.013, and no.036) with or without other Grade 3 metabolic events had gastro-intestinal malignancies.

Serious Adverse Events

No serious adverse events (SAEs) related to treatment with the study drug were reported.

Laboratory Testing:

Hematology and Coagulation

No significant trends in mean changes occurred after treatment in any of the cohorts for the following tests: basophil count, eosinophil count, lymphocyte count, hematocrit, hemoglobin, neutrophil count, platelet count, RBC, and PT. A trend for increased aPTT after treatment was observed in each cohort, although most mean values remained within the normal range. Mean and median white blood cell counts (WBC) tended to decrease in cohorts 3-6 from the day of dosing to day 4, but individual values remained within normal limits in all subjects except for two subjects in cohort 6: (1) subject no.26 had a low WBC (3700 K/ μ L) on the day of dosing that decreased to 2700

K/ μ L on Day 4 but then increased to at least 4000 K/ μ L for the remainder of the study and (2) subject no.32 had a normal WBC of 6.3 K/ μ L on the day of dosing that decreased to 4.5 K/ μ L on Day 4 and then varied between 4.3 and 6.0 K/ μ L.

Values for hematology tests that were considered clinically significant findings include:

Subject no.8 (in cohort 3) had a hematocrit of 32.3% and hemoglobin of 10.6 g/dL on the day of dosing that gradually decreased over time to 25.5% and 7.9 g/dL, respectively, on day 28. This subject's platelet count was 443,000 K/ μ L on the day of dosing and increased to 516,000 K/ μ L on day 28.

Subject no.14 (in cohort 4) had a hematocrit of 34.2% and hemoglobin of 10.8 g/dL at screening; these values gradually decreased over time to 26.4% and 8.3 g/dL, respectively, on day 14. This subject's aPTT was 33.1 seconds at screening, 34.4 seconds at day 4, and then increased to 49.6 seconds at day 7 and 53.6 seconds at day 14.

Subject no.33 (in cohort 6) had a hematocrit of 38.3% at screening and 33.1% on the day of dosing and hemoglobin of 12.3 g/dL at screening and 10.9 g/dL on the day of dosing; both stabilized for the duration of the study. This subject's platelet count was 116,000 K/ μ L on the day of dosing and decreased to 89,000 K/ μ L on day 4 but subsequently increased to 129,000 K/ μ L on Day 28. The PTT was normal at 31 seconds on the day of dosing but increased to 44.5 and 48.2 seconds on Days 14 and 28, respectively.

Summarizing the shift in hematology and coagulation lab values from the day of dosing to day 28 for the combined cohorts: The shift did not suggest any trend for values to shift to below or above the normal range at 28 days post-treatment. In particular, for both hematocrit and hemoglobin, no trend was observed for values to shift to below the normal range.

Chemistry

Summary of serum chemistry testing: No significant trends in median changes occurred after treatment in any of the cohorts for the following tests: ALT, AST, albumin, alkaline phosphatase, calcium, creatinine, glucose, potassium, sodium, bilirubin, total protein, and BUN. Mean levels of the following were increased, due to a high level observed in one subject: ALT and AST in cohort 6 at Day 28 due to levels of

406 U/L and 232 U/L, respectively, in subject no.35; total bilirubin in cohort 6 at Day 28 due to a level of 7.4 in subject no.35. Very high alkaline phosphatase levels in the following subjects accounted for elevated mean levels in their respective cohorts: subjects no.4 (cohort 2), no.24 (cohort 5), and no.22, 26, 30, 35, and 36 (all in cohort 6).

5 Chemistry tests: Subjects no.4 and no.22 had elevated ALT and AST tests on the day of dosing that subsequently decreased/normalized. Subject no.35 in cohort 6 had elevated levels of ALT and AST at day 28: 406 U/L and 232 U/L, respectively, but these levels normalized by day 56. This subject (no.35) was hospitalized for bile duct obstruction due to tumor progression and also had markedly elevated levels of total
10 bilirubin, 7.4 mg/dL, and alkaline phosphatase, 1176 U/L, at day 28. Otherwise, all ALT and AST elevations were <3X the upper limits of normal and tended to be sporadic. No subject other than no.35 had an abnormal total bilirubin level during participation in the study. Elevated alkaline phosphatase on the day of dosing was common, presumably due to tumor and/or metastatic disease, but a significant
15 progressive increase in this lab test only occurred in two subjects (no.4 who had a level of 383 U/L at screening, 493 U/L on the day of dosing and 609 U/L at Day 28 and no.36 who had a level of 163 U/L on the day of dosing and 377 U/L on Day 28). No subjects developed clinically significant post-treatment levels for any of the other chemistry tests.

20 Summarizing the shift in serum chemistry values from the day of dosing to day 28 for the combined cohorts: 5/15 subjects who had a normal level at the day of dosing had a low level of serum sodium on day 28. However, the sodium levels were abnormal only intermittently, usually only slightly below normal, and not clinically significant. The shift tables did not suggest any other trend for values to shift to below or above the
25 normal range at 28 days post-treatment.

Urinalysis

The frequency of an abnormality on urinalysis on the day of dosing (89.5%) and at screening (76.0%) was high, but no trends were observed at the post-dosing visits. A review of the data indicated that no clinically significant abnormalities occurred on
30 urinalysis, although a few subjects had small amounts of protein in their urine, and subject no.30 in cohort 6 had 2+ proteinuria at day 28.

Antibodies to Adenovirus 5

Serum samples from subjects tested for antibodies to Adenovirus 5 (total and IgG); increase in titers between pre- and post-dose for IgG antibodies are summarized in Table 4 and Figure 11. The post-dose samples were collected at day 28 or 56 in all but 3 subjects; these 3 had post-dose samples tested earlier due to the non-availability of samples at day 28. All post-dose IgG antibody titers increased at least 7-fold; 8 of 33 subjects had at least a 100-fold increase in IgG antibodies over the pre-dose titer. All post-dose total antibody titers to adenovirus 5 increased at least 5-fold; 10 of 26 subjects had at least a 625-fold increase in total antibodies over the pre-dose titer. There was no correlation between fold increase (total and IgG antibody titers) and dose level ($P > 0.05$, Pearson and Spearman correlation tests). Data collected at day 56 for cohort 7 subjects indicated a trend of decreased IgG levels, compared to day 28 (see Table 4 that follows).

Table 4: Summary of Anti-Adenovirus 5 Increase in IgG Antibody Titers and Total Antibody Titers

Cohort	Patient	Anti-Ad5 Titer			Anti-Ad5 IgG Titer			Post-dose (day 56)
		Pre-dose	Post-dose (day 28)	Fold increase	Pre-dose	Post-dose (day 28)	Fold increase	
1	1	62500	1562500	25	3500	43,740	12	
	2	2500	1562500	625	400	43,740	109	
	3	12500	1562500	125	1500	43,740	29	
2	4	2500	62500	25	300	5,500	18	
	5	500	12500	25	180	1500	8	
	6	2500	7812500	3125	350	35,000	100	
3	7	2500	12500	5	600	4100	7	
	8	2500	312500	125	950	43,740	46	
	9	2500	7812500	3125	1000	29,000	29	
4	10	12500	1562500	125	420	20,000	48	
	13	2500	1562500	625	200	9,000	45	
	14	2500	1562500	625	650	11,000	17	
5	20	12500	312500	25	90	13,000	144	
	21	2500	312500	125	300	14,000	47	
	24	12500	312500	25	1,200	12,000	10	
6	22	12500	1562500	125	850	11,500	14	
	25	2500	312500	125	850	11,000	13	
	26	2500	312500	125	70	11,000	157	
	27	12500	7812500	625	540	43,740	81	
	28	ND	312500	ND	700	43,740	62	
	29	12500	312500	25	120	18,000	150	
	30	62500	7812500	125	6000	43,740	7	
	32	2500	1562500	625	200	43,740	219	
	33	2500	7812500	3125	500	43,740	87	
	35	2500	62500	25	ND	ND	ND	
	36	2500	7812500	3125	400	30,000	75	

				80				
	38	12500	7812500	625	800	43,470	54	
7	39	62,500	1,562,500	25	800	30000	38	18000
	40	12,500	312,500	25	300	35000	117	22000
	41	62,500	7,812,500	125	200	7500	38	10000
	42	12,500	1,562,500	125	450	5500	12	4500
	43	62,500	1,562,500	25	140	7000	50	5000
	44	12,500	312,500	25	200	22000	110	NA

All subjects were also assessed as to their level of neutralizing Adenovirus 5 antibodies at baseline (Table 5). Results show that 35% had highly elevated baseline levels (>210) and 41% of the subjects had low levels (≤ 18) of neutralizing antibodies.

Table 5: Summary of Anti-Adenovirus 5 Neutralizing Antibody Titers at Baseline

Subject ID	Cohort	Titer	Subject ID	Cohort	Titer
001	1	620	027	6	5
002	1	750	028	6	940
003	1	210	029	6	5
004	2	10.5	030	6	1250
005	2	10.5	032	6	195
006	2	400	033	6	220
007	3	5	035	6	10.5
008	3	380	036	6	5
009	3	210	038	6	620
010	4	1050	039	7	1000
013	4	860	040	7	5
014	4	5	041	7	15
020	5	18	042	7	5
021	5	5	043	7	160
024	5	520	044	7	85
022	6	110			
025	6	210			
026	6	5			

No correlation could be discerned between the presence of neutralizing anti-Ad5 antibodies at baseline and disease progression at days 28 (FIG. 2) or 56 (FIGs. 3A, 3B Table 5) (Pearson Product Moment Correlation; $P > 0.050$; Spearman Rank Order Correlation; $P > 0.050$).

5 **Cytokine levels in peripheral blood in cohort 6**

Peripheral blood cytokine levels were measured in cohort 6 patients at baseline, and at the following times after dosing with AD5-PPE-1-3X-FAS-CHIMERA-: 6 hours, 4 days, 7 days, 14 days, 28 days, and 56 days post infusion. Results are summarized in Table 6 that follows.

10 Table 6: Summary of Mean Peripheral Blood Cytokine Levels in Cohort 6

<u>Cytokine</u>	<u>Baseline</u> <u>(n=10)</u>	<u>6 h</u> <u>(n=10)</u>	<u>D4</u> <u>(n=2)</u>	<u>D7</u> <u>(n=9)</u>	<u>D14</u> <u>(n=9)</u>	<u>D28</u> <u>(n=9)</u>	<u>D56</u> <u>(n=3)</u>
IL-6	10.38	1018.28	2.92	7.2	47.99	12.13	0
IL-8	21.85	181.68	42.6	33.93	43.68	31.59	21.62
VEGF	73.47	54.82	0	147.09	132.77	133.53	0
FGF	11.92	9.95	5.75	20.42	19.55	12.43	7.30
TNF-a	0	1.53	0	0	0	0	0
sTNFRI	1746.44	3143.89	1725.60	2383.03	2706.33	2222.37	1456.77
sTNFRII	5819.81	7509.75	10063.71	7921.62	10155.62	7717.02	5866.12

A significant increase in mean IL-6 levels occurred 6 hours post-infusion; this level returned to baseline by day 4. A smaller increase in TNFRII levels was noted, peaking between days 4 and 14. No major elevations occurred with the other measured cytokines.

Vital Signs

No significant post-treatment trends were observed for systolic BP, diastolic BP, and respiratory rate, and no subject developed any clinically significant abnormalities.

20 Significant elevations in temperature (>38 degrees Centigrade) occurred in 5 subjects at 6 hours post-infusion: one subject in cohort 5: no.20 (38.3 degrees Centigrade) and 4 subjects in cohort 6: no.26 (39.1 degrees Centigrade), no.27 (39.7 degrees Centigrade), no.32 (39.8 degrees Centigrade), and no.36 (39 degrees Centigrade). In each, the temperature had normalized prior to or by day 4 (which was the first recording of temperature following that of 6 hours post-infusion). The mean heart rate was increased to 101.2 beats/minute in cohort 6 at 6 hours post-dosing. This was due to a more rapid heart rate in the subjects that had experienced pyrexia in this

cohort (heart rate of 107-140 beats/minute). Weight is summarized herein: no major change in weight occurred, except for a decrease in mean weight at follow-up (75.0 kg at screening, 75.0 kg at day 56, and 63.5 kg at follow-up).

Physical Exams

- 5 No treatment-related or clinically significant changes on exams are apparent from the data of by-subject physical exams at screening and day 56.

ECGs

- ECG parameters at screening are summarized herein: At screening, 15 subjects had normal ECGs, and 11 had abnormalities that were considered not clinically significant. The original protocol specified that a follow-up ECG should be performed at the day 56 follow-up visit. As most subjects withdrew from the study prior to day 56, in cohorts 1-5 only subject no.7 had a follow-up ECG and this showed ECG changes considered not clinically significant.

- The protocol was later amended to obtain the follow-up ECG at the day 28 visit. In cohort 6, there were 4 follow-up ECGs obtained: two were normal and 2 had minor, non-clinically significant findings with no major changes from the screening ECG.

Biodistribution of Ad5-PPE-1-3X-fas-chimera

- Due to an error, no whole blood samples were drawn for some of the patients in cohorts 5 and 6[3]). Urine samples were tested for 11 of the 12 cohort 6 patients and for the 12 additional patients from lower cohorts tested for levels in blood.

Analysis of the Urine Samples for Presence of Adenovirus:

Maximum levels of Adenovirus Vector DNA detected in urine are summarized in Table 7.

Table 7: Maximum Levels of Adenovirus Vector in Urine (cohorts 1-6)

Cohort	Subject ID	Adenovirus Vector DNA copies/ μ g gDNA
1	001	0
1	002	3.2×10^3 (Day 28)
1	003	5.3 (Day 56)
2	004	6.2×10^2 (3hr)
2	005	0
2	006	0

83

3	007	0
3	008	0
3	009	2.2×10^3 (Day 4)
4	010	5.3 (Day 14)
4	014	1.1×10^3 (6hr)
5	024	5.3 (6hr)
6	022	1.1×10^4 (3hr)
6	025	1.5×10^4 (3hr)
6	026	5.3 (3hr)
6	028	5.3 (3hr)
6	029	1.6×10^7 (3hr)
6	030	4.7×10^5 (3hr)
6	032	5.3 (3hr)
6	033	2.3×10^4 (3hr)
6	035	1.8×10^4 (3hr)
6	036	0
6	038	0

VP- Viral particles; BLQ<20 copies; BLD<1.4 copies

Analysis of the Whole Blood Samples for the Presence of Adenovirus Vector

5 Average levels of Adenovirus Vector DNA, as detected by RT-PCR in whole blood for cohorts 1-6 are summarized over time in Figure 12A. Table 8 that follows shows the median values for cohorts 1-6. Before infusion of the adenovirus vector, none of the patients tested showed amplification of adenoviral gene (below detectable levels). A dose-dependent increase in average maximum levels of adenovirus vector
 10 DNA found in whole blood is evident from the data. At the end of the infusion all patients had individual blood virus levels in the range of 1.9×10^3 and 5.5×10^7 copies/ μ g gDNA, correlating positively with dose received.

In cohort 6 patients (Figure 12A, grey dashed line), average levels of adenovirus decreased from a range of 2.1×10^5 - 5.5×10^7 (end of infusion) to a range of 1.1×10^4 -
 15 2.6×10^5 copies/ μ g gDNA (three hours post infusion, see Figure 12B). Levels of adenovirus continued to decrease 6 hours post infusion and subsequently decreased throughout the final time points. By day 56, Adenovirus DNA levels were either all reduced by at least 2 log-fold, or were undetectable.

Table 8: Presence of Adenovirus Vector in Whole Blood: Median Values

Cohort	Dose vp	Median Adenovirus Vector DNA copies/ μ g gDNA at end of infusion (Maximum)
1	1×10^{10}	1.6×10^4
2	3×10^{10}	4.5×10^5
3	1×10^{11}	1.6×10^5
4	3×10^{11}	1.7×10^6
5	1×10^{12}	6.5×10^6
6	3×10^{12}	2.5×10^7

5

Analysis of the expression levels of fas-chimera transgene in whole blood

None of the 21 subjects tested had detectable levels of transgene cDNA (as determined by RT-PCR, representing blood mRNA levels) in whole blood. However, in one patient 01-036 (esophageal cancer) a sample from a subcutaneous metastasis was tested and detectable levels of adenovirus transgene expression were found in the aspirate on days 4 (1.4×10^5 copies/ μ g RNA) and 28 (3.9×10^5 copies/ μ g RNA) after treatment (Table 9), providing direct evidence of the specificity of the transgene expression in the target tumor tissue.

Table 9: Aspirate from tumor of patient 01-036 (copies/ μ g RNA)

time	Pt no.	cohort	sample	copies
Pre	36	6	Tumor	0.00E+00
Day 4	36	6	Tumor	1.40E+05
Day 28	36	6	Tumor	3.90E+04

15

Summary of Safety Results

No signs of significant safety issues with Ad5-PPE-1-3X-fas-chimera were observed in this study. The maximal therapeutic dose (MTD) was determined to be 10^3 virus particles per dose, in view of a dose limiting toxicity of a NCI grade 3 fever, shortly following dosing at the highest dose tested (cohort 7). Other than abnormal lab results, the most frequent adverse events were pyrexia, fatigue, chills, and constipation. Pyrexia and chills occurred mostly in the higher dose groups and were usually considered related to study medication. Although no trend for hematology values to

20

shift outside the normal range was observed, several subjects had declines in hemoglobin and hematocrit values after study treatment. No clinically significant post-treatment chemistry or urinalysis abnormalities occurred during the study with the exception of a markedly elevated alkaline phosphatase and elevations of ALT, AST, and total bilirubin occurring in a subject with bile duct obstruction due to progression of cancer. No clinically significant post-treatment changes in vital signs were observed, except for the occurrence of fever 6 hours post-infusion in one cohort 5 and 4 cohort 6 subjects; the cohort 6 subjects with fever also had increased heart rates, resulting in a mean increase in heart rate for cohort 6 at 6 hours post-infusion. No treatment-related changes were observed on physical exams or ECGs.

All subjects had pre-dose anti-Adenovirus 5 antibodies (total and IgG) with total antibody titers increasing at least 5-fold post-treatment. Figure 11 shows the anti-Adenovirus 5 antibodies in each of cohorts 1-6, measured at baseline, day 7, day 14 and day 28, and illustrates the tendency of the anti- Adenovirus 5 antibodies to plateau between 7 and 14 days post infusion, despite the variability observed between patients in the baseline antibody titer levels. Levels of anti-Adenovirus 5 antibodies (total and IgG) tended to increase post dosing, peaking on day 28 and tending to decrease by day 56 (FIG. 11). Overall, the fold increase was higher for the total anti-Adenovirus 5 titers than for the IgG titers, but no correlation was discerned between fold increase in anti-Adenovirus 5 antibodies and the dosage level. 34.6% of subjects had highly elevated levels of neutralizing antibodies to Adenovirus 5, measured at baseline, 23.1% had moderately elevated levels, and 42.3% had low levels. However, there was no correlation discernable between neutralizing anti-body titer at baseline and a clinical response (measured as stable disease). A significant increase in mean IL-6 blood levels occurred 6 hours post-dosing with Ad5-PPE-1-3X-fas-chimera; this level returned to baseline by day 4. No major elevations occurred with the other measured cytokines (IL-8, VEGF, FGF, and TNF-alpha).

In most subjects with detectable levels of Adenovirus 5 in the urine, the presence was transient, with levels detectable only within the initial 24 hours after the intravenous (IV) infusion of Ad5-PPE-1-3X-fas-chimera. The Ad5-PPE-1-3X-fas-chimera adenovirus vector was present in high copy numbers in whole blood directly after the IV infusion. The levels of adenovirus vector subsequently decreased with time

in whole blood. Samples with vector present in the whole blood were tested for the expression of the Fas-chimera transgene (RT-PCR for the transgene mRNA). None of the 21 subjects tested had detectable levels of transgene cDNA (cDNA is the RT-PCR reaction product representing blood mRNA levels) in whole blood.

5

PRELIMINARY EFFICACY ASSESSMENT

Disease Progression or Recurrence

Disease progression was assessed according to clinical deterioration and radiographic growth, based on RECIST criteria. In cohorts 1-5, at day 56, 3/14 patients had stable disease. In cohort 6, on day 56 (n=12), 1 PR, 4 SD ("stable disease") and 7
10 had progressive disease. Thus at day 56, 5/12 (42%) had stable disease or better. In cohort 7, at day 56, 4 out of 6 subjects (67%) had stable disease. In cohorts 1-6, at day 28, 21/26 (80.8%) of the subjects were considered not to have deterioration, one had deteriorated (5.6%), and 4 had no observation for this endpoint. Only 8 subjects from cohorts 1-6 had observations at the Day 56 visit, and all of these were negative for
15 deterioration.

Disease progression was also assessed by frequency of radiographic growth (measured according to % growth in the sum longest diameter of target lesions as defined in the RECIST scoring criteria). Where no new lesions were present and there was either no growth in the longest diameter sum of the target lesions or that growth
20 was no more than 20%, the subject was considered to have *stable radiographic disease* at that visit.

Reduction in refractory metastatic papillary thyroid cancer following multiple infusions of 3×10^{12} virus particles of Ad5-PPE-1-3X-fas-chimera

Of these patients, Subject 026, a 69 year-old Hispanic female, was enrolled with
25 metastatic papillary thyroid cancer that was resistant to radioiodine and was dosed in cohort 6 on March 16, 2009. Baseline CT scan showed a mass lesion in the neck with pressure on the airway (FIG. 4, arrows). Day 28 scan showed stable disease, and a follow-up scan 6 months (FIG. 5, arrows) and 12 months after treatment showed a greater than 30% reduction in the long diameter of the mass and no pressure on the
30 airway, with radiographic lucency suggestive of central necrosis (FIG. 5, blue arrow). Additionally, thyroglobulin levels have decreased in this patient: the level at baseline

was 426 ng/mL and 10 months later had decreased to 326 ng/mL (normal levels <55 mg/mL).

A second dose was administered one and one half years after the first dosing, and the patient was progression free at day 120 post infusion. Thyroglobulin levels at the time of second dosing were 281 ng/mL, rising to 477 ng/mL at day 28, and dropping to 382 ng/mL at day 56 post infusion. No dose limiting toxicities, severe side effects or cytokine storm were observed throughout the treatment period.(Figure 10A)

In another patient with a medullary thyroid cancer lesion, administration of 3×10^{12} virus particles of Ad5-PPE-1-3X-fas-chimera resulted in dramatic reduction in levels of the thyroid cancer biomarker calcitonin: levels were greatly elevated before administration (14, 331 pg/ml, normal = < 10 pg/ml), increased (16,324 pg/ml) at 56 days post infusion, but showed marked reduction (6600 pg/ml) at 120 days post infusion. At 120 days post-treatment the patient was still progression free. (Figure 10B)

Reduction in metastatic lesion of advanced neuroendocrine cancer following a single infusion of 3×10^{12} virus particles of Ad5-PPE-1-3X-fas-chimera.

Another patient in cohort 6, enrolled with advanced neuroendocrine cancer, was dosed in cohort 6 on March 16, 2009. Day 21 CT scan showed several hepatic metastases (FIGs. 6A and 7A, red circle). Follow-up CT scans at 50 (FIGs. 6B and 7B, red circle) and 112 (FIGs. 6C and 7C, red circle) days post dosing showed continued regression of one of these metastatic lesions. According to RECIST criteria, this patient was scored as "stable disease", and has maintained "stable disease" classification for four months afterwards.

Summary of Efficacy

Although this single infusion study with patients having advanced or metastatic solid organ cancer is small, certain trends can be discerned from the efficacy data.

On day 56 evaluation, three of the 14 patients in Cohorts 1 -5 had stable radiographic disease (SD); among the 12 Cohort-6 patients, five had stable disease on day 56, and one patient (with papillary thyroid carcinoma) had a near partial response on day 56 (out of 12 patients on cohort 6), which became a partial response (PR) later.

Among the 5 cohort 7 patients, 5 remained classified as having "stable disease" (SD). When the percent change in RECIST scores is plotted for days 0, 28 and 56, and correlated with the evaluations of stable and progressive disease, it can be seen that

three out of 14 (21%) in cohorts 1-5 were stable at day 56 (Figure 8). In cohorts 6 and 7 (Figure 9), however, 9 out of 17 patients were stable at day 56.

In this open-label, dose-ranging study evaluating a single IV infusion of safety and efficacy of administration of Ad5PPE-1-3X-fas-chimera (SEQ ID NO: 9) in the clinical setting, 3 subjects with advanced or metastatic cancer have been enrolled in each of the first 5 ascending dose cohorts and 12 subjects have been enrolled in the 6th cohort. Taken together, the data indicates Ad5-PPE-1-3X-fas-chimera is safe for systemic administration, in all of the doses tested, as no safety signal or dose-limiting toxicities (DLT) have been observed at any of the utilized doses. Although two serious adverse events were reported, these were related to progression of the cancer and unrelated to study treatment. Several subjects who received Ad5-PPE-1-3X-fas-chimera at one of the 2 highest doses developed transient pyrexia and chills shortly after receiving study treatment, events commonly occurring after the administration of adenovirus vectors. Clinically significant abnormalities on laboratory testing were infrequent and considered unrelated to Ad5-PPE-1-3X-fas-chimera treatment.

Maximally tolerated dose (MTD) was determined as 10^{13} virus particles per dose, in view of the single incident of dose limiting toxicity (NCI Grade 3 fever) observed in the cohort receiving the highest dose tested (cohort 7). Although being a small single infusion study among patients with multiple types of advanced, refractory cancer, evidence for efficacy of Ad5-PPE-1-3X-fas-chimera infusion includes patients with stable radiographic disease and one prolonged partial response among patients receiving 3×10^{12} virus particles of Ad5-PPE-1-3X-fas-chimera (cohort 6)(Table 10).

**Table 10: Disease response to a single dose of Ad5PPE-1-3X-Fas-chimera:
Percent stable disease at day 56, by indication (cohorts 6 and 7).**

Type of Cancer	Number of Patients	%SD at Day 56
Colorectal		
Adenocarcinoma	5	40%
Carcinoid/Neuroendocrine	4	75%

89

Non-small cell lung		
cancer	1	100%
Renal cell carcinoma	3	33%
Melanoma	1	0%
Thyroid cancer	2	100%
Merkle cell carcinoma	1	0%
Esophageal		
Adenocarcinoma	1	0%

In one patient suffering from esophageal cancer the subcutaneous metastasis was sampled and detectable levels of Ad5-PPE-1-3X-fas-chimera transgene expression were found in the aspirate on days 4 and 28 after treatment.

5

Example III

Effect of Ad5PPE-1-3X-fas chimera administration on Thyroid Cancer in the clinical setting

In order to determine the efficacy of administration of AD5PPE-1-3X-fas-chimera on Thyroid Cancer in the clinical setting, outcomes such as toxicity, adverse effects, antibody titer, biodistribution, disease progression and disease recurrence and survival were monitored in subjects with Thyroid Cancer tumors receiving intravenous infusion of the Ad5PPE-1-3X-fas chimera adenovirus vector.

MATERIALS AND EXPERIMENTAL METHODS

Indications:

Advanced progressive and radioiodine-refractory differentiated thyroid cancer (DTC) (papillary, follicular, Hurthle cell) cancer patients.

Safety objectives:

To evaluate the safety of a single systemic dose of the Ad5PPE-1-3X-fas chimera adenovirus vector in patients with advanced thyroid cancer.

Efficacy and pharmacodynamics objectives:

1. To evaluate the response to treatment for patients with advanced DTC with measurable disease using Response Evaluation Criteria in Solid Tumors (RECIST Criteria);

2. To assess the pharmacokinetic and pharmacodynamic profile of Ad5PPE-1-3X-fas chimera adenovirus vector;

3. Evaluation of changes in candidate biomarkers in response to Ad5PPE-1-3X-fas chimera adenovirus vector treatment.

5 4. To explore influences of pre-treatment tumor genetic alterations on response to Ad5PPE-1-3X-fas chimera adenovirus vector treatment using archival tumor materials.

Efficacy endpoints:

1. The primary efficacy endpoint is the proportion of patients who have
10 achieved an objective response to the study agent (according to RECIST criteria).

2. Secondary endpoints will include changes in thyroglobulin levels in response to treatment (in anti-thyroglobulin antibody-negative patients only).

Study design:

Prospective, open-label, single dose study in 2 groups of patients (parallel
15 enrolment):

Group A-Treatment of 12 evaluable patients with progressive thyroid cancer disease despite treatment with radioiodine, but naive to targeted anti-angiogenic therapies (e.g. tyrosine kinase inhibitors or anti-VEGF monoclonal antibodies). Subjects may also have had treatment with other cancer chemotherapy.

20 Group B -Treatment of 12 evaluable patients with progressive thyroid cancer despite prior treatment with radioiodine and with at least one anti-angiogenic therapy. Subjects may also have had treatment with other cancer chemotherapy.

Treatment plan and study duration:

Ad5PPE-1-3X-fas chimera adenovirus vectors are administered as a single
25 intravenous infusion of 3×10^{12} vp (virus particles). The post-infusion efficacy follow up period will be until disease progression occurs. The post-treatment safety and efficacy evaluation visits will be every four weeks until week 12 or disease progression (whichever occurs later). Thereafter, restaging evaluations will occur every 2 months until at least one year after study enrolment or until progression (the earlier). Formal
30 restaging of indicator lesions is performed every 8 weeks.

Population size:

Groups A and B of this study will each enroll 12 evaluable subjects, for a total of 24 evaluable subjects. Evaluable subject are subjects for whom the chosen evaluation criteria can be applied through the duration of the study. The trial is designed according to the 2-stage Simon statistical method. If at least 1 response is observed in the initial 12 patients, further 24 patients will be enrolled from that group (up to a total of 37 patients per group or 74 total).

Inclusion criteria:

1. Patients ≥ 18 years of age;
2. Histologically or cytologically confirmed advanced DTC (papillary, follicular, Hurthle cell);
3. Absence of sensitivity to therapeutic radioiodine;
4. No previous treatment with anti-angiogenic agents (Group A patients only);
5. Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan (Note: Disease that is measurable by physical examination only is not eligible, and CT and/or MRI are required in assessing indicator lesions);
6. Life expectancy > 3 months;
7. ECOG performance status (PS) 0, 1, or 2; Karnofsky performance status of $\geq 60\%$;
8. Objective evidence of tumor progression in the 6 month period prior to the Screening Visit, as assessed by:
 - i. Progressively increasing suitable tumor markers, where appropriate; and
 - ii. Unequivocal progression of objectively measured disease on successive appropriate imaging (e.g. CT scan). In cases of uncertainty of tumor progression, the Principal Investigator of the study will be available to assist in decisions.
9. Patients with a normal/acceptable hematological profile, as demonstrated by a peripheral leukocyte count > 3000 cells/ μL , an absolute neutrophil count > 1500 cells/ μL , hemoglobin $\geq 10\text{g/dL}$, platelets $> 100,000/\mu\text{L}$, and International Normalized Ratio (INR) $< 1.2 \times$ the Upper Limit of Normal (ULN);

10. Patients with adequate renal function, i.e. serum creatinine <1.5 times upper normal limits; and adequate hepatic function, as defined by ALT and AST $<2.5\times$ the upper limit of normal and total bilirubin below the upper limit of normal;

11. Males and females of childbearing potential must utilize, throughout the
5 course of the trial a standard contraception method;

12. Ability to understand and the willingness to sign a written informed consent document;

13. Willingness to comply with study requirements.

Exclusion Criteria:

- 10 1. Pregnant or breastfeeding females;
2. Disease that is measurable by physical examination only;
3. Presence of any of the following:
- Radiotherapy or chemotherapy <4 weeks prior to baseline visit;
 - Radiotherapy to $\geq 25\%$ of bone marrow;
 - 15 • Major surgery <4 weeks prior to baseline visit;
 - Concurrent and/or prior therapy with octreotide will be allowed, provided tumor progression on this therapy has been demonstrated;
 - Concurrent and/or prior therapy with biphosphonates will be allowed;
- 20 4. Any other ongoing investigational agents within 4 weeks before enrolment;
5. Patients, who suffered from an acute cardiac event within the last 12 months, including myocardial infarction, cardiac arrhythmia, admission for unstable angina, cardiac angioplasty, or stenting;
- 25 6. QTc prolongation (defined as QTc interval ≥ 500 msec) or other significant ECG abnormalities (e.g. frequent ventricular ectopy, evidence of ongoing myocardial ischemia);
7. Patients with active vascular disease, either myocardial or peripheral;
8. Patients with proliferative and/or vascular retinopathy;
9. Patients with known active liver disease (alcoholic, drug/toxin induced,
30 genetic, or autoimmune) other than related to tumor metastases;

10. Patients with known CNS metastatic disease (Exception: patients with treated CNS metastases stable by radiographic examinations >6 months after definitive therapy administered, are eligible);
11. Patients testing positive to one of the following viruses: HIV, HBV or
5 HCV;
12. Any of the following conditions:
- Serious or non-healing wound, ulcer, or bone fracture;
 - History of abdominal fistula, gastro-intestinal perforation, active diverticulitis, intra-abdominal abscess or gastro-intestinal tract bleeding within 28 days
10 of enrolment;
 - Any history of cerebrovascular accident (CVA) within 6 months of enrolment;
 - Current use of therapeutic warfarin (Note: Low molecular weight heparin and prophylactic low-dose warfarin [International Normalized Ratio (INR) <1.2 X
15 Upper Limit of Normal (ULN)] are permitted);
 - History of bleeding disorder, including patients with hemophilia, disseminated intravascular coagulation (DIC), or any other abnormality of coagulation potentially predisposing patients to bleeding;
 - Poorly controlled depression or anxiety disorder, or recent (within the
20 previous 6 months) suicidal ideation;
13. Patients with an ongoing requirement for an immunosuppressive treatment, including the use of glucocorticoids or cyclosporin, or with a history of chronic use of any such medication within the last 4 weeks before enrolment;
14. Uncontrolled intercurrent illness including, but not limited to ongoing or
25 active infection, or psychiatric illness/social situations that would limit compliance with study requirements.

Formulation, Dosage and Administration:

Ad5PPE-1-3X-fas chimera adenovirus vector is formulated as a sterile vector solution. The solution is supplied frozen (below -65°C), in single use vials. Each vial
30 contains 0.5 ml of vector solution at a specific viral titer. The vector solution is thawed and maintained on ice during dilution and handling.

Ad5PPE-1-3X-fas chimera adenovirus vector is administered as a single intravenous infusion, maximal dose being 1×10^{12} - 1×10^{13} virus particles (vp). Prior to infusion, the solution for injection is brought to room temperature. The vials are opened in a biological safety cabinet and diluted (by injection) 1:4 with of normal saline for infusion. A single infusion of diluted Ad5PPE-1-3X-fas chimera adenovirus vector is administered at a rate of 1 ml/minute. Multiple doses may be administered at predetermined minimal intervals.

Safety Evaluation:

1. Adverse events are recorded on an ongoing basis during. The events are followed until resolved, or until the study end, whichever comes sooner.

2. Vital signs are recorded at screening, prior to dosing, 30, 60 minutes, 4 and 6 hours after dosing and at all patient visits.

3. A physical examination is conducted in conjunction with each study visit.

4. Safety laboratory assessment (vital signs, blood haematology and chemistry, urine analysis) are conducted at screening, prior to dosing, and at all patient visits, starting from day 4 ± 1 until disease progression or Week 12, whichever occurs later.

5. After disease progression or Week 12 (whichever occurs later), each patient is contacted for safety follow-up by telephone every 2 months until 1 year after study enrolment.

Biodistribution:

Blood and urine samples for evaluation of levels of adenovirus vector DNA and the fas transgene are collected for adenovirus vector DNA: at several time points post-infusion.

Evaluation of Efficacy: Tumor Response

The effect of Ad5PPE-1-3X-fas chimera adenovirus vector treatment on tumor response is evaluated by measuring the tumor according to RECIST criteria (see above) at screening and at subsequent visits until disease progression. Changes in tumor volume are evaluated and analyzed based on radiological studies.

Biochemical and Laboratory Assays:

Antibodies: Serum samples are collected prior to dosing and at all patient visits, starting from Week 1, for analysis of levels of antibodies to the adenovirus (both total immunoglobulin, total IgG and Ad-5 neutralizing Abs) and to the fas-chimera transgene.

Tumor markers: TSH, anti-thyroglobulin antibody, and thyroglobulin are tested in conjunction with all follow-up evaluations.

Tumor measurement: Evaluation of biological effect on indicator lesion (CT, MRI).

Statistical Evaluation:

Patients are divided into two groups of subjects based upon previous treatment of their thyroid cancer: Group A, DTC radioiodine resistant and naïve to anti-angiogenics; Group B, DTC radioiodine resistant with progression on anti-angiogenics. These two groups are evaluated independently for efficacy and toxicity end points.

Patient recruitment for each group is in 2 stages:

Stage 1: Enter 12 patients into the study. 12 subjects for each group. If no clinical responses are observed, the therapy is considered ineffective in this patient population and the study is terminated. If at least 1 response is observed, the study group proceeds to Stage 2.

Stage 2: Enter an additional 25 evaluable patients into the each group study. If three or fewer responses are observed after all 37 evaluable patients have been evaluated for response, the therapy is considered insufficiently effective in this patient population. If 4 or more responses are observed, this is considered adequate evidence of promising activity and this treatment may be recommended for further testing in subsequent studies in this patient population.

Unless toxicity is encountered or the study is stopped at the interim analysis, this study will accruing 37 eligible subjects for each group and evaluable patients. In order to account for ineligibility, cancellation, major treatment violation, or other reasons or early withdrawal or drop out, an additional 4 patients will be enrolled for each group.

Thus 41 patients will be enrolled into this study for each group. Total of 82 subjects.

Assessments will be carried out according to the schedule in Table 10 that follows.

TABLE 10- SCHEDULE OF ASSESSMENTS

	Screening (≤ 2 wks from D ₀)	D ₀ Prior to Dosing day of dosing	Follow up after Dosing (D _{±1})	Day 4±1	Week 1 ±1 Day	Week 2 ±1 Day	Weeks 4 & 8 ±3 Days	Week 12, ±3 Days	Weeks ¹⁰ 20, 28, 36, 44, 52 ±3 Days	F/U ¹¹
Inclusion Criteria	X									
Exclusion Criteria	X									
Medical History	X									
Informed Consent	X									
Pregnancy Test ¹	X									
Physical Exam ECG	X							X		
Vital Signs ²	X	X	X				X	X	X	
Hematology ³	X	X		X	X	X	X	X	X	
Chemistry ⁴	X	X		X	X	X	X	X	X ¹²	
HIV, HBV, HCV	X									
Urinalysis ⁵	X	X			X	X	X	X	X	
ECG	X							X		
Drug infusion		X								
Antibody ⁶		X	X		X	X	X	X	X	
Distribution ⁷		X	X	X	X	X	X			
Concomitant Medications	X	X					X	X	X	X
Adverse Events		X	X	X	X	X	X	X	X	X
Tumor Measure ⁸	X						X	X	XX	
Tumor Markers ⁹	X						X	X	XX	

Legend

1. Women of childbearing potential will be tested for pregnancy with the use of a serum pregnancy test at Screening and Week 12
- 5 2. Vital signs (blood pressure, body temperature and heart rate) will be recorded at screening, prior to dosing at 30 and 60 minutes after dosing and at 6 hours post-dosing, and at all patient visits thereafter.
3. Hematology will include: complete blood count with differential, PT and PTT Fibrinogen
4. Chemistry will include: electrolytes (sodium, potassium, calcium), creatinine; bilirubin,
- 10 alkaline phosphatase, ALT and AST; total protein and albumin
5. Routine urine analysis
6. Blood samples will be collected for levels of serum antibodies against the adenovirus and the transgene
7. Blood and urine samples will be collected for biodistribution determination (levels of the
- 15 viral DNA and transgene). See protocol for details.
8. Evaluation of indicator lesion (CT, MRI, etc.) to be done at each visit until disease progression
9. TSH, anti-thyroglobulin antibody, and thyroglobulin should be tested at each visit until disease progression
- 20 10. Visits at Weeks 20, 28, 36, 44, and 52 to be conducted only if no disease progression has occurred prior to the visit

11. Telephone contact will be performed every 2 months after Week 12 or disease progression (whichever occurs later) until one year after study enrolment.

Thyroglobulin is to be tested every 2 months until 13 months post dosing or
5 until progression, whichever occurs first.

Example IV

Effect of Ad5PPE-1-3X-fas chimera administration Combined with Chemotherapy

In order to evaluate the combined therapeutic oncolytic effect of Ad5PPE-1-3X-fas chimera and chemotherapy on tumor size in cancer, systemic administration of
10 Ad5PPE-1-3X-fas chimera and concomitant chemotherapy in the rapidly metastasizing Lewis Lung Carcinoma model was chosen.

The Lewis Lung Cancer model provides a method for observing the effects of treatment on established, metastatic cancer.

Sunitinib (Sutent) targets tyrosine kinase, and inhibits the action of VEGF,
15 producing an anti-angiogenic effect, and is used, among others, in stromal tumors and advanced renal cell cancer.

Antimetastatic effects of a single systemic dose of Ad5PPE-1-3X-fas chimera and oral sunitinib in mice bearing lung metastases:

C57BL/6 male mice (13 to 19 in each group) aged 8 weeks were inoculated with
20 5×10^5 LLC cells into the left footpad. The foot was amputated under general anesthesia as soon as the primary tumor developed to 7 mm. 2 days later (post foot amputation) a single intravenous injection of Ad5PPE-1-3X-fas chimera (10^9 or 10^{11} virus particles) was administered through the tail vein. After receiving the vector, a daily regimen of oral sunitinib was administered, 40 or 80 mg/kg once a day, on days 1-5, 8-13 and 16-
25 17. Mouse sacrifice was scheduled for the 22nd day post primary tumor removal. Mouse well-being was monitored daily by observation and weighing. Results (Tumor burden) relate to the tumor mass, in grams (known as Tumor Burden).

Figures 13A and 13B detail the results of two groups of the metastatic mice receiving the combination therapy, compared to each treatment mode alone. While a
30 dose effect of the treatments could be discerned in the tumor burden of mice receiving 80 mg/kg sunitinib compared to those receiving 40 mg/kg sunitinib, and in the tumor burden of mice receiving 10^{11} Ad5PPE-1-3X fas-c compared to those receiving 10^9 Ad5PPE-1-3X fas-c, the results of combining the two treatment modes reveals a

2011204405 21 May 2015
5 statistically significant difference ($P < 0.05$) between the control group and all the treatment groups, the mean tumor burden in the control group being significantly greater than in each of the other groups. The high viral dose (10^{11} virus particles) and the low dose-combination treatment (10^9 virus particles and 80 mg/kg sunitinib), were found to be most effective in reducing the tumor burden, resulting in a statistically lower tumor burden than that of either the 10^9 virus particles and 40 mg/kg sunitinib groups. These combination groups also showed reduced variability and generally lower scores, compared to the other experimental groups. The results show that combined treatment of systemically administered AdPPE-1-3X-fas-chimera + oral sunitinib is effective against metastatic disease.

10 Taken together, these results indicate that when administered in combination with currently employed clinical chemotherapy protocols, Ad5PPE-1-3X fas-c can increase their therapeutic effectiveness and potentially allow reduced dosage and frequency of treatments.

15 Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.

20 All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting.


25 Any reference to publications cited in this specification is not an admission that the disclosures constitute common general knowledge in Australia.

CLAIMS

1. A method of treating a solid tumor in a human subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a virus particle comprising an adenoviral nucleic acid, which comprises a fas-chimera transgene transcriptionally linked to a PPE-1-3X promoter, wherein said therapeutically effective amount is about 3×10^{12} to about 1×10^{13} virus particles.
2. The method of claim 1, wherein said therapeutically effective amount is about 3×10^{12} virus particles.
3. The method of claim 1, wherein said therapeutically effective amount is about 1×10^{13} virus particles.
4. The method of any one of claims 1 to 3, wherein said fas-chimera transgene comprises the sequence as set forth in SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:4.
5. The method of any one of claims 1 to 4, wherein said PPE-1-3X promoter comprises the sequence as set forth in SEQ ID NO:6 or the complementary sequence thereof.
6. The method of any one of claims 1 to 4, wherein said PPE-1-3X promoter comprises the sequence as set forth in SEQ ID NO:8 or the complementary sequence thereof, the sequence as set forth in SEQ ID NO:7 or the complementary sequence thereof, or the sequence as set forth in SEQ ID NO:12.
7. The method of any one of claims 1 to 6, wherein said adenoviral nucleic acid is a non-replicating adenoviral nucleic acid.
8. The method of any one of claims 1 to 7, wherein said adenoviral nucleic acid is an adenovirus 5 nucleic acid.
9. The method of any one of claims 1 to 8, wherein said adenoviral nucleic acid comprises the nucleic acid sequence as set forth in SEQ ID NO:9.
10. The method of any one of claims 1 to 8, wherein said adenoviral nucleic acid comprises the nucleic acid sequence as set forth in SEQ ID NO:10.
11. The method of any one of claims 1 to 10, wherein said solid tumor is a thyroid cancer.

12. The method of any one of claims 1 to 10, wherein said solid tumor is a neuroendocrine cancer.
13. The method of any one of claims 1 to 12, wherein said solid tumor is a primary tumor.
14. The method of any one of claims 1 to 13, wherein said virus particle is administered systemically.
15. The method of claim 14, wherein said virus particle is administered systemically by a route selected from the group consisting of intra-articular administration, intravenous administration, intraperitoneal administration, subcutaneous administration, infusion, oral administration, rectal administration, nasal administration, and inhalation.
16. The method of any one of claims 1 to 15, comprising administering at least two separate doses of said virus particles.
17. The method of any one of claims 1 to 16, wherein said subject further receives a chemotherapeutic agent.
18. The method of claim 17, wherein said chemotherapeutic agent is administered prior to the administration of said virus particles or wherein said chemotherapeutic agent is administered concomitantly with said virus particles.
19. The method of claim 17 or claim 18, wherein said chemotherapeutic agent is sunitinib.
20. The method of any one of claims 1 to 19, wherein said administration decreases a Response Evaluation Criteria in Solid Tumors (RECIST) score in said subject.

Dated: 21 May 2015






FIG. 2




FIG. 3A




FIG. 3B




FIG. 4




FIG. 5

FIG. 6A



FIG. 6B




FIG. 6C

6/14





FIG. 7B



FIG. 7C






FIG. 8




FIG. 9




FIG. 10A




FIG. 10B




FIG. 11




FIG. 12A




FIG. 12B




FIG. 13A

	Average	SD	median	N
Vehicle	0.930	0.16	0.90	17
VB-111 1.00E+09	0.21	0.15	0.20	15
VB-111 1.00E+11	0.04	0.04	0.02	16
Sutent 40mg/kg	0.14	0.11	0.10	15
Sutent 80mg/kg	0.09	0.11	0.06	16
VB-111 1E9+Sutent 40mg/kg	0.20	0.17	0.16	14
VB-111 1E9+Sutent 80mg/kg	0.03	0.06	0.02	16
VB-111 1E11+ Sutent 40mg/kg	0.24	0.17	0.19	18
VB-111 1E11+Sute nt80mg/kg	0 06	010	0.02	16

FIG. 13B

SEQUENCE LISTING

<110> Vascular Biogenics Ltd.
Cohen, Yael
Sher, Naamit
Feige, Erez
Bangio, Livnat
Breitbart, Eyal

<120> METHODS FOR USE OF A SPECIFIC ANTI-ANGIOGENIC ADENOVIRAL AGENT

<130> 50375

<150> US 61/282,228
<151> 2010-01-05

<150> US 61/282,247
<151> 2010-01-07

<160> 644

<170> PatentIn version 3.5

<210> 1
<211> 34350
<212> DNA
<213> Artificial sequence

<220>
<223> Empty Ad5 vector sequence without repeats

<400> 1
catcatcaat aatatacctt attttggatt gaagccaata tgataatgag ggggtggagt 60
ttgtgacgtg gcgcggggcg tgggaacggg gcgggtgacg tagtagtgtg gcggaagtgt 120
gatgttgcaa gtgtggcgga acacatgtaa gcgacggatg tggcaaaagt gacgtttttg 180
gtgtgcgccg gtgtacacag gaagtgacaa ttttcgcgcg gttttaggcg gatgttgtaç 240
taaatttggg cgtaaccgag taagatttgg ccattttcgc gggaaaactg aataagagga 300
agtgaatatc gaataatttt gtgttactca tagcgcgtaa tatttgtcta gggccgcggg 360
gactttgacc gtttactgtg agactcgccc aggtgttttt ctccaggtgtt ttccgcgttc 420
cggttcaaag ttggcgtttt attattatag tcagtacgtc tcgagcatgc atctaggcgg 480
ccgcatggca gaaattcgcg aattcgctag cgtaaacgga tcctctagac gagatccgaa 540
cttgtttatt gcagcttata atggttacaa ataaagcaat agcatcacao atttcacaaa 600
taaagcattt ttttactgc attctagtgt tggtttgtcc aaactcatca atgtatctta 660
tcatgtctag atctgtactg aaatgtgtgg gcgtggctta aggggtgggaa agaatatata 720
aggtgggggt cttatgtagt tttgtatctg ttttgacgca gccgccgccg ccatgagcac 780
caactcgttt gatggaagca ttgtgagctc atatttgaca acgcgcatgc ccccatgggc 840
cggggtgcgt cagaatgtga tgggtccag cattgatggt cgccccgtcc tgcccgcaaa 900
ctctactacc ttgacctacg agaccgtgtc tggaaacgcc ttggagactg cagcctccgc 960
cgccgcttca gccgctgcag ccaccgccg cggtattgtg actgactttg ctttctgag 1020
cccgtttgca agcagtgcag ctccccgttc atccgccgc gatgacaagt tgacggtctt 1080
tttggcacia ttgattctt tgaccggga acttaatgtc gtttctcagc agctgttggg 1140
tctgcgccag caggtttctg cctgaaggc ttcctccct cccaatgcgg tttaaaacat 1200
aaataaaaaa ccagactctg tttggatttg gatcaagcaa gtgtcttgct gtctttattt 1260

aggggttttg	cgcgcgcggt	aggcccgga	ccagcggtct	cggtcggtga	gggtcctgtg	1320
tattttttcc	aggacgtggt	aaaggtgact	ctggatgttc	agatacatgg	gcataagccc	1380
gtctctgggg	tggaggtagc	accactgcag	agcttcatgc	tcgggggttg	tgttgtagat	1440
gatccagtcg	tagcaggagc	gctgggcgtg	gtgcctaaaa	atgtctttca	gtagcaagct	1500
gattgccagg	ggcaggccct	tgggtgaagt	gtttacaaag	cggttaagct	gggatgggtg	1560
catacgtggg	gatatgagat	gcactcttga	ctgtattttt	aggttggcta	tgttcccagc	1620
catatccctc	cggggattca	tgttgtagc	aaccaccagc	acagtgtatc	cggtgcactt	1680
gggaaatttg	tcattgtagct	tagaaggaaa	tgcgtggaag	aacttggaga	cgcccttgtg	1740
acctccaaga	ttttccatgc	attcgtccat	aatgatggca	atgggccac	ggcgggcggc	1800
ctgggcgaag	atatttctgg	gatacctaac	gtcatagtgt	tgttccagga	tgagatcgtc	1860
ataggccatt	tttacaaagc	gcggggcgag	ggtgccagac	tcgggtataa	tggttccatc	1920
cggcccaggg	gcgtagttag	cctcacagat	ttaaggttgg	gaaagaatat	ataaggtggg	1980
ggtcttatgt	agttttgtat	ctgttttgca	gcagccggcg	ccgccatgag	caccaactcg	2040
tttgatggaa	gcattgtgag	ctcatatttg	acaacgcgca	tgcccccatg	ggccgggggtg	2100
cgtcagaatg	tgatgggctc	cagcattgat	ggtcgccccg	tcctgccccg	aaactctact	2160
accttgacct	acgagaccgt	gtctggaacg	ccgttggaga	ctgcagcctc	cgccgccgct	2220
tcagccgctg	cagccaccgc	ccgcgggatt	gtgactgact	ttgctttcct	gagcccgctt	2280
gcaagcagtg	cagcttcccc	ttcatccgcc	cgcgatgaca	agttgacggc	tcttttgga	2340
caattggatt	ctttgaccgc	ggaacttaat	gtcgtttctc	agcagctgtt	ggatctgcgc	2400
cagcaggttt	ctgccctgaa	ggcttccctc	cctcccaatg	cggtttaaaa	cataaataaa	2460
aaaccagact	ctgtttggat	ttggatcaag	caagtgtctt	gctgtcttta	tttaggggtt	2520
ttgcgcgcgc	ggtaggcccc	ggaccagcgg	tctcggtcgt	tgagggctct	gtgtattttt	2580
tccaggacgt	ggtaaagggt	actctggatg	ttcagatata	tgggcataag	cccgtctctg	2640
gggtggaggt	agcaccactg	cagagcttca	tgctgcgggg	tgggtgtgta	gatgatccag	2700
tcgtagcagg	agcgtggggc	gtggtgccta	aaaatgtctt	tcagtagcaa	gctgattgcc	2760
aggggcaggc	ccttggtgta	agtgtttaca	aagcggttaa	gctgggatgg	gtgcatacgt	2820
ggggatatga	gatgcactct	ggactgtatt	tttaggttgg	ctatgttccc	agccatatcc	2880
ctccggggat	tcattgttgt	cagaaccacc	agcacagtgt	atccggtgca	cttgggaaat	2940
ttgtcatgta	gcttagaagg	aaatgcgtgg	aagaacttgg	agacgccctt	gtgacctcca	3000
agattttcca	tgcatctgtc	cataatgatg	gcaatggggc	cacgggcggc	ggcctgggcg	3060
aagatatttc	tgggatcact	aacgtcatag	ttgtgttcca	ggatgagatc	gtcataggcc	3120
atttttacaa	agcgcgggcg	gagggtgcca	gactgcggta	taatggttcc	atccggccca	3180
ggggcgtagt	tacctcaca	gatttgcaat	tcccacgctt	tgagttcaga	tggggggatc	3240
atgtctacct	gcggggcgat	gaagaaaacg	gtttccgggg	taggggagat	cagctgggaa	3300
gaaagcaggt	tcctgagcag	ctgcgactta	ccgcagccgg	tgggcccgtg	aatcacacct	3360
attaccggct	gcaactggta	gttaagagag	ctgcagctgc	cgatcatccct	gagcaggggg	3420
gccacttcgt	taagcatgtc	cctgactcgc	atgttttccc	tgaccaaata	cgccagaagg	3480

cgctcgccgc ccagcgatag cagttcttgc aaggaagcaa agtttttcaa cggtttgaga	3540
ccgtccgcgc taggcatgct tttgagcgtt tgaccaagca gttccaggcg gtcccacagc	3600
tcggtcacct gctctacggc atctcgatcc agcatatctc ctctgttctgc gggttggggc	3660
ggctttcgct gtacggcagt agtcggtgct cgtccagacg ggccagggtc atgtctttcc	3720
acgggcgcag ggtcctcgtc agcgtagtct gggtcacggt gaaggggtgc gctccgggct	3780
gcgcgctggc caggggtgcgc ttgaggctgg tcctgctggt gctgaagcgc tgccggtctt	3840
cgcctcgcgc gtcggccagg tagcatttga ccattggtgc atagtccagc cctccgcgcg	3900
cgtggccctt ggccgcgcagc ttgcccttgg aggaggcgcc gcacgagggg cagtgcagac	3960
ttttgagggc gtagagcttg ggccgcgagaa ataccgattc cggggagtag gcatccgcgc	4020
cgcaggcccc gcagacggtc tcgcattcca cgagccaggt gagctctggc cgttcggggg	4080
caaaaaccag gtttccccca tgctttttga tgcgtttctt acctctggtt tccatgagcc	4140
ggtgtccacg ctccgtgacg aaaaaggctgt ccgtgtcccc gtatacagac ttgagaggcc	4200
tgctctcgag cgggtgtccg cggctctcct cgtatagaaa ctccgaccac tctgagacaa	4260
aggctcgctt ccaggccagc acgaaggagg ctaagtggga ggggtagcgg tcgttgtcca	4320
ctagggggtc cactcgtctc aggggtgtgaa gacacatgct gccctcttcg gcatcaagga	4380
agggtgattg tttgtagggt taggccacgt gaccgggtgt tcctgaaggg gggctataaa	4440
aggggggtgg ggccgcttcg tcctcactct cttccgcctc gctgtctgcg agggccagct	4500
gttgggggtg gtactccctc tgaaaagcgg gcatgacttc tgcgctaaga ttgtcagttt	4560
ccaaaaacga ggaggatttg atattcacct ggcccgcggt gatgcctttg aggggtggccg	4620
catccatctg gtcagaaaag acaatctttt tgttgtcaag cttggtggca aacgaccgt	4680
agagggcgtt ggacagcaac ttggcgatgg agcgcagggt ttggtttttg tcgcgatcgg	4740
cgcgctcctt ggcccgcatg tttagctgca cgtattcgcg cgcaacgcac cgccattcgg	4800
gaaagacggt ggtgcgctcg tcgggcacca ggtgcacgcg ccaaccgcgg ttgtgcaggg	4860
tgacaaggtc aacgtgggtg gctacctctc cgcgtaggcg ctctgttggtc cagcagaggc	4920
ggccgcccct gcgcgagcag aatggcggta ggggtcttag ctgcgtctcg tccggggggt	4980
ctgcgtccac ggtaaagacc ccgggcagca ggccgcgcgc gaagtagtct atcttgcctc	5040
cttgcaagtc tagcgcctgc tgccatgcgc gggcgccaag cgcgcgctcg tatgggttga	5100
gtgggggacc ccattgcatg ggggtgggtg gcgcggaggc gtacatgccg caaatgtcgt	5160
aaacgtagag gggctctctg agtattccaa gatatgtagg gtageatctt ccaccgcgga	5220
tgctggcgcg cactgaatcg tatagttcgt gcgagggagc gaggaggctg ggaccgaggt	5280
tgctacgggc gggctgctct gctcggaaga ctatctgcct gaagatggca tgtgagttgg	5340
atgatattgt tggacgctgg aagacgttga agctggcgctc tgtgagacct accgcgtcac	5400
gcacgaagga ggcgtaggag tcgcgcagct tgttgaccag ctccgcgggtg acctgcacgt	5460
ctaggcgcca gtagtccagg gtttccttga tgatgtcata cttatcctgt cctttttttt	5520
tccacagctc gcggttgagg acaaaactct cgcggtcttt ccagtactct tggatcgga	5580
acccgtcgcc ctccgaacgg taagagccta gcatgtagaa ctgggtgacg gcctggtagg	5640
cgcagcatcc cttttctacg ggtagcgcgt atgcctgcgc ggccttcgag agcgaggtgt	5700

gggtgagcgc aaaggtgtcc ctgacatga ctttgaggtg ctggtatttg aagtcagtgt	5760
cgctgcaccc gccctgctcc cagagcaaaa agtccgtgcg ctttttgaa cgcggatttg	5820
gcagggcgaa ggtgacatcg ttgaagagta tctttccgc gcgaggcata aagttgcgtg	5880
tgatgcggaa ggggtccgcg acctcggaac ggttgtaaat tacctgggcg gcgagcacga	5940
tctcgtcaaa gcggttgatg ttgtggccca caatgtaaag ttccaagaag cgcgggatgc	6000
ccttgatgga aggcaatttt ttaagttcct cgtaggtgag ctcttcaggg gagctgagcc	6060
cgtgctctga aagggccag tctgcaagat gaggggtgga agcgacgaat gagctccaca	6120
ggtcacgggc cattagcatt tgcagggtgt cgcgaaaggt cctaaactgg cgacctatgg	6180
ccattttttc tggggtgatg cagtagaagg taagcgggtc ttgttcccag cgggtccatc	6240
caaggttcgc ggctaggctc cgcgcggcag tccactagagg ctcatctccg ccgaacttca	6300
tgaccagcat gaagggcacg agctgcttcc caaaggcccc catccaagta taggtctcta	6360
catcgtaggt gacaaagaga cgctcgggtc gaggatgcga gccgatcggg aagaactgga	6420
tctcccgcca ccaattggag gagggttat tgatgtggtg aaagtagaag tccctgcgac	6480
gggccgaaca ctcgtgctgg cttttgtaaa aacgtgcgca gtactggcag cgggtgcacg	6540
gctgtacatc ctgcacgagg ttgacctgac gaccgcgcac aaggaagcag agtgggaatt	6600
tgagccccct gcctggcggg ttggtggtgt ggtcttctac ttcggtctgt tgtccttgac	6660
cgtctggctg ctcgagggga gttacggtg atcggaccac cagccgcgcg gagcccaaa	6720
tccagatgtc cgcgcgcggc ggtcggagct tgatgacaac atcgcgcaga tgggagctgt	6780
ccatggtctg gagctccgcg ggcgtcaggt caggcgggag ctctgcagg tttacctgc	6840
atagacgggt cagggcgcgg gctagatcca ggtgatacct aatttccagg ggctggttg	6900
tggcggcgtc gatggcttg aagaggcgc atccccgcg cgcgactacg gtaccgcgcg	6960
gcgggcggtg ggcgcggggg gtgtccttg atgatgcatc taaaagcggg gacgcgggcg	7020
agcccccgga ggtagggggg gctcgggacc cgcggggaga gggggcagg gcacgtcggc	7080
gccgcgcgcg ggcaggagct ggtgctgcgc gcgtagggtt ctggcgaacg cgacgacgcg	7140
gcggttgatc tctgaatct ggcgcctctg cgtgaagacg acgggcccgg tgagcttgaa	7200
cctgaaagag agttcgacag aatcaatttc ggtgtcgtt acggcgccct ggcgcaaaat	7260
ctcctgcacg tctcctgagt tgtcttgata ggcgatctcg gccatgaact gctcgatctc	7320
ttcctcctgg agatctccgc gtccggctcg ctccacggtg gcggcgaggt cgttggaat	7380
gcgggccatg agctgcgaga aggcgttgag gcctccctcg ttccagacgc ggctgtagac	7440
cacgccccct tcggcatcgc gggcgcgcgt gaccacctgc gcgagattga gctccacgtg	7500
ccgggcgaag acggcgtagt ttgcagcgct ctgaaagagg tagttgaggg tgggtggcgt	7560
gtgttctgcc acgaagaagt acataacca gcgtcgcaac gtggattcgt tgatatcccc	7620
caaggcctca aggcgtcca tggcctcgta gaagtccacg gcgaagttga aaaactggga	7680
gttgcgcgcc gacacgggta actcctcctc cagaagacgg atgagctcgg cgacagtgtc	7740
gcgcacctcg cgctcaaagg ctacaggggc ctcttcttct tcttcaatct cctcttccat	7800
aagggcctcc cttcttctt cttctggcgg cgggtggggga ggggggacac ggcggcgacg	7860
acggcgcacc gggaggcggg cgacaaagcg ctcgatcatc tccccgcggc gacggcgcat	7920

gggtctcggtg acggcgcggc cgttctcgcg gggcgcgagc tggaagacgc cgcccgcat	7980
gtcccgggta tgggttggcg gggggtgcc atgcggcagg gatacggcgc taacgatgca	8040
tctcaacaat tgttgtagt gttactccgc gccgaggac ctgagcgagt ccgcatcgac	8100
cggatcggaa aacctctcga gaaaggcgtc taaccagtca cagtcgcaag gtaggctgag	8160
caccgtggcg ggcggcagcg ggcggcggtc ggggttggtt ctggcgaggg tgctgctgat	8220
gatgtaatta aagtaggcgg tcttgagacg gcggatggtc gacagaagca ccatgtcctt	8280
gggtccggcc tgctgaatgc gcaggcggtc ggccatgcc caggcttcgt ttgacatcg	8340
gcgcaggctt ttgtagtagt cttgcatgag cttttctacc ggcacttctt cttctccttc	8400
ctcttgctct gcattctctt catctatcgc tgcggcgcg gcggagtttg gccgtaggtg	8460
gcgccctctt cctcccatgc gtgtgacccc gaagccctc atcggtgaa gcagggctag	8520
gtcggcgaca acgcgctcgg ctaatatggc ctgctgcacc tgcgtgaggg tagactggaa	8580
gtcatccatg tccacaaagc ggtggtatgc gcccggttg atggtgtaag tgcagttggc	8640
cataacggac cagttaacgg tctggtgacc cggtgcgag agctcggtgt acctgagacg	8700
cagagtaagc ctcgagtcaa atacgtatgc gttgcaagtc cgcaccaggc actggtatcc	8760
cacaaaaaag tgcggcgcg gctggcggtg gaggggccag cgtagggtgg ccggggctcc	8820
ggggcgcgaga tcttccaaca taaggcgatg atatccgtag atgtacctgg acatccaggt	8880
gatgccggcg gcggtggtg aggcgcgcgg aaagtgcgg acgcggttcc agatgttgcg	8940
cagcgcgaaa aagtgtctca tggtcgggac gctctggccg gtcaggcgcg cgcaatcgtt	9000
gacgtcttag accgtgcaaa aggagagcct gtaagcgggc actcttccgt ggtctggtgg	9060
ataaatctgc aagggtatca tggcgagcga ccgggggttc agccccgtat ccggccgtcc	9120
gccgtgatcc atgcggttac cgcccgctg tcgaaccag gtgtgcgacg tcagacaacg	9180
ggggagtgct ccttttggtt tccttcagg cgcgcggtt gctgcgctag cttttttggc	9240
cactggccgc gcgcagcgta agcggttagg ctgaaagcg aaagcattaa gtggtcgt	9300
ccctgtagcc ggagggttat tttccaaggg ttgagtcgcg ggacccccgg ttcgagctct	9360
ggaccggccg gactgcggcg aacgggggtt tgcctccccg tcatgcaaga ccccgcttgc	9420
aaattcctcc ggaaacaggg acgagccctt tttttgctt tcccagatgc atccggtgct	9480
gcggcagatg cgccccctc ctcagcagcg gcaagagcaa gagcagcggc agacatgcag	9540
ggcaccctcc cctctccta ccgcgtcagg agggcgaca tccgcggttg acgcggcagc	9600
agatggtgat tacgaacccc cgcgcgccg ggcggcgac tacctggact tggaggaggg	9660
cgagggcctg gcgcggctag gagcgccctc tcctgagcgg caccgaaggg tgcagctgaa	9720
gcgtgatacg cgtgaggcgt acgtgccg cgagaacctg tttcgcgacc gcgagggaga	9780
ggagcccag gagatgcggg atcgaaagt ccacgcagg cgcgagctgc ggcatggcct	9840
gaatcgcgag cggttgctgc gcgaggagga ctttgagccc gacgcgcgaa ccgggattag	9900
tcccgcgcgc gcacacgtgg cggcgccga cctggttaacc gcatacgagc agacggtgaa	9960
ccaggagatt aactttcaaa aaagcttta caaccacgtg cgtacgcttg tggcgcgca	10020
ggaggtggct ataggactga tgcatctgtg ggactttgta agcgcgctgg agcaaaaccc	10080
aaatagcaag ccgctcatgg cgcagctgtt ccttatagt cagcacagca gggacaacga	10140

ggcattcagg gatgcgctgc taaacatagt agagcccag ggccgctggc tgctcgattt	10200
gataaacatc ctgcagagca tagtggtgca ggagcgcagc ttgagcctgg ctgacaaggt	10260
ggccgccatc aactattcca tgcttagcct gggcaagttt tacgcccga agatatacca	10320
tacccttac gttcccatag acaaggaggt aaagatcgag gggttctaca tgcgcatggc	10380
gctgaagggtg cttacctga gcgacgacct gggcgtttat cgcaacgagc gcatccacaa	10440
ggccgtgagc gtgagccggc ggcgcgagct cagcgaccgc gagctgatgc acagcctgca	10500
aagggccctg gctggcacgg gcagcggcga tagagaggcc gagtccact ttgacgcggg	10560
cgctgacctg cgctggggcc caagccgacg cggcctggag gcagctgggg ccggacctgg	10620
gctggcgggtg gcaccgcgc gcgctggcaa cgtcgccggc gtggaggaat atgacgagga	10680
cgatgagtac gagccagagg acggcgagta ctaagcgggtg atgtttctga tcagatgatg	10740
caagacgcaa cggaccggcg ggtcgggcg gcgctgcaga gccagccgtc cggcctaac	10800
tccacggacg actggcgcca ggtcatggac cgcacatgt cgctgactgc gcgcaatcct	10860
gacgcgttcc ggcagcagcc gcaggccaac cggctctccg caattctgga agcggtggtc	10920
ccggcgcgcg caaacccac gcacgagaag gtgctggcga tcgtaaacgc gctggccgaa	10980
aacagggcca tccggcccga cgaggccggc ctggtctacg acgcgtgct tcagcgcgtg	11040
gctcgttaca acagcggcaa cgtgcagacc aacctggacc ggctgggtgg ggatgtgcgc	11100
gaggccgtgg cgcagcgtga gcgcgcgag cagcagggca acctgggctc catggttgca	11160
ctaaacgcct tcctgagtac acagcccgc aacgtgccgc ggggacagga ggactacacc	11220
aactttgtga gcgcactgcg gctaattgtg actgagacac cgcaaagtga ggtgtaccag	11280
tctgggccag actatTTTTT ccagaccagt agacaaggcc tgacagaccgt aaacctgagc	11340
caggctttca aaaacttgca ggggctgtgg ggggtgcggg ctcccacagg cgaccgcgcg	11400
accgtgtcta gcttctgac gcccaactcg cgcctgttgc tgctgcta at agcgccttc	11460
acggacagtg gcagcgtgct ccgggacaca tacctaggtc acttctgac actgtaccgc	11520
gaggccatag gtcaggcgca tgtggacgag catactttcc aggagattac aagtgtcagc	11580
cgcgcgctgg ggcaggagga cagggcgagc ctggaggcaa ccctaaacta cctgctgacc	11640
aaccggcggc agaagatccc ctgctgcac agtttaaaca gcgaggagga gcgcattttg	11700
cgctacgtgc agcagagcgt gagccttaac ctgatgcgcg acggggtaac gccagcgtg	11760
gcgctggaca tgaccgcgcg caacatggaa ccgggcctgt atgcctcaa cgggccgttt	11820
atcaaccgcc taatggacta cttgcatgc gcggccggc tgaacccga gtatttcacc	11880
aatgccatct tgaacccga ctggtaccg cccctgtt tctacaccg gggattcgag	11940
gtgcccagg gtaacgatgg attcctctgg gacgacatag acgacagcgt gttttccccg	12000
caaccgcaga ccctgctaga gttgcaacag cgcgagcagg cagaggcggc gctgcgaaag	12060
gaaagcttcc gcaggccaag cagcttgtcc gatctaggcg ctgcggcccc gcggtcagat	12120
gctagtagcc catttccaag cttgataggg tctcttacc gactcgcac caccgccccg	12180
cgctgctgg gcgaggagga gtacctaaac aactcgtgc tgcagccga gcgcgaaaaa	12240
aacctgcctc cggcatttcc caacaacggg atagagagcc tagtgacaa gatgagtaga	12300
tggaagacgt acgcgcagga gcacaggac gtgccaggcc cgcgccgcc caccgctcgt	12360

caaaggcacg accgtcagcg gggctctggtg tgggaggacg atgactcggc agacgacagc	12420
agcgtcctgg atttgggagg gagtggcaac ccgtttgcgc accttcgccc caggctgggg	12480
agaatgtttt aaaaaaaaaa aaagcatgat gcaaaataaa aaactcacca aggccatggc	12540
accgagcggtt ggttttcttg tattccctt agtatgcggc gcgcggcgat gtatgaggaa	12600
ggctctctc cctctacga gagtgtggtg agcgcggcgc cagtggcggc ggcgtgggt	12660
tctcccttcg atgtccctt ggacccgcgc tttgtgcctc cgcggtacct gcggcctacc	12720
ggggggagaa acagcatccg ttactctgag ttggcacccc tatcgacac caccgtgtg	12780
tacctggtgg acaacaagtc aacggatgtg gcatccctga actaccagaa cgaccacagc	12840
aactttctga ccacggctcat tcaaaacaat gactacagcc cgggggaggc aagcacacag	12900
accatcaatc ttgacgaccg gtcgcactgg ggcggcgacc tgaaaacat cctgcatacc	12960
aacatgccaa atgtgaacga gttcatgttt accaataagt ttaaggcgcg ggtgatggtg	13020
tcgcgcttgc ctactaagga caatcagggt gagctgaaat acgagtgggt ggagttcacg	13080
ctgcccagg gcaactactc cgagaccatg accatagacc ttatgaacaa cgcgatcgtg	13140
gagcactact tgaaagtggg cagacagaac ggggttcttg aaagcgacat cggggtaaag	13200
tttgacaccc gcaacttcag actgggggtt gaccccgta ctggtcttgt catgcctggg	13260
gtatatacaa acgaagcctt ccatccagac atcattttgc tgccaggatg cggggtggac	13320
ttcacccaca gccgcctgag caacttggtg ggcacccgca agcggcaacc cttccaggag	13380
ggctttagga tcacctacga tgatctggag ggtggtaaca ttcccgact gttggatgtg	13440
gacgcctacc aggcgagctt gaaagatgac accgaacagg gcgggggtgg cgcaggcggc	13500
agcaacagca gtggcagcgg cgcggaagag aactccaacg cggcagccgc ggcaatgcag	13560
ccggtggagg acatgaacga tcatgccatt cgcggcgaca cctttgccac acgggctgag	13620
gagaagcgcg ctgaggccga agcagcggcc gaagctgccg ccccgctgc gcaaccgag	13680
gtcgagaagc ctgagaagaa accggtgatc aaaccctga cagaggacag caagaaacgc	13740
agttacaacc taataagcaa tgacagcacc ttcacccagt accgcagctg gtaccttgca	13800
tacaactacg gcgacctca gaccggaatc cgctcatgga ccctgctttg cactcctgac	13860
gtaacctgcg gctcggagca ggtctactgg tcgttgccag acatgatgca agaccccggtg	13920
accttcgct ccacgcgcca gatcagcaac tttccggtgg tggcgccga gctgttggcc	13980
gtgcaactca agagcttcta caacgaccag gccgtctact cccaactcat ccgccagttt	14040
acctctctga cccacgtgtt caatcgcttt ccgagaacc agattttggc gcgcccgcca	14100
gccccacca tcaccaccgt cagtgaacac gttcctgctc tcacagatca cgggacgcta	14160
ccgctgcgca acagcatcgg aggagtccag cgagtacca ttactgacgc cagacgccgc	14220
acctgcccct acgtttacaa ggcctgggc atagtctgc cgcgcgtcct atcgagccgc	14280
actttttgag caagcatgtc catccttata tcgcccagca ataacacagg ctggggcctg	14340
cgcttcccaa gcaagatgtt tggcggggcc aagaagcgt ccgaccaaca ccagtgccg	14400
gtgcgcgggc actaccgcgc gccctggggc gcgcacaaac gcggccgcac tgggcgcacc	14460
accgtcgatg acgccatcga cgcggtggtg gaggaggcgc gcaactacac gccacgccg	14520
ccaccagtgt ccacagtgga cgcggccatt cagaccgtgg tgcgcggagc ccggcgctat	14580

gctaaaatga agagacggcg gaggcgcgta gcacgtcgcc accgccgcg acccggeact	14640
gccgccaac gcggggcggc ggccctgctt aaccgcgcac gtcgcaccgg ccgacggcg	14700
gccatgcggg ccgctcgaag gctggccgcg ggtattgtca ctgtgcccc caggccagg	14760
cgacgagcgg ccgccgcagc agccgcggcc attagtgtca tgactcaggg tcgcaggggc	14820
aacgtgtatt ggggtgcgca ctcggttagc ggccgtcgcg tgcccgtcg caccgcgcc	14880
ccgcgcaact agattgcaag aaaaaactac ttagactcgt actgttgat gtatccagcg	14940
gcggcgcgcg gcaacgaagc tatgtccaag cgcaaatca aagaagagat gctccaggtc	15000
atcgcgccgg agatctatgg ccccccgaag aaggaagagc aggattacaa gcccgaag	15060
ctaaagcggg tcaaaaagaa aaagaaagat gatgatgat aacttgacga cgaggtggaa	15120
ctgctgcacg ctaccgcgcc caggcgacgg gtacagtga aaggctcgac cgtaaacgt	15180
gttttgcgac ccggcaccac cgtagctttt acgcccggtg agcgctccac ccgcaccta	15240
aagcgctgt atgatgaggt gtacggcgac gaggacctgc ttgagcaggc caacgagcg	15300
ctcggggagt ttgcctacgg aaagcggcat aaggacatgc tggcggtgcc gctggacgag	15360
ggcaacccaa caccatagct aaagcccgta aactgcagc aggtgctgcc cgcgcttgca	15420
ccgtccgaag aaaagcgcgg cctaaagcgc gagtctggtg acttggcacc caccgtgcag	15480
ctgatgttac ccaagcgcca gcgactggaa gatgtcttg aaaaaatgac cgtggaacct	15540
gggctggagc ccgaggtccg cgtgcggcca atcaagcagg tggcgccggg actgggcgtg	15600
cagaccgtgg acgttcagat acccactacc agtagacca gtattgccac cgccacagag	15660
ggcatggaga cacaaacgtc ccgggttgcc tcagcggtgg cggatgccgc ggtgcaggcg	15720
gtcgctgcgg ccgcgtccaa gacctctacg gaggtgcaa cggaaccgtg gatgtttcg	15780
gtttcagccc ccgggcgcc gcgcggtcg aggaagtac gcgcgccag cgcgctactg	15840
cccgaatatg ccctacatcc ttccattgcy cctaccccc gctatcgtg ctacacctac	15900
cgccccagaa gacgagcaac taccgcagc cgaaccacca ctggaaccgg ccgcgcgct	15960
cgccgtcgcc agcccggtct gggcccgatt tccgtgcga gggtggtcg cgaaggaggc	16020
aggacctggt tgcgtccaa agcgcgtac caccacagca tcgtttaaa gccggtcttt	16080
gtggttcttg cagatatggc cctcacctgc cgccctcggt tcccgggtgc gggattccga	16140
ggaagaatgc accgtaggag gggcatggcc ggccacggcc tgacgggcgg catgcgtcgt	16200
gcgcaccacc ggcgggcgcg cgcgtcgac cgtcgcatgc gcggcggtat cctgcccctc	16260
cttattccac tgatcgccg gcgcatggc gccgtgccc gaattgcac cgtggccttg	16320
caggcgcgag gacactgatt aaaaacaagt tgcattgtga aaatcaaaa taaaaagtct	16380
ggactctcac gctcgcttg ttctgtact atttttaga atggaagaca tcaactttgc	16440
gtctctggcc ccgcgacag gctcgcgccc gtcatggga aactggcaag atatcggcac	16500
cagcaatatg agcgggtggc cttcagctg gggtcgctg tggagcgga ttaaaaattt	16560
cggttccacc gttagaact atggcagcaa ggccgtgaac agcagcacag gccagatgct	16620
gagggataag ttgaaagagc aaaatttcca acaaaagggt gtagatggcc tggcctctgg	16680
cattagcggg gtggtggacc tggccaacca ggcagtcaa aataagatta acagtaagct	16740
tgatccccgc cctcccgtag aggagcctcc accggccgtg gagacagtgt ctccagagg	16800

gcgtggcgaa aagcgtccgc gccccgacag ggaagaaact ctggtgacgc aaatagacga	16860
gcctccctcg tacgaggagg cactaaagca aggcctgccc accaccgctc ccacgcgcgc	16920
catggctacc ggagtgtctg gccagcacac acccgtaacg ctggacctgc ctcccccg	16980
cgacaccag cagaaacctg tgctgccagg cccgaccgcc gttgttgtaa cccgtcctag	17040
ccgcgcgtcc ctgcgccgcg ccgccagcgg tccgcgatcg ttgcggccc tagccagtgg	17100
caactggcaa agcacactga acagcatcgt gggctctggg gtgcaatccc tgaagcgccg	17160
acgatgcttc tgatagctaa cgtgtcgtat gtgtgtcatg tatgcgtcca tgtcgccgcc	17220
agaggagctg ctgagccgcc gcgcgccgcg tttccaagat ggctaccctc tcgatgatgc	17280
cgcagtggtc ttacatgcac atctcgggcc aggacgcctc ggagtacctg agccccgggc	17340
tggtgcagtt tgccccgcgc accgagacgt acttcagcct gaataacaag tttagaaacc	17400
ccacggtggc gcctacgcac gacgtgacca cagaccggtc ccagcgtttg acgctgcggt	17460
tcacccctgt ggaccgtgag gatactgcgt actcgtacaa ggcgcggttc accctagctg	17520
tgggtgataa ccgtgtgctg gacatggcct ccacgtactt tgacatccgc ggcgtgctgg	17580
acagggggcc tacttttaag ccctactctg gcactgccta caacgccctg gctcccaagg	17640
gtgccccaaa tccttgcgaa tgggatgaag ctgctactgc tcttgaaata aacctagaag	17700
aagaggacga tgacaacgaa gacgaagtag acgagcaagc tgagcagcaa aaaactcacg	17760
tatttgggca ggcgccctat tctgtataa atattacaaa ggagggtatt caaatagggtg	17820
tcgaaggcca aacacctaaa tatgccgata aaacatttca acctgaacct caaataggag	17880
aatctcagtg gtacgaaaca gaaattaatc atgcagctgg gagagtccca aaaaagacta	17940
cccaatgaa accatgttac ggttcatatg caaaacccac aaatgaaaat ggagggcaag	18000
gcattcttgt aaagcaacaa atgggaaagc tagaaagcca agtggaatg caatttttct	18060
caactactga ggcagccgca ggcaatgggtg ataacttgac tcctaaagtg gtattgtaca	18120
gtgaagatgt agatatagaa accccagaca ctcatatttc ttacatgccc actattaagg	18180
aaggtaaact acgagaacta atgggccaac aatctatgcc caacaggcct aattacattg	18240
cttttaggga caattttatt ggtctaattg attacaacag cagggttaat atgggtgttc	18300
tggcgggcca agcatcgagc ttgaatgctg ttgtagattt gcaagacaga aacacagagc	18360
tttcatacca gcttttgctt gattccattg gtgatagaac caggctactt tctatgtgga	18420
atcaggctgt tgacagctat gatccagatg ttagaattat tgaaaatcat ggaactgaag	18480
atgaacttcc aaattactgc ttccactgg gaggtgtgat taatacagag actcttaccg	18540
aggtaaaacc taaaacaggt caggaaaatg gatgggaaaa agatgctaca gaattttcag	18600
ataaaaatga aataagagtt ggaaataatt ttgccatgga aatcaatcta aatgccaaac	18660
tgtggagaaa ttctctgtac tccaacatag cgctgtatct gcccgacaag ctaaagtaca	18720
gtccttccaa cgtaaaaatt tctgataacc caaacaccta cgactacatg aacaagcgag	18780
tggtggctcc cgggctagtg gactgctaca ttaaccttgg agcacgctgg tcccttgact	18840
atatggacaa cgtcaaccca ttttaaccacc accgcaatgc tggcctgcgc taccgctcaa	18900
tgttgctggg caatggctgc tatgtgccct tccacatcca ggtgcctcag aagttctttg	18960
ccattaaaaa cctccttctc ctgccgggct catacaccta cgagtggaac ttcaggaagg	19020

atgttaacat ggttctgcag agctccctag gaaatgacct aagggttgac ggagccagca	19080
ttaagtttga tagcatttgc ctttacgcca ctttcttccc catggcccac aacaccgcct	19140
ccacgcttga ggccatgctt agaaacgaca ccaacgacca gtcctttaac gactatctct	19200
ccgccgcaa catgctctac cctatacccg ccaacgctac caacgtgccc atatccatcc	19260
cctcccgcaa ctggcgggct ttccgcggtt gggccttcac gcgccttaag actaaggaaa	19320
ccccatcact gggctcgggc tacgaccctt attacaccta ctctggctct ataccctacc	19380
tagatggaac cttttaccte aaccacacct ttaagaaggt ggccattacc tttgactctt	19440
ctgtcagctg gcctggcaat gaccgcctgc ttacccccaa cgagtttgaa attaagcgct	19500
cagttgacgg ggagggttac aacgttgccc agtgaacat gaccaaagac tggttcctgg	19560
tacaaatgct agctaactat aacattggct accagggctt ctatatccca gagagctaca	19620
aggaccgcat gtactccttc tttagaaact tccagcccat gagccgtcag gtggtggatg	19680
atactaaata caaggactac caacaggtgg gcacccctaca ccaacacaa aactctggat	19740
ttgttggtta ccttgccccc accatgcgcg aaggacaggc ctaccctgct aacttccct	19800
atccgcttat aggcaagacc gcagttgaca gcattaccca gaaaaagttt ctttgcgatc	19860
gcaccctttg gcgcacccca ttctccagta actttatgtc catgggcgca ctcacagacc	19920
tgggcaaaaa ctttctctac gccaaactccg cccacgcgct agacatgact tttgaggtgg	19980
atcccatgga cgagcccacc cttctttatg tttgtttga agtctttgac gtggtccgtg	20040
tgcaccagcc gcaccgcggc gtcacgaaa ccgtgtacct gcgcacgccc ttctcgccg	20100
gcaacgccac aacataaaga agcaagcaac atcaacaaca gctgccgcca tgggctccag	20160
tgagcaggaa ctgaaagcca ttgtcaaaga tcttggttgt gggccatatt ttttgggcac	20220
ctatgacaag cgctttccag gctttgtttc tccacacaag ctgcctgctg ccatagtcaa	20280
tacggccggt cgcgagactg ggggcgtaca ctggatggcc tttgcctgga acccgactc	20340
aaaaacatgc tacctctttg agcccttttg cttttctgac cagcgactca agcaggttta	20400
ccagtttgag tacgagtcac tcctgcgcg tagcgccatt gcttcttccc ccgaccgctg	20460
tataacgctg gaaaagtcca cccaaagcgt acaggggccc aactcgccg cctgtggact	20520
attctgctgc atgtttctcc acgcctttgc caactggccc caaactccca tggatcacia	20580
ccccaccatg aaccttatta ccggggtacc caactccatg ctcaacagtc ccaggtaca	20640
gcccaccctg cgtcgcaacc aggaacagct ctacagcttc ctggagcgcc actcgcccta	20700
cttccgcagc cacagtgcgc agattaggag cgccacttct ttttgtcact tgaaaaacat	20760
gtaaaaataa tgtactagag acactttcaa taaaggcaaa tgcttttatt tgtacactct	20820
cgggtgatta ttaccacca cccttgccgt ctgcgccgtt taaaaatcaa aggggttctg	20880
ccgcgcatcg ctatgcgcca ctggcaggga cacgttgca tactggtgtt tagtgctcca	20940
cttaaaactca ggcacaacca tccgcggcag ctcggtgaag ttttactcc acaggctgcg	21000
caccatcacc aacgcgttta gcaggtcggg cgccgatatc ttgaagtcgc agttggggcc	21060
tccgccctgc gcgcgcgagt tgcgatacac aggggtgcag cactggaaca ctatcagcgc	21120
cgggtggtgc acgctggcca gcacgctctt gtcggagatc agatccgcgt ccaggtcctc	21180
cgcggtgtgc agggcgaacg gagtcaactt tggtagctgc cttcccaaaa agggcgcgctg	21240

cccaggcttt gagttgact cgcaccgtag tggcatcaaa aggtgaccgt gcccggtctg 21300
 ggcgttagga tacagcgct gcataaaagc cttgatctgc ttaaagcca cctgagcctt 21360
 tgcgccttca gagaagaaca tgccgcaaga cttgccggaa aactgattgg ccggacaggc 21420
 cgcgtcgtgc acgcagcacc ttgcgtcgggt gttggagatc tgcaccacat ttcggcccca 21480
 ccggttcttc acgatcttgg ccttgctaga ctgctccttc agcgcgcgt gcccgtttcc 21540
 gctcgtcaca tccatttcaa tcacgtgctc cttatttato ataagtcttc cgtgtagaca 21600
 cttagctcg ccttcgatct cagcgcagcg gtgcagccac aacgcgcagc ccgtgggctc 21660
 gtgatgcttg taggtcacct ctgcaaacga ctgcaggtac gcctgcagga atcgcccat 21720
 catcgtcaca aaggctcttg tgctgggtgaa ggtcagctgc aaccgcgggt gctcctcgtt 21780
 cagccaggtc ttgcatacgg ccgcagagc ttcacttgg tcaggcagta gtttgaagtt 21840
 cgcctttaga tcgttatcca cgtggtactt gtccatcagc gcgcgcgcag cctccatgcc 21900
 cttctccac gcagacacga tcggcacact cagcgggttc atcaccgtaa tttcacttcc 21960
 cgcttcgctg ggctcttctt cttctcttgg cgtccgcata ccacgcgcca ctgggtcgtc 22020
 ttcattcagc cgcgcgactg tgcgcttacc tcctttgcca tgcttgatta gcaccggtgg 22080
 gttgctgaaa cccaccattt gtagcgccac atcttctctt tcttctcgc tgtccacgat 22140
 tacctctggt gatggcgggc gctcgggctt gggagaaggc cgcttctttt tcttcttggg 22200
 cgcaatggcc aaatccgccg ccgaggtcga tggccgcggg ctgggtgtgc gcggcaccag 22260
 cgcgtcttgt gatgagtctt cctcgtcctc ggactcgata cgcgcgctca tccgcttttt 22320
 tgggggcgcc cggggaggcg gcggcgacgg ggacggggac gacacgtcct ccatggttgg 22380
 gggacgtcgc gccgcaccgc gtccgcgctc ggggggtggt tcgcgctgct cctcttcccg 22440
 actggccatt tccttctcct ataggcagaa aaagatcatg gagtcatcg agaagaagga 22500
 cagcctaacc gccccctctg agttcgccac caccgcctcc accgatgccg ccaacgcgcc 22560
 taccaccttc cccgtcgagg caccctcgct tgaggaggag gaagtgatta tcgagcagga 22620
 cccaggtttt gtaagcgaag acgacgagga ccgctcagta ccaacagagg ataaaaagca 22680
 agaccaggac aacgcagagg caaacgagga acaagtcggg cggggggacg aaaggcatgg 22740
 cgactaccta gatgtgggag acgacgtgct gttgaagcat ctgcagcgcc agtgcgccat 22800
 tatctgcgac gcgttgcaag agcgcagcga tgtgcccctc gccatagcgg atgtcagcct 22860
 tgcctacgaa cgccacctat tctcaccgcg cgtaccccc aaacgccaag aaaacggcac 22920
 atgcgagccc aaccgcgcc tcaacttcta ccccgatatt gccgtgccag aggtgcttgc 22980
 cacctatcac atctttttcc aaaactgcaa gataccccta tcctgccgtg ccaaccgcag 23040
 ccgagcggac aagcagctgg ccttgcggca gggcgctgct atacctgata tcgcctcgtc 23100
 caacgaagtg ccaaaaatct ttgagggtct tggacgcgac gagaagcgcg cggcaaacgc 23160
 tctgcaacag gaaaacagcg aaaatgaaag tactctgga gtgttggtgg aactcgaggg 23220
 tgacaacgcg cgcctagcgg tactaaaacg cagcatcgag gtcaaccact ttgcctaccc 23280
 ggcacttaac ctacccccca aggtcatgag cacagtcag agtgagctga tcgtgcgccg 23340
 tgcgagccc ctggagaggg atgcaaattt gcaagaacaa acagaggagg gcctacccgc 23400
 agttggcgac gagcagctag cgcgtgggt tcaaacgcgc gagcctgccg acttggagga 23460

gcgacgcaaa ctaatgatgg ccgcagtgct cgttaccgtg gagcttgagt gcatgcagcg	23520
gttctttgct gacccggaga tgcagcgcaa gctagaggaa acattgcaact acacctttcg	23580
acagggctac gtacgccagg cctgcaagat ctccaacgtg gagctctgca acctgggtctc	23640
ctaccttga attttgacg aaaaccgcct tgggcaaaac gtgcttcatt ccacgctcaa	23700
ggcgagggcg cgccgcgact acgtccgcga ctgcgtttac ttatttctat gctacacctg	23760
gcagacggcc atgggcgttt ggcagcagtg cttggaggag tgcaacctca aggagctgca	23820
gaaactgcta aagcaaaact tgaaggacct atggacggcc ttcaacgagc gctccgtggc	23880
cgcgcacctg gcggacatca ttttccccga acgcctgctt aaaaccctgc aacagggctc	23940
gccagacttc accagtcaaa gcatgttgca gaactttagg aactttatcc tagagcgctc	24000
aggaatcttg cccgccacct gctgtgcaact tcctagcgac tttgtgcca ttaagtaccg	24060
cgaatgccct ccgcgcgttt ggggccactg ctaccttctg cagctagcca actaccttgc	24120
ctaccactct gacataatgg aagacgtgag cggtagcggg ctactggagt gtcactgtcg	24180
ctgcaaccta tgcaccccg accgctccct ggtttgcaat tcgcagctgc ttaacgaaag	24240
tcaaattatc ggtaccttg agctgcaggg tccctcgctt gacgaaaagt ccgcggctcc	24300
ggggttgaaa ctactccgg ggctgtggac gtcggcttac cttcgcaa at ttgtacctga	24360
ggactaccac gccacgaga ttaggttcta cgaagaccaa tcccggccgc ctaatgcgga	24420
gcttaccgcc tgcgtcatta cccaggcca cattcttggc caattgcaag ccatcaacaa	24480
agcccgccaa gagtttctgc tacgaaagg acggggggtt tacttgacc cccagtccgg	24540
cgaggagctc aacccaatcc ccccgccgc gcagccctat cagcagcagc cgcgggccct	24600
tgcttcccag gatggcacc aaaaagaagc tgcagctgcc gccgccacc acggacgagg	24660
aggaatactg ggacagtcag gcagaggagg ttttggacga ggaggaggag gacatgatgg	24720
aagactggga gagcctagac gaggaagctt ccgaggtcga agaggtgtca gacgaaacac	24780
cgtcacccctc ggtcgcattc ccctcgccg cgcccagaa atcggaacc ggttccagca	24840
tggtacaac ctccgctcct caggcgccgc cggcactgcc cgttcgccga cccaaccgta	24900
gatgggacac cactggaacc agggccggtt agtccaagca gccgccgcg ttagcccaag	24960
agcaacaaca gcgccaaggc taccgctcat ggcgcgggca caagaacgcc atagttgctt	25020
gcttgcaaga ctgtgggggc aacatctcct tcgcccgcg ctttcttctc taccatcacg	25080
gcgtggcctt cccccgtaac atcctgcatt actaccgtca tctctacagc ccatactgca	25140
ccggcggcag cggcagcaac agcagcggcc acacagaagc aaagcgacc ggatagcaag	25200
actctgacaa agcccaagaa atccacagcg gcggcagcag caggaggagg agcgtgcgt	25260
ctggcgccca acgaaccgt atcgaccgc gagcttagaa acaggatttt tccactctg	25320
tatgctatat ttcaacagag caggggcca gaacaagagc tgaaaataaa aaacaggtct	25380
ctgcgatccc tcaccgcag ctgcctgtat cacaaaagc aagatcagct tcggcgcacg	25440
ctggaagacg cggaggtct cttcagtaaa tactgcgcgc tgactcttaa ggactagttt	25500
cgcgcccttt ctcaaattta agcgcgaaaa ctacgtcatc tccagcggcc acaccggcg	25560
ccagcacctg ttgtcagcg cattatgagc aaggaaattc ccacgcccta catgtggagt	25620
taccagccac aaatgggact tgcggctgga gctgccaag actactcaac ccgaataaac	25680

tacatgagcg	cgggacccca	catgatatacc	cgggtcaacg	gaatacgcgc	ccaccgaaac	25740
cgaattctcc	tggaacaggc	ggctattacc	accacacctc	gtaataacct	taatccccgt	25800
agttggcccc	ctgccctggt	gtaccaggaa	agtcccgctc	ccaccactgt	ggtacttccc	25860
agagacgccc	aggccgaagt	tcagatgact	aactcagggg	cgcagcttgc	gggcggcttt	25920
cgtcacaggg	tgcggtcgcc	cgggcagggg	ataactcacc	tgacaatcag	agggcgagggt	25980
attcagctca	acgacgagtc	ggtgagctcc	tcgcttggtc	tccgtccgga	cgggacattt	26040
cagatcggcg	gcgccggcgc	ctcttcattc	acgcctcgtc	aggcaatcct	aactctgcag	26100
acctcgctct	ctgagccgcg	ctctggaggg	attggaactc	tgcaatttat	tgaggagttt	26160
gtgccatcgg	tctactttaa	ccccttctcg	ggacctcccg	gccactatcc	ggatcaattt	26220
attcctaact	ttgacgcggt	aaaggactcg	gcggacggct	acgactgaat	gttaagtggg	26280
gaggcagagc	aactgcgcct	gaaacacctg	gtccactgtc	gccgccacaa	gtgctttgcc	26340
cgcgactccg	gtgagttttg	ctactttgaa	ttgcccgagg	atcatatcga	gggcccggcg	26400
cacggcgctc	ggcttaccgc	ccaggggagag	cttgcccgtg	gcctgattcg	ggagtttacc	26460
cagcgccccc	tgctagttag	gcgggacagg	ggacctgtg	ttctcactgt	gatttgcaac	26520
tgctctaacc	ctggattaca	tcaagatctt	tggtgccatc	tctgtgctga	gtataataaa	26580
tacagaaatt	aaaatatact	ggggctccta	tcgccatcct	gtaaacgcca	ccgtcttcac	26640
ccgcccgaagc	aaaccaaggc	gaaccttacc	tggtactttt	aacatctctc	cctctgtgat	26700
ttacaacagt	ttcaaccagc	acggagtgag	tctacgagag	aacctctccg	agctcagcta	26760
ctccatcaga	aaaaacacca	ccctccttac	ctgccgggaa	cgtacgagtg	cgtcacccgc	26820
cgtcgcacca	cacctaccgc	ctgaccgtaa	accagacttt	ttccggacag	acctcaataa	26880
ctctgtttac	cagaacagga	ggtgagctta	gaaaaccctt	agggatttag	gccaaaggcg	26940
cagctactgt	ggggtttatg	aacaattcaa	gcaactctac	gggctattct	aattcagggt	27000
tctctagaat	cggggttggg	gttattctct	gtcttgtgat	tctctttatt	cttataactaa	27060
cgttctctcg	cctaaggctc	gccgcctgct	gtgtgcacat	ttgcatttat	tgtcagcttt	27120
ttaaacgctg	gggtcgccac	ccaagatgat	taggtacata	atcctagggt	tactcacctt	27180
tgcgtcagcc	cacggtagca	cccaaaagggt	ggattttaag	gagccagcct	gtaatgttac	27240
attcgcagct	gaagctaatt	agtgcaccac	tcttataaaa	tgaccacag	aacatgaaaa	27300
gctgcttatt	cgcacaaaaa	acaaaattgg	caagtatgct	gtttatgcta	tttggcagcc	27360
aggtgacact	acagagtata	atgttacagt	tttcagggtt	aaaagtcata	aaacttttat	27420
gtatactttt	ccatttttatg	aaatgtgcga	cattaccatg	tacatgagca	aacagtataa	27480
gttgtggccc	ccacaaaatt	gtgtggaaaa	cactggcact	ttctgctgca	ctgctatgct	27540
aattacagtg	ctcgcttttg	tctgtaccct	actctatatt	aaatacaaaa	gcagacgcag	27600
ctttattgag	gaaaagaaaa	tgctttaatt	tactaagtta	caaagcta	gtcaccacta	27660
actgctttac	tcgctgcttg	caaaaacaat	tcaaaaagtt	agcattataa	ttagaatagg	27720
atttaaaccc	cccggtcatt	tctgtctcaa	taccattccc	ctgaacaatt	gactctatgt	27780
gggatatgct	ccagcgctac	aaccttgaa	tcaggcttcc	tggtatgtcag	catctgactt	27840
tggccagcac	ctgtcccgcg	gatttgttcc	agtccaacta	cagcgaccca	ccctaacaga	27900

gatgaccaac acaaccaacg cggcgcgcgc taccggactt acatctacca caaatacacc	27960
ccaagtttct gcctttgtca ataactggga taacttgggc atgtggtggt tctccatagc	28020
gcttatgttt gtatgcctta ttattatgtg gctcatctgc tgcctaaagc gcaaacgcgc	28080
ccgaccaccc atctatagtc ccatcattgt gctacaccca aacaatgatg gaatccatag	28140
attggacgga ctgaaacaca tgttttttct tcttacagta tgattaaatg agacatgatt	28200
cctcgagttt ttatattact gacccttggt gcgctttttt tgtgcgtgct ccacattggc	28260
tgcggtttct cacatcgaag tagactgcat tccagccttc acagtctatt tgccttacgg	28320
atgtgtcacc ctcacgctca tctgcagcct catcactgtg gtcacgcctt ttatccagt	28380
cattgactgg gtctgtgtgc gctttgcata tctcagacac catccccagt acagggacag	28440
gactatagct gagcttctta gaattcttta attatgaaat ttactgtgac ttttctgctg	28500
attatttgca ccctatctgc gttttgttcc ccgacctcca agcctcaaag acatatatca	28560
tgcagattca ctcgtatatg gaatatcca agttgctaca atgaaaaaag cgatctttcc	28620
gaagcctggg tatatgcaat catctctgtt atggtgttct gcagtaccat cttagcccta	28680
gctatatatc cctaccttga cattggctgg aacgcaatag atgccatgaa ccaccaact	28740
ttccccgcgc ccgctatgct tccactgcaa caagttgttg ccggcggcct tgtcccagcc	28800
aatcagcctc gccacacctc tcccaccccc actgaaatca gctactttaa tctaacagga	28860
ggagatgact gacacctag atctagaaat ggacggaatt attacagagc agcgctgct	28920
agaaagacgc agggcagcgg ccgagcaaca gcgcatgaat caagagctcc aagacatggt	28980
taacttgcac cagtgcacaaa ggggtatctt ttgtctggta aagcaggcca aagtcaccta	29040
cgacagtaat accaccggac accgccttag ctacaagttg ccaaccaagc gtcagaaatt	29100
ggtggtcatg gtgggagaaa agcccattac cataactcag cactcggtag aaaccgaagg	29160
ctgcattcac tcacctgtgc aaggacctga ggatctctgc acccttatta agaccctgtg	29220
cggtctcaaa gatcttattc cctttaacta ataaaaaaa ataataaagc atcacttact	29280
taaaatcagt tagcaaatth ctgtccagtt tattcagcag cacctccttg cctcctccc	29340
agctctggta ttgcagcttc ctcttggtg caaactttct ccacaatcta aatggaatgt	29400
cagtttctc ctgttctgt ccatccgcac ccactatctt catgttggtg cagatgaagc	29460
gcgcaagacc gtctgaagat acctcaacc ccgtgtatcc atatgacacg gaaaccggtc	29520
ctccaactgt gccttttctt actcctccct ttgtatcccc caatgggttt caagagagtc	29580
cccctggggt actctctttg cgcctatccg aacctctagt tacctccaat ggcatgcttg	29640
cgctcaaaat gggcaacggc ctctctctgg acgaggccgg caaccttacc tcccaaatg	29700
taaccactgt gagcccacct ctcaaaaaaa ccaagtcaaa cataaacctg gaaatatctg	29760
caccctcac agttacctca gaagccctaa ctgtggctgc cgccgcacct ctaatggctg	29820
cgggcaacac actcaccatg caatcacagg ccccgctaac cgtgcacgac tccaaactta	29880
gcattgccac ccaaggaccc ctcacagtgt cagaaggaaa gctagccctg caaacatcag	29940
gccccctcac caccaccgat agcagtaccc ttactatcac tgcctcacc cctctaacta	30000
ctgccactgg tagcttgggc attgacttga aagagcccat ttatacacia aatggaaaac	30060
taggactaaa gtacggggct cctttgcatg taacagacga cctaaacact ttgaccgtag	30120

caactgggtcc aggtgtgact attaataata cttccttgca aactaaagt actggagcct	30180
tgggttttga ttcacaaggc aatatgcaac ttaatgtagc aggaggacta aggattgatt	30240
ctcaaaacag acgccttata cttgatgtta gttatccgtt tgatgctcaa aaccaactaa	30300
atctaagact aggacagggc cctcttttta taaactcagc ccacaacttg gatattaact	30360
acaacaaagg cctttacttg tttacagctt caaacaattc caaaaagctt gaggttaacc	30420
taagcactgc caaggggttg atgtttgacg ctacagccat agccattaat gcaggagatg	30480
ggcttgaatt tggttcacct aatgcaccaa acacaaatcc cctcaaaaca aaaattggcc	30540
atggcctaga atttgattca aacaaggcta tggttcctaa actaggaact ggccttagtt	30600
ttgacagcac aggtgccatt acagtaggaa acaaaaaataa tgataagcta actttgtgga	30660
ccacaccagc tccatctcct aactgtagac taaatgcaga gaaagatgct aaactcactt	30720
tggctttaac aaaatgtggc agtcaaatac ttgctacagt ttcagttttg gctgttaaag	30780
gcagtttggc tccaatatct ggaacagttc aaagtgtcga tcttattata agatttgacg	30840
aaaatggagt gctactaaac aattccttcc tggaccaga atattggaac tttagaaatg	30900
gagatcttac tgaaggcaca gcctatacaa acgctgttgg atttatgcct aacctatcag	30960
cttatccaaa atctcacggt aaaactgcc aagtaacat tgtcagtcga gtttacttaa	31020
acggagacaa aactaaacct gtaacactaa ccattacact aaacggtaca caggaaacag	31080
gagacacaac tccaagtgc tactctatgt cattttcatg ggactgggtc gccacaaact	31140
acattaatga aatatttgcc acatcctctt acactttttc atacattgcc caagaataaa	31200
gaatcgtttg tgttatgttt caacgtgttt atttttcaat tgcagaaaat ttcaagtcat	31260
ttttcattca gtagtatagc cccaccacca catagcttat acagatcacc gtaccttaat	31320
caaactcaca gaaccctagt attcaacctg ccacctccct cccaacacac agagtacaca	31380
gtcctttctc cccggctggc cttaaaaagc atcatatcat gggtaacaga catattctta	31440
gggtgtatat tccacacggt ttctgtcga gccaaacgct catcagtgat attaataaac	31500
tccccgggca gctcacttaa gttcatgtcg ctgtccagct gctgagccac aggtgctgt	31560
ccaacttgcg gttgcttaac gggcggcgaa ggagaagtcc acgcctacat gggggtagag	31620
tcataatcgt gcatcaggat agggcggttg tgctgcagca gcgcgcgaat aaactgctgc	31680
cgccgcgct cgcctctgca ggaatacaac atggcagtg tctcctcagc gatgattcgc	31740
accgccgcga gcataaggcg ccttgtctc cgggcacagc agcgcacct gatctcactt	31800
aaatcagcac agtaactgca gcacagcacc acaatatgt tcaaaatccc acagtgaag	31860
gcgctgtatc caaagctcat ggcggggacc acagaaccca cgtggccatc ataccacaag	31920
cgcaggtaga ttaagtggcg acccctcata aacacgctgg acataaacat tacctctttt	31980
ggcatgttgt aattcaccac ctcccggtac catataaacc tctgattaaa catggcgcca	32040
tccaccacca tcctaaacca gctggccaaa acctgccgc cggctataca ctgcagggaa	32100
ccgggactgg aacaatgaca gtggagagcc caggactcgt aaccatggat catcatgctc	32160
gtcatgatat caatgttggc acaacacagc cacacgtgca tacacttct caggattaca	32220
agctcctccc gcgttagaac catatcccag ggaacaaccc attcctgaat cagcgtaaat	32280
cccacactgc aggaagacc tcgcacgtaa ctcacgttgt gcattgtcaa agtgttacat	32340

16

tcgggcagca gcggatgac ctccagtatg gtagcgcggy tttctgtctc aaaaggaggt	32400
agacgatccc tactgtacgg agtgcgccga gacaaccgag atcgtgttg tctagtgtc	32460
atgccaaatg gaacgccgga cgtagtcata tttcctgaag caaaaccagg tgcgggcgtg	32520
acaaacagat ctgcgtctcc ggtctcgccg cttagatcgc tctgtgtagt agttgtagta	32580
tatccactct ctcaaagcat ccaggcgccc cctggcttcg ggttctatgt aaactccttc	32640
atgcgcgct gccctgataa catccaccac cgcagaataa gccacacca gccaacctac	32700
acattcggtc tgcgagtcac acacgggagg agcgggaaga gctggaagaa ccatgttttt	32760
ttttttattc caaaagatta tccaaaacct caaaatgaag atctattaag tgaacgcgct	32820
cccctcgggt ggctgtgtca aactctacag ccaaagaaca gataatggca tttgtaagat	32880
gttgacacat ggcttccaaa agggcaaagg cctcacgct caagtggacg taaaggctaa	32940
acccttcagg gtgaatctcc tctataaaca ttccagcacc ttcaacctg cccaaataat	33000
tctcatctcg ccaccttctc aatatatctc taagcaaatc ccgaatatta agtccggcca	33060
ttgtaaaaat ctgctccaga gcgcctcca ccttcagcct caagcagcga atcatgattg	33120
caaaaattca ggttcctcac agacctgtat aagattcaaa agcgggaacat taacaaaaat	33180
accgcatcc cgtaggtccc ttgcgaggc cagctgaaca taatcgtgca ggtctgcacg	33240
gaccagcgcg gccacttccc cgccaggaac catgacaaaa gaaccacac tgattatgac	33300
acgcatactc ggagctatgc taaccagcgt agccccgatg taagcttggt gcattggcgg	33360
cgatataaaa tgcaagggtc tgctcaaaaa atcaggcaaa gcctcgcgca aaaaagaaag	33420
cacatcgtag tcatgctcat gcagataaag gcaggtaagc tccggaacca ccacagaaaa	33480
agacaccatt tttctctcaa acatgtctgc gggtttctgc ataaacacaa aataaaataa	33540
caaaaaaaca tttaaacatt agaagcctgt cttacaacag gaaaaacaac ccttataagc	33600
ataagacgga ctacggccat gccggcgtga ccgtaaaaaa actggtcacc gtgattaaaa	33660
agcaccaccg acagctctc ggtcatgtcc ggagtcataa tgtaagactc ggtaaacaca	33720
tcagggtgat tcacatcggt cagtgtctaa aagcgaccga aatagcccgg gggaatacat	33780
accgcgaggc gtagagacaa cattacagcc cccataggag gtataacaaa attaatagga	33840
gagaaaaaca cataaacacc tgaaaaaccc tcctgcctag gcaaaatagc accctcccgc	33900
tccagaacaa catacagcgc ttccacagcg gcagccataa cagtcagcct taccagtaaa	33960
aaagaaaacc tattaataaa acaccactcg acacggcacc agctcaatca gtcacagtgt	34020
aaaaaaggcg caagtgcaga gcgagtatat ataggactaa aaaatgacgt aacggttaaa	34080
gtccacaaaa aacaccgaga aaaccgcacg cgaacctacg ccagaaaacg aaagccaaaa	34140
aaccacaaac ttcctcaaat cgtaacttcc gttttcccac gttacgtcac ttcccatttt	34200
aagaaaacta caattcccaa cacatacaag ttactccgcc ctaaaacctc cgtcaccgcg	34260
cccggttcca cgccccgcgc caggtcacia actccacccc ctcatatca tattggcttc	34320
aatccaaaat aaggtatatt attgatgatg	34350

<210> 2
 <211> 590
 <212> DNA
 <213> Artificial sequence

<220>

<223> TNFR portion of the TNFR-Fas chimera (Fas-c)

<400> 2

```

atgggcctct ccaccgtgcc tgacctgctg ctgccgctgg tgctcctgga gctgttggtg      60
ggaatatacc cctcaggggt tattggactg gtccctcacc taggggacag ggagaagaga      120
gatagtgtgt gtccccaagg aaaatatatc caccctcaaa ataattcgat ttgctgtacc      180
aagtgccaca aaggaaccta cttgtacaat gactgtccag gcccggggca ggatacggac      240
tgcagggagt gtgagagcgg ctccctcacc gcttcagaaa accacctcag aactgcctc      300
agctgctcca aatgccgaaa ggaaatgggt caggtggaga tctcttcttg cacagtggac      360
cgggacaccg tgtgtggctg caggaagaac cagtaccggc attattggag tgaaaacctt      420
ttccagtgtt tcaattgcag cctctgcctc aatgggaccg tgcacctctc ctgccaggag      480
aaacagaaca ccgtgtgcac ctgccatgca ggtttctttc taagagaaaa cgagtgtgtc      540
tcctgtagta actgtaagaa aagcctggag tgcacgaagt tgtgcctacc      590

```

<210> 3

<211> 511

<212> DNA

<213> Artificial sequence

<220>

<223> Fas portion of the TNFR-Fas chimera (Fas-c)

<400> 3

```

aagcttagga tccagatcta acttgggggtg gctttgtctt cttcttttgc caattccact      60
aattgttttg gtgaagagaa aggaagtaca gaaaacatgc agaaagcaca gaaaggaaaa      120
ccaaggttct catgaatctc caaccttaaa tcctgaaaca gtggcaataa atttatctga      180
tgttgacttg agtaaatata tcaccactat tgctggagtc atgacactaa gtcaagttaa      240
aggctttgtt cgaaagaatg gtgtcaatga agccaaaata gatgagatca agaatgacaa      300
tgtccaagac acagcagaac agaaagtcca actgcttcgt aattggcatc aacttcatgg      360
aaagaaagaa gcgtatgaca cattgattaa agatctcaaa aaagccaatc ttgtactct      420
tgcagagaaa attcagacta tcactctcaa ggacattact agtgactcag aaaattcaaa      480
cttcagaaat gaaatccaaa gcttggctta g              511

```

<210> 4

<211> 1101

<212> DNA

<213> Artificial sequence

<220>

<223> TNFR1-Fas chimera (Fas-c) coding sequence

<400> 4

```

atgggcctct ccaccgtgcc tgacctgctg ctgccgctgg tgctcctgga gctgttggtg      60
ggaatatacc cctcaggggt tattggactg gtccctcacc taggggacag ggagaagaga      120
gatagtgtgt gtccccaagg aaaatatatc caccctcaaa ataattcgat ttgctgtacc      180
aagtgccaca aaggaaccta cttgtacaat gactgtccag gcccggggca ggatacggac      240
tgcagggagt gtgagagcgg ctccctcacc gcttcagaaa accacctcag aactgcctc      300
agctgctcca aatgccgaaa ggaaatgggt caggtggaga tctcttcttg cacagtggac      360

```

18

cgggacaccg tgtgtggctg caggaagaac cagtaccggc attattggag tgaaaacett 420
 ttccagtgt tcaattgcag cctctgcctc aatgggaccg tgcacctctc ctgccaggag 480
 aaacagaaca ccgtgtgcac ctgccatgca ggtttcttct taagagaaaa cgagtgtgtc 540
 tcctgtagta actgtaagaa aagcctggag tgcacgaagt tgtgcctacc aagcttagga 600
 tccagatcta acttgggggtg gctttgtctt cttcttttgc caattccact aattgtttgg 660
 gtgaagagaa aggaagtaca gaaaacatgc agaaagcaca gaaaggaaaa ccaaggttct 720
 catgaatctc caaccttaaa tcctgaaaca gtggcaataa atttatctga tgttgacttg 780
 agtaaatata tcaccactat tgctggagtc atgacactaa gtcaagttaa aggctttgtt 840
 cgaaagaatg gtgtcaatga agccaaaata gatgagatca agaatagaca tgtccaagac 900
 acagcagaac agaaagttca actgcttcgt aattggcatc aacttcattg aaagaaagaa 960
 gcgtatgaca cattgattaa agatctcaaa aaagccaatc tttgtactct tgcagagaaa 1020
 attcagacta tcacctctca ggacattact agtgactcag aaaattcaaa cttcagaaat 1080
 gaaatccaaa gcttgggtcta g 1101

<210> 5
 <211> 6
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Hypoxia responsive element - E-box

<400> 5 6
 gcacgt

<210> 6
 <211> 44
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Murine endothelial specific enhancer element

<400> 6 44
 gtacttcata cttttcattc caatgggggtg actttgcttc tgga

<210> 7
 <211> 143
 <212> DNA
 <213> Artificial sequence

<220>
 <223> A triplicate copy of a murine enhancer sequence originated from the PPE-1 promoter

<400> 7 60
 gtacttcata cttttcattc caatgggggtg actttgcttc tggaggggtga ctttgccttct
 ggagccagta cttcatactt ttcattgtac ttcatacttt tcattccaat ggggtgactt 120
 tgcttctgga ggctagctgc cag 143

<210> 8
 <211> 47
 <212> DNA
 <213> Artificial sequence

<220>

<223> EDC fragment

<400> 8

ctggagggtg actttgcttc tggagccagt acttcatact tttcatt

47

<210> 9

<211> 36460

<212> DNA

<213> Artificial sequence

<220>

<223> PPE-1-3X-FasC vir1 construct including repeat sequences

<220>

<221> misc_feature

<222> (460)..(1437)

<223> A modified murine pre-proendothelin-1 promoter (PPE-1-3X)

<220>

<221> misc_feature

<222> (1202)..(1207)

<223> Hypoxia response element

<220>

<221> misc_feature

<222> (1438)..(1468)

<223> Linker containing Restriction sites (NotI, PstI, BamHI)

<220>

<221> misc_feature

<222> (1469)..(2058)

<223> TNFR portion of the Fas-TNFR-1 chimera (Fas-c)

<220>

<221> misc_feature

<222> (2059)..(2569)

<223> FAS portion of the Fas-TNFR-1 chimera (Fas-c)

<220>

<221> misc_feature

<222> (2801)..(4062)

<223> Duplication - copy 1

<220>

<221> misc_feature

<222> (4063)..(5315)

<223> Duplication - copy 2

<400> 9

catcatcaat aatatacctt attttggatt gaagccaata tgataatgag ggggtggagt

60

ttgtgacgtg gcgcggggag tgggaacggg gcgggtagcg tagtagtggtg gcggaagtgt

120

gatgttgcaa gtgtggcgga acacatgtaa gcgacggatg tggcaaaagt gacgtttttg

180

gtgtgcgccg gtgtacacag gaagtgacaa ttttcgcgcg gtttttaggcg gatgtttag

240

taaatttggg cgtaaccgag taagatttgg ccattttcgc gggaaaactg aataagagga

300

agtgaatct gaataatttt gtgttactca tagcgcgtaa tatttgtcta gggccgagg

360

gactttgacc gtttacgtgg agactcgccc aggtgttttt cttaggtgtt ttccgcgttc

420

cgggtcaaag ttggcggttt attattatag tcagtacgta cgtgtacttc tgatcggcga

480

tactagggag ataaggatgt acctgacaaa accacattgt tgttggtatc attattattt

540

agttttcctt ccttgctaac tcctgacgga atctttctca ctcacaaatgc gaagtacttt

600

agtttagaaa agacttggtg gaaggggtgg tgggtgaaaa gtaggggtgat cttccaaact

660

aatctggttc cccgcccgcc ccagtagctg ggattcaaga gcgaagagtg gggatcgctc

720

ccttgtttga tcagaaagac ataaaaggaa aatcaagtga acaatgatca gccccacetc	780
caccocaccc ccctgcgcgc gcacaataca atctatttaa ttgtacttca tacttttcat	840
tccaatgggg tgactttgct tctggagaaa ctcttgattc ttgaactctg gggctggcag	900
ctagcctcca gaagcaaagt caccocattg gaatgaaaag tatgaagtac aatgaaaagt	960
atgaagtact ggctccagaa gcaaagtcac cctccagaag caaagtcacc ccattggaat	1020
gaaaagtatg aagtacgcta gcaaaagggg aagcgggctg ctgctctctg caggttctgc	1080
agcggctctct gtctagtggg tgttttcttt ttcttagccc tgcccttgga ttgtcagacg	1140
gcgggcgtct gcctctgaag ttagccgtga ttctctctag agccgggtct tatctctggc	1200
tgcacgttgc ctgtgggtga ctaatcacac aataacattg tttagggctg gaataaagtc	1260
agagctgttt accccacetc tataggggtt caatataaaa aggcggcgga gaactgtccg	1320
agtcagaagc gttcctgcac cggcgtgag agcctgaccc ggtctgctcc gctgtcctg	1380
cgcgtgcct cccggtgcc cgcgacgctt tcgccccagt ggaagggcca cttgctgcgg	1440
ccgctaattc tgcagatcgg gatccggcat gggcctctcc accgtgcctg acctgctgct	1500
gccgtggtg ctctggagc tgttggtggg aatatacccc tcaggggtta ttggactggt	1560
ccctcaccta ggggacaggg agaagagaga tagtgtgtgt cccaaggaa aatatatcca	1620
ccctcaaaat aattcgattt gctgtaccaa gtgccacaaa ggaacctact tgtacaatga	1680
ctgtccaggc cgggggcagg atacggactg cagggagtgt gagagcggct ccttcaccgc	1740
ttcagaaaac cacctcagac actgcctcag ctgctccaaa tgccgaaagg aaatgggtca	1800
ggtggagatc tcttcttgca cagtggaccg ggacaccgtg tgtggctgca ggaagaacca	1860
gtaccggcat tattggagtg aaaacctttt ccagtgttc aattgcagcc tctgcctcaa	1920
tgggaccgtg cacctctcct gccaggagaa acagaacacc gtgtgcacct gccatgcagg	1980
tttctttcta agagaaaacg agtgtgtctc ctgtagtaac tgtaagaaaa gcctggagtg	2040
cacgaagttg tgctaccaa gcttaggatc cagatctaac ttgggggtggc tttgtcttct	2100
tcttttgcca attccactaa ttgtttgggt gaagagaaag gaagtacaga aaacatgcag	2160
aaagcacaga aaggaaaacc aaggttctca tgaatctcca accttaaate ctgaaacagt	2220
ggcaataaat ttatctgatg ttgacttgag taaatatatc accactattg ctggagtcat	2280
gacactaagt caagttaaag gctttgttcg aaagaatggt gtcaatgaag ccaaaataga	2340
tgagatcaag aatgacaatg tccaagacac agcagaacag aaagttcaac tgcttcgtaa	2400
ttggcatcaa cttcatggaa agaaagaagc gtatgacaca ttgattaaag atctcaaaaa	2460
agccaatctt tgtactcttg cagagaaaat tcagactatc atcctcaagg acattactag	2520
tgactcagaa aattcaaact tcagaaatga aatccaaagc ttgggtctagc tcgagcatgc	2580
atctaggcgg ccgcatggca gaaattcgcg aattcgtctg cgtaacggga tcctctagac	2640
gagatccgaa cttgtttatt gcagcttata atggttacia ataaagcaat agcatcacia	2700
atttcacaaa taaagcattt ttttactgc attctagtgt tggtttgtcc aaactcatca	2760
atgtatctta tcatgtctag atctgtactg aaatgtgtgg gcgtggctta aggggtggaa	2820
agaatatata aggtgggggt cttatgtagt tttgtatctg ttttgagca gccgcgccg	2880
ccatgagcac caactcgttt gatggaagca ttgtgagctc atatttgaca acgcgcatgc	2940

ccccatgggc cggggtgctg cagaatgtga tgggctccag cattgatggt cgccccgtcc	3000
tgccccgcaaa ctctactacc ttgacctacg agaccgtgtc tggaacgccg ttggagactg	3060
cagcctccgc cgcgcgttca gccgctgcag ccaccgcccg cgggattgtg actgactttg	3120
ctttcctgag cccgcttgca agcagtgcag cttcccgttc atccgcccgc gatgacaagt	3180
tgacggctct tttggcacia ttggattctt tgaccggga acttaatgtc gtttctcagc	3240
agctgttga tctgcgccag caggtttctg cctgaaggc ttctctcccct cccaatgcgg	3300
tttaaaacat aaataaaaaa ccagactctg tttggatttg gatcaagcaa gtgtcttgct	3360
gtctttatth aggggttttg cgcgcgcggg agggccggga ccagcgggtct cggctcgttg	3420
gggtcctgtg ttttttttcc aggacgtggt aaagggtgact ctggatgttc agatacatgg	3480
gcataagccc gtctctgggg tggaggtagc accactgcag agcttcatgc tgcgggggtg	3540
tggtgtagat gatccagtcg tagcaggagc gctgggcgtg gtgcctaaaa atgtctttca	3600
gtagcaagct gattgccagg ggcaggccct tgggtgaagt gtttaciaag cggttaagct	3660
gggatgggtg catacgtggg gatagagat gcactcttga ctgtatthtt aggttggtta	3720
tgttcccagc catatccctc cggggattca tgtgtgcag aaccaccagc acagtgtatc	3780
cgggtgcactt gggaaatttg tcatgtagct tagaaggaaa tgcgtggaag aacttggtga	3840
cgccttctg acctccaaga ttttccatgc attcgtccat aatgatggca atggggccac	3900
gggcggcggc ctgggcgaag atatttctg gatcactaac gtcatagttg tgttccagga	3960
tgagatcgtc ataggccatt tttaciaagc gcggcgggag ggtgccagac tgcggtataa	4020
tggttccatc cggcccgagg gcgtagttag cctcacagat ttaagggtg gaaagaatat	4080
ataagggtgg ggtcttatgt agttttgtat ctgttttgca gcagccgccg ccgccatgag	4140
caccaactcg tttgatgaa gcattgtgag ctcatatttg acaacgcgca tgcccccatg	4200
ggccgggggt cgtcagaatg tgatgggtc cagcattgat ggtcgccccg tctgccccg	4260
aaactctact accttgacct acgagaccgt gtctggaacg ccgttggtga ctgcagcctc	4320
cgcgcgcgtc tcagccgctg cagccaccgc ccgcgggatt gtgactgact ttgctttcct	4380
gagcccgctt gcaagcagtg cagcttcccg ttcacccg ccgcatgaca agttgacggc	4440
tcttttgga caattggatt ctttgaccg ggaacttaat gtcgtttctc agcagctgtt	4500
ggatctgcgc cagcaggttt ctgcctgaa ggcttctctc cctcccaatg cggtttaaaa	4560
cataaataaa aaaccagact ctgtttgat ttgatcaag caagtgtctt gctgtcttta	4620
tttaggggtt ttgcgcgcgc ggtaggcccg ggaccagcgg tctcggtcgt tgagggctct	4680
gtgtatthtt tccaggacgt ggtaaagggt actctggatg ttcagataca tgggcataag	4740
cccgtctctg ggggtggagg agcaccactg cagagcttca tgcctggggg tgggtgtgta	4800
gatgatccag tcgtagcagg agcgtgggc gtggtgccta aaaatgtctt tcagtagcaa	4860
gctgattgcc aggggcaggc ccttggtgta agtgtttaca aagcgggtta gctgggatgg	4920
gtgcatacgt ggggatatga gatgcactt ggactgtatt tttagggttg ctatgttccc	4980
agccatatcc ctccgggat tcatgtgtg cagaaccacc agcacagtgt atccggtgc	5040
cttgggaaat ttgtcatgta gcttagaagg aaatgcgtgg aagaacttg agacgccctt	5100
gtgacctcca agattttcca tgcattcgtc cataatgatg gcaatggggc cagggcggc	5160

ggcctgggcg aagatatattc tgggatcact aacgtcatag ttgtgttcca ggatgagatc	5220
gtcataggcc atttttataa agcgcgggcg gagggtgcca gactgcggta taatggttcc	5280
atccggccca ggggcgtagt taccctcaca gatttgcatt tcccacgctt tgagttcaga	5340
tggggggatc atgtctacct gcggggcgat gaagaaaacg gtttccgggg taggggagat	5400
cagctgggaa gaaagcaggt tcctgagcag ctgcgactta ccgcagccgg tgggcccgta	5460
aatcacacct attaccggct gcaactggta gttaagagag ctgcagctgc cgtcatccct	5520
gagcaggggg gccacttcgt taagcatgtc cctgactcgc atgttttccc tgaccaaate	5580
cgccagaagg cgctcgccgc ccagcgatag cagttcttgc aaggaagcaa agtttttcaa	5640
cggtttgaga ccgtccggcg taggcatgct tttgagcgtt tgaccaagca gttccaggcg	5700
gtcccacagc tcggtcacct gctctacggc atctcgatcc agcatatctc ctctgttctgc	5760
gggttggggc ggctttcgct gtacggcagt agtcgggtgct cgtccagacg ggccagggtc	5820
atgtctttcc acgggcgcag ggtcctcgtc agcgtagtct gggtcacggt gaaggggtgc	5880
gctccgggct gcgcgctggc cagggtgcgc ttgaggtggt tcctgctggt gctgaagcgc	5940
tgccgggtctt cgccctgcgc gtcggccagg tagcatttga ccatggtgtc atagtccaga	6000
ccctccggcg cgtggccctt ggcgcgagc ttgcccttgg aggaggcgcc gcacgagggg	6060
cagtgcagac ttttgagggc gtagagcttg ggcgcgagaa ataccgattc cggggagtag	6120
gcatccgcgc cgcaggcccc gcagacggtc tcgcattcca cgagccagggt gagctctggc	6180
cgttcggggt caaaaaccag gtttcccca tgctttttga tgcgtttctt acctctggtt	6240
tccatgagcc ggtgtccacg ctcggtgacg aaaaggctgt ccgtgtcccc gtatacagac	6300
ttgagaggcc tgtcctcgag cgggtgtccg cggctcctct cgtatagaaa ctcggtaccac	6360
tctgagacaa aggtctcgct ccagggcagc acgaaggagg ctaagtggga ggggtagcgg	6420
tcgttgtcca ctagggggtc cactcgctcc aggggtgtgaa gacacatgtc gccctcttcg	6480
gcatcaagga aggtgattgg tttgtagggt tagggcacgt gaccgggtgt tcctgaaggg	6540
gggtataaaa agggggtggg ggcgcgctcg tcctcactct ctccgcacg gctgtctgcg	6600
agggccagct gttgggggtg gtactccctc tgaaaagcgg gcatgacttc tgcgctaaga	6660
ttgtcagttt ccaaaaacga ggaggatttg atattcacct ggcccgcggt gatgcctttg	6720
aggggtggcg catccatctg gtcagaaaag acaatctttt tgttgtcaag cttggtggca	6780
aacgaccgct agagggcggt ggacagcaac ttggcgatgg agcgaggggt ttggtttttg	6840
tcgcgatcgg cgcgctcctt ggccgcgatg tttagctgca cgtattcgcg cgcaacgcac	6900
cgccattcgg gaaagacggt ggtgcgctcg tcgggcacca ggtgcacgcg ccaaccgcgg	6960
ttgtgcaggg tgacaaggte aacgctggtg gctacctctc cgcgtaggcg ctctgttggtc	7020
cagcagaggc ggccgcccct gcgcgagcag aatggcggtg gggggtctag ctgcgtctcg	7080
tccggggggt ctgcgtccac ggtaaaagacc ccgggcagca ggcgcgctgc gaagtagtct	7140
atcttgcatc cttgcaagtc tagcgctctg tgccatgcgc gggcggaag cgcgcgctcg	7200
tatgggttga gtgggggacc ccatggcatg ggggtgggtg gcgcggaggc gtacatgccg	7260
caaatgtcgt aaacgtagag gggctctctg agtattccaa gatatgtagg gtagcatctt	7320
ccaccgcgga tgctggcgcg cacgtaatcg tatagttctg gcgagggagc gaggaggtcg	7380

ggaccgaggt tgctacgggc gggetgctct gctcgggaaga ctatctgcct gaagatggca	7440
tgtgagttgg atgatatggt tggacgctgg aagacgttga agctggcgtc tgtgagacct	7500
accgcgtcac gcacgaagga ggcttaggag tcgcgcagct tgttgaccag ctcggcggtg	7560
acctgcacgt ctagggcgca gtagtcagg gtttccttga tgatgtcata cttatcctgt	7620
cccttttttt tccacagctc gcggttgagg acaaactctt cgcggtcttt ccagtactct	7680
tggatcgga acccgctcgc ctccgaacgg taagagccta gcatgtagaa ctggttgacg	7740
gcctggtagg cgcagcatcc cttttctacg ggtagcgcgt atgcctgcgc ggccttcg	7800
agcgaggtgt gggtagcgc aaaggtgtcc ctgaccatga ctttgaggta ctggtatttg	7860
aagtcagtgt cgtcgcaccc gccctgctcc cagagcaaaa agtcgctgcg ctttttgaa	7920
cgcggatttg gcagggcgaa ggtgacatcg ttgaagagta tctttccgc gcgaggcata	7980
aagttgcgtg tgatcgga ggtcccgcc acctcggaac ggttgtaaat tacctggcg	8040
gcgagcacga tctcgtcaaa gccgttgatg ttgtggcca caatgtaaag ttccaagaag	8100
cgcgggatgc cttgatgga aggaatttt ttaagttcct ctaggtgag ctcttcagg	8160
gagctgagcc cgtgctctga aaggcccgag tctgcaagat gaggttgga agcgacgaat	8220
gagctccaca ggtcaccggc cattagcatt tgcaggtggt cgcgaaaggt cctaaactgg	8280
cgacctatgg ccattttttc tggggtgatg cagtagaagg taagcgggtc ttgttccag	8340
cggcccatc caagttcgc ggctaggtct cgcgcggcag tctactagagg ctcatctccg	8400
ccgaacttca tgaccagcat gaaggcacg agctgcttcc caaaggcccc catccaagta	8460
taggtctcta catcgtaggt gacaagaga cgctcgggtc gaggatgca gccgatcggg	8520
aagaactgga tctcccgcca ccaattggag gagtggctat tgatgtggtg aaagtagaag	8580
tccctgcgac gggccgaaca ctctgctgg cttttgtaaa aacgtgcgca gtactggcag	8640
cgggtcacgg gctgtacatc ctgcacgagg ttgacctgac gaccgcgcac aaggaagcag	8700
agtgggaatt tgagccctc gcctggcggg tttggctggt ggtcttctac ttcgctgct	8760
tgtccttgac cgtctggctg ctcgagggga gttacggtgg atcggaccac cacgccgcgc	8820
gagcccaaag tccagatgtc cgcgcgcggc ggtcggagct tgatgacaac atcgcgcaga	8880
tgggagctgt ccatggtctg gagctccgc ggcgtcaggt caggcgggag ctctgcagg	8940
tttacctcgc atagacgggt caggcgcgg gctagatcca ggtgatacct aatttccagg	9000
ggctggttg tggcggcgtc gatggttgc aagagccgc atccccgcgg cgcgactacg	9060
gtaccgcgcg gcgggcgggt ggccgcgggg gtgtccttgg atgatgcac taaaagcgg	9120
gacgcgggcg agccccgga ggtaggggg gctccggacc cgcgggaga ggggaggg	9180
gcacgtcggc gccgcgcgcg ggcaggagct ggtgctgcgc gcgtagggtg ctggcgaacg	9240
cgacgacgcg gcggttgatc tctgaatct ggcgcctctg cgtgaagacg acgggcccgg	9300
tgagcttga cctgaaagag agttcgacag aatcaatttc ggtgtcgttg acggcgcct	9360
ggcgcaaat ctctgcacg tctctgagt tgtcttgata ggcgatctcg gccatgaact	9420
gctcgatctc ttctctctgg agatctccgc gtccggtcgc ctccacggtg gcggcgaggt	9480
cgttgaaat gcgggccatg agctgcgaga aggcgttgag gcctccctcg ttccagacgc	9540
ggctgtagac cagccccct tcggcatcgc gggcgcgcat gaccacctgc gcgagattga	9600

gctccacgtg cggggcgaag acggcgtagt ttcgcaggcg ctgaaagagg tagttgaggg	9660
tggtggcggg gtgttctgcc acgaagaagt acataacca gcgtcgcaac gtggattcgt	9720
tgatatcccc caaggcctca aggcgctcca tggcctcgta gaagtcacg gcgaagttga	9780
aaaactggga gttgcgcgcc gacacgggta actcctcctc cagaagacgg atgagctcgg	9840
cgacagtgtc gcgcacctcg cgctcaaagg ctacaggggc ctcttcttct tcttcaatct	9900
cctcttccat aagggcctcc ccttcttctt cttctggcgg cgggtggggga ggggggacac	9960
ggcggcgacg acggcgccacc gggaggcggg cgacaaaagc ctcgatcatc tccccgcggc	10020
gacggcgcat ggtctcgggt acggcgcggc cgttctcgcg ggggcgcagt tggaaagacg	10080
cgcccgatcat gtcccggtta tgggttgccg gggggctgcc atgcggcagg gatacggcgc	10140
taacgatgca tctcaacaat tggtgtgtag gtactccgcc gccgagggac ctgagcgagt	10200
ccgcacgcac cggatcgga aacctctcga gaaaggcgtc taaccagtca cagtcgcaag	10260
gtaggctgag caccgtggcg ggcggcagcg ggcggcggtc ggggttggtt ctggcgagg	10320
tgctgctgat gatgtaatta aagtaggcgg tcttgagacg gcggtggtc gacagaagca	10380
ccatgtcctt gggtcggcc tgctgaatgc gcaggcggtc ggccatgcc caggcttcgt	10440
tttgacatcg gcgcaggctt ttgtagtagt cttgcatgag cctttctacc ggcacttctt	10500
cttctccttc ctcttgctct gcactctctt catctatcgc tgcggcggcg gcggagtttg	10560
gccgtagggt gcgcctctt cctcccatgc gtgtgacccc gaagcccctc atcggtgaa	10620
gcagggctag gtcggcgaca acgcgctcgg ctaatatggc ctgctgcacc tgcgtgagg	10680
tagactggaa gtcacccatg tccacaaagc ggtggtatgc gcccggttg atggtgtaag	10740
tgcagttggc cataacggac cagttaacgg tctggtgacc cggctgcgag agctcgggtg	10800
acctgagacg cgagtaagcc ctcgagtcaa atacgtagtc gttgcaagtc cgcaccaggt	10860
actggtatcc caccaaaaag tgcggcggcg gctggcggtg gaggggccag cgtagggtgg	10920
ccggggctcc gggggcgaga tcttccaaca taaggcgatg atatccgtag atgtacctgg	10980
acatccaggt gatgccggcg gcggtggtgg aggcgcgcgg aaagtgcgcg acgcggttcc	11040
agatgttgcg cagcgcaaaa aagtgtcca tggctcggac gctctggccg gtcaggcgcg	11100
cgcaatcggt gacgctctag accgtgcaaa aggagagcct gtaagcgggc actcttccgt	11160
ggctctggtg ataaattcgc aagggtatca tggcgagcga ccgggggttc agccccgtat	11220
ccggccgtcc gccgtgatcc atgcggttac cggcccgctg tcgaaccag gtgtgcgacg	11280
tcagacaacg ggggagtgtc ccttttggtt tcttccagg cgcggcggct gctgcgctag	11340
cttttttgcc cactggccgc gcgcagcgta agcggttagg ctggaaagcg aaagcattaa	11400
gtggctcgtc ccctgtagcc ggagggttat tttccaaggg ttgagtcgcg ggacccccgg	11460
ttcgagtctc ggaccggccg gactgcggcg aacgggggtt tgctccccg tcatgcaaga	11520
ccccgcttgc aaattcctcc ggaaacaggg acgagcccct tttttgcttt tcccagatgc	11580
atccggtgct gcggcagatg cggccccctc ctacgcagcg gcaagagcaa gagcagcggc	11640
agacatgcag ggcacctcc cctcctccta ccgcgtcagg aggggcgaca tccgcggttg	11700
acgcggcagc agatggtgat tacgaacccc cgcggcgccg ggccccgcac tacctggact	11760
tggaggaggg cgagggcctg gcgcggctag gagcgcctc tctgagcgg cacccaaggg	11820

tgcagctgaa gcgatgatacg cgtgagggcgt acgtgccgcg gcagaacctg tttcgcgacc	11880
gcgagggaga ggagcccagag gagatgcggg atcgaaagt ccacgcaggg cgcgagctgc	11940
ggcatggcct gaatcgcgag cggttgctgc gcgaggagga ctttgagccc gacgcgcgaa	12000
ccgggattag tcccgcgcgc gcacacgtgg cggccgcga cctggtaacc gcatacgagc	12060
agacggtgaa ccaggagatt aactttcaaa aaagctttaa caaccacgtg cgtacgcttg	12120
tggcgcgcga ggaggtggct ataggactga tgcactctgt ggactttgta agcgcgctgg	12180
agcaaaaccc aaatagcaag ccgctcatgg cgcagctgtt ccttatagtg cagcacagca	12240
gggacaacga ggcattcagg gatgcgctgc taaacatagt agagcccag ggccgctggc	12300
tgctcgattt gataaacatc ctgcagagca tagtggtgca ggagcgcagc ttgagcctgg	12360
ctgacaaggt ggccgcacac aactattcca tgcttagcct gggcaagttt tacgcccgca	12420
agatatacca taccctttac gttcccatag acaaggaggt aaagatcgag gggttctaca	12480
tgcgcatggc gctgaagggtg cttacettga gcgacgacct gggcgtttat cgcaacgagc	12540
gcatccacaa ggccgtgagc gtgagccggc ggcgcgagct cagcgaccgc gagctgatgc	12600
acagcctgca aagggccctg gctggcacgg gcagcggcga tagagaggcc gagtccact	12660
ttgacgcggg cgtgacctg cgtggggccc caagccgacg cgccctggag gcagctgggg	12720
ccggacctgg gctggcgggtg gcaccgcgc gcgctggcaa cgtcggcggc gtggaggaat	12780
atgacgagga cgatgagtac gagccagagg acggcgagta ctaagcgggt atgtttctga	12840
tcagatgatg caagacgcaa cggaccggc ggtgcggggc gcgctgcaga gccagccgtc	12900
cggccttaac tccacggacg actggcgcca ggtcatggac cgcacatgt cgtgactgc	12960
gcgcaatcct gacgcgttcc ggcagcagcc gcagggcaac cggctctccg caattctgga	13020
agcgggtggtc ccggcgcgcg caaaccacac gcacgagaag gtgctggcga tcgtaaacgc	13080
gctggccgaa aacagggcca tccggcccga cgagccggc ctggtctacg acgcgctgct	13140
tcagcgcgtg gctcgttaca acagcggcaa cgtgcagacc aacctggacc ggctgggtgg	13200
ggatgtgcgc gaggcctgg cgcagcgtga gcgcgcgag cagcagggca acctgggctc	13260
catggttgca ctaaacgcct tcctgagtac acagcccgcc aacgtgccgc ggggacagga	13320
ggactacacc aactttgtga gcgcaactgc gctaattgtg actgagacac cgcaaagtga	13380
ggtgtaccag tctgggcccag actatttttt ccagaccagt agacaaggcc tgcagaccgt	13440
aaacctgagc caggctttca aaaacttgca ggggctgtgg ggggtgcggg ctcccacagg	13500
cgaccgcgcg accgtgtcta gcttgcgtgac gcccaactcg cgctgttgct tgctgctaat	13560
agcgccttc acggacagtg gcagcgtgtc ccgggacaca tacctaggtc acttgcgtgac	13620
actgtaccgc gagggccatag gtcaggcgca tgtggacgag catactttcc aggagattac	13680
aagtgtcagc cgcgcgctgg ggcaggagga cacgggcagc ctggaggcaa ccctaaacta	13740
cctgctgacc aaccgggggc agaagatccc ctcgttgca agtttaacaa gcgaggagga	13800
gcgcattttg cgctacgtgc agcagagcgt gagccttaac ctgatgcgcg acggggtaac	13860
gccagcgtg gcgctggaca tgaccgcgcg caacatggaa ccgggcatgt atgcctcaaa	13920
ccggccgttt atcaaccgcc taatggacta cttgcatcgc gcggccgcg tgaacccgga	13980
gtatttcacc aatgccatct tgaacccgca ctggctaccg cccctgggtt tctacaccgg	14040

gggattcgag	gtgcccgagg	gtaacgatgg	attcctcttg	gacgacatag	acgacagcgt	14100
gttttccccg	caaccgcaga	ccctgctaga	gttgcaacag	cgcgagcagg	cagaggcggc	14160
gctgcgaaaag	gaaagcttcc	gcaggccaag	cagcttgtcc	gatctaggcg	ctgcggcccc	14220
gcggtcagat	gctagtagcc	catttccaag	cttgataggg	tctcttacca	gcactcgcac	14280
cacccgcccc	cgctgctgg	gcgaggagga	gtacctaaac	aactcgctgc	tgcagccgca	14340
gcgcgaaaaa	aacctgcctc	cggcatttcc	caacaacggg	atagagagcc	tagtggacaa	14400
gatgagtaga	tggaagacgt	acgcgcagga	gcacagggac	gtgccaggcc	cgcgccccgc	14460
cacccgtcgt	caaaggcacg	accgtcagcg	gggtctggtg	tgggaggacg	atgactcggc	14520
agacgacagc	agcgtcctgg	atttgggagg	gagtggcaac	cgttttgccg	accttcgccc	14580
caggctgggg	agaatgtttt	aaaaaaaaa	aaagcatgat	gcaaaataaa	aaactcacca	14640
aggccatggc	accgagcgtt	ggttttcttg	tattccccct	agtatgcggc	gcgcggcgat	14700
gtatgaggaa	ggtcctcctc	cctcctacga	gagtgtggtg	agcgcgcgcc	cagtggcggc	14760
ggcgctgggt	tctcccttcg	atgctcccc	ggaccgcgg	tttgtgcctc	cgcggtacct	14820
gcgcgcctacc	ggggggagaa	acagcatccg	ttactctgag	ttggcacccc	tattcgacac	14880
cacccgtgtg	tacctggtgg	acaacaagtc	aacggatgtg	gcacccctga	actaccagaa	14940
cgaccacagc	aactttctga	ccacggtcat	tcaaaacaat	gactacagcc	cgggggaggc	15000
aagcacacag	accatcaatc	ttgacgaccg	gtcgacttgg	ggcgggcacc	tgaaaaccat	15060
cctgcatacc	aacatgcaa	atgtgaacga	gttcatgttt	accaataagt	ttaaggcgcg	15120
ggtgatggtg	tcgcgcttgc	ctactaagga	caatcaggtg	gagctgaaat	acgagtgggt	15180
ggagttcacg	ctgcccaggg	gcaactactc	cgagaccatg	accatagacc	ttatgaacaa	15240
cgcgatcgtg	gagcactact	tgaaagtggg	cagacagaac	ggggttcttg	aaagcgacat	15300
cggggtaaag	tttgacaccc	gcaacttcag	actgggggtt	gaccccgcca	ctgggtcttg	15360
catgcctggg	gtatatacaa	acgaagcctt	ccatccagac	atcattttgc	tgcaggatg	15420
cggggtggac	ttcacccaca	gcgccttag	caacttgttg	ggcatccgca	agcggaacc	15480
cttcaggag	ggcttttaga	tcacctacga	tgatctggag	ggtggtaaca	ttcccgcact	15540
gttgatgtg	gacgcctacc	aggcgagctt	gaaagatgac	accgaacagg	gcgggggttg	15600
cgcaggcggc	agcaacagca	gtggcagcgg	cgcggaagag	aactccaacg	cgcgagccgc	15660
ggcaatgcag	ccggtggagg	acatgaacga	tcatgccatt	cgcgcgacac	cctttgccac	15720
acgggctgag	gagaagcgcg	ctgaggccga	agcagcgccc	gaagctgccg	cccccgctgc	15780
gcaacccgag	gtcgagaagc	ctcagaagaa	accggtgac	aaacccctga	cagaggacag	15840
caagaaacgc	agttacaacc	taataagcaa	tgacagcacc	ttcacccagt	accgcagctg	15900
gtaccttgca	tacaactacg	gcgacctca	gaccggaatc	cgctcatgga	ccctgctttg	15960
cactcctgac	gtaacctgcg	gctcggagca	ggtctactgg	tcgttgccag	acatgatgca	16020
agaccccggtg	accttcgct	ccacgcgcca	gacagcaac	tttcgggtgg	tgggcgcga	16080
gctgttgccc	gtgcactcca	agagcttcta	caacgaccag	gccgtctact	cccaactcat	16140
ccgccagttt	acctctctga	cccacgtgtt	caatcgcttt	cccagaaacc	agattttggc	16200
gcgcccgcga	gccccacca	tcaccaccgt	cagtgaatac	gttctgctc	tcacagatca	16260

cgggacgcta ccgctgcgca acagcatcgg aggagtccag cgagtgacca ttactgacgc	16320
cagacgccgc acctgcccct acgtttacaa ggccctgggc atagtctcgc cgcgcgtcct	16380
atcgagccgc actttttgag caagcatgtc catccttata tcgcccagca ataacacagg	16440
ctggggcctg cgcttcccaa gcaagatgtt tggcggggcc aagaagcgt ccgaccaaca	16500
cccagtgcgc gtgcgcgggc actaccgcgc gccctggggc gcgcacaaac gcggccgcac	16560
tgggcgcacc accgtcgatg acgccatcga cgcggtggtg gaggaggcgc gcaactacac	16620
gcccacgccg ccaccagtgt ccacagtgga cgcggccatt cagaccgtgg tgcgcggagc	16680
ccggcgctat gctaaaatga agagacggcg gaggcgcgta gcacgtcgcc accgcgcgcg	16740
acccggcact gccgcccac gcgcggcggc ggccctgctt aaccgcgcac gtcgcaccgg	16800
ccgacgggcg gccatgcggg ccgctcgaag gctggccgcg ggtattgtca ctgtgcccc	16860
caggtccagg cgacgagcgg ccgccgcagc agccgcggcc attagtgtca tgactcaggg	16920
tcgcaggggc aacgtgtatt ggtgcgcga ctcggttagc ggctgcgcg tgcgcgtgcg	16980
caccgcgcc ccgcgcaact agattgcaag aaaaaactac ttagactcgt actgttgtat	17040
gtatccagcg gcggcggcgc gcaacgaagc tatgtccaag cgaaaaatca aagaagagat	17100
gctccaggtc atcgcgccg agatctatgg cccccgaag aaggaagagc aggattacaa	17160
gccccgaaag ctaaagcggg tcaaaaagaa aaagaaagat gatgatgatg aacttgacga	17220
cgaggtggaa ctgctgcacg ctaccgcgcc caggcgacgg gtacagtgga aaggctcacg	17280
cgtaaaacgt gttttgcgac ccggcaccac cgtagtcttt acgcccgtg agcgtccac	17340
ccgcacctac aagcgcgtgt atgatgaggt gtacggcgac gaggacctgc ttgagcaggc	17400
caacgagcgc ctcggggagt ttgcctacgg aaagcggcat aaggacatgc tggcggtgcc	17460
gctggacgag ggcaacccaa caccatgcct aaagcccgta aactgcagc aggtgctgcc	17520
cgcgcttgca ccgtccgaag aaaagcgcgg cctaaagcgc gagtctggtg acttggcacc	17580
caccgtgcag ctgatggtac ccaagcgcga gcgactggaa gatgtcttg aaaaaatgac	17640
cgtggaacct gggctggagc ccgaggtccg cgtgcggcca atcaagcagg tggcgccggg	17700
actggcgctg cagaccgtgg acgttcagat acccaactacc agtagcacca gtattgccac	17760
cgccacagag ggcatggaga caaaaacgtc cccggttgcc tcagcgggtg cggatgccgc	17820
ggtgcaggcg gtcgctgcgg ccgcgtccaa gacctctacg gaggtgcaaa cggacccgtg	17880
gatgtttcgc gtttcagccc cccggcgccc gcgcggttcg aggaagtacg gcgcgccag	17940
cgcgctactg cccgaatatg cctacatcc ttccattgcg cctacccccg gctatcgtgg	18000
ctacacctac cgccccagaa gacgagcaac taccgcagc cgaaccacca ctggaaccgc	18060
ccgccgccgt cgccgtcgcc agcccggtct ggccccgatt tccgtgcgca gggtggtcgc	18120
cgaaggaggc aggacctgg tgctgccaac agcgcgtac caccacagca tcgtttaaaa	18180
gccggtcttt gtggttcttg cagatatggc cctcacctgc cgctccgtt tcccgggtgc	18240
gggattccga ggaagaatgc accgtaggag gggcatggcc ggccacggcc tgacggcgcg	18300
catgcgtcgt gcgcaccacc ggcgcgggcg cgcgtgcgac cgtcgcagtc gcggcggtat	18360
cctgccctc cttattccac tgatcgccgc ggcgattggc gccgtgccc gaattgcatc	18420
cgtggccttg caggcgcgga gacactgatt aaaaacaagt tgcatgtgga aaaatcaaaa	18480

taaaaagtct ggactctcac gctcgcttgg tcctgtaact atttttaga atggaagaca	18540
tcaactttgc gtctctggcc ccgcgacacg gctcgcgccc gttcatggga aactggcaag	18600
ataticggcac cagcaatatg agcgggtggcg ccttcagctg gggctcgctg tggagcggca	18660
ttaaaaattht cggttccacc gttaagaact atggcagcaa ggcctggaac agcagcacag	18720
gccagatgct gagggataag ttgaaagagc aaaatttcca aaaaagggtg gtagatggcc	18780
tggcctctgg cattagcggg gtggtggacc tggccaacca ggagtgcaa aataagatta	18840
acagtaagct tgatccccgc cctcccgtag aggagcctcc accggccgtg gagacagtgt	18900
ctccagaggg gcgtggcgaa aagcgtccgc gccccgacag ggaagaaact ctggtgacgc	18960
aaatagacga gcctccctcg tacgaggagg cactaaagca aggcctgccc accaccctgc	19020
ccatcgcgcc catggctacc ggagtgtggt gccagcacac acccgtaacg ctggacctgc	19080
ctccccccgc cgacaccag cagaaacctg tgtgtccagg cccgaccgcc gttgtttaa	19140
cccgtcctag ccgcgcgtcc ctgcccgcg cccgacgagg tccgcatcg ttgcgcccg	19200
tagccagtgg caactggcaa agcacactga acagcatcgt gggctctggg gtgcaatccc	19260
tgaagcgccg acgatgcttc tgatagctaa cgtgtcgtat gtgtgtcatg tatgcgtcca	19320
tgctcgccgc agaggagctg ctgagccgcc gcgcgcccgc tttccaagat ggctaccct	19380
tcgatgatgc cgcagtggtc ttacatgcac atctcggggc aggacgcctc ggagtacctg	19440
agccccgggc tgggtgcagtt tgcccgcgcc accgagacgt acttcagcct gaataacaag	19500
tttagaaacc ccacgggtgc gcctacgcac gacgtgacca cagaccggtc ccagcgtttg	19560
acgtgcgggt tcacccctgt ggaccgtag gatactgct actcgtaaa ggcgcgggtc	19620
accctagctg tgggtgataa ccgtgtgctg gacatggctt ccacgtactt tgacatccgc	19680
ggcgtgctg acagggggcc tacttttaag ccctactctg gactgccta caacgccctg	19740
gctcccaagg gtgccccaaa tccttgcgaa tgggatgaag ctgctactgc tcttgaaata	19800
aacctagaag aagaggacga tgacaacgaa gacgaagtag acgagcaagc tgagcagcaa	19860
aaaactcacg tatttgggca ggcgccttat tctggtataa atattacaaa ggagggtatt	19920
caaataagggt tcgaagggtca aacacctaaa tatgccgata aaacatttca acctgaacct	19980
caaataggag aatctcagtg gtacgaaaca gaaattaatc atgcagctgg gagagtccta	20040
aaaaagacta ccccaatgaa accatgttac ggttcatatg caaaaccac aaatgaaaat	20100
ggaggggcaag gcattcttgt aaagcaacaa aatggaaagc tagaaagtca agtggaaatg	20160
caatttttct caactactga ggcagccgca ggcaatggtg ataacttgac tcctaaagt	20220
gtattgtaca gtgaagatgt agatatagaa accccagaca ctcatatttc ttacatgccc	20280
actattaagg aaggtaaact acgagaacta atgggccaac aatctatgcc caacaggcct	20340
aattacattg cttttaggga caattttatt ggtctaattg attacaacag cacgggtaat	20400
atgggtgttc tggcgggcca agcatcgag ttgaatgctg ttgtagattt gcaagacaga	20460
aacacagagc tttcatacca gcttttgctt gattccattg gtgatagaac caggactttt	20520
tctatgtgga atcaggctgt tgacagctat gatccagatg ttagaattat tgaaaatcat	20580
ggaactgaag atgaacttcc aaattactgc tttccactgg gaggtgtgat taatacagag	20640
actcttacca aggtaaaacc taaaacaggt caggaaaatg gatgggaaaa agatgctaca	20700

gaattttcag ataaaaatga aataagagtt ggaaataatt ttgccatgga aatcaatcta	20760
aatgcccaacc tgtggagaaa ttctctgtac tccaacatag cgctgtattt gcccgacaag	20820
ctaaagtaca gtccttccaa cgtaaaaatt tctgataacc caaacaccta cgactacatg	20880
aacaagcgag tgggtggctcc cgggctagtg gactgctaca ttaaccttgg agcacgctgg	20940
tcccttgact atatggacaa cgtaaccca tttaaccacc accgcaatgc tggcctgcgc	21000
taccgctcaa tgttgctggg caatggtcgc tatgtgccct tccacatcca ggtgcctcag	21060
aagtcttttg ccattaaaaa cctccttctc ctgcggggct catacaccta cgagtggaac	21120
ttcaggaagg atgttaacat ggttctgcag agctccctag gaaatgacct aagggttgac	21180
ggagccagca ttaagtttga tagcatttgc ctttacgcca ccttcttccc catggcccac	21240
aacaccgcct ccacgcttga ggccatgctt agaaacgaca ccaacgacca gtcctttaac	21300
gactatctct cgcgcgcaa catgctctac cctatacccg ccaacgctac caacgtgccc	21360
atatccatcc cctcccgcaa ctggggggct ttccgcggt gggccttcac gcgccttaag	21420
actaaggaaa ccccatcact gggctcgggc tacgaccctt attacaccta ctctggctct	21480
ataccctacc tagatggaac cttttacctc aaccacacct ttaagaaggt ggccattacc	21540
tttgactctt ctgtcagctg gcctggcaat gaccgcctgc ttacccccaa cgagtgtgaa	21600
attaagcgct cagttgacgg ggagggttac aacgttgccc agtgtaacat gaccaaagac	21660
tggttccttg taaaaatgct agctaactat aacattggct accaggggtt ctatatccca	21720
gagagctaca aggaccgcat gtactccttc tttagaaact tccagcccat gagccgtcag	21780
gtggtgatg atactaaata caaggactac caacaggtgg gcatcctaca ccaacacaa	21840
aactctggat ttgttggtta ccttgcccc accatgcgcg aaggacaggc ctaccctgct	21900
aacttcccct atccgcttat aggcaagacc gcagttgaca gcattaccca gaaaaagttt	21960
ctttgcgac gcaccctttg gcgcatccca ttctccagta actttatgtc catgggcgca	22020
ctcacagacc tgggccaata ccttctctac gccaaactccg cccacgcgct agacatgact	22080
tttgaggttg atcccatgga cgagcccacc cttctttatg ttttgtttga agtctttgac	22140
gtggtcogtg tgcaccagcc gcaccgggc gtcacgaaa ccgtgtacct gcgcacgccc	22200
ttctcgccg gcaacgccac aacataaaga agcaagcaac atcaacaaca gctgccgcca	22260
tgggctccag tgagcaggaa ctgaaagcca ttgtcaaaga tcttggttgt gggccatatt	22320
ttttgggcac ctatgacaag cgctttccag gctttgtttc tccacacaag ctgcctgcg	22380
ccatagtcaa tacggcgggt cgcgagactg ggggcgtaca ctggatggcc tttgcctgga	22440
accgcactc aaaaacatgc tacctctttg agccctttgg cttttctgac cagcgactca	22500
agcaggttta ccagtttgag tacgagtcac tcctgcgcg tagcgccatt gcttcttccc	22560
ccgaccgctg tataacgctg gaaaagtcca cccaaagcgt acaggggccc aactcgccg	22620
cctgtggact attctgctgc atgtttctcc acgcctttgc caactggccc caaactccca	22680
tggatcacia cccaccatg aaccttatta ccgggggtacc caactccatg ctcaacagtc	22740
cccaggtaca gccaccctg cgtcgcaacc aggaacagct ctacagcttc ctggagcgcc	22800
actcgcccta cttccgcagc cacagtgcgc agattaggag cgccacttct ttttgtcact	22860
tgaaaaacat gtaaaaaata tgtactagag acactttcaa taaaggcaaa tgcttttatt	22920

tgtacactct cgggtgatta tttaccccca cccttgccgt ctgcgccgtt taaaaatcaa	22980
aggggttctg ccgcgcacgc ctatgcgcca ctggcaggga cacgttgoga tactggtgtt	23040
tagtgctcca cttaaactca ggcacaacca tccgcggcag ctcggtgaag ttttactcc	23100
acaggctgcg caccatcacc aacgcgttta gcaggtcggg cgccgatatc ttgaagtcgc	23160
agttggggcc tccgccctgc gcgcgcgagt tgcgatacac agggttgcag cactggaaca	23220
ctatcagcgc cgggtggtgc acgtggcca gcacgtctt gtcggagatc agatccgcgt	23280
ccaggctctc cgcgttgctc agggcgaaac gagtcaactt tggtagctgc cttcccaaaa	23340
agggcgcggtg ccaggtctt gagttgact cgacccgtag tggcatcaaa aggtgaccgt	23400
gcccgtctg ggcgttagga tacagcgct gcataaaagc cttgatctgc ttaaaagcca	23460
cctgagcctt tgcgccttca gagaagaaca tgccgaaga cttgccgaa aactgattgg	23520
ccggacaggc cgcgtcgtgc acgcagcacc ttgcgtcgtt gttggagatc tgcaccacat	23580
ttcggcccca ccggttcttc acgatcttgg ccttgctaga ctgctcttc agcgcgcgt	23640
gcccgttttc gctcgtcaca tccatttcaa tcacgtgctc cttatttate ataatgcttc	23700
cgtgtagaca cttaagctcg ccttcgatct cagcgcagcg gtgcagccac aacgcgcagc	23760
ccgtgggctc gtgatgctt taggtcacct ctgcaaacga ctgcaggta gcctgcagga	23820
atcgcccat catcgtcaca aaggtcttgt tgctggtgaa ggtcagctgc aaccgcggt	23880
gctcctcgtt cagccaggtc ttgcatacgg ccgccagagc ttccacttgg tcaggcagta	23940
gtttgaagtt cgcctttaga tcgttatcca cgtggtactt gtccatcagc gcgcgcgag	24000
cctccatgcc cttctccac gcagacacga tcggcacact cagcgggttc ataccgtaa	24060
tttcaacttc cgttcgctg ggtcttctt cttctcttg cgtccgcata ccacgcgcca	24120
ctgggtcgtc ttcattcagc cgcgcactg tgcgcttacc tcctttgcca tgcttgatta	24180
gcaccggtgg gttgctgaaa ccaccattt gtagcgcac atcttctctt tcttctcgc	24240
tgtccacgat tacctctggt gatggcgggc gtcgggctt gggagaagg cgcttcttt	24300
tcttcttggg cgcaatggc aaatccgcc ccgaggtcga tggccgcggg ctgggtgtgc	24360
gcggcaccag cgcgtctgt gatgagtctt cctcgtctc ggactcgata cgcgcctca	24420
tccgttttt tgggggcgc cggggaggcg gcggcgacgg ggacggggac gacacgtct	24480
ccatggttgg gggacgtcgc gccgcaccgc gtccgcgctc gggggtggt tcgcgtgct	24540
cctcttcccg actggccatt tccttctct ataggcagaa aaagatcatg gattcagtcg	24600
agaagaagga cagcctaacc gcccctctg agttcgcac caccgcctcc accgatgccg	24660
ccaacgcgc taccaccttc ccgctcgagg ccccccgct tgaggaggag gaagtgatta	24720
tcgagcagga ccaggtttt gtaagcgaag acgacgagga ccgctcagta ccaacagagg	24780
ataaaaagca agaccaggac aacgcagagg caaacgagga acaagtcggg cggggggacg	24840
aaaggcatgg cgactaccta gatgtgggag acgacgtgct gttgaagcat ctgcagcgcc	24900
agtgcgccat tatctgcgac gcgttgcaag agcgcagcga tgtgccccct gccatagcgg	24960
atgtcagcct tgcctacgaa gcgcacctat tctcaccgcg cgtaccccc aaacgccaag	25020
aaaacggcac atgcgagccc aaccgcgcc tcaacttcta cccgtatatt gccgtgccag	25080
aggtgcttgc cacctatcac atctttttcc aaaactgcaa gatacccccta tctgcccgtg	25140

ccaaccgcag ccgagcggac aagcagctgg ccttgcggca gggcgctgtc atacctgata	25200
tcgcctcgct caacgaagt ccaaaaatct ttgaggtct tggacgcgac gagaagcgcg	25260
cggaacacgc tctgcaacag gaaaacagcg aaaatgaaag tcaactctgga gtgttggtgg	25320
aactcgaggg tgacaacgcg cgcctagccg tactaaaaag cagcatcgag gtcaccact	25380
ttgcctaccc ggcacttaac ctacccccca aggtcatgag cacagtcag agtgagctga	25440
tcgtgcgcg tgcgagccc ctggagaggg atgcaaattt gcaagaacaa acagaggagg	25500
gcctacccgc agttggcgac gacgagctag cgcgctggct tcaaacgcgc gagcctgccg	25560
acttgaggga gcgacgcaa ctaatgatgg ccgcagtgt cgttaccgtg gagcttgagt	25620
gcatgcagcg gttctttgct gaccgggaga tgcagcgcaa gctagaggaa acattgcact	25680
acacctttcg acagggctac gtacgccagg cctgcaagat ctccaacgtg gagctctgca	25740
acctggtctc ctaccttgga attttgacg aaaaccgcct tgggcaaac gtgcttcatt	25800
ccacgctcaa gggcgaggcg cgcgcgact acgtccgcga ctgcgtttac ttatttctat	25860
gctacacctg gcagacggcc atgggcgttt ggcagcagtg cttggaggag tgcaacctca	25920
aggagctgca gaaactgcta aagcaaaact tgaaggacct atggacggcc ttcaacgagc	25980
gctccgtggc cgcgcacctg gcggacatca ttttccccga acgcctgctt aaaaccctgc	26040
aacaggggtct gccagacttc accagtcaaa gcatgttgca gaactttagg aactttatcc	26100
tagagcgctc aggaatcttg cccgccacct gctgtgact tcctagcgac tttgtgcca	26160
ttaagtaccg cgaatgccct ccgcgcgttt ggggccactg ctaccttctg cagctagcca	26220
actaccttgc ctaccactct gacataatgg aagacgtgag cggtgacggt ctactggagt	26280
gtcactgtcg ctgcaacctg tgcacccgc accgctccct ggtttgcaat tcgcagctgc	26340
ttaacgaaag tcaaattatc ggtacctttg agctgcaggg tccctcgcct gacgaaaagt	26400
ccgcggctcc ggggttgaaa ctcaactccg ggctgtggac gtcggcttac cttcgcaaat	26460
ttgtacctga ggactaccac gcccacgaga ttaggttcta cgaagaccaa tcccgcccgc	26520
ctaatacgga gcttaccgcc tgcgtcatta ccagggcca cattcttggc caattgcaag	26580
ccatcaacaa agcccgcga gagtttctgc tacgaaagg acggggggtt tacttgacc	26640
cccagtcgag cgaggagctc aacccaatcc ccccgccgcc gcagccctat cagcagcagc	26700
cgcgggcctt tgcttccag gatggcacc aaaagaagc tgcagctgcc gccgccacc	26760
acggacgagg aggaatactg ggacagtcag gcagaggagg ttttgacga ggaggaggag	26820
gacatgatgg aagactggga gagcctagac gaggaagctt ccgaggtcga agaggtgtca	26880
gacgaaacac cgtcaccttc ggtcgcattc ccctcgccg cgcgccagaa atcggcaacc	26940
ggttccagca tggtacaac ctccgtcct caggcgccgc cggcactgcc cgttcgccga	27000
cccaaccgta gatgggacac cactggaacc agggccggt agtccaagca gccgccgccg	27060
ttagcccaag agcaacaaca gcgccaaggc taccgtcat ggcgcgggca caagaacgcc	27120
atagttgctt gcttgcaaga ctgtgggggc aacatctcct tcgcccgcg ctttcttctc	27180
taccatcacg gcgtggcctt ccccgtaac atcctgcatt actaccgtca tctctacagc	27240
ccatactgca ccggcggcag cggcagcaac agcagcgcc acacagaagc aaaggcgacc	27300
ggatagcaag actctgacaa agcccaagaa atccacagcg gcggcagcag caggaggagg	27360

agcgctgcgt ctggcgccca acgaacccgt atcgaccgcg gagcttagaa acaggatttt	27420
tcccactctg tatgctatat ttcaacagag caggggccaa gaacaagagc tgaaaataaa	27480
aaacaggtct ctgcgatccc tcacccgcag ctgcctgtat cacaaaagcg aagatcagct	27540
tcggcgcacg ctggaagacg cggaggctct cttcagtaaa tactgcgcgc tgactcttaa	27600
ggactagttt cgcgcctttt ctcaaattta agcgcgaaaa ctacgtcatc tccagcggcc	27660
acaccggcg ccagcacctg ttgtcagcgc cattatgagc aaggaaattc ccacgcccta	27720
catgtggagt taccagccac aaatgggact tgcggctgga gctgccaaag actactcaac	27780
ccgaataaac tacatgagcg cgggacccca catgatatcc cgggtcaacg gaatacgcgc	27840
ccaccgaaac cgaattctcc tggaacaggc ggctattacc accacacctc gtaataacct	27900
taatccccgt agttggcccg ctgccttgtt gtaccaggaa agtcccgctc ccaccactgt	27960
ggtacttccc agagacgccc aggccgaagt tcagatgact aactcagggg cgcagcttgc	28020
gggcggcttt cgtcacaggg tgcggtcgcc cgggcagggt ataactcacc tgacaatcag	28080
agggcgaggt attcagctca acgacgagtc ggtgagctcc tcgcttggtc tccgtccgga	28140
cgggacattt cagatcggcg gcgcggccg ctcttcattc acgcctcgtc aggcaatcct	28200
aactctgcag acctcgtcct ctgagccgcg ctctggaggc attggaactc tgcaatttat	28260
tgaggagttt gtgccatcgg tctactttaa ccccttctcg ggacctcccg gccactatcc	28320
ggatcaattt attcctaact ttgacgcggt aaaggactcg gcggacggct acgactgaat	28380
gttaagtgga gaggcagagc aactgcgctt gaaacacctg gtccactgtc gccgccacaa	28440
gtgctttgcc cgcgactccg gtgagttttg ctactttgaa ttgcccgagg atcatatcga	28500
gggcccggcg cacggcgtcc ggcttaccgc ccagggagag cttgcccgta gcctgattcg	28560
ggagtttacc cagcgcctcc tgctagttga gcgggacagg ggacctgtg ttctcactgt	28620
gatttgcaac tgtcctaacc ctggattaca tcaagatctt tggtgccatc tctgtgctga	28680
gtataataaa tacagaaatt aaaatatact ggggctccta tcgccatcct gtaaacgcca	28740
ccgtcttcac ccgcccaagc aaaccaaggc gaaccttacc tggacttttt aacatctctc	28800
cctctgtgat ttacaacagt ttcaacccag acggagttag tctacgagag aacctctccg	28860
agctcagcta ctccatcaga aaaaacacca ccctccttac ctgccgggaa cgtacgagtg	28920
cgtcacccgc cgtcgacca cacctaccgc ctgaccgtaa accagacttt ttccggacag	28980
acctcaataa ctctgtttac cagaacagga ggtgagctta gaaaaccctt agggatttag	29040
gccaaaggcg cagctactgt ggggtttatg aacaattcaa gcaactctac gggctattct	29100
aattcaggtt tctctagaat cggggttggg gttattctct gtcttgatgat tctctttatt	29160
cttatactaa cgcttctctg cctaaggctc gccgcctgct gtgtgcacat ttgcatttat	29220
tgtcagcttt ttaaagctg gggtcgccac ccaagatgat taggtacata atcctaggtt	29280
tactcacctc tgcgtcagcc cacggtacca cccaaaaggc ggattttaag gagccagcct	29340
gtaatgttac attcgcagct gaagctaatt agtgaccacac tcttataaaa tgcaccacag	29400
aacatgaaaa gctgcttatt cgccacaaaa acaaaattgg caagtatgct gtttatgcta	29460
tttggcagcc aggtgacact acagagtata atgttacagt tttccagggt aaaagtcata	29520
aaacttttat gtatactttt ccatttttatg aaatgtgcga cattaccatg tacatgagca	29580

aacagtataa gttgtggccc ccacaaaatt gtgtggaaaa cactggcact ttctgctgca	29640
ctgctatgct aattacagt ctcgctttgg tctgtaccct actctatatt aaatacaaaa	29700
gcagacgcag ctttattgag gaaaagaaaa tgccttaatt tactaagtta caaagcta	29760
gtcaccacta actgctttac tcgctgcttg caaaacaaat tcaaaaagtt agcattataa	29820
ttagaatagg atttaaacc cccgggtcatt tcctgctcaa taccattccc ctgaacaatt	29880
gactctatgt gggatatgct ccagcgctac aaccttgaag tcaggcttcc tggatgtcag	29940
catctgactt tggccagcac ctgtcccgcg gatttgttcc agtccaacta cagcgacca	30000
ccctaacaga gatgaccaac acaaccaacg cggccgcgcg taccggactt acatctacca	30060
caaatacacc ccaagtttct gcctttgtca ataactggga taacttgggc atgtggtggt	30120
tctccatagc gcttatgttt gtatgcctta ttattatgtg gctcatctgc tgcctaaagc	30180
gcaaacgcgc ccgaccaccc atctatagtc ccactcattgt gctacacca aacaatgatg	30240
gaatccatag attggacgga ctgaaacaca tgttcttttc tcttacagta tgattaaatg	30300
agacatgatt cctcgagttt ttatattact gaccttgtt gcgtttttt tgtgcgtgct	30360
ccacattggc tgcggtttct cacatcgaag tagactgcat tccagccttc acagtctatt	30420
tgctttacgg atttgtcacc ctacgctca tctgcagcct catcactgtg gtcacgcct	30480
ttatccagtg cattgactgg gtctgtgtgc gctttgcata tctcagacac catccccagt	30540
acagggacag gactatagct gagcttctta gaattcttta attatgaaat ttactgtgac	30600
ttttctgctg attatttga ccctatctgc gttttgttcc ccgacctca agcctcaaag	30660
acatatatca tgcagattca ctcttatatg gaatttcca agttgctaca atgaaaaaag	30720
cgatctttcc gaagcctggt tatatgcaat catctctgtt atggtgttct gcagtaccat	30780
cttagcccta gctatatatc cctaccttga cattggctgg aacgcaatag atgccatgaa	30840
ccaccaact ttccccgcgc ccgctatgct tccactgcaa caagttgttg ccggcggtt	30900
tgtcccagcc aatcagcctc gccaccttc tcccaccccc actgaaatca gctactttaa	30960
tctaacagga ggagatgact gacaccctag atctagaaat ggacggaatt attacagagc	31020
agcgctgct agaagacgc agggcagcgg ccgagcaaca gcgcatgaat caagagctcc	31080
aagacatggt taacttgca cagtgcmeta ggggtatctt ttgtctggtg aagcaggcca	31140
aagtcaccta cgacagtaat accaccggac accgccttag ctacaagttg ccaaccaagc	31200
gtcagaaatt ggtggtcatg gtgggagaaa agcccattac cataactcag cactcggtag	31260
aaaccgaagg ctgcattcac tcacctgtc aaggacctga ggatctctgc acccttatta	31320
agacctgtg cggctcmeta gatcttattc cctttaacta ataaaaaaaa ataataaagc	31380
atcacttact taaaatcagt tagcaaattt ctgtccagtt tattcagcag cacctcctg	31440
ccctctccc agctctggtg ttgcagcttc ctctggctg caaactttct ccacaatcta	31500
aatggaatgt cagtttctc ctgttctgt ccacgcgcac ccactatctt catgttgtg	31560
cagatgaagc gcgcaagacc gtctgaagat accttcaacc ccgtgtatcc atatgacag	31620
gaaaccggtc ctccaactgt gccttttctt actctcctt ttgtatccc caatgggttt	31680
caagagagtc ccctggggt actctctttg cgcctatccg aacctctagt tacctccaat	31740
ggcatgcttg cgctcaaaat gggcaacggc ctctctctgg acgaggccgg caaccttacc	31800

tcccaaatg taaccactgt gagccacct ctcaaaaaa ccaagtcaa cataaacctg	31860
gaaatatctg caccctcac agttacctca gaagccctaa ctgtggctgc cgccgcacct	31920
ctaattggtcg cgggcaacac actcaccatg caatcacagg ccccgctaac cgtgcacgac	31980
tccaaactta gcattgccac ccaaggaccc ctacacagtgt cagaaggaaa gctagccctg	32040
caaacatcag gccccctcac caccaccgat agcagtaccc ttactatcac tgcctcaccc	32100
cctctaacta ctgccactgg tagcttgggc attgacttga aagagcccat ttatacacia	32160
aatggaaaac taggactaaa gtacggggct cctttgcatg taacagacga cctaaacact	32220
ttgaccgtag caactggtcc aggtgtgact attaataata cttccttgca aactaaagtt	32280
actggagcct tgggttttga ttcacaaggc aatatgcaac ttaatgtagc aggaggacta	32340
aggattgatt ctcaaacag acgccttata cttgatgtta gttatccgtt tgatgctcaa	32400
aaccaactaa atctaagact aggacagggc cctcttttta taaactcagc ccacaacttg	32460
gatattaact acaacaaagg cctttacttg tttacagctt caaacaattc caaaaagctt	32520
gaggttaacc taagcactgc caaggggttg atgtttgacg ctacagccat agccattaat	32580
gcaggagatg ggcttgaatt tggttcacct aatgcaccaa acacaaatcc cctcaaaaca	32640
aaaattggcc atggcctaga atttgattca aacaaggcta tggttcctaa actaggaact	32700
ggccttagtt ttgacagcac aggtgccatt acagtaggaa acaaaaataa tgataagcta	32760
actttgtgga ccacaccagc tccatctcct aactgtagac taaatgcaga gaaagatgct	32820
aaactcactt tggctttaac aaaatgtggc agtcaaatac ttgctacagt ttcagttttg	32880
gctgttaaag gcagtttggc tccaatatct ggaacagttc aaagtgtcga tcttattata	32940
agatttgacg aaaatggagt gctactaaac aattccttcc tggaccocaga atattggaac	33000
tttagaaatg gagatcttac tgaaggcaca gcctatacaa acgctgttggt atttatgcct	33060
aacctatcag cttatccaaa atctcacggt aaaactgcc aagtaacat tgtcagtcaa	33120
gtttacttaa acggagacaa aactaaacct gtaacactaa ccattacact aaacggtaca	33180
caggaaacag gagacacaac tccaagtga tactctatgt cattttcatg ggactggtct	33240
ggccacaact acattaatga aatatttgcc acatcctctt acactttttc atacattgcc	33300
caagaataaa gaatcgtttg tgttatgttt caacgtgttt atttttcaat tgcagaaaat	33360
ttcaagtcatt ttttcattca gtagtatagc cccaccacca catagcttat acagatcacc	33420
gtaccttaat caaactcaca gaaccctagt attcaacctg ccacctccct cccaacacac	33480
agagtacaca gtcctttctc cccggctggc cttaaaaagc atcatatcat gggtaacaga	33540
catattctta ggtgttatat tccacacggt ttcctgtcga gccaaacgct catcagtgat	33600
attaataaac tccccgggca gctcacttaa gttcatgtcg ctgtccagct gctgagccac	33660
aggctgctgt ccaacttgcg gttgcttaac gggcggcgaa ggagaagtcc acgcctacat	33720
gggggtagag tcataatcgt gcacagcatg agggcggtgg tgctgcagca gcgcgcgaat	33780
aaactgctgc cgccgccgct ccgtcctgca ggaatacaac atggcagtgg tctcctcagc	33840
gatgatcgcc accgcccgca gcataaggcg ccttgctcctc cgggcacagc agcgaccct	33900
gatctcactt aaatcagcac agtaactgca gcacagcacc acaatattgt tcaaaatccc	33960
acagtgcaag gcgctgtatc caaagctcat ggcggggacc acagaacca cgtggccatc	34020

ataccacaag cgcaggtaga ttaagtggcg acccctcata aacacgctgg acataaacat	34080
tacctctttt ggcatgttgt aattcaccac ctcccgttac catataaacc tctgattaaa	34140
catggcgcca tccaccacca tcctaaacca gctggccaaa acctgcccgc cggctataca	34200
ctgcagggaa cggggactgg aacaatgaca gtggagagcc caggactcgt aaccatggat	34260
catcatgctc gtcatgatat caatgttggc acaacacagg cacacgtgca tacacttcct	34320
caggattaca agctcctccc gcgttagaac catatcccag ggaacaaccc attcctgaat	34380
cagcgtaaatt cccacactgc agggagacc tcgcacgtaa ctcacgttgt gcattgtcaa	34440
agtgttacat tcgggcagca gcggatgac ctccagtatg gtagcgcggt tttctgtctc	34500
aaaaggaggt agacgatecc tactgtacgg agtgcgccga gacaaccgag atcgtgttgg	34560
tcgtagtgtc atgccaaatg gaacgccgga cgtagtata tttcctgaag caaaaccagg	34620
tgccggcggtg acaaacagat ctgcgtctcc ggtctcgccg cttagatcgc tctgtgtagt	34680
agttgtagta tatccactct ctcaaagcat ccaggcgccc cctggcttcg ggttctatgt	34740
aaactccttc atgcgcgctt gccctgataa catccaccac cgcagaataa gccacacca	34800
gccaacctac acattcgttc tgcgagtcac acacgggagg agcgggaaga gctggaagaa	34860
ccatgttttt ttttttattc caaaagatta tccaaaacct caaaatgaag atctattaag	34920
tgaacgcgct cccctccggt ggctgtgtca aactctacag ccaaagaaca gataatggca	34980
tttgaagat gttgcacaat ggcttccaaa aggcacacgg ccctcacgtc caagtggacg	35040
taaaggctaa acccttcagg gtgaatctcc tctataaaca ttccagcacc ttcaaccatg	35100
cccaaataat tctcatctcg ccacctctc aatatatctc taagcaaate ccgaatatta	35160
agtccggcca ttgtaaaaat ctgctccaga gcgccctcca ccttcagcct caagcagcga	35220
atcatgattg caaaaattca ggttcctcac agacctgtat aagattcaaa agcgggaacat	35280
taacaaaaat accgcgatcc cgtaggctcc ttgcagggc cagctgaaca taatcgtgca	35340
ggtctgcacg gaccagcgcg gccacttccc cgccaggaac catgacaaaa gaaccacac	35400
tgattatgac acgcatactc ggagctatgc taaccagcgt agccccgatg taagcttgtt	35460
gcatggggcg cgatataaaa tgcaaggtgc tgctcaaaaa atcaggcaaa gcctcgcgca	35520
aaaaagaaag cacatcgtag tcatgtcat gcagataaag gcaggtgaag tccggaacca	35580
ccacagaaaa agacaccatt tttctctcaa acatgtctgc gggtttctgc ataaacacaa	35640
aataaaataa caaaaaaaca tttaaaccatt agaagcctgt cttacaacag gaaaaaac	35700
ccttataagc ataagacgga ctacggccat gccggcgtga ccgtaaaaaa actggtcacc	35760
gtgattaaaa agcaccaccg acagctcctc ggtcatgtcc ggagtcataa tgtaagactc	35820
ggtaaacaca tcaggttgat tcacatcggt cagtgtctaa aagcgaccga aatagcccgg	35880
gggaatacat acccgagggc gtagagacaa cattacagcc cccataggag gtataacaaa	35940
attaatagga gagaaaaaca cataaacacc tgaaaaaccc tcctgcctag gcaaaatagc	36000
accctccgcg tccagaacaa catacagcgc ttccacagcg gcagccataa cagtcagcct	36060
taccagtaaa aaagaaaacc tattaaaaaa acaccactcg acacggcacc agctcaatca	36120
gtcacagtgt aaaaaagggc caagtgcaga gcgagtatat ataggactaa aaaatgacgt	36180
aacggttaaa gtccacaaaa aacacccaga aaaccgcacg cgaacctacg cccagaaacg	36240

```

aaagccaaaa aaccacaaac ttcctcaa at cgtcacttcc gttttccac gttacgtcac 36300
ttcccatitt aagaaaacta caattcccaa cacatacaag ttactccgcc ctaaaaccta 36360
cgtcacccgc cccgttccca cgccccgcgc caggtcacia actccacccc ctcatatca 36420
tattggcttc aatccaaaat aaggtatat attgatgatg 36460

```

```

<210> 10
<211> 35203
<212> DNA
<213> Artificial sequence

```

```

<220>
<223> PPE-1-3X-FasC vir1 construct (lacking repeats)

```

```

<220>
<221> misc_feature
<222> (460)..(1437)
<223> A modified murine pre-proendothelin-1 promoter (PPE-1-3X)

```

```

<220>
<221> misc_feature
<222> (1202)..(1207)
<223> Hypoxia response element

```

```

<220>
<221> misc_feature
<222> (1438)..(1468)
<223> Linker

```

```

<220>
<221> misc_feature
<222> (1469)..(2058)
<223> TNFR portion of the Fas-TNFR-1 chimera (Fas-c)

```

```

<220>
<221> misc_feature
<222> (2059)..(2569)
<223> FAS portion of the Fas-TNFR-1 chimera (Fas-c)

```

```

<400> 10
catcatcaat aatatacctt attttggatt gaagccaata tgataatgag ggggtggagt 60
ttgtgacgtg ggcgggggcg tgggaacggg gcggtgacg tagtagtgtg gcggaagtgt 120
gatgttgcaa gtgtggcgga acacatgtaa gcgacggatg tggcaaaagt gacgtttttg 180
gtgtgcgccc gtgtacacag gaagtacaaa ttttcgcgcg gttttaggcg gatgtttag 240
taaatttggg cgtaaccgag taagatttgg ccattttcgc gggaaaactg aataagagga 300
agtgaatct gaataatatt gtgttactca tagcgcgtaa tatttgtcta gggccgcggg 360
gactttgacc gtttactgtg agactcgccc aggtgttttt cttaggtgtt ttccgcgttc 420
cgggtcaaaag ttggcgtttt attattatag tcagtacgta cgtgtacttc tgatcggcga 480
tactagggag ataaggatgt acctgacaaa accacattgt tgttgttatc attattattt 540
agttttcctt ccttgctaac tcctgacgga atctttctca cctcaaatgc gaagtacttt 600
agtttagaaa agacttggtg gaaggggtgg tgggtgaaaa gtaggggtgat cttccaaact 660
aatctgggtc cccgccccgc ccagtagctg ggattcaaga gcgaagagtg gggatcgctc 720
ccttgtttga tcagaaagac ataaaaggaa aatcaagtga acaatgatca gccccacctc 780
caccacccc ccctgcgcgc gcacaataca atctatttaa ttgtacttca tacttttcat 840
tccaatgggg tgactttgct tctggagaaa ctcttgattc ttgaactctg gggctggcag 900

```

ctacgctcca gaagcaaagt caccacattg gaatgaaaag tatgaagtac aatgaaaagt 960
 atgaagtact ggctccagaa gcaaagtcac cctccagaag caaagtcacc ccattggaat 1020
 gaaaagtatg aagtacgcta gcaaaagggg aagcgggctg ctgctctctg caggttctgc 1080
 agcggctctct gtctagtggg tgttttcttt ttcttagccc tgcccttgga ttgtcagacg 1140
 gcgggcgtct gcctctgaag ttagccgtga ttctcttag agcgggtct tatctctggc 1200
 tgcacgttgc ctgtgggtga ctaatcacac aataacattg tttagggtg gaataaagtc 1260
 agagctgttt accccactc tataggggtt caataaaaa aggcggcgga gaactgtccg 1320
 agtcagaagc gttcctgcac cggcgtgag agcctgaccc ggtctgctcc gctgtccttg 1380
 cgcgtgcct cccggtgcc cgcgacgctt tcgcccaggt ggaagggcca ctgctgcgg 1440
 ccgctaattc tgcagatcgg gatccggcat gggcctctcc accgtgcctg acctgctgct 1500
 gccgtggtg ctcttgagc tgttggtggg aatatacccc tcaggggtta ttggactggt 1560
 ccctcaccta ggggacaggg agaagagaga tagtgtgtgt cccaaggaa aatatatcca 1620
 ccctcaaat aattcgattt gctgtaccaa gtgccacaaa ggaacctact tgtacaatga 1680
 ctgtccaggc cggggcagg atacggactg cagggagtgt gagagcggct ccttcaccgc 1740
 ttcagaaaac cacctcagac actgcctcag ctgctccaaa tgccgaaagg aaatgggtca 1800
 ggtggagatc tcttcttgca cagtggaccg ggacaccgtg tgtggctgca ggaagaacca 1860
 gtaccggcat tattggagtg aaaacctttt ccagtgttc aattgcagcc tctgcctcaa 1920
 tgggaccgtg cacctctcct gccaggagaa acagaacacc gtgtgcacct gccatgcagg 1980
 tttctttcta agagaaaacg agtgtgtctc ctgtagtaac tgtaagaaaa gcctggagtg 2040
 cacgaagttg tgcctaccaa gcttaggatc cagatctaac ttgggggtggc tttgtcttct 2100
 tcttttgcca attccactaa ttgtttgggt gaagagaaag gaagtacaga aaacatgcag 2160
 aaagcacaga aaggaaaacc aaggttctca tgaatctcca accttaaatc ctgaaacagt 2220
 ggcaataaat ttatctgatg ttgacttgag taaatatatc accactattg ctggagtcac 2280
 gacactaagt caagttaaag gctttgttcg aaagaatggt gtcaatgaag ccaaaataga 2340
 tgagatcaag aatgacaatg tccaagacac agcagaacag aaagttcaac tgcttcgtaa 2400
 ttggcatcaa cttcatggaa agaaagaagc gtatgacaca ttgattaaag atctcaaaaa 2460
 agccaatctt tgtactcttg cagagaaaat tcagactatc atcctcaagg acattactag 2520
 tgactcagaa aattcaaact tcagaaatga aatccaaagc ttggtctagc tcgagcatgc 2580
 atctaggcgg ccgcatggca gaaattcgcg aattcgtag cgtaacgga tcctctagac 2640
 gagatccgaa cttgtttatt gcagcttata atggttacia ataaagcaat agcatcacia 2700
 atttcacaaa taaagcattt ttttactgc attctagtgt tgggttggtc aaactcatca 2760
 atgtatctta tcatgtctag atctgtactg aaatgtgtgg gcgtggctta aggggtggaa 2820
 agaatatata aggtgggggt cttatgtagt tttgtatctg ttttgacga gccgcgcgcg 2880
 ccatgagcac caactcgttt gatggaagca ttgtgagctc atatttgaca acgcgcatgc 2940
 ccccatgggc cgggtgctg cagaatgtga tgggtccag cattgatggt cggccgtcc 3000
 tgcccgcaaa ctctactacc ttgacctacg agaccgtgtc tggaacgccg ttggagactg 3060
 cagcctccgc cgcgcttca gccgtgcag ccaccgccg cgggattgtg actgactttg 3120

ctttcctgag cccgcttgca agcagtgcag cttcccggtc atccgccccg gatgacaagt	3180
tgacggctct tttggcacia ttggattctt tgacccggga acttaattgtc gtttctcagc	3240
agctgttgga tctgcgccag caggtttctg ccttgaaggc ttcttccccct cccaatgcgg	3300
tttaaaacat aaataaaaaa ccagactctg tttggatttg gatcaagcaa gtgtcttgct	3360
gtctttatatt aggggttttg cgcgcgcggt agggccggga ccagcgggtct cggtcgttga	3420
gggtcctgtg tattttttcc aggacgtggt aaaggtagact ctggatgttc agatacatgg	3480
gcataagccc gtctctgggg tggaggtagc accactgcag agcttcatgc tgcgggggtg	3540
tggtgtagat gatccagtcg tagcaggagc gctgggcgtg gtgcctaaaa atgtctttca	3600
gtagcaagct gattgccagg ggcaggccct tgggtgaagt gtttaciaag cggttaagct	3660
gggatgggtg catacgtggg gatatgagat gcatcttgga ctgtattttt aggttggcta	3720
tgttcccagc catatccctc cggggattca tgtgtgcag aaccaccagc acagtgtatc	3780
cgggtgcactt gggaaatttg tcatgtagct tagaaggaaa tgcgtggaag aacttggaga	3840
cgccttctg acctccaaga ttttccatgc attcgtccat aatgatggca atgggcccac	3900
gggcggcggc ctgggcgaag atatttctgg gatcactaac gtcatagttg tgttccagga	3960
tgagatcgtc ataggccatt tttacaaagc gcgggcggag ggtgccagac tgcggtataa	4020
tggttccatc cggcccaggg gcgtagttag cctcacagat ttgcatttcc cacgctttga	4080
gttcagatgg ggggatcatg tctacctgcg gggcgatgaa gaaaacggtt tccggggtag	4140
gggagatcag ctgggaagaa agcagggttc tgagcagctg cgacttaccg cagccggtgg	4200
gcccgtaaat cacacctatt accggtgcga actggtagtt aagagagctg cagctgccgt	4260
catccctgag cagggggggc acttcgttaa gcatgtccct gactcgcag ttttccctga	4320
ccaaatccgc cagaaggcgc tcgcccacca gcgatagcag ttcttgcaag gaagcaaagt	4380
ttttcaacgg tttgagaccg tccgcgtag gcatgctttt gagcgtttga ccaagcagtt	4440
ccaggcggtc ccacagctcg gtcacctgct ctacggcatc tcgattccagc atatctctc	4500
gtttcgcggg ttggggcggc tttcgtgta cggcagtagt cgggtgctcg ccagacgggc	4560
cagggtcatg tctttccacg ggcgcagggt cctcgtcagc gtagtctggg tcacggtgaa	4620
ggggtgcgct cggggtgcg cgctggccag ggtgcgcttg aggctgggtc tgctggtgct	4680
gaagcgtgc cggctcttcg cctgcgcgtc ggccaggtag catttgacca tgggtgcata	4740
gtccagcccc tccgcggcgt ggccttggc gcgcagcttg cccttgagg aggcgccga	4800
cgaggggagc tgcagacttt tgagggcgta gagcttgggc gcgagaaata ccgattccgg	4860
ggagtaggca tccgcgccgc agggcccgca gacggtctcg cattccacga gccaggtag	4920
ctctggccgt tcggggtcaa aaaccagggt tcccccatgc tttttgatgc gtttcttacc	4980
tctggtttcc atgagccggt gtccacgctc ggtgacgaaa aggctgtccg tgtcccgtga	5040
tacagacttg agaggcctgt cctcagcggg tgttccgagg tctctctcgt atagaaactc	5100
ggaccactct gagacaaagg ctgcgtcca ggccagcacg aaggaggcta agtgggagg	5160
gtagcggctg ttgtccacta ggggtccac tcgctccagg gtgtgaagac acatgtcgcc	5220
ctcttcggca tcaaggaagg tgattgggtt gtaggtgtag gccacgtgac cgggtgttcc	5280
tgaagggggg ctataaaagg ggggtggggc gcgttcgtcc tcaactctct cgcctcgt	5340

gtctgcgagg gccagctgtt ggggtgagta ctccctctga aaagcgggca tgacttctgc	5400
gctaagattg tcagtttcca aaaacgagga ggatttgata ttcacctggc ccgcggtgat	5460
gcctttgagg gtggccgcat ccatctggtc agaaaagaca atctttttgt tgtcaagctt	5520
ggtggcaaac gacccgtaga gggcgttgga cagcaacttg gcgatggagc gcagggtttg	5580
gtttttgtcg cgatcgggcg gctccttggc cgcgatgttt agctgcacgt attcgcgcgc	5640
aacgcaccgc cattcgggaa agacggtggt gcgctcgtcg ggcaccaggt gcacgcgcca	5700
accgcggttg tgcagggtga caaggtcaac gctggtggct acctctccgc gtaggcgctc	5760
gttggtccag cagaggcggc cgcccttgcg cgagcagaat ggcggtaggg ggtctagctg	5820
cgtctcgtcc ggggggtctg cgtccacggt aaagaccccg ggcagcaggc gcgcgtcgaa	5880
gtagtctatc ttgcatcctt gcaagtctag cgctctgtgc catgcgcggg cggcaagcgc	5940
gcgctcgtat ggggttgagt ggggacccca tggcatgggg tgggtgagcg cggaggcgta	6000
catgccgcaa atgtcgtaaa cgtagagggg ctctctgagt attccaagat atgtagggtg	6060
gcatcttcca ccgcggtatg tggcgcgcac gtaatcgtat agttcgtgcg agggagcgag	6120
gaggtcggga ccgaggttgc tacggcgggg ctgctctgct cggaagacta tctgcctgaa	6180
gatggcatgt gagttgatg atatggttg acgctggaag acgttgaagc tggcgtctgt	6240
gagacctacc gcgtcacgca cgaaggaggc gtaggagtcg cgacgcttgt tgaccagctc	6300
ggcggtgacc tgcacgtcta gggcgagta gtccagggtt tccttgatga tgtcatactt	6360
atcctgtccc ttttttttcc acagctcgcg gttgaggaca aactcttcgc ggtctttcca	6420
gtactcttgg atcggaaacc cgctcgccctc cgaacggtaa gagcctagca tgtagaactg	6480
gttgacggcc tggtaggcgc agcatccctt ttctacgggt agcgcgtatg cctgcgcggc	6540
cttccggagc gaggtgtggg tgagcgcaaa ggtgtccctg accatgactt tgaggtagt	6600
gtatttgaag tcagtgtcgt cgcatccgcc ctgctccag agcaaaaagt ccgtgcgctt	6660
tttggaaacg ggatttgga gggcgaaggt gacatcgtt aagagtatct ttcccgcgcg	6720
aggcataaag ttgctgtgta tgcggaaggg tcccggcacc tcggaacggt tgttaattac	6780
ctggcgggcg agcacgatct cgtcaaagcc gttgatgttg tggcccacaa tgtaaagttc	6840
caagaagcgc gggatgccct tgatggaagg caatttttta agttcctcgt aggtgagctc	6900
ttcaggggag ctgagcccg gctctgaaag ggcccagtct gcaagatgag ggttggaagc	6960
gacgaatgag ctccacaggt cacgggccat tagcatttgc aggtggtcgc gaaaggctct	7020
aaactggcga cctatggcca ttttttctgg ggtgatgcag tagaaggtaa gcgggtcttg	7080
ttcccagcgg tccatccaa ggttcgcggc taggtctcgc gcggcagtca ctagaggctc	7140
atctccgcg aacttcatga ccagcatgaa gggcacgagc tgcttcccaa agggcccat	7200
ccaagtatag gtctctacat cgtaggtgac aaagagacgc tcggtgcgag gatgcgagcc	7260
gatcggaag aactggtatc cccgccacca attggaggag tggctattga tgtggtgaaa	7320
gtagaagtcc ctgcgacggg ccgaacactc gtgctggctt ttgtaaaaac gtgcgcagta	7380
ctggcagcgg tgcacgggct gtacatcctg cacgaggttg acctgacgac cgcgcacaa	7440
gaagcagagt gggaatttga gccctcgcg tggcggtttt ggctggtggt cttctacttc	7500
ggctgcttgt ccttgaccgt ctggctgctc gaggggagtt acggtggatc ggaccaccac	7560

gccgcgcgag cccaaagtcc agatgtccgc gcgcggcggt cggagcttga tgacaacatc 7620
 gcgcagatgg gagctgtcca tggctctggag ctcccgcggc gtcaggtcag gcgggagctc 7680
 ctgcagggtt acctcgcata gacgggtcag ggcgcgggct agatccaggt gatacctaata 7740
 ttccaggggc tggttggtgg cggcgtcgat ggcttgcaag aggcgcgcat cccgcggcgc 7800
 gactacggta ccgcgcggcg ggcgtgggc cgcgggggtg tccttggtg atgcatctaa 7860
 aagcggtgac gcgggcgagc ccccgagggt aggggggggt cgcgaccgc cgggagaggg 7920
 ggcaggggca cgtcggcgcc gcgcgcgggc aggagctggg gtcgcgcgcg taggttgctg 7980
 gcgaacgcga cgacgcggcg gttgatctcc tgaatctggc gcctctgcgt gaagacgacg 8040
 ggcccgggtga gcttgaacct gaaagagagt tcgacagaat caatttcggg gtcgttgacg 8100
 gcggcctggc gcaaaatctc ctgcacgtct cctgagttgt cttgataggc gatctcggcc 8160
 atgaactgct cgatctcttc ctctggaga tctccgcgtc cggctcgtc caggttggcg 8220
 gcgaggtcgt tggaaatgcg ggccatgagc tgcgagaagg cgttgaggcc tccctcgttc 8280
 cagacgcggc tgtagaccac gccccttcg gcacgcggg cgcgcacgac cacctgcgcg 8340
 agattgagct ccacgtgccg ggcgaagacg gcgtagtttc gcaggcgctg aaagaggtag 8400
 ttgaggggtg tggcgggtgt ttctgccacg aagaagtaca taaccacgagc tcgcaacgtg 8460
 gattcgttga tatccccc aa ggcctcaagg cgctccatgg cctcgtagaa gtccacggcg 8520
 aagttgaaaa actgggagtt gcgcgccgac acggttaact cctcctccag aagacggatg 8580
 agctcggcga cagtgtcgcg cacctcgcgc tcaaaggcta caggggcctc ttcttcttct 8640
 tcaatctcct ctcccataag ggcctcccct tcttcttctt ctggcggcgg tgggggaggg 8700
 gggacacggc ggcgacgacg gcgcaccggg aggcggtcga caaagcgctc gatcatctcc 8760
 ccgcggcgac ggcgcacgtt ctcggtgacg gcgcggccgt tctcggggg gcgcagttgg 8820
 aagacgccgc ccgtcatgtc ccggttatgg gttggcgggg ggctgccatg cggcagggat 8880
 acggcgctaa cgatgcacat caacaattgt tgtgtaggta ctccgccgc gagggacctg 8940
 agcgagtcgc catcgaccgg atcggaac ctctcgagaa aggcgtctaa ccagtcacag 9000
 tcgcaaggta ggctgagcac cgtggcgggc ggcagcgggc ggcggtcggg gttgtttctg 9060
 gcggaggtgc tgctgatgat gtaattaaag taggcgtct tgagacggcg gatggtcgac 9120
 agaagacca tgtccttggg tccggcctgc tgaatcgca ggcggtcggc catgcccag 9180
 gcttcgtttt gacatcggcg caggctcttg tagtagtct gcacgacgtc ttctaccggc 9240
 acttcttctt ctcttctc ttgtcctgca tctctgcat ctatcgctgc ggcggcgcg 9300
 gagtttgcc gtaggtggcg cctcttct cccatgcgtg tgaccccgaa gccctcatc 9360
 ggctgaagca ggcctaggtc ggcgacaacg cgctcggcta atatggcctg ctgcacctgc 9420
 gtgagggtag actggaagtc atccatgtcc acaaagcggg ggtatgcgcc cgtgttgatg 9480
 gtgtaagtgc agttggccat aacggaccag ttaacggtct ggtgaccgg ctgcgagagc 9540
 tcggtgtacc tgagacgcga gtaagccctc gagtcaaata cgtagtcgtt gcaagtcgc 9600
 accaggtact ggtatccac caaaaagtgc ggcggcggt ggcggtagag gggccagcgt 9660
 aggggtggcg ggcctccggg ggcgagatct tccaacataa ggcgatgata tccgtagatg 9720
 tacctggaca tccaggtgat gccggcgcg gtggtggagg cgcgcggaaa gtcgcggacg 9780

cggttccaga tgttgcgcag cggcaaaaag tgctccatgg tcgggacgct ctggccggtc	9840
aggcgcgcgc aatcgttgac gctctagacc gtgcaaaaagg agagcctgta agcgggcact	9900
cttccgtgggt ctggtggata aattcgcaag ggtatcatgg cggacgaccg gggttcgagc	9960
cccgtatccg gccgtccgcc gtgatccatg cggttaccgc ccgctgtcg aaccaggtg	10020
tgcgacgtca gacaacgggg gagtgctcct tttggcttcc ttccaggcgc ggcggctgct	10080
gcgctagctt ttttggccac tggccgcgcg cagcgtaagc ggtaggctg gaaagcgaaa	10140
gcattaagtg gctcgtctcc tgtagccgga gggttatatt ccaagggtg agtcgcggga	10200
cccccggttc gagtctcgga ccggccggac tgcggcgcaac gggggtttgc ctccccgtca	10260
tgaagaccc cgcttgcaaa ttctccgga aacagggacg agcccccttt ttgcttttcc	10320
cagatgcac cggtgctgcg gcagatgcgc cccctcctc agcagcgga agagcaagag	10380
cagcggcaga catgcagggc accctcccct cctcctaccg cgtcaggagg ggcgacatcc	10440
gcggttgacg cggcagcaga tggtagttac gaacccccgc ggcgcgggc ccggcactac	10500
ctggacttgg aggagggcga gggcctggcg cggctaggag cgcctctcc tgagcggcac	10560
ccaagggtgc agctgaagcg tgatacgctg gaggcgtacg tgccgcggca gaacctgttt	10620
cgcgaccgcg aggagagga gcccgaggag atcggggac gaaagtcca cgcaggcgc	10680
gagctgcggc atggcctgaa tcgcgagcgg ttgctgcgcg aggaggactt tgagcccgc	10740
gcgcgaaccg ggattagtcc cgcgcgcgca cacgtggcgg ccgccgacct ggtaaccgca	10800
tacgagcaga cgggtaacca ggagattaac tttcaaaaaa gctttaacaa ccacgtgcgt	10860
acgcttgtgg cgcgcgagga ggtggctata ggactgatgc atctgtggga ctttgaagc	10920
gcgctggagc aaaacccaaa tagcaagccg ctcatggcgc agctgttctt tatagtgcag	10980
cacagcaggg acaacgaggc attcagggat gcgctgctaa acatagtaga gcccgagggc	11040
cgctggctgc tcgatttgat aaacatcctg cagagcatag tggcgagga gcgcagctt	11100
agcctggctg acaagggtgc cgcctcaac tattccatgc ttagcctggg caagttttac	11160
gcccgaaga tataccatac cccttacgtt cccatagaca aggaggtaaa gatcgagggg	11220
ttctacatgc gcatggcgct gaagggtgctt accttgagcg acgacctggg cgtttatcgc	11280
aacgagcgc tccacaaggc cgtgagcgtg agccggcggc gcgagctcag cgaccgcgag	11340
ctgatgcaca gcctgcaaa ggcctggct ggcacgggca gcggcgatag agaggccgag	11400
tcctactttg acgcgggcgc tgacctgcgc tgggccccaa gccgacgcgc cctggaggca	11460
gctggggccg gacctgggct ggcggtggca cccgcgcgcg ctggcaacgt cggcggcgtg	11520
gaggaatatg acgaggacga tgagtacgag ccagaggacg gcgagtacta agcggtagt	11580
tttctgatca gatgatgcaa gacgcaacg acccggcggt gcggcgggcg ctgcagagcc	11640
agccgtccg ccttaactcc acggacgact ggcgccaggt catggaccgc atcatgtcgc	11700
tgactgcgcg caatcctgac gcgttccggc agcagccgca ggccaaccg ctctccgcaa	11760
ttctggaagc ggtgggtccc gcgcgcgcaa accccacgca cgagaagggt ctggcgatcg	11820
taaacgcgct ggccgaaaac agggccatcc ggcgcgacga ggcggcctg gtctacgacg	11880
cgctgcttca gcgcgtggct cgttacaaca gcggcaacgt gcagaccaac ctggaccggc	11940
tgggtggggga tgtgcgcgag gccgtggcgc agcgtgagcg cgcgcagcag cagggcaacc	12000

tgggctccat ggttgcaacta aacgccttcc tgagtacaca gcccgcacaac gtgcgcggg	12060
gacaggagga ctacaccaac tttgtgagcg cactgcggct aatggtgact gagacaccgc	12120
aaagtgaggt gtaccagtct gggccagact attttttcca gaccagtaga caaggcctgc	12180
agaccgtaaa cctgagccag gctttcaaaa acttgcaggg gctgtggggg gtgcgggctc	12240
ccacaggcga ccgcgcgacc gtgtctagct tgctgacgcc caactcgcgc ctgttgctgc	12300
tgctaatagc gcccttcacg gacagtggca gcggtgcccg ggacacatac ctaggtcact	12360
tgctgacact gtaccgcgag gccataggtc aggcgcatgt ggacgagcat actttccagg	12420
agattacaag tgtcagccgc gcgctggggc aggaggacac gggcagcctg gaggcaaccc	12480
taaactacct gctgaccaac cggcggcaga agatcccctc gttgcacagt ttaaacagcg	12540
aggaggagcg ctttttgcgc tacgtgcagc agagcgtgag ccttaacctg atgcgcgacg	12600
gggtaacgcc cagcgtggcg ctggacatga ccgcgcgcaa catggaaccg ggcatgtatg	12660
cctcaaaccg gccgtttatc aaccgcctaa tggactactt gcctcgcgcg gccgccgtga	12720
accccagta tttcaccaat gccatcttga acccgcactg gctaccgccc cctggtttct	12780
acaccggggg attcgaggtg ccgagggta acgatggatt cctctgggac gacatagacg	12840
acagcgtgtt tttcccgcaa ccgcagaccc tgctagagtt gcaacagcgc gagcaggcag	12900
aggcggcgct gcgaaaggaa agcttccgca ggccaagcag cttgtccgat ctaggcgctg	12960
cggccccgcg gtcagatgct agtagcccat ttccaagctt gatagggtct cttaccagca	13020
ctcgcaccac ccgccgcgc ctgctggggc aggaggagta cctaaacaac tcgctgctgc	13080
agccgcagcg cgaaaaaac ctgcctccg catttcccaa caacgggata gagagcctag	13140
tggaacaagat gagtagatgg aagacgtacg cgcaggagca cagggacgtg ccaggccccg	13200
gcccgccac ccgtcgtcaa aggcacgacc gtcagcggg tctggtgtgg gaggacgatg	13260
actcggcaga cgacagcagc gtcttggtt tgggaggagg tggcaaccg tttgcgcacc	13320
ttcgccccag gctggggaga atgttttaaa aaaaaaaaa gcctgatgca aaataaaaaa	13380
ctcaccaagg ccatggcacc gagcgttgg tttcttgat tccccttagt atgcggcgcg	13440
cggcgatgta tgaggaaagt cctctccct cctacgagag tgtggtgagc gcggcgccag	13500
tggcggcggc gctgggttct cccttcgatg ctcccctgga ccgcgcgtt gtgcctccgc	13560
ggtacctgcg gcctaccggg gggagaaaca gcctccgtta ctctgagttg gcaccctat	13620
tcgacaccac ccgtgtgtac ctgggtggaca acaagtcaac ggatgtggca tccctgaact	13680
accagaacga ccacagcaac tttctgacca cggctattca aaacaatgac tacagcccgg	13740
gggaggcaag cacacagacc atcaatcttg acgaccggtc gcaactggggc ggcgacctga	13800
aaaccatcct gcataccaac atgccaaatg tgaacgagtt catgtttacc aataagtta	13860
aggcgcgggt gatggtgtcg cgcttgccca ctaaggacaa tcagggtggag ctgaaatacg	13920
agtgggtgga gttcacgctg ccgaggggca actactccga gaccatgacc atagacctta	13980
tgaacaacgc gatcgtggag cactacttga aagtggcgag acagaacggg gttctggaaa	14040
gcgacatcgg ggtaaagttt gacaccgcga acttcagact ggggtttgac ccgcactg	14100
gtcttgcctat gcctggggta tatacaaacg aagccttcca tccagacatc attttgctgc	14160
caggatgcgg ggtggacttc acccacagcc gcctgagcaa cttgttgggc atccgcaagc	14220

ggcaaccctt ccaggagggc tttaggatca cctacgatga tctggagggt ggtaacattc	14280
ccgcactgtt ggatgtggac gcctaccagg cgagcttgaa agatgacacc gaacaggggc	14340
gggggtggcg aggcggcagc aacagcagtg gcagcgggcg ggaagagaac tccaacgcgg	14400
cagccgcggc aatgcagccg gtggaggaca tgaacgatca tgccattcgc ggcgacacct	14460
ttgccacacg ggctgaggag aagcgcgctg aggccgaagc agcgggcgaa gctgccgccc	14520
ccgtgcgca acccgaggtc gagaagcctc agaagaaacc ggtgatcaaa cccctgacag	14580
aggacagcaa gaaacgcagt tacaacctaa taagcaatga cagcaccttc acccagtagc	14640
gcagctggta ccttgcatat aactacggcg accctcagac cggaatccgc tcatggaccc	14700
tgctttgcac tctcgacgta acctgcggct cggagcaggt ctactggctg ttgccagaca	14760
tgatgcaaga ccccgtagcc ttccgctcca cgcgccagat cagcaacttt ccggtggtgg	14820
gcgcgcgagc gttgcccgtg cactccaaga gcttctacaa cgaccaggcc gtctactccc	14880
aactcatccg ccagtttacc tctctgaccc acgtgttcaa tcgctttccc gagaaccaga	14940
ttttggcgcg cccgccagcc cccaccatca ccaccgtcag tgaaaacgtt cctgctctca	15000
cagatcacgg gacgctaccg ctgcgcaaca gcatcggagg agtccagcga gtgaccatta	15060
ctgacgccag acgcgcgacc tgcccctacg tttacaaggc cctgggcata gtctcgccgc	15120
gcgtcctatc gagccgcaact ttttgagcaa gcatgtccat ccttatatcg cccagcaata	15180
acacaggctg gggcctgcgc ttccaagca agatgtttgg cggggccaag aagcgctccg	15240
accaacaccc agtgcgcgctg cgcgggcact accgcgcgcc ctggggcgcg cacaaacgcg	15300
gccgcactgg gcgcaccacc gtgatgacg ccatcgacgc ggtggtggag gaggcgcgca	15360
actacacgcc cacgcgcga ccagtgtcca cagtggacgc ggccattcag accgtggtgc	15420
gcggagcccg gcgctatgct aaaatgaaga gacggcgag gcgcgtagca cgtcgccacc	15480
gccgcgacc cggcactgcc gcccaacgcg cggcgggcg cctgcttaac cgcgcacgct	15540
gcaccggccg acggggcgcc atgcgggccc ctcgaaggct ggccgcgggt attgtcactg	15600
tgccccccag gtccaggcga cgagcggccg ccgcagcagc cgcggccatt agtgctatga	15660
ctcagggtcg caggggcaac gtgtattggg tgcgcgactc ggttagcggc ctgcgcgtgc	15720
ccgtgcgcac ccgcccccg cgcaactaga ttgaagaaa aaactactta gactcgtact	15780
gttgatgta tccagcggcg gcggcgcgca acgaagctat gtccaagcgc aaaatcaaa	15840
aagagatgct ccaggtcacg gcgcgggaga tctatggccc cccgaagaag gaagagcagg	15900
attacaagcc ccgaaagcta aagcgggtca aaaagaaaa gaaagatgat gatgatgaac	15960
ttgacgacga ggtggaactg ctgcacgcta ccgcgccag gcgacgggta cagtggaaa	16020
gtcgacgcgt aaaacgtgtt ttgcgacccg gcaccaccgt agtctttacg cccggtgagc	16080
gctccacccg cacctacaag cgcgtgtatg atgaggtgta cggcgacgag gacctgctg	16140
agcaggccaa cgagcgcctc ggggagtttg cctacggaaa gcggcataag gacatgctgg	16200
cgttgccgct ggacgagggc aaccaaacac ctagcctaaa gcccgtaaca ctgcagcagg	16260
tgctgcccgc gcttgaccg tccgaagaaa agcgcggcct aaagcgcgag tctggtgact	16320
tggcacccac cgtgcagctg atggtaccca agcgcgcagc actggaagat gtcttgaaa	16380
aaatgaccgt ggaacctggg ctggagcccg aggtccgct gcggccaatc aagcaggtgg	16440

cgccgggact	gggcgtgcag	accgtggacg	ttcagatacc	cactaccagt	agcaccagta	16500
ttgccaccgc	cacagagggc	atggagacac	aaacgtcccc	ggttgccctca	gcggtggcgg	16560
atgccgcggt	gcaggcggtc	gctgcggccg	cgtccaagac	ctctacggag	gtgcaaacgg	16620
acccgtggat	gtttcgcgtt	tcagcccccc	ggcggccgcg	ccgttcgagg	aagtacggcg	16680
ccgccagcgc	gctactgccc	gaatatgccc	tacatccttc	cattgcgcct	acccccggct	16740
atcgtggcta	cacctaccgc	cccagaagac	gagcaactac	ccgacgccga	accaccactg	16800
gaaccgcgcg	ccgccgtcgc	cgtcgccagc	ccgtgctggc	cccgatttcc	gtgcgcaggg	16860
tggctcgcga	aggaggcagg	accctggtgc	tgccaacagc	gcgctaccac	cccagcatcg	16920
tttaaaagcc	ggtcttttgt	gttcttgtag	atatggccct	cacctgccgc	ctccgtttcc	16980
cggtgccggg	attccgagga	agaatgcacc	gtaggagggg	catggccggc	cacggcctga	17040
cgggcggcat	gcgtcgtgcg	caccaccggc	ggcggcgcgc	gtcgcaccgt	cgcatgcgcg	17100
gcggtatcct	gccccctctt	attccactga	tcgcgcgcgc	gattggcgcc	gtgcccggaa	17160
ttgcatccgt	ggccttgtag	gcgcagagac	actgattaaa	aacaagttgc	atgtggaaaa	17220
atcaaaataa	aaagtctgga	ctctcacgct	cgcttggtcc	tgtaactatt	ttgtagaatg	17280
gaagacatca	actttgcgtc	tctggccccg	cgacacggct	cgcgcccggt	catgggaaac	17340
tggcaagata	tcggcaccag	caatatgagc	ggtggcgccct	tcagctgggg	ctcgctgtgg	17400
agcggcatta	aaaatttcgg	ttccaccgtt	aagaactatg	gcagcaaggc	ctggaacagc	17460
agcacaggcc	agatgctgag	ggataagttg	aaagagcaaa	atttccaaca	aaagtggtga	17520
gatggcctgg	cctctggcat	tagcgggggtg	gtggacctgg	ccaaccaggc	agtgcaaaat	17580
aagattaaca	gtaagcttga	tccccgccct	cccgtagagg	agcctccacc	ggccgtggag	17640
acagtgtctc	cagagggggc	tggcgaaaag	cgtccgcgcc	ccgacaggga	agaaactctg	17700
gtgacgcaaa	tagacgagcc	tccctcgtag	gaggaggcac	taaagcaagg	cctgcccacc	17760
acccgtccca	tcgcgcccat	ggctaccgga	gtgctggggc	agcacacacc	cgtaacgctg	17820
gacctgcctc	cccccgccga	caccacgagc	aaacctgtgc	tgccaggccc	gaccgcccgt	17880
gttgtaaccc	gtcctagccg	cgcgctccctg	cgccgcgcgc	ccagcggtcc	gcgatcgttg	17940
cggcccgtag	ccagtggcaa	ctggcaaagc	acactgaaca	gcacgctggg	tctgggggtg	18000
caatccctga	agcgcgcgac	atgcttctga	tagctaactg	gtcgtatgtg	tgtcatgtat	18060
gcgtccatgt	cgccgccaga	ggagctgctg	agccgcgcgc	cgcccgcttt	ccaagatggc	18120
taccctctcg	atgatgccgc	agtgtcttta	catgcacatc	tcgggccagg	acgcctcgga	18180
gtacctgagc	cccgggctgg	tgcagtttgc	ccgcgccacc	gagacgtact	tcagcctgaa	18240
taacaagttt	agaaacccca	cgggtggcgc	tacgcacgac	gtgaccacag	accggtccca	18300
gcgtttgacg	ctgcggttca	tccctgtgga	ccgtgaggat	actgcgtact	cgtacaaggc	18360
gcggttcacc	ctagctgtgg	gtgataaccg	tgtgctggac	atggcttcca	cgtactttga	18420
catccgcggc	gtgctggaca	ggggccctac	ttttaagccc	tactctggca	ctgcctacaa	18480
cgccttggtc	cccaagggtg	ccccaaatcc	ttgcgaatgg	gatgaagctg	ctactgctct	18540
tgaataaaac	ctagaagaag	aggacgatga	caacgaagac	gaagtagacg	agcaagctga	18600
gcagcaaaaa	actcacgtat	ttgggcaggc	gccttattct	ggtataaata	ttacaaagga	18660

gggtattcaa ataggtgtcg aaggtcaaac acctaaatat gccgataaaa catttcaacc	18720
tgaacctcaa ataggagaat ctacgtggta cgaacacagaa attaatcatg cagctgggag	18780
agtcctaaaa aagactaccc caatgaaacc atgttacggt tcatatgcaa aacccacaaa	18840
tgaaaatgga gggcaaggca ttcttgtaaa gcaacaaaat ggaaagctag aaagtcaagt	18900
ggaaatgcaa tttttctcaa ctactgaggc agccgcaggc aatgggtgata acttgactcc	18960
taaagtggta ttgtacagtg aagatgtaga tatagaaacc ccagacactc atatttctta	19020
catgcccact attaaggaag gtaactcacg agaactaatg ggccaacaat ctatgcccac	19080
caggcctaata tacattgctt ttagggacaa ttttattggt ctaatgtatt acaacagcac	19140
gggtaatatg ggtgttcttg cgggccaagc atcgcagttg aatgctgttg tagatttgca	19200
agacagaaac acagagcttt cataccagct tttgcttgat tccattgggt atagaaccag	19260
gtacttttct atgtggaatc aggtgttgga cagctatgat ccagatgtta gaattattga	19320
aaatcatgga actgaagatg aacttccaaa ttactgcttt ccactgggag gtgtgattaa	19380
tacagagact cttaccaag taaaacctaa aacaggtcag gaaaatggat gggaaaaaga	19440
tgctacagaa ttttcagata aaaatgaaat aagagttgga aataattttg ccatggaaat	19500
caatctaaat gccaacctgt ggagaaattt cctgtactcc aacatagcgc tgtatttgcc	19560
cgacaagcta aagtacagtc cttccaacgt aaaaaattct gataacccaa acacctacga	19620
ctacatgaac aagcgagtgg tggctcccg gctagtggac tgctacatta acctggagc	19680
acgctgggtcc cttgactata tggacaacgt caaccattt aaccaccacc gcaatgctgg	19740
cctgcgctac cgctcaatgt tgctgggcaa tggctgctat gtgcccttcc acatccaggt	19800
gcctcagaag ttctttgcca ttaaaaacct ccttctctg ccgggctcat acacctacga	19860
gtggaacttc aggaaggatg ttaacatggt tctgcagagc tccctaggaa atgacctaa	19920
ggttgacgga gccagcatta agtttgatag catttgccct tacgccacct tcttcccat	19980
ggcccacaa accgcctcca cgcttgaggc catgcttaga aacgacacca acgaccagtc	20040
ctttaacgac tatctctccg ccgccaacat gctctaccct ataccgcca acgctaccaa	20100
cgtgcccata tccatccct cccgcaactg ggcggcttcc cgcggctggg ccttcacgcg	20160
ccttaagact aaggaaacct catcactggg ctcgggctac gacccttatt acacctactc	20220
tggctctata ccctacctag atggaacctt ttacctcaac cacaccttta agaagggtggc	20280
cattaccttt gactctctg tcagctggcc tggcaatgac cgcctgctta ccccaacga	20340
gtttgaaatt aagcgctcag ttgacgggga gggttacaac gttgccagat gtaacatgac	20400
caaagactgg ttcctggtac aaatgctagc taactataac attggctacc agggcttcta	20460
tatcccagag agctacaagg accgcatgta ctcttcttt agaaacttcc agcccatgag	20520
ccgtcaggtg gtggatgata ctaaatataa ggactacca cagggtgggca tcctacacca	20580
acacaacaac tctggatttg ttggctacct tgccccacc atgcgcgaag gacaggccta	20640
ccctgctaac ttccctatc cgcttatagg caagaccgca gttgacagca ttaccagaa	20700
aaagtttctt tgcgatcgca ccctttggcg catccattc tccagtaact ttatgtccat	20760
gggcgcactc acagacctgg gccaaaacct tctctacgcc aactccgcc acgcgctaga	20820
catgactttt gaggtggatc ccatggacga gccaccctt ctttatgttt tgtttgaagt	20880

ctttgacgtg gtcggtgtgc accagccgca ccgcgggcgtc atcgaaaccg tgtacctgcg	20940
cacgccccttc tcggccggga acgccacaac ataaagaagc aagcaacatc aacaacagct	21000
gccgccatgg gctccagtga gcaggaactg aaagccattg tcaaagatct tggttgtggg	21060
ccatattttt tgggcaccta tgacaagcgc ttccaggtt ttgtttctcc acacaagctc	21120
gcctgcgcca tagtcaatac ggccgggtgc gagactgggg gcgtacctg gatggccttt	21180
gcctggaacc cgcactcaaa aacatgctac ctctttgagc cctttggctt ttctgaccag	21240
cgactcaagc aggtttacca gtttgagtac gagtactccc tgcgcgtag cgcattgct	21300
tcttcccccg accgctgtat aacgctggaa aagtccaccc aaagcgtaca ggggcccac	21360
tcggccgcct gtggactatt ctgtgcatg ttctccacg cctttgcaa ctggcccaa	21420
actcccatgg atcacaaccc caccatgaac ctattaccg gggtagccaa ctccatgctc	21480
aacagtcccc aggtacagcc caccctgctc cgcaaccagg aacagctcta cagcttctg	21540
gagcgccact cgccttactt ccgcagccac agtgcgcaga ttaggagcgc cacttcttt	21600
tgctacttga aaaacatgta aaaataatgt actagagaca ctttcaataa aggcaaatgc	21660
ttttatttgt acactctcgg gtgattattt acccccaccc ttgccgtctg cgcggttta	21720
aaatcaaagg ggttctgccc cgcctcgtta tgcgccactg gcagggacac gttgcgatac	21780
tggtgttttag tgctccactt aaactcaggc acaaccatcc gcggcagctc ggtgaagttt	21840
tcactccaca ggctgcgcac catcaccaac gcgttttagca ggtcggggcg cgatatcttg	21900
aagtcgcagt tggggcctcc gccctgcgcg cgcgagttgc gatacacagg gttgcagcac	21960
tggaacacta tcagcgccgg gtggtgcacg ctggccagca cgctcttgct ggagatcaga	22020
tccgcgtcca ggtcctccgc gttgctcagg gcgaacggag tcaactttgg tagctgcctt	22080
cccaaaaagg gcgcgtgccc aggttttag ttgcaactgc accgtagtgg catcaaaagg	22140
tgaccgtgcc cggctctgggc gttaggatac agcgcttga taaaagcctt gatctgctta	22200
aaagccacct gagcctttgc gccttcagag aagaacatgc cgcaagactt gccggaaaac	22260
tgattggccg gacaggccgc gtctgcacg cagcaccttg cgtcgggtgt ggagatctgc	22320
accacatttc ggccccaccg gttcttcacg atcttggcct tgctagactg ctcttcagc	22380
gcgcgtgcc cgttttgcgt cgtcacatcc atttcaatca cgtgctcctt atttatcata	22440
atgcttccgt gtagacactt aagctcgcct tcgatctcag cgcagcggtg cagccacaac	22500
gcgcagcccg tgggctogtg atgctttag gtcacctctg caaacgactg caggtacgcc	22560
tgcaggaatc gccccatcat cgtcacaaag gtcttgttgc tgggaaggt cagctgcaac	22620
ccgcgggtgct cctcgttcag ccaggtcttg catacggccg ccagagcttc cacttggtca	22680
ggcagtagtt tgaagtctgc ctttagatcg ttatccacgt ggtacttgct catcagcgcg	22740
cgcgcagcct ccatgccctt ctcccacgca gacacgatcg gcacactcag cgggttcac	22800
accgtaattt cactttccgc ttgcgtgggc tcttctctt cctcttgct ccgcatacca	22860
cgcgccactg ggtcgtcttc attcagccgc cgcactgtgc gcttacctcc tttgccatgc	22920
ttgattagca ccggtgggtt gctgaaaccc accatttgta gcgccacatc ttctctttct	22980
tctcgtctgt ccacgattac ctctgggtgat ggcggggcgt cgggcttggg agaagggcgc	23040
ttctttttct tcttgggcgc aatggccaaa tccgcgcgcg aggtcgtatg ccgcgggctg	23100

gggtgtgcgcg gcaccagcgc gtcttgtgat gagtcttcct cgtcctcggg ctcgatacgc	23160
cgcctcatcc gcttttttgg gggcgcccgg ggaggcggcg gcgacgggga cggggacgac	23220
acgtcctcca tgggtggggg acgtcgcgcc gcaccgcgtc cgcgctcggg ggtgggttcg	23280
cgtgctcct cttcccgact ggccatttcc ttctcctata ggcagaaaaa gatcatggag	23340
tcagtcgaga agaaggacag cctaaccgcc ccctctgagt tcgccaccac cgcctccacc	23400
gatgcgcga acgcgcctac caccttcccc gtcgaggcac ccccgcttga ggaggaggaa	23460
gtgattatcg agcaggaccc aggttttgta agcgaagacg acgaggaccg ctcagtacca	23520
acagaggata aaaagcaaga ccaggacaac gcagaggcaa acgaggaaca agtcgggcgg	23580
ggggacgaaa ggcatggcga ctacctagat gtgggagacg acgtgctgtt gaagcatctg	23640
cagcgccagt gcgccattat ctgcgacgcg ttgcaagagc gcagcgatgt gccctcgc	23700
atagcggatg tcagccttgc ctacgaacgc cacctattct caccgcgcgt acccccaaaa	23760
cgccaagaaa acggcacatg cgagcccaac ccgcgcctca acttctacct cgtatttgcc	23820
gtgccagagg tgcttgccac ctatcacatc tttttccaaa actgcaagat acccctatcc	23880
tgccgtgcca accgcagccg agcggacaag cagctggcct tgcggcaggg cgtgtcata	23940
cctgatatcg cctcgcctca cgaagtgcc aaaaatcttg agggctcttg acgcgacgag	24000
aagcgcgcgg caaacgcctc gcaacaggaa aacagcgaaa atgaaagtca ctctggagt	24060
ttggtggaac tcgaggggtg caacgcgcgc ctagccgtac taaaacgcag catcgaggtc	24120
accactttg cctaccgcgc acttaacctc ccccccaagg tcatgagcac agtcctgagt	24180
gagctgatcg tgcgccttgc gcagcccctg gagagggatg caaatgtgca agaacaaaca	24240
gaggagggcc taccgcagct tggcgacgag cagctagcgc gctggcttca aacgcgcgag	24300
cctgccgact tggaggagcg acgcaacta atgatggccg cagtgtcgt taccgtggag	24360
cttgagtga tgcagcggtt ctttctgac ccggagatgc agcgcaagct agaggaaaca	24420
ttgcactaca ctttctgaca gggctacgta cgccaggcct gcaagatctc caacgtggag	24480
ctctgcaacc tggctctcta ctttgaatt ttgcacgaaa accgccttgg gcaaaacgtg	24540
cttcattcca cgctcaaggg cgaggcgcgc cgcgactacg tccgcgactg cgtttactta	24600
tttctatgct acacctggca gacggccatg ggcgtttggc agcagtgtt ggaggagtgc	24660
aacctcaagg agctgcagaa actgtctaaag caaaacttga aggacctatg gacggccttc	24720
aacgagcgct ccgtggccgc gcacctggcg gacatcattt tccccgaacg cctgcttaaa	24780
accctgcaac agggctctgc agacttcacc agtcaaagca tgttgacgaa ctttaggaac	24840
tttatcctag agcgctcagg aatcttgccc gccacctgct gtgcacttcc tagcgacttt	24900
gtgccatta agtaccgcga atgccctccg ccgctttggg gccactgcta ctttctgag	24960
ctagccaact accttgccca ccactctgac ataatggaag acgtgagcgg tgacggtcta	25020
ctggagtgtc actgtcgtg caacctatgc accccgcacc gctccctggg ttgcaattcg	25080
cagctgctta acgaaagtca aattatcggg acctttgagc tgcagggtcc ctcgcctgac	25140
gaaaagtccg cggtccggg gttgaaactc actccggggc tgtggacgtc ggcttacctt	25200
cgcaaatttg tacctgagga ctaccacgcc cagagatta ggttctacga agaccaatcc	25260
cgcccgccca atgcggagct taccgcctgc gtcattaccc agggccacat tcttgccaa	25320

ttgcaagcca tcaacaaagc ccgccaagag tttctgctac gaaagggacg gggggtttac	25380
ttggaccccc agtccggcga ggagctcaac ccaatcccc cgccgcccga gccctatcag	25440
cagcagccgc gggcccttgc ttcccaggat ggcacccaaa aagaagctgc agctgccgcc	25500
gccacccacg gacgaggagg aatactggga cagtcaggca gaggaggttt tggacaggga	25560
ggaggaggac atgatggaag actgggagag cctagacgag gaagcttcg aggtcgaaga	25620
ggtgtcagac gaaacaccgt caccctcggt cgcattcccc tcgccggcgc ccagaaaac	25680
ggcaaccggt tccagcatgg ctacaacctc cgctcctcag gcgccgccg cactgcccg	25740
tcgccgaccc aaccgtagat gggacaccac tggaaccagg gccggtaagt ccaagcagcc	25800
gccgccgtta gcccaagagc aacaacagcg ccaaggctac cgctcatggc gcgggcacaa	25860
gaacgccata gttgcttgct tgcaagactg tgggggcaac atctccttcg ccgccgctt	25920
tcttctctac catcacggcg tggccttccc ccgtaacatc ctgcattact accgtcatct	25980
ctacagccca tactgcaccg gcggcagcgg cagcaacagc agcggccaca cagaagcaaa	26040
ggcgaccgga tagcaagact ctgacaaaag ccaagaaatc cacagcggcg gcagcagcag	26100
gaggaggagc gctgcgtctg gcgcccacg aaccctatc gaccgcgag cttagaaaca	26160
ggatttttcc cactctgtat gctatatctc aacagagcag gggccaagaa caagagctga	26220
aaataaaaaa cagggtctctg cgatccctca ccgcgagctg cctgtatcac aaaagcgaag	26280
atcagcttcg gcgcacgctg gaagacgcgg aggtctctct cagtaaatac tgcgcgctga	26340
ctcttaagga ctagtttcgc gccctttctc aaatttaagc gcgaaaacta cgtcatctcc	26400
agcggccaca ccgggcgcca gcacctgttg tcagcgccat tatgagcaag gaaattccca	26460
cgcctacat gtggagtac cagccacaaa tgggacttgc ggctggagct gcccaagact	26520
actcaaccg aataaactac atgagcgcgg gaccccat gatatcccg gtcaacggaa	26580
tacgcgcccc ccgaaaccga attctcctgg aacaggcggc tattaccacc acacctcgta	26640
ataaccttaa tccccgtagt tggcccgtg ccctggtgta ccaggaaagt ccgctccca	26700
ccactgtggt acttcccaga gacgccagc ccgaagtca gatgactaac tcaggggcgc	26760
agcttgccgg cggttttcgt cacagggtgc ggtcgcccg gcagggtata actcacctga	26820
caatcagagg gcgaggatt cagctcaacg acgagtcggt gagctcctcg cttggtctcc	26880
gtccggacgg gacatttcag atcggcggcg ccggcgctc ttcattcacg cctcgtcagg	26940
caatcctaac tctgcagacc tcgtcctctg agccgcgctc tggaggcatt ggaactctgc	27000
aatattattga ggagtttgat ccacgggtct actttaacct cttctcgga cctcccggcc	27060
actatccgga tcaatttatt cctaactttg acgcggtaaa ggactcggcg gacggctacg	27120
actgaatggt aagtggagag gcagagcaac tgcgcctgaa acacctggc cactgtcgcc	27180
gccacaagtg ctttgccgc gactccggtg agttttgcta ctttgaattg ccgaggatc	27240
atatcgaggg ccgggcgcac ggcgtccggc ttaccgcca gggagagctt gcccgtagcc	27300
tgattcggga gtttaccag cgcacctgc tagttgagcg ggacagggga ccctgtgttc	27360
tcactgtgat ttgcaactgt cctaaccctg gattacatca agatctttgt tgccatctct	27420
gtgctgagta taataaatac agaaattaa atatactggg gctcctatcg ccacccgtga	27480
aacgccaccg tcttcaccgg cccaagcaaa ccaaggcgaa ccttacctgg tacttttaac	27540

atctctccct ctgtgattta caacagtttc aaccagacg gagtgagtct acgagagAAC	27600
ctctccgagc tcagctactc catcagaaaa aacaccaccc tccttacctg ccgggaacgt	27660
acgagtgcgt caccggccgc tgcaccacac ctaccgcctg accgtaaac agactttttc	27720
cggacagacc tcaataactc tgittaccag aacaggaggt gagcttagaa aacccttagg	27780
gtattaggcc aaaggcgag ctactgtggg gtttatgaac aattcaagca actctacggg	27840
ctattctaata tcaggtttct ctagaatcgg ggttgggggtt attctctgtc ttgtgattct	27900
ctttattctt ataactaacg ttctctgcct aaggctcgcc gcctgctgtg tgcacatttg	27960
catttattgt cagcttttta aacgctgggg tgcacacca agatgattag gtacataatc	28020
ctaggtttac tcacccttgc gtcagccac ggtaccaccc aaaagggtga ttttaaggag	28080
ccagcctgta atgttacatt cgcagctgaa gctaataagt gcaccactct tataaaatgc	28140
accacagAAC atgaaaagct gcttattcgc cacaAAAAa aaattggcaa gtatgctgtt	28200
tatgctattt ggcagccag tgcactaca gagtataatg ttacagtttt ccagggtaaa	28260
agtcataaaa cttttatgta tacttttcca ttttatgaaa tgtgcgacat taccatgtac	28320
atgagcaaac agtataagtt gtggccccc caaaattgtg tggaaaacac tggcactttc	28380
tgtgcactg ctatgctaata tacagtgtc gctttggtct gtaccctact ctatattaaa	28440
tacaaaagca gacgcagctt tattgaggaa aagaaaatgc cttaatttac taagttacaa	28500
agctaagtgc accactaact gctttactcg ctgcttgcaa aacaaattca aaaagttagc	28560
attataatta gaataggatt taaaccccc ggtcatttcc tgcacaatac cattccccctg	28620
aacaattgac tctatgtggg atatgtcca gcgtacaaac cttgaagtca ggcttccctg	28680
atgtcagcat ctgactttgg ccagcacctg tcccgcggtt ttgttccagt ccaactacag	28740
cgcacccccc taacagagat gaccaacaca accaacgcgg ccgcgcgtac cggacttaca	28800
tctaccacaa atacaccccc agtttctgcc tttgtcaata actgggataa cttgggcatg	28860
tggtgggttct ccatagcgct tatgtttgta tgccttatta ttatgtggct catctgctgc	28920
ctaaagcgca aacgcgccc accaccatc tatagtccca tcattgtgct acacccaaac	28980
aatgatggaa tccatagatt ggacggactg aaacacatgt tcttttctct tacagtatga	29040
ttaaatgaga catgattcct cgagttttta tattactgac ccttggttgc ctttttttgt	29100
gcgtgctcca cattggctgc ggtttctcac atcgaagtag actgcattcc agccttcaca	29160
gtctatttgc tttacggatt tgtcacctc acgctcatct gcagcctcat cactgtggtc	29220
atcgctttta tccagtgcct tgactgggtc tgtgtgcgt ttgcatatct cagacaccat	29280
ccccagtaca gggacaggac tatagctgag cttcttagaa ttctttaatt atgaaattta	29340
ctgtgacttt tctgtgatt atttgacccc tatctgcgtt ttgttccccg acctccaagc	29400
ctcaaagaca tatatcatgc agattcactc gtatatggaa tattccaagt tgctacaatg	29460
aaaaaagcga tctttccgaa gcctgggttat atgcaatcat ctctgttatg gtgttctgca	29520
gtaccatctt agccctagct atatatccct accttgacat tggctggAAC gcaatagatg	29580
ccatgaacca cccaactttc ccgcgcgcc ctatgcttcc actgcaacaa gttgttgccg	29640
gcggctttgt ccagccaat cagcctcgcc caccttctcc cacccccact gaaatcagct	29700
actttaatct aacaggagga gatgactgac accctagatc tagaaatgga cggaattatt	29760

acagagcagc gcctgctaga aagacgcagg gcagcggccg agcaacagcg catgaatcaa	29820
gagctccaag acatgggttaa cttgcaccag tgcaaaagggt gtatcttttg tctggtaaag	29880
caggccaaag tcacctacga cagtaatacc accggacacc gccttagcta caagttgcca	29940
accaagcgtc agaaattggt ggtcatggtg ggagaaaagc ccattacat aactcagcac	30000
tcggtagaaa ccgaaggctg cattcactca ccttgtcaag gacctgagga tctctgcacc	30060
cttattaaga ccctgtgcgg tctcaaagat cttattccct ttaactaata aaaaaaata	30120
ataaagcatc acttacttaa aatcagttag caaattttctg tccagtttat tcagcagcac	30180
ctccttgccc tcctcccagc tctgggtattg cagcttcctc ctggctgcaa actttctcca	30240
caatctaaat ggaatgtcag tttcctcctg ttctgtcca tcgcaccca ctatcttcat	30300
gttggtgcag atgaagcgcg caagaccgtc tgaagatacc ttcaaccccg tgtatccata	30360
tgacacggaa accggtcctc caactgtgcc tttcttact cctcccttg tatccccaa	30420
tgggtttcaa gagagtcccc ctgggggtact ctctttgcgc ctatccgaac ctctagttac	30480
ctccaatggc atgcttgccg tcaaatggg caacggcctc tctctggacg aggccggcaa	30540
ccttacctcc caaaatgtaa ccaactgtgag cccacctctc aaaaaacca agtcaaacat	30600
aaacctggaa atatctgcac ccctcacagt tacctcagaa gccctaactg tggctgccgc	30660
cgcacctcta atggtcgcgg gcaacacact caccatgcaa tcacaggccc cgctaaccgt	30720
gcacgactcc aaacttagca ttgccacca aggaccctc acagtgtcag aaggaaagct	30780
agccctgcaa acatcaggcc ccctcaccac caccgatagc agtaccctta ctatcactgc	30840
ctcacccct ctaactactg ccaactggtag cttgggcatt gacttgaaag agcccattta	30900
tacacaaaat ggaaaactag gactaaagta cggggctcct ttgcatgtaa cagacgacct	30960
aaacactttg accgtagcaa ctggtccagg tgtgactatt aataatactt ccttgcaaac	31020
taaagttact ggagccttgg gttttgattc acaaggcaat atgcaactta atgtagcagg	31080
aggactaagg attgattctc aaaacagacg ccttatactt gatgttagtt atccgtttga	31140
tgctcaaac caactaaatc taagactagg acaggccct ctttttataa actcagccca	31200
caacttggat attactaca acaaaggcct ttacttgttt acagcttcaa acaattccaa	31260
aaagcttgag gttaacctaa gcaactgcaa ggggttgatg tttgacgcta cagccatagc	31320
cattaatgca ggagatgggc ttgaatttgg ttacctaatt gcaccaaaca caaatcccct	31380
caaaacaaaa attggccatg gcctagaatt tgattcaaac aaggctatgg ttcctaaact	31440
aggaaactggc cttagttttg acagcacagg tgccattaca gtaggaaaca aaaataatga	31500
taagctaact ttgtggacca caccagctcc atctcctaac tgtagactaa atgcagagaa	31560
agatgctaaa ctacttttg tcttaacaaa atgtggcagt caaatacttg ctacagtttc	31620
agttttggct gttaaaggca gtttggctcc aatatctgga acagttcaaa gtgctcatct	31680
tattataaga tttgacgaaa atggagtgtc actaaacaat tccttcttg acccagaata	31740
ttggaacttt agaaatggag atcttactga aggcacagcc tatacaaacg ctgttggtt	31800
tatgcctaac ctatcagctt atccaaaatc tcacggtaaa actgcaaaaa gtaacattgt	31860
cagtcaagtt tacttaaagc gagacaaaac taaacctgta aactaacca ttactactaa	31920
cggtagacag gaaacaggag acacaactcc aagtgcatac tctatgtcat tttcatggga	31980

ctggtctggc cacaactaca ttaatgaaat atttgccaca tcctcttaca ctttttcata	32040
cattgcccac gaataaagaa tcgtttgtgt tatgtttcaa cgtgtttatt tttcaattgc	32100
agaaaatttc aagtcatttt tcattcagta gtatagcccc accaccacat agcttataca	32160
gatcaccgta ccttaatcaa actcacagaa ccctagtatt caacctgcca cctccctccc	32220
aacacacaga gtacacagtc ctttctcccc ggctggcctt aaaaagcatc atatcatggg	32280
taacagacat attcttaggt gttatatctc acacggtttc ctgtcgagcc aaacgctcat	32340
cagtgatatt aataaactcc ccgggcagct cacttaagtt catgtcgtg tccagctgct	32400
gagccacagg ctgctgtcca acttgcggtt gcttaacggg cggcgaagga gaagtccacg	32460
cctacatggg ggtagagtca taatcgtgca tcaggatagg gcggtggtgc tgcagcagcg	32520
cgccaataaa ctgctgccgc cgccgctccg tcctgcagga atacaacatg gcagtggctt	32580
cctcagcgat gattcgcacc gcccgagca taaggcgctt tgcctccgg gcacagcagc	32640
gcacctgat ctcaactaaa tcagcacagt aactgcagca cagcaccaca atattgttca	32700
aaatcccaca gtgcaaggcg ctgtatccaa agctcatggc ggggaccaca gaaccacgt	32760
ggccatcata ccacaagcgc aggtagatta agtgcgacc cctcataaac acgctggaca	32820
taaacattac ctcttttggc atgttgtaat tcaccacctc ccggtaccat ataaacctct	32880
gattaaacat ggcgccatcc accaccatcc taaaccagct ggccaaaacc tgcccgcgg	32940
ctatacactg cagggaaacc ggactggaac aatgacagt gagagcccag gactcgtaac	33000
catggatcat catgctcgtc atgatatcaa tgttggcaca acacaggcac acgtgcatac	33060
acttcctcag gattacaagc tcctcccgcg ttagaacat atcccaggga acaaccatt	33120
cctgaatcag cgtaaatccc aactgcagg gaagacctcg cacgtaactc acgttgtgca	33180
ttgtcaaagt gttacattcg ggcagcagcg gatgatcctc cagtatggtg gcgcgggttt	33240
ctgtctcaaa aggaggtaga cgatccctac tgtacggagt gcgccgagac aaccgagatc	33300
gtgttggtcg tagtgtcatg ccaaatggaa cgccggacgt agtcatatct cctgaagcaa	33360
aaccagggtc gggcgtgaca aacagatctg cgtctccggt ctgcgcgctt agatcgctct	33420
gtgtagtagt tgtagtatat ccactctctc aaagcatcca ggcgccccct ggcttcgggt	33480
tctatgtaaa ctcttcatg cgccgctgcc ctgataacat ccaccaccgc agaataagcc	33540
acaccagcc aacctacaca ttcttctgc gagtcacaca cgggaggagc gggaagagct	33600
ggaagaacca tgtttttttt ttatttccaa aagattatcc aaaacctcaa aatgaagatc	33660
tattaagtga acgcgctccc ctccggtggc gtggtcaaac tctacagcca aagaacagat	33720
aatggcattt gtaagatggt gcacaatggc ttccaaaagg caaacggccc tcacgtccaa	33780
gtggacgtaa aggctaaacc cttcagggtg aatctcctct ataaacattc cagcaccttc	33840
aaccatgccc aaataattct catctcgcca ccttctcaat atatctctaa gcaaattccc	33900
aatattaagt ccggccattg taaaaatctg ctccagagcg cctccacct tcagcctcaa	33960
gcagcgaatc atgattgcaa aaattcaggt tcctcacaga cctgtataag attcaaaagc	34020
ggaacattaa caaaaatacc gcgatcccg aggtcccttc gcagggccag ctgaacataa	34080
tcgtgcaggt ctgcacggac cagcgcggcc acttccccgc cagggaacct gacaaaagaa	34140
cccacactga ttatgacacg catactcgga gctatgctaa ccagcgtagc cccgatgtaa	34200

gcttggtgca tgggcgggcga tataaaatgc aaggtgctgc tcaaaaaatc aggcaaagcc 34260
 tcgcgcaaaa aagaaagcac atcgtagtca tgetcatgca gataaaggca ggtaagctcc 34320
 ggaaccacca cagaaaaaga caccattttt ctctcaaaca tgtctgcggg tttctgcata 34380
 aacacaaaat aaaataacaa aaaaacattt aaacattaga agcctgtctt acaacaggaa 34440
 aaacaaccct tataagcata agacggacta cggccatgcc ggcgtgacgc taaaaaaact 34500
 ggtcaccgtg attaaaaagc accaccgaca gctcctcggg catgtccgga gtcataatgt 34560
 aagactcggg aaacacatca ggttgattca catcggtcag tgctaaaaag cgaccgaaat 34620
 agcccggggg aatacatacc cgcaggcgta gagacaacat tacagccccc ataggaggta 34680
 taacaaaatt aataggagag aaaaacacat aaacacctga aaaaccctcc tgcctaggca 34740
 aaatagcacc ctcccgtcc agaacaacat acagcgcttc cacagcggca gccataacag 34800
 tcagccttac cagtaaaaaa gaaaacctat taaaaaaaca ccactcgaca cggcaccagc 34860
 tcaatcagtc acagtgtaaa aaagggccaa gtgcagagcg agtatatata ggactaaaaa 34920
 atgacgtaac ggttaaagtc cacaaaaaac acccagaaaa ccgcacgcga acctacgcc 34980
 agaaacgaaa gccaaaaaac ccacaacttc ctcaaactgt cacttccgtt tttccacgtt 35040
 acgtcacttc ccattttaag aaaactacaa ttcccaacac atacaagta ctcgcgccta 35100
 aaacctagtc caccgcgcgc gttccacgc cccgcgccac gtcacaaact ccacccctc 35160
 attatcatat tggcttcaat ccaaaataag gtatattatt gat 35203

<210> 11
 <211> 33093
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Empty Ad5 vector sequence (repeats included)

<400> 11
 catcatcaat aatatacctt attttggtt gaagccaata tgataatgag ggggtggagt 60
 ttgtgacgtg gcgcggggcg tgggaacggg gcgggtgacg tagtagtgtg gcggaagtgt 120
 gatgttgcaa gtgtggcgga acacatgtaa gcgacggatg tggcaaaagt gacgtttttg 180
 gtgtgcgcgc gtgtacacag gaagtgacaa ttttcgcgcg gttttaggcg gatgtttag 240
 taaatttggg cgtaaccgag taagatttgg ccattttcgc gggaaaactg aataagagga 300
 agtgaaatct gaataatttt gtgttactca tagcgcgtaa tatttgtcta gggccgcggg 360
 gactttgacc gtttacgtgg agactcgcgc aggtgttttt ctcagggtgtt ttccgcgttc 420
 cgggtcaaaag ttggcgtttt attattatag tcagtacgtc tcgagcatgc atctaggcgg 480
 ccgcatggca gaaattcgcg aattcgctag cgtaaacgga tcctctagac gagatccgaa 540
 cttgtttatt gcagcttata atggttacaa ataaagcaat agcatcacia atttcacaaa 600
 taaagcattt ttttactgac attctagtgt tggtttgtcc aaactcatca atgtatctta 660
 tcatgtctag atctgtactg aaatgtgtgg gcgtggctta aggggtgggaa agaatatata 720
 aggtgggggt cttatgtagt tttgtatctg ttttcgagca gccgcgcgcg ccatgagcac 780
 caactcgttt gatggaagca ttgtgagctc atatttgaca acgcgcatgc ccccatgggc 840
 cggggtgcgt cagaatgtga tgggctccag cattgatggt cgcccggtcc tgcccgcaaa 900

ctctactacc ttgacctacg agaccgtgtc ttggaacgccg ttggagactg cagcctccgc	960
cgccgcttca gccgctgcag ccaccgcccg cgggattgtg actgactttg ctttctgag	1020
cccgccttga agcagtgca cttcccgttc atccgcccgc gatgacaagt tgacggctct	1080
tttggcaciaa ttggattctt tgaccggga acttaatgtc gtttctcagc agctgttgga	1140
tctgcgccag caggtttctg ccctgaaggc ttctcccct cccaatgcg tttaaaacat	1200
aaataaaaaa ccagactctg tttggatttg gatcaagcaa gtgtcttgct gtctttattt	1260
aggggttttg cgccgcggt agggccggga ccagcggctc cggctgtga gggctctgtg	1320
tattttttcc aggacgtggt aaaggtgact ctggatgttc agatacatgg gcataagccc	1380
gtctctgggg ttgaggtagc accactgcag agcttcatgc tgcggggtgg tgtttagat	1440
gatccagtcg tagcaggagc gctggcggtg gtgcctaaaa atgtctttca gtagcaagct	1500
gattgccagg ggcaggccct tgggtgaagt gtttaciaag cggttaagct gggatgggtg	1560
catagctggg gatagagat gcatcttga ctgtattttt aggttggtc tgttccagc	1620
catatccctc cggggattca tgtgtgcag aaccaccagc acagtgtatc cgtgcactt	1680
gggaaatttg tcatgtagct tagaaggaaa tgcgtggaag aacttgaga cggccttgtg	1740
acctccaaga tttccatgc attcgtccat aatgatggca atgggccac gggcggggc	1800
ctgggcgaag atatttctgg gatcactaac gtcatagttg tgttccagga tgagatcgc	1860
atagccatt tttaciaagc gcggcgagg ggtgccagac tgcggtataa tggttccatc	1920
cggccaggg gcgtagtac cctcacagat ttgcatttcc cagccttga gttcagatgg	1980
ggggatcatg tctacctgcg gggcgatgaa gaaaacggt tccgggtag gggagatcag	2040
ctgggaagaa agcaggttcc tgagcagctg cgacttaccg cagccggtgg gcccgtaaat	2100
cacacctatt accggtgca actggtagt aagagagctg cagctgccgt catccctgag	2160
caggggggcc acttcgttaa gcatgtccct gactgcagat tttccctga ccaaatccgc	2220
cagaaggcgc tcgccccca gcgatagcag ttcttgcaag gaagcaaagt tttcaacgg	2280
tttgagaccg tccgcgtag gcatgctttt gagcgtttga ccaagcagtt ccaggcggtc	2340
ccacagctcg gtcacctgct ctacggcatc tcgatccagc atatctctc gtttcgggg	2400
ttggggcggc tttcgtgta cggcagtagt cggctgctgt ccagacgggc cagggtcatg	2460
tctttccacg ggcgcagggt cctcgtcagc gtagtctggg tcacggtgaa ggggtgcgt	2520
ccgggtgctg cgctggccag ggtgcgctt aggtgtgtcc tgctggtgct gaagcgtgc	2580
cggctctcgc cctgcgcgtc ggccaggtag catttgacca tgggtgcata gtccagcccc	2640
tccgcggcgt gggccttggc gcgcagctt cccttgagg aggcgccga cgaggggcag	2700
tgcagacttt tgaggcgta gagcttggc gcgagaaata ccgattccgg ggagtaggca	2760
tccgcgccgc agggcccgca gacggtctc cattccacga gccaggtgag ctctggcgt	2820
tcggggtcaa aaaccaggt tccccatgc tttttgatgc gtttcttacc tctggtttcc	2880
atgagccggt gtccacgctc ggtgacgaaa aggtgtccg tgtcccgtg tacagacttg	2940
agaggcctgt cctcagcgg tgttccgctg tcctcctcgt atagaaactc ggaccactct	3000
gagacaaagg ctgcgtcca ggccagcacg aaggaggcta agtgggagg gtagcggtcg	3060
ttgtccacta ggggtccac tcgctccagg gtgtgaagac acatgtcgcc ctcttcggca	3120

tcaaggaagg tgattggttt gtaggtgtag gccacgtgac cgggtgttcc tgaagggggg	3180
ctataaaagg ggggtggggg gcgttcgtcc tcactctctt ccgcatcgct gtctgcgagg	3240
gccagctgtt ggggtgagta ctccctctga aaagcgggca tgacttctgc gctaagattg	3300
tcagtttcca aaaacgagga ggatttgata ttcacctggc ccgcggtgat gcctttgagg	3360
gtggccgcat ccactctggc agaaaagaca atctttttgt tgtcaagctt ggtggcaaac	3420
gacccgtaga gggcgttgga cagcaacttg gcgatggagc gcagggtttg gtttttgtcg	3480
cgatcggcgc gctccttgcc cgcgatgttt agctgcacgt attcgcgcgc aacgcaccgc	3540
cattcgggaa agacggtggt gcgctcgtcg ggcaccaggt gcacgcgcca accgcggtt	3600
tgcagggtga caaggtcaac gctggtggct acctctccgc gtaggcgctc gttggtccag	3660
cagaggcggc cgcccttgcc cgagcagaat ggcggtaggg ggtctagctg cgtctcgtcc	3720
ggggggtctg cgtccacggt aaagaccccg ggcagcaggc gcgcgtcgaa gtagtctatc	3780
ttgcatcctt gcaagtctag cgcctgctgc catgcgcggg cggcaagcgc gcgctcgat	3840
gggttgagtg ggggacccca tggcatgggg tgggtgagcg cggaggcgta catgccgcaa	3900
atgtcgtaaa cgtagagggg ctctctgagt attccaagat atgtagggtg gcactctcca	3960
ccgcggatgc tggcgcgcac gtaatcgat agttcgtgcg agggagcgag gaggtcggga	4020
ccgagggtgc tacggggcgg ctgctctgct cggaagacta tctgcctgaa gatggcatgt	4080
gagttggatg atatggttgg acgctggaag acgttgaaag tggcgtctgt gagacctacc	4140
gcgtcacgca cgaaggaggc gtaggagtcg cgcagcttgt tgaccagctc ggcggtgacc	4200
tgcacgtcta gggcgagta gtccaggggt tccttgatga tgcataactt atcctgtccc	4260
ttttttttcc acagctcgcg gttgaggaca aactcttcgc ggtctttcca gtactcttg	4320
atcggaacc cgctcgccctc cgaacggtaa gagcctagca tgtagaactg gttgacggcc	4380
tggtaggcgc agcatccctt ttctacgggt agcgcgtatg cctgcgcggc cttccggagc	4440
gaggtgtggg tgagcgcaaa ggtgtccctg accatgactt tgaggtagtg gtatttgaag	4500
tcagtgtcgt cgcacccgcc ctgctcccag agcaaaaagt ccgtgcgctt tttggaacgc	4560
ggatttgcca gggcgaaggt gacatcgttg aagagtatct ttcccgcgcg aggcataaag	4620
ttgcgtgtga tgcggaaggg tcccggcacc tcggaacggt tgttaattac ctgggcggcg	4680
agcacgatct cgtcaaagcc gttgatgttg tggcccacaa tgtaaagttc caagaagcgc	4740
gggatgccct tgatggaagg caatttttta agttcctcgt aggtgagctc ttcaggggag	4800
ctgagcccggt gctctgaaa ggcccagtct gcaagatgag ggttggaagc gacgaatgag	4860
ctccacaggt cacgggccat tagcatttgc aggtggtcgc gaaaggctct aaactggcga	4920
cctatggcca ttttttctgg ggtgatgcag tagaaggtaa gcgggtcttg ttcccagcgg	4980
tcccatccaa ggctcgcggc taggtctcgc gcggcagtca ctagaggctc atctccgccg	5040
aacttcatga ccagcatgaa gggcacgagc tgcttcccaa agggcccccatt ccaagtatag	5100
gtctctacat cgtaggtgac aaagagacgc tcggtgcgag gatgcgagcc gatcgggaa	5160
aactggatct cccgccacca attggaggag tggctattga tgtggtgaaa gtagaagtcc	5220
ctgcgacggg ccgaacactc gtgctggctt ttgtaaaaac gtgcgcagta ctggcagcgg	5280
tgcacgggct gtacatcctg cagcaggttg acctgacgac cgcgcacaag gaagcagagt	5340

gggaatttga gccctcgcc tggcggttt ggctggtgt cttctacttc ggctgcttgt	5400
ccttgaccgt ctggctgctc gaggggagtt acggtggatc ggaccaccac gccgcgcgag	5460
cccaaagtcc agatgtccgc gcgcggcggt cgagagcttga tgacaacatc gcgcagatgg	5520
gagctgtcca tggctctggag ctcccgcggc gtcaggtcag gcgggagctc ctgcaggttt	5580
acctcgcata gacgggtcag ggcgcgggct agatccaggt gatacctaatt tccaggggc	5640
tggttggtgg cggcgtcgat ggcttgcaag aggcgcgcatc ccgcgcggcg gactacggta	5700
ccgcgcggcg ggcgggtggc cgcggggggtg tccttgatg atgcatctaa aagcggtgac	5760
gcgggcgagc ccccgaggt agggggggct ccggaccgc cgaggagagg ggaggggca	5820
cgctcgcgcc gcgcgcggc aggagctggt gctgcgcgcg taggttgctg gcgaacgcga	5880
cgacgcggcg gttgatctcc tgaatctggc gcctctgctg gaagacgacg gggccggtga	5940
gcttgaacct gaaagagagt tcgacagaat caatttcggt gtcggtgacg gcggcctggc	6000
gcaaatctc ctgcacgtct cctgagttgt cttgataggc gatctcggcc atgaactgct	6060
cgatctcttc ctctggaga tctccgcgtc cggtcgctc caggtggcg gcgaggtcgt	6120
tggaaatgag ggccatgagc tgcgagaagg cgttgaggcc tcctcgttc cagacgcggc	6180
tgtagaccac gccccttcg gcctcgcg gcgcgcatgac cactcgcg agattgagct	6240
ccacgtgccc ggcaagacg gcgtagtctc gcaggcgctg aaagaggtag ttgaggtgg	6300
tggcggtgtg ttctgccacg aagaagtaca taaccacgcg tcgcaacgtg gattcgttga	6360
tatcccccac ggcccaagg cgctccatgg cctcgtagaa gtccacggcg aagttgaaaa	6420
actgggagtt gcgcgccgac acggttaact cctcctccag aagacggatg agctcgcgca	6480
cagtgtcgcg cactcgcg tcaaaggcta caggggcctc ttcttcttct tcaatctcct	6540
cttcataag ggccctccct tcttcttctt ctggcgcgcg tgggggaggg gggacacggc	6600
ggcgacgacg gcgcaccggg aggcgggtcga caaagcgctc gatcatctcc ccgcgcgac	6660
ggcgcatggt ctcggtgacg gcgcggcgct tctcgcgggg gcgcagttgg aagacgccgc	6720
ccgtcatgtc ccggttatgg gttggcgggg ggctgccatg cggcagggat acggcgctaa	6780
cgatgcatct caacaattgt tgtgtaggta ctccgccgc gagggacctg agcgagtccg	6840
catcgaccgg atcgaaaac ctctcgagaa aggcgtctaa ccagtcacag tcgcaaggta	6900
ggctgagcac cgtggcgggc ggcagcgggc ggcggtcggg gttgtttctg gcggaggtgc	6960
tgtgatgat gtaattaaag taggcgtct tgagacggcg gatggtcgac agaagcacca	7020
tgtccttggg tcggcctgc tgaatgcgca ggcggtcggc catgccccag gcttcgtttt	7080
gacatcgcg caggtctttg tagtagtctt gcctgagcct ttctaccggc acttcttctt	7140
ctccttctc ttgtcctgca tctcttgcat ctatcgctgc ggcgcgcg gagtttgcc	7200
gtaggtggcg ccctcttct cccatgcgtg tgaccccgaa gccctcctc ggctgaagca	7260
gggctaggtc ggcgacaacg cgctcggtc atatggcctg ctgcacctgc gtgagggtag	7320
actggaagtc atccatgtcc acaaagcggt ggtatgcgcc cgtgttgatg gtgtaagtgc	7380
agttggccat aacggaccag ttaacggtct ggtgaccgg ctgcgagagc tcggtgtacc	7440
tgagacgcga gtaagccctc gagtcaaata cgtagtcgtt gcaagtccgc accaggtact	7500
ggtatccac caaaaagtgc ggcggcggt ggcggtagag gggccagcgt aggggtggcg	7560

gggctccggg ggcgagatct tccaacataa ggcgatgata tccgtagatg tacctggaca	7620
tccaggtgat gccggcgggc gtggtggagg cgcgcggaaa gtcgcggacg cggttccaga	7680
tgttgcgag cggaaaaa tgctccatgg tcgggacgct ctggccggtc aggcgcgcgc	7740
aatcggtgac gctctagacc gtgcaaaagg agagcctgta agcgggcact cttccgtggt	7800
ctggtggata aattcgcaag ggtatcatgg cggacgaccg gggttcgagc cccgtatccg	7860
gccgtccgcc gtgatccatg cggttaccgc ccgcgtgtcg aaccaggtg tgcgacgtca	7920
gacaacgggg gagtgtcctt ttggcttcc ttccaggcgc ggcggctgct gcgctagctt	7980
ttttggccac tggcgcgcgc cagcgtaagc ggttaggctg gaaagcgaaa gcattaagtg	8040
gctcgctccc tgtagcggga gggttatttt ccaagggtg agtcgcggga cccccggttc	8100
gagtctcgga ccggccggac tgcggcgaac gggggtttgc ctccccgtca tgcaagacc	8160
cgcttgcaaa ttctccgga aacagggacg agcccccttt ttgcttttcc cagatgcac	8220
cgggtgtgcg gcagatgcgc cccctcctc agcagcggca agagcaagag cagcggcaga	8280
catgcagggc accctcccct cctcctaccg cgtcaggagg ggcgacatcc gcggttgacg	8340
cggcagcaga tgggtattac gaacccccgc ggcgcgggc ccggcactac ctggacttgg	8400
aggagggcga gggcctggcg cggctaggag cgccctctcc tgagcggcac ccaagggtgc	8460
agctgaagcg tgatacgcgt gaggcgtacg tgccgcggca gaacctgtt cgcgaccgcg	8520
aggagagga gcccgaggag atgcgggatc gaaagttcca cgcagggcgc gagctgcggc	8580
atggcctgaa tcgcgagcgg ttgctgcgcg aggaggactt tgagcccgac gcgcgaaccg	8640
ggattagtcc cgcgcgcgca cactggcg cgccgacct ggtaacgca tacgagcaga	8700
cggngaacca ggagattaac ttcaaaaaa gctttaacaa ccacgtgcgt acgcttgtgg	8760
cgcgcgagga ggtggctata ggactgatgc atctgtggga ctttgaagc gcgctggagc	8820
aaaacccaaa tagcaagccg ctcatggcg agctgttcct tatagtgcag cacagcaggg	8880
acaacgaggc attcagggat gcgctgctaa acatagtaga gcccgagggc cgctggctgc	8940
tcgatttgat aaacatcctg cagagcatag tggtcagga gcgcagcttg agcctggctg	9000
acaaggtggc cgcatcaac tattccatgc ttagcctggg caagttttac gcccgcaaga	9060
tataccatac cccttacgtt cccatagaca aggaggtaaa gatcgagggg ttctacatgc	9120
gcatggcgct gaaggtgctt accttgagcg acgacctggg cgtttatcgc aacgagcgca	9180
tccacaaggc cgtgagcgtg agccggcggc gcgagctcag cgaccgcgag ctgatgcaca	9240
gcctgcaaa ggccttggtt ggcacgggca gcggcgatag agaggccgag tcctactttg	9300
acgcggggcg tgacctgcgc tgggccccaa gccgacgcgc cctggaggca gctggggccg	9360
gacctgggct ggcggtggca ccgcgcgcgc ctggcaacgt cggcggcgct gaggaatatg	9420
acgaggacga tgagtacgag ccagaggacg gcgagtacta agcgggtgatg tttctgatca	9480
gatgatgcaa gacgcaacgg acccggcggt gcggggcgcg ctgcagagcc agccgtccgg	9540
ccttaactcc acggacgact ggcgccaggt catggaccgc atcatgtcgc tgactgcgcg	9600
caatcctgac gcgttccggc agcagccgca ggccaaccgg ctctccgcaa ttctggaagc	9660
ggtgggtccc gcgcgcgcaa accccacgca cgagaaggtg ctggcgatcg taaacgcgct	9720
ggccgaaaac agggccatcc ggcccagcga ggccggcctg gtctacgacg cgctgcttca	9780

gcgcgtggct cgttacaaca ggcgcaacgt gcagaccaac ctggaccggc tggtagggga	9840
tgtgcgcgag gccgtggcgc agcgtgagcg cgcgcagcag cagggcaacc tgggtccat	9900
ggttgacta aacgccttcc tgagtacaca gcccgccaac gtgccgcggg gacaggagga	9960
ctacaccaac tttgtgagcg cactgcggt aatggtgact gagacaccgc aaagtgaggt	10020
gtaccagtct gggccagact attttttcca gaccagtaga caaggcctgc agaccgtaa	10080
cctgagccag gctttcaaaa acttgacagg gctgtggggg gtgcgggctc ccacaggcga	10140
ccgcgcgacc gtgtctagct tgctgacgcc caactcgcgc ctgttgctgc tgctaatagc	10200
gcccttcacg gacagtggca gcgtgtcccg ggacacatac ctaggctact tgctgacact	10260
gtaccgcgag gccataggtc aggcgcgtgt ggacgagcat actttccagg agattacaag	10320
tgtagccgc gcgctggggc aggaggacac gggcagcctg gaggcaacc taaactacct	10380
gtgaccaac cggcggcaga agatccctc gttgcacagt ttaaaccagc aggaggagcg	10440
cattttgcgc tacgtgcagc agagcgtgag ccttaacctg atgcgcgacg gggtaacgcc	10500
cagcgtggcg ctggacatga ccgcgcgcaa catggaaccg ggcatgtatg cctcaaaccg	10560
gccgtttatc aaccgcctaa tggactactt gcatcgcgcg gccgccgtga accccgagta	10620
tttccaat gccatcttga accgcactg gctaccgcc cctggtttct acaccggggg	10680
attcgaggtg cccgagggt aagatggatt cctctgggac gacatagacg acagcgtgtt	10740
ttccccgcaa ccgcagacc tgctagagtt gcaacagcgc gagcaggcag aggcggcgct	10800
gcgaaaggaa agcttccgca ggccaagcag cttgtccgat ctaggcgctg cgccccgcg	10860
gtcagatgct agtagcccat ttccaagctt gatagggtct cttaccagca ctgcaccac	10920
ccgcccgcgc ctgctgggcg aggaggagta cctaaacaac tcgctgctgc agccgcagcg	10980
cgaaaaaaac ctgcctccg catttccaa caacgggata gagagcctag tggacaagat	11040
gagtagatgg aagacgtacg cgcaggagca caggacgtg ccaggcccgc gcccgccac	11100
ccgtcgtcaa aggcacgacc gtcagcggg tctggtgtgg gaggacgatg actcggcaga	11160
cgacagcagc gtcctggatt tgggaggag tggcaaccg tttgcgcacc ttcgcccag	11220
gctggggaga atgtttttaa aaaaaaaaaa gcatgatgca aaataaaaaa ctcaccaagg	11280
ccatggcacc gagcgttgg tttcttgat tccccctagt atgcggcgcg cggcgatgta	11340
tgaggaggt cctctccct cctacgagag tgtggtgagc gcggcgccag tggcgcggc	11400
gctgggttct cccttcgatg ctccccctga ccgcggtt gtgcctccgc ggtacctgcg	11460
gcctaccggg gggagaaaca gcatccgtta ctctgagttg gcacccctat tcgacaccac	11520
ccgtgtgtac ctggtggaca acaagtcaac ggatgtggca tccctgaact accagaacga	11580
ccacagcaac tttctgacca cggtcattca aaacaatgac tacagcccgc gggaggcaag	11640
cacacagacc atcaatcttg acgaccggtc gactggggc ggcgacctga aaaccatcct	11700
gcataccaac atgccaaatg tgaacgagtt catgtttacc aataagttta aggcgggggt	11760
gatggtgtcg cgcttgcta ctaaggacaa tcaggtggag ctgaaatacg agtgggtgga	11820
gttcacgctg cccgaggga actactccga gaccatgacc atagacctta tgaacaacgc	11880
gatcgtggag cactacttga aagtgggcag acagaacggg gttctggaaa gcgacatcgg	11940
ggtaaaagttt gacaccgcga acttcagact ggggtttgac ccgctcactg gtcttgcac	12000

gcctggggta tatacaaacg aagccttcca tccagacatc attttgctgc caggatgcgg	12060
ggtggacttc accccacagcc gcctgagcaa cttgttgggc atccgcaagc ggcaaccctt	12120
ccaggagggc tttaggatca cctacgatga tctggagggt ggtaacattc ccgcaactgt	12180
ggatgtggac gcctaccagg cgagcttgaa agatgacacc gaacagggcg ggggtggcgc	12240
aggcggcagc aacagcagtg gcagcggcgc ggaagagaa tccaacgcgg cagccgcggc	12300
aatgcagccg gtggaggaca tgaacgatca tgccattcgc ggcgacacct ttgccacacg	12360
ggctgaggag aagcgcgctg aggcgaagc agcggccgaa gctgccgccc ccgctgcgca	12420
acccgaggtc gagaagcctc agaagaaacc ggtgatcaaa cccctgacag aggacagcaa	12480
gaaacgcagt taacaacctaa taagcaatga cagcaccttc acccagtacc gcagctggta	12540
ccttgcatat aactacggcg accctcagac cggaatccgc tcatggacct tgctttgcac	12600
tcctgacgta acctgcggct cggagcaggt ctactggctg ttgccagaca tgatgcaaga	12660
ccccgtgacc ttccgctcca cgcgccagat cagcaacttt ccggtgggtg gcgccgagct	12720
gttgcccggt cactccaaga gcttctacaa cgaccaggcc gtctactccc aactcatccg	12780
ccagtttacc tctctgacct acgtgttcaa tcgctttccc gagaaccaga ttttggcgcg	12840
cccgcagcc cccaccatca ccacgctcag tgaacacgtt cctgctctca cagatcacgg	12900
gacgctaccg ctgcgcaaca gcatcggagg agtccagcga gtgaccatta ctgacgccag	12960
acgcgcacc tgccctacg ttacaaggc cctgggcata gtctcgccgc gcgtcctatc	13020
gagccgcaact tttgagcaa gcatgtccat ccttatatcg ccagcaata acacaggctg	13080
gggcctgccc ttccaagca agatgtttgg cggggccaag aagcgtccg accaacaccc	13140
agtgcgcgtg cgcgggcact accgcgcgc ctggggcgcg cacaacgcg gccgcactgg	13200
gcgcaccacc gtcgatgacg ccacgacgc ggtggtggag gaggcgcgca actacacgcc	13260
cacgcgcgca ccagtgtcca cagtggacgc ggccattcag accgtggtgc gcggagcccg	13320
gcgctatgct aaaatgaaga gacggcggag gcgcgtagca cgctcgccacc gccgcgacc	13380
cggcactgcc gcccaacgcg cggcggcggc cctgcttaac cgcgcacgtc gcaccggcgc	13440
acggggcgcc atgcgggccc ctggaaggct ggccgcgggt attgtcactg tgccccccag	13500
gtccaggcga cgagcggccc ccgcagcagc cgcggccatt agtgctatga ctcagggtcg	13560
caggggcaac gtgtattggg tgcgcgactc ggttagcggc ctgcgcgtgc ccgtgcgcac	13620
ccgccccccg cgcaactaga ttgcaagaaa aaactactta gactcgtact gttgtatgta	13680
tccagcggcg gcgcgcgcga acgaagctat gtccaagcgc aaaatcaaag aagagatgct	13740
ccaggtcatc gcgcgggaga tctatggccc cccgaagaag gaagagcagg attacaagcc	13800
ccgaaagcta aagcgggtca aaaagaaaaa gaaagatgat gatgatgaac ttgacgacga	13860
ggtggaactg ctgcacgcta ccgcgcccag gcgacgggta cagtggaaaag gtcgacgcgt	13920
aaaacgtggt ttgcgacccc gcaccaccgt agtctttacg cccggtgagc gctccaccgc	13980
cacctacaag cgcgtgtatg atgagggtga cggcgacgag gacctgcttg agcaggccaa	14040
cgagcgctc ggggagtttg cctacggaaa gcggcataag gacatgctgg cgttgccgct	14100
ggacgagggc aacccaacac ctacgctaaa gcccgtaaca ctgcagcagg tgctgcccgc	14160
gcttgacccg tccgaagaaa agcgcggcct aaagcgcgag tctggtgact tggcaccac	14220

cgtgcagctg atggtaccca agcgcagcg actggaagat gtcttgaaa aaatgaccgt	14280
ggaacctggg ctggagcccc aggtccgct ggcgccaatc aagcagggtg cgccgggact	14340
gggcgtgcag accgtggacg ttcagatacc cactaccagt agcaccagta ttgccaccgc	14400
cacagagggc atggagacac aaacgtcccc ggttgccctca gcggtggcgg atgccgcggt	14460
gcaggcggtc gctgcggccg cgtccaagac ctctacggag gtgcaaacgg acccgtggat	14520
gtttcgcggt tcagcccccc ggcgcccgcg ccgttcgagg aagtacggcg ccgccagcgc	14580
gctactgccc gaatatgccc tacatccttc cattgcgcct acccccggct atcgtggcta	14640
cacctaccgc ccagaagac gagcaactac ccgacgccga accaccactg gaaccgcgcg	14700
ccgcgctgc cgtgcgccag ccgtgctggc ccgattttcc gtgcgcaggg tggctcgcga	14760
aggaggcagg accctggtgc tgccaacagc gcgctaccac ccagcatcg tttaaaagcc	14820
ggtctttgtg gttcttgca atattggccct cactgcccgc ctccgtttcc cgtgcccggg	14880
attccgagga agaattgcacc gtaggagggg catggccggc caccgctga cggcgggcat	14940
gcgtcgtgcg caccaccggc ggcggcgcg gtcgcaccgt cgcattgcgc gcggtatcct	15000
gcccctcctt attccactga tcgcgcggcg gattggcgcc gtgcccggaa ttgcatccgt	15060
ggccttgca ggcgagagac actgattaaa aacaagttgc atgtggaaaa atcaaaataa	15120
aaagtctgga ctctcacgct cgcttgggtc tgtaactatt ttgtagaatg gaagacatca	15180
acttttcgtc tctggccccg cgacacggct cgcgcccgtt catgggaaac tggcaagata	15240
tcggcaccag caatatgagc ggtggcgccct tcagctgggg ctgcgtgtgg agcggcatta	15300
aaaatttcgg ttccaccgtt aagaactatg gcagcaaggc ctggaacagc agcacaggcc	15360
agatgctgag ggataagttg aaagagcaaa atttccaaca aaaggtggta gatggcctgg	15420
cctctggcat tagcgggggtg gtggacctgg ccaaccaggc agtgcaaaat aagattaaca	15480
gtaagcttga tccccgccct ccgtagagg agcctccacc ggccgtggag acagtgtctc	15540
cagaggggagc tggcgaaaag cgtccgcgcc ccgacaggga agaaactctg gtgacgcaaa	15600
tagacgagcc tccctcgtac gaggaggcac taaagcaagg cctgccacc acccgtccca	15660
tcgcgcccac ggctaccgga gtgctgggac agcacacacc cgtaacgctg gacctgcctc	15720
ccccgcccga caccagcag aaacctgtgc tgccaggccc gaccgcccgt gttgtaacct	15780
gtcctagccg cgcgtccctg cgccgcgcgc ccagcgggtc gcgacggtt cgcccgtag	15840
ccagtggcaa ctggcaaagc aactgaaca gcatcgtggg tctgggggtg caatccctga	15900
agcgcgcagc atgcttctga tagctaactg gtcgtatgtg tgtcatgtat gcgtccatgt	15960
cgccgccaga ggagctgctg agccgcgcgc cgcccgtttt ccaagatggc tacccttcg	16020
atgatgccgc agtggtctta catgcacatc tcgggccagg acgcctcgga gtacctgagc	16080
ccggggctgg tgcagtttgc ccgcgccacc gagacgtact tcagcctgaa taacaagttt	16140
agaaacccca cgggtggcgc tacgcacgac gtgaccacag accggtccca gcgtttgacg	16200
ctgcggttca tccctgtgga ccgtgaggat actgcgtact cgtacaaggc gcggttcacc	16260
ctagctgtgg gtgataaccg tgtgtgggac atggcttcca cgtactttga catccgcggc	16320
gtgctggaca ggggcccctac ttttaagccc tactctggca ctgcctacaa cgccctggct	16380
cccaagggtg ccccaaatcc ttgcgaatgg gatgaagctg ctactgctct tgaaataaac	16440

ctagaagaag aggacgatga caacgaagac gaagtagacg agcaagctga gcagcaaaaa	16500
actcacgtat ttgggcaggc gccttattct ggtataaata ttacaaagga gggatttcaa	16560
ataggtgtcg aagggtcaaac acctaaatat gccgataaaa catttcaacc tgaacctcaa	16620
ataggagaat ctcaagtggta cgaacacagaa attaatcatg cagctgggag agtcctaaaa	16680
aagactaccc caatgaaacc atgttacggc tcataatgcaa aacccacaaa tgaaaatgga	16740
gggcaaggca ttcttgtaaa gcaacaaaat ggaaagctag aaagtcaagt ggaaatgcaa	16800
tttttctcaa ctactgaggc agccgcaggc aatgggtgata acttgactcc taaagtggta	16860
ttgtacagtg aagatgtaga tatagaaacc ccagacactc atatttctta catgccact	16920
attaaggaag gtaactcacg agaactaatg ggccaacaat ctatgcccaa caggccta	16980
tacattgctt ttagggacaa ttttattggc ctaatgtatt acaacagcac gggtaatatg	17040
gggtgtcttg cgggccaagc atcgagttg aatgctgtg tagatttgca agacagaaac	17100
acagagcttt cataccagct tttgcttgat tccattgggtg atagaaccag gtacttttct	17160
atgtggaatc aggtgtgtga cagctatgat ccagatgtta gaattattga aaatcatgga	17220
actgaagatg aacttccaaa ttactgcttt ccactgggag gtgtgattaa tacagagact	17280
cttaccaagg taaaacctaa aacaggtcag gaaaatggat gggaaaaaga tgctacagaa	17340
ttttcagata aaaatgaaat aagagttgga aataattttg ccatggaaat caatctaat	17400
gccaacctgt ggagaaatct cctgtactcc aacatagcgc tgtatttgcc cgacaagcta	17460
aagtacagtc cttccaacgt aaaaatttct gataacccaa acacctacga ctacatgaac	17520
aagcgagtgg tggctcccg gctagtggac tgctacatta accttgagc acgctggtcc	17580
cttgactata tggacaacgt caaccattt aaccaccacc gcaatgctgg cctgcgctac	17640
cgctcaatgt tgctgggcaa tggctcgctat gtgccttcc acatccaggt gcctcagaag	17700
ttctttgcca ttaaaaacct ccttctcctg ccgggctcat acacctacga gtggaacttc	17760
aggaaggatg ttaacatggt tctgcagagc tccctaggaa atgacctaa ggttgacgga	17820
gccagcatta agtttgatag catttgctt tacgccacct tcttcccat ggcccacaac	17880
accgcctcca cgcttgaggc catgcttaga aacgacacca acgaccagtc ctttaacgac	17940
tatctctccg ccgccaacat gctctaccct ataccgcca acgctaccaa cgtgccata	18000
tccatccct cccgcaactg ggcggctttc cgggctggg ccttcacgcg ccttaagact	18060
aaggaaacct catcactggg ctgggctac gaccttatt acacctactc tggctctata	18120
ccctacctag atggaacctt ttacctcaac cacaccttta agaagggtggc cattacctt	18180
gactcttctg tcagctggc tggcaatgac cgctgttta ccccaacga gtttgaaatt	18240
aagcgtcag ttgacggga gggttacaac gttgccagc gtaacatgac caaagactgg	18300
ttctggtac aaatgctagc taactataac attggctacc agggcttcta tatcccagag	18360
agctacaagg accgcatgta ctcttcttt agaaacttcc agcccatgag ccgtcaggtg	18420
gtggatgata ctaaatacaa ggactaccaa caggtggga tcctacacca acacaacaac	18480
tctggatttg ttggtacct tgccccacc atgcgcgaag gacaggccta cctgctaac	18540
ttccctatc cgcttatagg caagaccgca gttgacagca ttaccagaa aaagtttctt	18600
tgcgatcgca ccctttggc catccattc tccagtaact ttatgtccat gggcgactc	18660

acagacctgg gccaaaacct tctctacgcc aactccgccc acgcgctaga catgactttt	18720
gaggtggatc ccatggacga gccaccctt ctttatgttt tgtttgaagt ctttgacgtg	18780
gtccgtgtgc accagccgca ccgcggcgtc atcgaaaccg tgtacctgcg cacgcccttc	18840
tcggccggca acgccacaac ataaagaagc aagcaacatc aacaacagct gccgccatgg	18900
gctccagtga gcaggaactg aaagccattg tcaaagatct tggttgtggg ccataatttt	18960
tgggcaccta tgacaagcgc tttccaggct ttgtttctcc acacaagctc gcctgcgcca	19020
tagtcaatac ggccggctgc gagactgggg gcgtacactg gatggccttt gcctggaacc	19080
cgcactcaaa aacatgctac ctctttgagc cctttggctt ttctgaccag cgactcaagc	19140
aggtttacca gtttgagtac gagtcactcc tgcgcgtag cgccattgct tcttcccccg	19200
accgctgtat aacgctggaa aagtccaccc aaagcgtaca ggggcccac tcggccgcct	19260
gtggactatt ctgctgcatg tttctccacg cctttgccaa ctggcccac actcccatgg	19320
atcacaaccc caccatgaac cttattaccg gggtaaccaa ctccatgctc aacagtcccc	19380
aggtacagcc caccctgcgt cgcaaccagg aacagctcta cagcttcctg gagcgccact	19440
cgccctactt ccgcagccac agtgcgcaga ttaggagcgc cacttctttt tgtcacttga	19500
aaaacatgta aaaataatgt actagagaca ctttcaataa aggcaaatgc ttttatttgt	19560
acactctcgg gtgattattt acccccaccc ttgccgtctg cgccgtttta aaatcaaagg	19620
ggttctgcgg cgcatcgcta tgcgccactg gcagggacac gttgcgatac tgggtgttag	19680
tgtccactt aaactcaggc acaaccatcc gcggcagctc ggtgaagttt tcactccaca	19740
ggctgcgcac catcaccaac gcgttttagc ggtcggggcg cgatatcttg aagtcgcagt	19800
tggggcctcc gccctgcgcg ccgcagttgc gatacacagg gttgcagcac tggaacacta	19860
tcagcgccgg gtggtgcacg ctggccagca cgctcttgtc ggagatcaga tccgcgtcca	19920
ggctctccgc gttgctcagg gcgaacggag tcaactttgg tagctgcctt cccaaaaagg	19980
gcgcgtgccc aggtcttgag ttgcactcgc accgtagtgg catcaaaagg tgaccgtgcc	20040
cggctctggg gttaggatac agcgctgca taaaagcctt gatctgctta aaagccacct	20100
gagcctttgc gccttcagag aagaacatgc cgcaagactt gccggaaaac tgattggccg	20160
gacaggccgc gtcgtgcacg cagcaccttg cgtcgggtgt ggagatctgc accacatttc	20220
ggccccaccg gttcttcacg atcttggcct tgctagactg ctccctcagc gcgcgctgcc	20280
cgttttcgct cgtcacatcc atttcaatca cgtgctcctt atttatcata atgcttcgt	20340
gtagacactt aagctcgct tcgatctcag cgcagcgggt cagccacaac gcgcagcccg	20400
tgggctcgtg atgcttgtag gtcacctctg caaacgactg caggtacgcc tgcaggaatc	20460
gccccatcat cgtcacaaaag gtcttgttgc tgggtgaagg cagctgcaac ccgcggtgct	20520
cctcgctcag ccaggtcttg catacgcccg ccagagcttc cacttgggtca ggtagtagtt	20580
tgaagtgcg ctttagatcg ttatccacgt ggtacttgct catcagcgcg cgcgcagcct	20640
ccatgccctt ctcccacgca gacacgatcg gcacactcag cgggttcac accgtaattt	20700
cactttccgc ttcgctgggg tcttctctct cctcttgctg ccgcatacca cgcgccactg	20760
ggctcgtctt attcagccgc cgcactgtgc gcttacctcc ttgccatgc ttgattagca	20820
ccggtggggt gctgaaaccc accatttgta gcgccacatc ttctctttct tctcgtctgt	20880

ccacgattac ctctggtgat ggcgggcgct cgggcttggg agaagggcgc ttctttttct	20940
ttctggggcg aatggccaaa tccgccgccg aggtogatgg ccgcgggctg ggtgtgcgcg	21000
gcaccagcgc gtcttgtgat gagtcttcct cgtcctcgga ctcgatacgc cgcctcatcc	21060
gcttttttgg gggcgcccgg ggagggcgcg gcgacgggga cggggacgac acgtcctcca	21120
tggttggggg acgtcgcgcc gcaccgcgtc cgcgctcggg ggtggtttcg cgtgctcct	21180
cttcccgact ggccatttcc ttctcctata ggagaaaaa gatcatggag tcagtcgaga	21240
agaaggacag cctaaccgcc ccctctgagt tgcgccacc cgcctccacc gatgccgcca	21300
acgcgcctac caccttcccc gtgcaggcac ccccgcttga ggaggaggaa gtgattatcg	21360
agcaggaccc aggttttcta agcgaagacg acgaggaccg ctgagtagca acagaggata	21420
aaaagcaaga ccaggacaac gcagaggcaa acgaggaaca agtcggggcg ggggacgaaa	21480
ggcatggcga ctacntagat gtgggagacg acgtgctgtt gaagcatctg cagcgccagt	21540
gcgccattat ctgcgacgcg ttgcaagagc gcagcgatgt gccctcgcg atagcggatg	21600
tcagccttgc ctacgaacgc cacctattct caccgcgcgt acccccaaaa cgccaagaaa	21660
acggcacatg cgagcccaac ccgcgcctca acttctacc cgtatttgcc gtgccagagg	21720
tgcttgccac ctatcacatc tttttccaaa actgcaagat acccctatcc tgccgtgcca	21780
accgcagccg agcggacaag cagctggcct tgccgcaggg cgctgtcata cctgatatcg	21840
cctcgctcaa cgaagtgcc aaaaatcttg aggtcttgg acgcgacgag aagcgcgcgg	21900
caaacgctct gcaacaggaa aacagcga aaatgaagtca ctctggagtg ttggtggaac	21960
tcgaggggtga caacgcgcgc ctgaccgtac taaaacgcag catcgaggtc acccactttg	22020
cctaccgggc acttaacctc cccccaagg tcatgagcac agtcatgagt gagctgatcg	22080
tgccgcgtgc gcagcccctg gagagggatg caaatgtgca agaacaaaca gagggggcc	22140
taccgcagtg tggcgacgag cagctagcgc gctggcttca aacgcgcgag cctgccgact	22200
tgaggagagc acgcaaaact atgatggccg cagtgtcgtt taccgtggag cttgagtgca	22260
tgacgcggtt ctttgctgac ccggagatgc agcgaagct agaggaaaca ttgcactaca	22320
cctttcgaca gggctacgta cgcaggcct gcaagatctc caacgtggag ctctgcaacc	22380
tggtctccta ccttgaatt ttgcacgaaa accgccttg gcaaaacgtg cttcattcca	22440
cgtcaaggg cgaggcgcg cgcgactacg tccgcgactg cgtttactta tttctatgct	22500
acacctggca gacggccatg ggcgtttggc agcagtgtt ggaggagtgc aacctcaagg	22560
agctgcagaa actgctaaag caaaacttga aggacctatg gacggccttc aacgagcgct	22620
ccgtggccgc gcacctggcg gacatcattt tccccgaac cctgcttaa accctgcaac	22680
agggctctgc agacttcacc agtcaaagca tgtgcagaa ctttaggaac tttatcctag	22740
agcgtcagg aatcttgccc gccacctgct gtgcacttcc tagcgacttt gtgccatta	22800
agtaccgcga atgcctccg ccgctttggg gccactgcta ccttctgcag ctgaccaact	22860
accttgcta ccactctgac ataattggaag acgtgagcgg tgacggtcta ctggagtgtc	22920
actgtcgtg caacctatgc acccgcacc gctccctggt ttgcaattcg cagctgttta	22980
acgaaagtca aattatcgg acctttgagc tgcagggctc ctgcctgac gaaaagtccg	23040
cggctccggg gttgaaactc actccggggc tgtggacgtc ggcttacctt cgcaaatttg	23100

tacctgagga ctaccacgcc caccagatta ggttctacga agaccaatcc cgcccgcccta	23160
atgcggagct taccgcctgc gtcattaccc agggccacat tcttggccaa ttgcaagcca	23220
tcaacaaagc ccgccaagag tttctgctac gaaagggacg gggggtttac ttggaccccc	23280
agtccggcga ggagctcaac ccaatcccc cgccgccgca gccctatcag cagcagccgc	23340
gggcccctgc ttcccaggat ggcacccaaa aagaagctgc agctgccgcc gccacccacg	23400
gacgaggagg aatactggga cagtcaggca gaggaggttt tggacgagga ggaggaggac	23460
atgatggaag actgggagag cctagacgag gaagcttccg aggtcgaaga ggtgtcagac	23520
gaaacaccgt caccctcgtt cgcatcccc tcgccggcgc ccagaaaatc ggcaaccggt	23580
tccagcatgg ctacaacctc cgctcctcag gcgcgcgcgc cactgccctg tcgccgaccc	23640
aaccgtagat gggacaccac tggaaccagg gccggtaagt ccaagcagcc gccgcccgtta	23700
gcccagagc aacaacagcg ccaaggctac cgctcatggc gcgggcacaa gaacgccata	23760
gttgcttgct tgcaagactg tgggggcaac atctccttcg ccgcccgtt tcttctctac	23820
catcacggcg tggccttccc ccgtaacatc ctgcattact accgtcatct ctacagccca	23880
tactgcaccg gcggcagcgg cagcaacagc agcggccaca cagaagcaaa ggcgaccgga	23940
tagcaagact ctgacaaagc ccaagaaatc cacagcggcg gcagcagcag gaggaggagc	24000
gctgcgtctg gcgcccacg aaccgctatc gaccgcgag cttagaaaca ggatttttcc	24060
cactctgtat gctatatattc aacagagcag gggccaagaa caagagctga aaataaaaaa	24120
caggtctctg cgatccctca ccgcagctg cctgtatcac aaaagcgaag atcagcttcg	24180
gcgcacgctg gaagacgcgg aggtctctct cagtaataac tgcgcgctga ctcttaagga	24240
ctagtttgcg gccctttctc aaatttaagc gcgaaaacta cgctcatctcc agcggccaca	24300
ccggcgcca gcacctgttg tcagcgccat tatgagcaag gaaattccca cgccctacat	24360
gtggagttac cagccacaaa tgggacttgc ggctggagct gcccaagact actcaaccg	24420
aataaactac atgagcgcgg gacccacat gatatcccgg gtcaacggaa tacgcgcccc	24480
ccgaaaccga attctcctgg aacaggcggc tattaccacc acacctcgta ataaccttaa	24540
tccccgtagt tggcccgcgt ccctggtgta ccaggaaagt ccgctccca ccactgtggt	24600
acttcccaga gacgcccagg ccgaagtcca gatgactaac tcaggggcgc agcttgccgg	24660
cggtttcgt caccaggtgc ggtcgcccgg gcagggtata actcacctga caatcagagg	24720
gcgaggtatt cagctcaacg acgagtcggt gagctcctcg cttggtctcc gtccggacgg	24780
gacatttcag atcggcggcg ccggccgctc ttcattcacg cctcgtcagg caatcctaac	24840
tctgcagacc tcgtcctctg agccgcgctc tggaggcatt ggaactctgc aatttattga	24900
ggagtttggt ccacgtgtct actttaaccc cttctcgga cctcccgcc actatccgga	24960
tcaatttatt cctaactttg acgcggtaaa ggactcggcg gacggctacg actgaatgtt	25020
aagtggagag gcagagcaac tgcgcctgaa acacctggc cactgtcgcc gccacaagt	25080
ctttgcccgc gactccggtg agttttgcta ctttgaattg cccgaggatc atatcgagg	25140
ccggcgcac ggcgtccggc ttaccgcca gggagagctt gcccgtagcc tgattcggga	25200
gtttaccag cgccccctgc tagttgagcg ggacagggga ccctgtgttc tcaactgtgat	25260
ttgcaactgt cctaaccctg gattacatca agatctttgt tgccatctct gtgctgagta	25320

taataaatac agaaattaaa atatactggg gctcctatcg ccacccctgta aacgccaccg	25380
tcttcacccg cccaagcaaa ccaaggcgaa ccttacctgg tacttttaac atctctccct	25440
ctgtgattta caacagtttc aaccagacg gagtgagtct acgagagaac ctctccgagc	25500
tcagctactc catcagaaaa aacaccaccc tccttacctg ccgggaacgt acgagtgcgt	25560
caccggccgc tgcaccacac ctaccgcctg accgtaaacc agactttttc cggacagacc	25620
tcaataactc tgtttaccag aacaggaggt gagcttagaa aacccttagg gtattaggcc	25680
aaaggcgag ctactgtggg gtttatgaac aattcaagca actctacggg ctattctaata	25740
tcaggtttct ctagaatcgg ggttggggtt attctctgtc ttgtgattct ctttattctt	25800
atactaacgc ttctctgcct aaggetcgcc gcctgctgtg tgcacatttg catttattgt	25860
cagcttttta aacgctgggg tcgccacca agatgattag gtacataatc ctaggtttac	25920
tcaccttgcc gtcagccac ggtaccaccc aaaagggtga ttttaaggag ccagcctgta	25980
atgttacatt cgcagctgaa gctaagagt gcaccactct tataaatgc accacagaac	26040
atgaaaagct gcttattcgc caaaaaaca aaattggcaa gtatgctgtt tatgctattt	26100
ggcagccagg tgacactaca gagtataatg ttacagtttt ccagggtaaa agtcataaaa	26160
cttttatgta tactttttcca ttttatgaaa tgtgcgacat taccatgtac atgagcaaac	26220
agtataagtt gtggccccc caaaattgtg tggaaaacac tggcactttc tgctgcactg	26280
ctatgctaat tacagtgtc gctttggtct gtaccctact ctatattaaa taaaaagca	26340
gacgcagctt tattgaggaa aagaaaatgc cttaatctac taagttacaa agctaagtgc	26400
accactaact gctttactcg ctgcttgcaa aacaaattca aaaagttagc attataatta	26460
gaataggatt taaaccccc ggtcatttcc tgctcaatac cattcccctg aacaattgac	26520
tctatgtggg atatgtccca gcgctacaac cttgaagtca ggcttcctgg atgtcagcat	26580
ctgactttgg ccagcacctg tcccgggat ttgttccagt ccaactacag cgaccaccc	26640
taacagagat gaccaacaca accaacgcgg ccgcccgtac cggacttaca tctaccacaa	26700
atacaccca agtttctgcc tttgtcaata actgggataa cttgggcatg tgggtgttct	26760
ccatagcgtc tatgtttgta tgccttatta ttatgtggct catctgctgc cttaaagcga	26820
aacgcgccc accaccatc tatagtccca tcattgtgct acacccaaac aatgatggaa	26880
tccatagatt ggacggactg aaacacatgt tcttttctct tacagtatga ttaaatgaga	26940
catgattcct cgagttttta tattactgac cttgttgctg ctttttttgt gcgtgctcca	27000
cattggctgc ggtttctcac atcgaagtag actgcattcc agccttcaca gtctatttgc	27060
tttacggatt tgtcacctc acgctcatct gcagcctcat cactgtggtc atcgcttta	27120
tccagtgcac tgactgggtc tgtgtgcgct ttgcatactc cagacacccat cccagtaga	27180
gggacaggac tatagctgag cttcttagaa ttctttaatt atgaaattta ctgtgacttt	27240
tctgtgatt atttgaccc tatctgcgtt ttgttcccc accccaagc ctcaaagaca	27300
tatatcatgc agattcactc gtatatggaa tattccaagt tgctacaatg aaaaaagcga	27360
tctttccgaa gcctggttat atgcaatcat ctctgttatg gtgttctgca gtaccatctt	27420
agccctagct atatatccct accttgacat tggctggaac gcaatagatg ccatgaacca	27480
cccaactttc cccgcgccc ctatgcttcc actgcaacaa gttgttgccg gcggctttgt	27540

cccagccaat cagcctcgcc caccttctcc cccccccact gaaatcagct actttaatct	27600
aacaggagga gatgactgac accctagatc tagaaatgga cggaattatt acagagcagc	27660
gcctgctaga aagacgcagg gcagcggccg agcaacagcg catgaatcaa gagctccaag	27720
acatggttaa cttgcaccag tgcaaaagggt gtatcttttg tctggtaaag caggccaaa	27780
tcacctacga cagtaatacc accggacacc gccttagcta caagttgcca accaagcgtc	27840
agaaattggg ggtcatgggt ggagaaaagc ccattacat aactcagcac tcggtagaaa	27900
ccgaaggctg cattcactca ccttgtcaag gacctgagga tctctgcacc cttattaaga	27960
ccctgtgcgg tctcaaagat cttattccct ttaactaata aaaaaaata ataaagcatc	28020
acttacttaa aatcagttag caaatctctg tccagtttat tcagcagcac ctccttgccc	28080
tcctcccagc tctggatttg cagcttcctc ctggctgcaa actttctcca caatctaaat	28140
ggaatgtcag tttctcctg ttcctgtcca tccgcaccca ctatcttcat gttgttgag	28200
atgaagcgcg caagaccgtc tgaagatacc ttcaaccccg tgatatccata tgacacggaa	28260
accggtcctc caactgtgcc tttcttact cctcccttg tatccccaa tgggtttcaa	28320
gagagtcccc ctgggggtact ctctttgcgc ctatccgaac ctctagttac ctccaatggc	28380
atgcttgccg tcaaaatggg caacggcctc tctctggacg aggcgggcaa ccttacctcc	28440
caaaatgtaa ccactgtgag cccacctctc aaaaaaacca agtcaaacat aaacctggaa	28500
atatctgcac ccctcacagt tacctcagaa gccctaactg tggctgccgc cgcacctcta	28560
atggctcgcg gcaacacact caccatgcaa tcacaggccc cgctaaccgt gcacgactcc	28620
aaacttagca ttgccaccca aggaccctc acagtgtcag aaggaaagct agccctgcaa	28680
acatcaggcc ccctcaccac caccgatagc agtaccctta ctatcactgc ctcaccccct	28740
ctaactactg ccactggtag cttgggcatt gacttgaaag agcccattta tacacaaaat	28800
ggaaaactag gactaaagta cggggctcct ttgcatgtaa cagacgacct aaacactttg	28860
accgtagcaa ctggtccagg tgtgactatt aataatactt ccttgcaaac taaagttact	28920
ggagccttgg gttttgatcc acaaggcaat atgcaactta atgtagcag aggactaagg	28980
attgattctc aaaacagacg ccttatactt gatgttagtt atccgtttga tgctcaaaac	29040
caactaaatc taagactagg acagggccct ctttttataa actcagccca caacttggat	29100
attaactaca acaaaggcct ttacttggtt acagcttcaa acaattccaa aaagcttgag	29160
gttaacctaa gcactgcca ggggttgatg tttgacgcta cagccatagc cattaatgca	29220
ggagatgggc ttgaatttgg ttcacctaat gcaccaaaca caaatcccct caaaacaaaa	29280
attggccatg gcctagaatt tgattcaaac aaggctatgg ttcctaaact aggaactggc	29340
cttagttttg acagcacagg tgccattaca gtaggaaaca aaaataatga taagctaact	29400
ttgtggacca caccagctcc atctcctaac ttagactaa atgcagagaa agatgctaaa	29460
ctcacttttg tcttaacaaa atgtggcagt caaatacttg ctacagtttc agttttggct	29520
gttaaaggca gtttggtccc aatatctgga acagtcaaa gtgctcatct tattataaga	29580
tttgacgaaa atggagtgt actaaacaat tccttctcgg acccagaata ttggaacttt	29640
agaaatggag atcttactga aggcacagcc tatacaaagc ctgttggtat tatgcctaac	29700
ctatcagctt atccaaaatc tcacggtaaa actgcaaaa gtaacattgt cagtcaagtt	29760

tacttaaacy gagacaaaac taaacctgta acactaacca ttactactaaa cggtagacag	29820
gaaacaggag acacaactcc aagtgcatac tctatgtcat ttcatggga ctggtctggc	29880
cacaactaca ttaatgaaat atttgccaca tctctttaca ctttttcata cattgcccac	29940
gaataaagaa tcgtttgtgt tatgtttcaa cgtgtttatt ttccaattgc agaaaatttc	30000
aagtcatttt tcattcagta gtatagcccc accaccacat agcttataca gatcacgta	30060
ccttaataca actcacagaa ccctagtatt caacctgcca cctccctccc aacacacaga	30120
gtacacagtc ctttctcccc ggctggcctt aaaaagcatc atatcatggg taacagacat	30180
attcttaggt gttatattcc acacggtttc ctgtcgagcc aaacgctcat cagtgatatt	30240
aataaactcc ccgggcagct cacttaagtt catgtcgctg tccagctgct gagccacagg	30300
ctgctgtcca acttgccggtt gcttaacggg cggcgaagga gaagtccacg cctacatggg	30360
ggtagagtca taatcgtgca tcaggatagg gcggtgggtc tgcagcagcg cgcgaataaa	30420
ctgctgccgc cgcgcctccg tctgcagga atacaacatg gcagtgggtc cctcagcgat	30480
gattcgcacc gccgcagca taaggcgcct tgtcctccgg gcacagcagc gcaccctgat	30540
ctcacttaaa tcagcacagt aactgcagca cagcaccaca atattgttca aaatcccaca	30600
gtgcaaggcg ctgtatccaa agctcatggc ggggaccaca gaaccacgt ggccatcata	30660
ccacaagcgc aggtagatta agtggcgacc cctcataaac acgctggaca taaacattac	30720
ctcttttggc atgttgtaat tcaccacctc ccggtacat ataaacctct gattaaacat	30780
ggcgccatcc accaccatcc taaaccagct ggccaaaacc tgcccgccgg ctataactg	30840
cagggaaccg ggactggaac aatgacagtg gagagcccag gactcgtaac catggatcat	30900
catgctcgtc atgatataca tgttggcaca acacaggcac acgtgcatac acttctcag	30960
gattacaagc tcctcccgcg ttagaaccat atcccaggga acaaccatt cctgaatcag	31020
cgtaaatccc aactgcagc gaagacctcg cagctaactc acgttgtgca ttgtcaaagt	31080
gttacattcg ggcagcagcg gatgatctc cagtatggta gcgcggggtt ctgtctcaa	31140
aggaggtaga cgatccctac tgtacggagt gcgcgcgagc aaccgagatc gtgttggtcg	31200
tagtgtcatg ccaaatggaa cgcgggacgt agtcataatt cctgaagcaa aaccagggtc	31260
ggcgctgaca aacagatctg cgtctccggt ctgcgcgctt agatcgctct gtgtagtagt	31320
tgtagtatat ccactctctc aaagcatcca ggcgccccct ggcttcgggt tctatgtaaa	31380
ctccttcatg cgcgcgtgcc ctgataacat ccaccaccgc agaataagcc acaccagcc	31440
aacctacaca ttcgttctgc gagtcacaca cgggaggagc gggaagagct ggaagaacca	31500
tgtttttttt ttatttccaa aagattatcc aaaacctcaa aatgaagatc tattaagtga	31560
acgcgctccc ctccggtggc gtggtcaaac tctacagcca aagaacagat aatggcattt	31620
gtaagatgtt gcacaatggc ttccaaaagg caaacggccc tcacgtccaa gtggacgtaa	31680
aggctaacc cttcagggtg aatctcctct ataacattc cagcaccttc aaccatgccc	31740
aaataattct catctcgcca cttctcaat atatctctaa gcaaatcccg aatattaagt	31800
ccggccattg taaaaatctg ctccagagcg cctccacct tcagcctcaa gcagcgaatc	31860
atgattgcaa aaattcaggt tctcacaga cctgtataag attcaaaagc ggaacattaa	31920
caaaaatacc gcgatcccg aggtcccttc gcagggccag ctgaacataa tcgtgcaggt	31980

ctgcacggac cagcgcggcc acttccccgc caggaacccat gacaaaagaa cccacactga 32040
 ttatgacacg catactcgga gctatgctaa ccagcgtagc cccgatgtaa gcttggttga 32100
 tgggcggcga tataaaatgc aaggtgctgc tcaaaaaatc aggcaaagcc tcgcgcaaaa 32160
 aagaaagcac atcgtagtca tgctcatgca gataaaggca ggtaagctcc ggaaccacca 32220
 cagaaaaaga caccatTTTT ctctcaaaca tgctcgcggtg tttctgcata aacacaaaat 32280
 aaaataacaa aaaaacattt aaacattaga agcctgtctt acaacaggaa aaacaaccct 32340
 tataagcata agacggacta cggccatgcc ggcgtgaccg taaaaaaact ggtcaccgtg 32400
 attaaaaagc accaccgaca gtcctcgggt catgtccgga gtcataatgt aagactcgggt 32460
 aaacacatca ggttgattca catcgggtcag tgctaaaaag cgaccgaaat agcccggggg 32520
 aatacatacc cgcaggcgta gagacaacat tacagccccc ataggaggta taacaaaatt 32580
 aataggagag aaaaacacat aaacacctga aaaaccctcc tgcctaggca aaatagcacc 32640
 ctcccgctcc agaacaacat acagcgcttc cacagcggca gccataacag tcagccttac 32700
 cagtaaaaaa gaaaacctat taaaaaaaca ccactcgaca cggcaccagc tcaatcagtc 32760
 acagtgtaaa aaagggccaa gtgcagagcg agtatatata ggactaaaaa atgacgtaac 32820
 ggttaaagtc cacaaaaaac acccagaaaa ccgcacgcga acctacgcc agaaacgaaa 32880
 gccaaaaaac ccacaacttc ctcaaatcgt cacttccgtt tccccagtt acgtcacttc 32940
 ccattttaag aaaactacaa ttccaacac atacaagtta ctccgcccta aaacctacgt 33000
 caccgcgcc gttccacgc cccgcgccac gtcacaaact ccaccccctc attatcatat 33060
 tggcttcaat ccaaaataag gtatattatt gat 33093

<210> 12
 <211> 978
 <212> DNA
 <213> Artificial sequence

<220>
 <223> PPE-1-3X promoter

<400> 12
 acgtgtactt ctgatcggcg atactaggga gataaggatg tacctgacaa aaccacattg 60
 ttgttggttat cattattatt tagttttcct tccttgctaa ctctgacgg aatctttctc 120
 acctcaaatg cgaagtactt tagtttagaa aagacttggg ggaaggggtg gtggtggaaa 180
 agtaggggtga tcttccaaac taatctggtt ccccgccgc cccagtagct gggattcaag 240
 agcgaagagt ggggatcgtc cccttggttg atcagaaaga cataaaagga aaatcaagtg 300
 aacaatgatc agccccacct ccaccccacc ccctgcgcg cgcacaatac aatctattta 360
 attgtacttc atacttttca ttccaatggg gtgactttgc ttctggagaa actcttgatt 420
 cttgaactct ggggctggca gctagcctcc agaagcaaag tcacccatt ggaatgaaaa 480
 gtatgaagta caatgaaaag tatgaagtac tggctccaga agcaaagtca ccctccagaa 540
 gcaaagtcac ccattggaa tgaaaagtat gaagtacgt agcaaaagg gaagcgggct 600
 gctgctctct gcaggttctg cagcggctc tgctagtgg gtgttttctt tttcttagcc 660
 ctgcccctgg attgtcagac ggcgggcgtc tgctctgaa gttagccgtg atttctcta 720
 gagccgggtc ttatctctgg ctgcacgttg cctgtgggtg actaatcaca caataacatt 780

68

gttttagggct ggaataaagt cagagctgtt taccocccact ctataggggt tcaatataaa 840
 aaggcggcgg agaactgtcc gagtcagaag cgttctctgca ccggcgctga gagcctgacc 900
 cggctctgctc cgctgtcctt gcgcgctgcc tcccggtctgc ccgcgacgt ttcgccccag 960
 tggaagggcc acttgctg 978

<210> 13
 <211> 1334
 <212> DNA
 <213> Mus musculus

<400> 13
 gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtagtgt cttctgatcg 60
 gcgatactag ggagataagg atgtacctga caaaaccaca ttgttgttgt tatcattatt 120
 atttagtttt ccttccttgc taactcctga cggaaatctt ctcacctcaa atgcgaagta 180
 ctttagttta gaaaagactt ggtggaaggg gtggtggtgg aaaagtaggg tgatcttcca 240
 aactaatctg gttccccgcc cgccccagta gctgggattc aagagcgaag agtggggatc 300
 gtccccctgt ttgatcagaa agacataaaa ggaaaatcaa gtgaacaatg atcagcccca 360
 cctccacccc acccccctgc gcgcgcacaa tacaatctat ttaattgtac ttcatacttt 420
 tcattccaat ggggtgactt tgcttctgga gaaactcttg attcttgaac tctggggctg 480
 gcagctagca aaagggaag cgggctgctg ctctctgcag gttctgcagc ggtctctgtc 540
 tagtgggtgt tttctttttc ttagccctgc ccctggattg tcagacggcg ggcgtctgcc 600
 tctgaagtta gccgtgattt cctctagagc cgggtcttat ctctggtgc acgttgctg 660
 tgggtgacta atcacacaat aacattgttt agggctggaa taaagtcaga gctgtttacc 720
 cccactctat aggggttcaa tataaaaagg cggcgagaa ctgtccgagt cagacgcgtt 780
 cctgcaccgg cgtgagagc ctgaccgggt ctgctccgct gtccttgccg gctgectccc 840
 ggctgcccgc gacgttttcg cccagtgga agggccactt gctgaggacc gcgctgagat 900
 ctaaaaaaaaa aacaaaaaac aaaaaacaaa aaaaccaga ggcgatcaga gcgaccagac 960
 accgtcctct tcgttttgca ttgagttcca ttgcaaccg agttttcttt tttcctttt 1020
 tccccactct tctgaccctt ttgcagaatg gattattttc ccgtgatctt ctctctgctg 1080
 ttctgactt tccaaggagc tccagaaaca ggtaggcgcc acttgcaat ctttctactt 1140
 cagegcagca gttatcgctt ctgttttcca cttttctttc tttcttttct ttcattcttt 1200
 cctttttatt tttttttta attactgaag ctccagcagc aagtgcctta caattaatta 1260
 acttctgtgt gaagcgaaag aaataaaacc cctgtttgaa tacagctgac tacaaccgag 1320
 tatcgcatag cttc 1334

<210> 14
 <211> 5
 <212> DNA
 <213> Artificial sequence

<220>
 <223> wild type element M9

<400> 14
 ctgga

5

<210> 15
 <211> 5
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> wild type element M4

 <400> 15
 cattc

<210> 16
 <211> 5
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> wild type element M5

 <400> 16
 caatg

<210> 17
 <211> 5
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> wild type element M6

 <400> 17
 ggggtg

<210> 18
 <211> 5
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> wild type element M7

 <400> 18
 acttt

<210> 19
 <211> 5
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> wild type element M8

 <400> 19
 gcttc

<210> 20
 <211> 5
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> wild type element M1

 <220>
 <221> misc_feature
 <222> (1)..(6)
 <223> n is a, c, g, or t

5

5

5

5

5

<400> 20
gtact 5

<210> 21
<211> 5
<212> DNA
<213> Artificial sequence

<220>
<223> wild type element M3

<220>
<221> misc_feature
<222> (1)..(6)
<223> n is a, c, g, or t

<400> 21
ctttt 5

<210> 22
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<400> 22
gggtgacttt gcttctgga 19

<210> 23
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(15)
<223> At least one residue mutated or absent

<400> 23
gggtgacttt gcttctgga 19

<210> 24
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (12)..(16)
<223> At least one residue mutated or absent

<400> 24

71

ggggtgactt tgcttctgg

19

<210> 25
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(15)
<223> At least one residue mutated or absent

<400> 25
caatggggtg gcttctgga

19

<210> 26
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (12)..(16)
<223> At least one residue mutated or absent

<400> 26
ccaatggggt ggcttctgg

19

<210> 27
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(15)
<223> At least one residue mutated or absent

<400> 27
gggtgacttt gcttctgga

19

<210> 28
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (12)..(16)
<223> At least one residue mutated or absent

<400> 28
ggggtgactt tgcttctgg

19

72

<210> 29
 <211> 44
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (36)..(40)
 <223> At least one residue mutated or absent

<400> 29
 gtacttcata cttttcattc caatggggtg actttgcttc tgga

44

<210> 30
 <211> 39
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (31)..(35)
 <223> At least one residue mutated or absent

<400> 30
 gtactctttt cattccaatg gggtgacttt gcttctgga

39

<210> 31
 <211> 39
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (31)..(35)
 <223> At least one residue mutated or absent

<400> 31
 gtacttcata cattccaatg gggtgacttt gcttctgga

39

<210> 32
 <211> 39
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (31)..(35)
 <223> At least one residue mutated or absent

<400> 32
 gtacttcata cttttcaatg gggtgacttt gcttctgga

39

<210> 33

73

<211> 39
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (31)..(35)
 <223> At least one residue mutated or absent

<400> 33
 gtacttcata cttttcattc gggtagacttt gcttctgga 39

<210> 34
 <211> 34
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (26)..(30)
 <223> At least one residue mutated or absent

<400> 34
 gtactcattc caatggggtg actttgcttc tgga 34

<210> 35
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (21)..(25)
 <223> At least one residue mutated or absent

<400> 35
 gtactcaatg gggtagacttt gcttctgga 29

<210> 36
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (16)..(20)
 <223> At least one residue mutated or absent

<400> 36
 gtactgggtg actttgcttc tgga 24

<210> 37
 <211> 34
 <212> DNA

74

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (26)..(30)

<223> At least one residue mutated or absent

<400> 37

gtacttcata caatgggggtg actttgcttc tgga

34

<210> 38

<211> 29

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (21)..(25)

<223> At least one residue mutated or absent

<400> 38

gtacttcata gggtgacttt gcttctgga

29

<210> 39

<211> 34

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (26)..(30)

<223> At least one residue mutated or absent

<400> 39

gtacttcata cttttgggtg actttgcttc tgga

34

<210> 40

<211> 34

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (26)..(30)

<223> At least one residue mutated or absent

<400> 40

gtactctttt caatgggggtg actttgcttc tgga

34

<210> 41

<211> 34

<212> DNA

<213> Artificial sequence

75

```

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (26)..(30)
<223> At least one residue mutated or absent

<400> 41
gtacttcata cattcgggtg actttgcttc tgga
34

<210> 42
<211> 34
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (26)..(30)
<223> At least one residue mutated or absent

<400> 42
gtactctttt cattcgggtg actttgcttc tgga
34

<210> 43
<211> 44
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (36)..(40)
<223> At least one residue mutated or absent

<400> 43
gtacttcata cttttcattc caatggggtg actttgcttc tgga
44

<210> 44
<211> 39
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (31)..(35)
<223> At least one residue mutated or absent

<400> 44
gtactctttt cattccaatg gggtgacttt gcttctgga
39

<210> 45
<211> 39
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

```

<220>
<221> misc_feature
<222> (31)..(35)
<223> At least one residue mutated or absent

<400> 45
gtacttcata cattccaatg gggtagcttt gcttctgga 39

<210> 46
<211> 39
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (31)..(35)
<223> At least one residue mutated or absent

<400> 46
gtacttcata cttttcaatg gggtagcttt gcttctgga 39

<210> 47
<211> 39
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (31)..(35)
<223> At least one residue mutated or absent

<400> 47
gtacttcata cttttcattc gggtagcttt gcttctgga 39

<210> 48
<211> 39
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (31)..(35)
<223> At least one residue mutated or absent

<400> 48
gtacttcata cttttcattc caatgacttt gcttctgga 39

<210> 49
<211> 39
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

77

<220>
<221> misc_feature
<222> (31)..(35)
<223> At least one residue mutated or absent

<400> 49
gtacttcata cttttcattc caatggggtg gcttctgga 39

<210> 50
<211> 34
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (26)..(30)
<223> At least one residue mutated or absent

<400> 50
gtactcattc caatggggtg actttgcttc tgga 34

<210> 51
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (21)..(25)
<223> At least one residue mutated or absent

<400> 51
gtactcaatg gggtgacttt gcttctgga 29

<210> 52
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (16)..(20)
<223> At least one residue mutated or absent

<400> 52
gtactgggtg actttgcttc tgga 24

<210> 53
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature

78

<222> (11)..(15)
 <223> At least one residue mutated or absent

<400> 53
 gtactacttt gcttctgga

19

<210> 54
 <211> 34
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (26)..(30)
 <223> At least one residue mutated or absent

<400> 54
 gtacttcata caatgggggtg actttgcttc tgga

34

<210> 55
 <211> 28
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (21)..(25)
 <223> At least one residue mutated or absent

<400> 55
 cattccaatg gggtgacttt gcttctgg

28

<210> 56
 <211> 23
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (16)..(20)
 <223> At least one residue mutated or absent

<400> 56
 cattcggtg actttgcttc tgg

23

<210> 57
 <211> 19
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (11)..(15)
 <223> At least one residue mutated or absent

<400> 57
cattcacttt gcttctgga 19

<210> 58
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(15)
<223> At least one residue mutated or absent

<400> 58
cttttcattc gcttctgga 19

<210> 59
<211> 23
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (16)..(20)
<223> At least one residue mutated or absent

<400> 59
cattccaatg actttgcttc tgg 23

<210> 60
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(15)
<223> At least one residue mutated or absent

<400> 60
cattccaatg gcttctgga 19

<210> 61
<211> 23
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (16)..(20)
<223> At least one residue mutated or absent

<400> 61

80

cattccaatg ggggtgcttc tgg

23

<210> 62
 <211> 19
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (11)..(15)
 <223> At least one residue mutated or absent

<400> 62
 cattcgggtg gcttctgga

19

<210> 63
 <211> 23
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (16)..(20)
 <223> At least one residue mutated or absent

<400> 63
 caatgggggtg actttgcttc tgg

23

<210> 64
 <211> 19
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (11)..(15)
 <223> At least one residue mutated or absent

<400> 64
 caatgggggtg gcttctgga

19

<210> 65
 <211> 19
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (11)..(15)
 <223> At least one residue mutated or absent

<400> 65
 caatgacttt gcttctgga

19

81

<210> 66
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(15)
<223> At least one residue mutated or absent

<400> 66
cattccaatg gcttctgga

19

<210> 67
<211> 28
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (21)..(25)
<223> At least one residue mutated or absent

<400> 67
cattccaatg gggtgacttt gcttctgg

28

<210> 68
<211> 23
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (16)..(20)
<223> At least one residue mutated or absent

<400> 68
cattccaatg actttgcttc tgg

23

<210> 69
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(15)
<223> At least one residue mutated or absent

<400> 69
cattccaatg gcttctgga

19

<210> 70

82

<211> 23
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (16)..(20)
<223> At least one residue mutated or absent

<400> 70
cattccaatg ggggtggcttc tgg

23

<210> 71
<211> 43
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(5)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (36)..(40)
<223> At least one residue mutated or absent

<400> 71
gtacttcata cttttcattc caatgggggtg actttgcttc tgg

43

<210> 72
<211> 43
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(5)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (36)..(40)
<223> At least one residue mutated or absent

<400> 72
gtacttcata cttttcattc caatgggggtg actttgcttc tgg

43

<210> 73
<211> 38
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature

83

<222> (4)..(5)
 <223> At least one residue mutated or absent

 <220>
 <221> misc_feature
 <222> (31)..(35)
 <223> At least one residue mutated or absent

 <400> 73
 gtactctttt cattccaatg gggtgacttt gcttctgg 38

 <210> 74
 <211> 38
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> Exemplary element X variant

 <220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

 <220>
 <221> misc_feature
 <222> (31)..(35)
 <223> At least one residue mutated or absent

 <400> 74
 gtacttcata cattccaatg gggtgacttt gcttctgg 38

 <210> 75
 <211> 33
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> Exemplary element X variant

 <220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

 <220>
 <221> misc_feature
 <222> (26)..(30)
 <223> At least one residue mutated or absent

 <400> 75
 gtactcattc caatgggggtg actttgcttc tgg 33

 <210> 76
 <211> 43
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> Exemplary element X variant

 <220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

 <220>
 <221> misc_feature

84

<222> (36)..(40)
 <223> At least one residue mutated or absent

<400> 76
 gtacttcata cttttcattc caatggggtg actttgcttc tgg

43

<210> 77
 <211> 38
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (31)..(35)
 <223> At least one residue mutated or absent

<400> 77
 gtacttcata cttttcattc ggggtgacttt gcttctgg

38

<210> 78
 <211> 38
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (31)..(35)
 <223> At least one residue mutated or absent

<400> 78
 gtacttcata cttttcattc caatgacttt gcttctgg

38

<210> 79
 <211> 38
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (31)..(35)
 <223> At least one residue mutated or absent

<400> 79
 gtacttcata cttttcattc caatggggtg gcttctgg

38

<210> 80
 <211> 33
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (26)..(30)
 <223> At least one residue mutated or absent

<400> 80
 gtacttcata cttttcattc actttgcttc tgg 33

<210> 81
 <211> 33
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (26)..(30)
 <223> At least one residue mutated or absent

<400> 81
 gtacttcata cttttcattc ggggtggcttc tgg 33

<210> 82
 <211> 28
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (21)..(25)
 <223> At least one residue mutated or absent

<400> 82
 gtacttcata cttttcattc gcttctgg 28

<210> 83
 <211> 33
 <212> DNA

86

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (4)..(5)

<223> At least one residue mutated or absent

<220>

<221> misc_feature

<222> (26)..(30)

<223> At least one residue mutated or absent

<400> 83

gtacttcata cttttcattc caatggcttc tgg

33

<210> 84

<211> 33

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (4)..(5)

<223> At least one residue mutated or absent

<220>

<221> misc_feature

<222> (26)..(30)

<223> At least one residue mutated or absent

<400> 84

gtacttcata cattcgggtg actttgcttc tgg

33

<210> 85

<211> 33

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (4)..(5)

<223> At least one residue mutated or absent

<220>

<221> misc_feature

<222> (26)..(30)

<223> At least one residue mutated or absent

<400> 85

gtacttcata cattccaatg actttgcttc tgg

33

<210> 86

<211> 33

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

87

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (26)..(30)
 <223> At least one residue mutated or absent

<400> 86
 gtacttcata cattccaatg gggaggcttc tgg

33

<210> 87
 <211> 28
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (21)..(25)
 <223> At least one residue mutated or absent

<400> 87
 gtacttcata cattcacttt gcttctgg

28

<210> 88
 <211> 28
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (21)..(25)
 <223> At least one residue mutated or absent

<400> 88
 gtacttcata cattcgggtg gcttctgg

28

<210> 89
 <211> 23
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

88

<220>
 <221> misc_feature
 <222> (16)..(20)
 <223> At least one residue mutated or absent

<400> 89
 gtacttcata cattcgcttc tgg 23

<210> 90
 <211> 28
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (21)..(25)
 <223> At least one residue mutated or absent

<400> 90
 gtacttcata cattccaatg gcttctgg 28

<210> 91
 <211> 38
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (31)..(35)
 <223> At least one residue mutated or absent

<400> 91
 gtactctttt cattccaatg gggtgacttt gcttctgg 38

<210> 92
 <211> 33
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (26)..(30)
 <223> At least one residue mutated or absent

<400> 92
 gtactctttt cattcgggtg actttgcttc tgg 33

<210> 93
 <211> 33
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (26)..(30)
 <223> At least one residue mutated or absent

<400> 93
 gtactctttt cattccaatg actttgcttc tgg 33

<210> 94
 <211> 33
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (26)..(30)
 <223> At least one residue mutated or absent

<400> 94
 gtactctttt cattccaatg gggtggcttc tgg 33

<210> 95
 <211> 28
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (21)..(25)
 <223> At least one residue mutated or absent

<400> 95
 gtactctttt cattcacttt gcttctgg 28

90

<210> 96
 <211> 28
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (21)..(25)
 <223> At least one residue mutated or absent

<400> 96
 gtactctttt cattcgggtg gcttctgg

28

<210> 97
 <211> 23
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (16)..(20)
 <223> At least one residue mutated or absent

<400> 97
 gtactctttt cattcgcttc tgg

23

<210> 98
 <211> 28
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (21)..(25)
 <223> At least one residue mutated or absent

<400> 98
 gtactctttt cattccaatg gcttctgg

28

<210> 99
 <211> 33
 <212> DNA
 <213> Artificial sequence

91

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (26)..(30)
 <223> At least one residue mutated or absent

<400> 99
 gtactcattc caatggggtg actttgcttc tgg

33

<210> 100
 <211> 28
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (21)..(25)
 <223> At least one residue mutated or absent

<400> 100
 gtactcattc gggtgacttt gcttctgg

28

<210> 101
 <211> 28
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (21)..(25)
 <223> At least one residue mutated or absent

<400> 101
 gtactcattc caatgacttt gcttctgg

28

<210> 102
 <211> 28
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>

92

<221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (21)..(25)
 <223> At least one residue mutated or absent

<400> 102
 gtactcattc caatggggtg gcttctgg 28

<210> 103
 <211> 23
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (16)..(20)
 <223> At least one residue mutated or absent

<400> 103
 gtactcattc actttgcttc tgg 23

<210> 104
 <211> 23
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (16)..(20)
 <223> At least one residue mutated or absent

<400> 104
 gtactcattc ggggtggcttc tgg 23

<210> 105
 <211> 23
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>

93

<221> misc_feature
 <222> (16)..(20)
 <223> At least one residue mutated or absent

<400> 105
 gtactcattc caatggcttc tgg

23

<210> 106
 <211> 43
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (36)..(40)
 <223> At least one residue mutated or absent

<400> 106
 gtacttcata cttttcattc caatgggggtg actttgcttc tgg

43

<210> 107
 <211> 38
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (31)..(35)
 <223> At least one residue mutated or absent

<400> 107
 gtactctttt cattccaatg gggtgacttt gcttctgg

38

<210> 108
 <211> 38
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (31)..(35)
 <223> At least one residue mutated or absent

<400> 108

94

gtacttcata cattccaatg gggtgacttt gcttctgg

38

<210> 109
 <211> 38
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (31)..(35)
 <223> At least one residue mutated or absent

<400> 109
 gtacttcata cttttcaatg gggtgacttt gcttctgg

38

<210> 110
 <211> 33
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (26)..(30)
 <223> At least one residue mutated or absent

<400> 110
 gtactcattc caatggggtg actttgcttc tgg

33

<210> 111
 <211> 33
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (26)..(30)
 <223> At least one residue mutated or absent

<400> 111
 gtacttcata caatggggtg actttgcttc tgg

33

<210> 112
 <211> 33

<212> DNA
 <213> Artificial sequence

 <220>
 <223> Exemplary element X variant

 <220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

 <220>
 <221> misc_feature
 <222> (26)..(30)
 <223> At least one residue mutated or absent

 <400> 112
 gtactctttt caatggggtg actttgcttc tgg 33

 <210> 113
 <211> 28
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> Exemplary element X variant

 <220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

 <220>
 <221> misc_feature
 <222> (21)..(25)
 <223> At least one residue mutated or absent

 <400> 113
 gtactcaatg gggtgacttt gcttctgg 28

 <210> 114
 <211> 38
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> Exemplary element X variant

 <220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

 <220>
 <221> misc_feature
 <222> (31)..(35)
 <223> At least one residue mutated or absent

 <400> 114
 gtacttcata cttttcattc caatgacttt gcttctgg 38

 <210> 115
 <211> 38
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (31)..(35)
 <223> At least one residue mutated or absent

<400> 115
 gtacttcata cttttcattc caatggggtg gcttctgg 38

<210> 116
 <211> 33
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (26)..(30)
 <223> At least one residue mutated or absent

<400> 116
 gtacttcata cttttcattc caatggcttc tgg 33

<210> 117
 <211> 33
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (26)..(30)
 <223> At least one residue mutated or absent

<400> 117
 gtactctttt cattccaatg actttgcttc tgg 33

<210> 118
 <211> 33
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)

97

<223> At least one residue mutated or absent

<220>

<221> misc_feature

<222> (26)..(30)

<223> At least one residue mutated or absent

<400> 118

gtacttcata cattccaatg actttgcttc tgg

33

<210> 119

<211> 33

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (4)..(5)

<223> At least one residue mutated or absent

<220>

<221> misc_feature

<222> (26)..(30)

<223> At least one residue mutated or absent

<400> 119

gtacttcata cttttcaatg actttgcttc tgg

33

<210> 120

<211> 28

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (4)..(5)

<223> At least one residue mutated or absent

<220>

<221> misc_feature

<222> (21)..(25)

<223> At least one residue mutated or absent

<400> 120

gtactcattc caatgacttt gcttctgg

28

<210> 121

<211> 28

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (4)..(5)

<223> At least one residue mutated or absent

<220>

<221> misc_feature

<222> (21)..(25)

98

<223> At least one residue mutated or absent

<400> 121

gtacttcata caatgacttt gcttctgg

28

<210> 122

<211> 28

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (4)..(5)

<223> At least one residue mutated or absent

<220>

<221> misc_feature

<222> (21)..(25)

<223> At least one residue mutated or absent

<400> 122

gtactctttt caatgacttt gcttctgg

28

<210> 123

<211> 23

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (4)..(5)

<223> At least one residue mutated or absent

<220>

<221> misc_feature

<222> (16)..(20)

<223> At least one residue mutated or absent

<400> 123

gtactcaatg actttgcttc *gg

23

<210> 124

<211> 33

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (4)..(5)

<223> At least one residue mutated or absent

<220>

<221> misc_feature

<222> (26)..(30)

<223> At least one residue mutated or absent

<400> 124

gtactctttt cattccaatg gggtggcttc tgg

33

<210> 125
 <211> 33
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (26)..(30)
 <223> At least one residue mutated or absent

<400> 125
 gtacttcata cattccaatg gggtaggcttc tgg 33

<210> 126
 <211> 33
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (26)..(30)
 <223> At least one residue mutated or absent

<400> 126
 gtacttcata cttttcaatg gggtaggcttc tgg 33

<210> 127
 <211> 28
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (21)..(25)
 <223> At least one residue mutated or absent

<400> 127
 gtactcattc caatgggggtg gcttctg 28

<210> 128
 <211> 28
 <212> DNA
 <213> Artificial sequence

100

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (21)..(25)
 <223> At least one residue mutated or absent

<400> 128
 gtacttcata caatggggtg gcttctgg

28

<210> 129
 <211> 28
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (21)..(25)
 <223> At least one residue mutated or absent

<400> 129
 gtactctttt caatggggtg gcttctgg

28

<210> 130
 <211> 23
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (16)..(20)
 <223> At least one residue mutated or absent

<400> 130
 gtactcaatg ggggtggcttc tgg

23

<210> 131
 <211> 28
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

101

<220>
<221> misc_feature
<222> (4)..(5)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (21)..(25)
<223> At least one residue mutated or absent

<400> 131
gtactctttt cattccaatg gcttctgg 28

<210> 132
<211> 28
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(5)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (21)..(25)
<223> At least one residue mutated or absent

<400> 132
gtacttcata cattccaatg gcttctgg 28

<210> 133
<211> 28
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(5)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (21)..(25)
<223> At least one residue mutated or absent

<400> 133
gtacttcata cttttcaatg gcttctgg 28

<210> 134
<211> 23
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(5)
<223> At least one residue mutated or absent

102

<220>
<221> misc_feature
<222> (16)..(20)
<223> At least one residue mutated or absent

<400> 134
gtactcattc caatggcttc tgg 23

<210> 135
<211> 23
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(5)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (16)..(20)
<223> At least one residue mutated or absent

<400> 135
gtacttcata caatggcttc tgg 23

<210> 136
<211> 23
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(5)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (16)..(20)
<223> At least one residue mutated or absent

<400> 136
gtactctttt caatggcttc tgg 23

<210> 137
<211> 43
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(5)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (36)..(40)
<223> At least one residue mutated or absent

103

<400> 137
gtacttcata cttttcattc caatggggtg actttgcttc tgg

43

<210> 138
<211> 38
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(5)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (31)..(35)
<223> At least one residue mutated or absent

<400> 138
gtactctttt cattccaatg gggtgacttt gcttctgg

38

<210> 139
<211> 38
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(5)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (31)..(35)
<223> At least one residue mutated or absent

<400> 139
gtacttcata cattccaatg gggtgacttt gcttctgg

38

<210> 140
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(5)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (26)..(30)
<223> At least one residue mutated or absent

<400> 140
gtactcattc caatggggtg actttgcttc tgg

33

<210> 141

104

<211> 38
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (31)..(35)
 <223> At least one residue mutated or absent

<400> 141
 gtacttcata cttttcattc caatgacttt gcttctgg 38

<210> 142
 <211> 38
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (31)..(35)
 <223> At least one residue mutated or absent

<400> 142
 gtacttcata cttttcattc caatgggggtg gcttctgg 38

<210> 143
 <211> 33
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (26)..(30)
 <223> At least one residue mutated or absent

<400> 143
 gtacttcata cttttcattc caatggcttc tgg 33

<210> 144
 <211> 33
 <212> DNA
 <213> Artificial sequence

<220>

105

<223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (26)..(30)
 <223> At least one residue mutated or absent

<400> 144
 gtactctttt cattccaatg actttgcttc tgg 33

<210> 145
 <211> 33
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (26)..(30)
 <223> At least one residue mutated or absent

<400> 145
 gtacttcata cattccaatg actttgcttc tgg 33

<210> 146
 <211> 28
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (21)..(25)
 <223> At least one residue mutated or absent

<400> 146
 gtactcattc caatgacttt gcttctgg 28

<210> 147
 <211> 33
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature

106

<222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (26)..(30)
 <223> At least one residue mutated or absent

<400> 147
 gtactctttt cattccaatg gggaggcttc tgg

33

<210> 148
 <211> 33
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (26)..(30)
 <223> At least one residue mutated or absent

<400> 148
 gtacttcata cattccaatg gggaggcttc tgg

33

<210> 149
 <211> 28
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (21)..(25)
 <223> At least one residue mutated or absent

<400> 149
 gtactcattc caatgggggtg gcttctgg

28

<210> 150
 <211> 28
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature

107

<222> (21)..(25)
 <223> At least one residue mutated or absent

<400> 150
 gtactctttt cattccaatg gcttctgg 28

<210> 151
 <211> 28
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (21)..(25)
 <223> At least one residue mutated or absent

<400> 151
 gtacttcata cattccaatg gcttctgg 28

<210> 152
 <211> 23
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(5)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (16)..(20)
 <223> At least one residue mutated or absent

<400> 152
 gtactcattc caatggcttc tgg 23

<210> 153
 <211> 43
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (16)..(20)
 <223> At least one residue mutated or absent

<400> 153
 gtacttcata cttttcattc caatgggggtg actttgcttc tgg 43

<210> 154
 <211> 19
 <212> DNA

108

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (7)..(11)

<223> At least one residue mutated or absent

<400> 154

acttttcatt ccaatgggg

19

<210> 155

<211> 19

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (6)..(10)

<223> At least one residue mutated or absent

<400> 155

cttttcattc caatgggggt

19

<210> 156

<211> 19

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (5)..(9)

<223> At least one residue mutated or absent

<400> 156

ttttcattcc aatgggggtg

19

<210> 157

<211> 19

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (4)..(8)

<223> At least one residue mutated or absent

<400> 157

tttcattcca atgggggtga

19

<210> 158

<211> 19

<212> DNA

<213> Artificial sequence

109

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (8)..(12)
<223> At least one residue mutated or absent

<400> 158
tacttttcat tccaatggg

19

<210> 159
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (9)..(13)
<223> At least one residue mutated or absent

<400> 159
atacttttca ttccaatgg

19

<210> 160
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (10)..(14)
<223> At least one residue mutated or absent

<400> 160
catacttttc attccaatg

19

<210> 161
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(15)
<223> At least one residue mutated or absent

<400> 161
tcatactttt cattccaat

19

<210> 162
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (12)..(16)
<223> At least one residue mutated or absent

<400> 162
ttcatacttt tcattccaa

19

<210> 163
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(8)
<223> At least one residue mutated or absent

<400> 163
ttccaatggg gtgactttg

19

<210> 164
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (5)..(9)
<223> At least one residue mutated or absent

<400> 164
attccaatgg ggtgacttt

19

<210> 165
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<400> 165
cattccaatg gggtgactt

19

<210> 166
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

111

<220>
<221> misc_feature
<222> (7)..(11)
<223> At least one residue mutated or absent

<400> 166
tcattccaat ggggtgact 19

<210> 167
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (8)..(12)
<223> At least one residue mutated or absent

<400> 167
ttcattccaa tggggtgac 19

<210> 168
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (9)..(13)
<223> At least one residue mutated or absent

<400> 168
tttcattcca atggggtga 19

<210> 169
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (10)..(14)
<223> At least one residue mutated or absent

<400> 169
ttttcattcc aatggggtg 19

<210> 170
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature

112

<222> (11)..(15)
 <223> At least one residue mutated or absent

<400> 170
 cttttcattc caatggggt

19

<210> 171
 <211> 19
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (12)..(16)
 <223> At least one residue mutated or absent

<400> 171
 acttttcatt ccaatgggg

19

<210> 172
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(13)
 <223> At least one residue mutated or absent

<400> 172
 tttcattcca atggggtgac ttg

24

<210> 173
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (5)..(14)
 <223> At least one residue mutated or absent

<400> 173
 ttttcattcc aatggggtga cttt

24

<210> 174
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (6)..(15)
 <223> At least one residue mutated or absent

113

<400> 174
 cttttcattc caatggggtg actt 24

<210> 175
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (7)..(16)
 <223> At least one residue mutated or absent

<400> 175
 acttttcatt ccaatggggt gact 24

<210> 176
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (8)..(17)
 <223> At least one residue mutated or absent

<400> 176
 tacttttcat tccaatgggg tgac 24

<210> 177
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (9)..(18)
 <223> At least one residue mutated or absent

<400> 177
 atacttttca ttccaatggg gtga 24

<210> 178
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (10)..(19)
 <223> At least one residue mutated or absent

<400> 178

114

catacttttc attccaatgg ggtg

24

<210> 179
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (11)..(20)
 <223> At least one residue mutated or absent

<400> 179
 tcatactttt cattccaatg gggg

24

<210> 180
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (11)..(21)
 <223> At least one residue mutated or absent

<400> 180
 ttcatacttt tcattccaat gggg

24

<210> 181
 <211> 19
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (5)..(9)
 <223> At least one residue mutated or absent

<400> 181
 ttttcattcc aatgggggtg

19

<210> 182
 <211> 19
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(8)
 <223> At least one residue mutated or absent

<400> 182
 tttcattcca atgggggtga

19

115

<210> 183
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (5)..(9)
<223> At least one residue mutated or absent

<400> 183
attccaatgg ggtgacttt

19

<210> 184
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(8)
<223> At least one residue mutated or absent

<400> 184
ttccaatggg gtgactttg

19

<210> 185
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<400> 185
cattccaatg gggtgactt

19

<210> 186
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (7)..(11)
<223> At least one residue mutated or absent

<400> 186
tcattccaat ggggtgact

19

<210> 187

116

<211> 19
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (8)..(12)
 <223> At least one residue mutated or absent

<400> 187
 ttcatccaa tggggtgac

19

<210> 188
 <211> 19
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (9)..(13)
 <223> At least one residue mutated or absent

<400> 188
 tttcatcca atggggtga

19

<210> 189
 <211> 19
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (10)..(14)
 <223> At least one residue mutated or absent

<400> 189
 ttttcattcc aatggggtg

19

<210> 190
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (5)..(14)
 <223> At least one residue mutated or absent

<400> 190
 ttttcattcc aatggggtga cttt

24

<210> 191
 <211> 25
 <212> DNA

117

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (11)..(20)

<223> At least one residue mutated or absent

<400> 191

tcatactttt cattccaatg ggggtg

25

<210> 192

<211> 23

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (4)..(8)

<223> At least one residue mutated or absent

<400> 192

tttcattcca atgggggtgac ttt

23

<210> 193

<211> 19

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (5)..(9)

<223> At least one residue mutated or absent

<400> 193

ttttcattcg ggtgacttt

19

<210> 194

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (5)..(9)

<223> At least one residue mutated or absent

<400> 194

ttttcattcc aatgactttg cttc

24

<210> 195

<211> 19

<212> DNA

<213> Artificial sequence

118

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (5)..(9)
<223> At least one residue mutated or absent

<400> 195
ttttcattca ctttgcttc 19

<210> 196
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (5)..(9)
<223> At least one residue mutated or absent

<400> 196
attccaatgg ggtgacttt 19

<210> 197
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (5)..(9)
<223> At least one residue mutated or absent

<400> 197
attccaatga ctttgcttc 19

<210> 198
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(8)
<223> At least one residue mutated or absent

<400> 198
ttccaatgac tttgcttct 19

<210> 199
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

119

<220>
<221> misc_feature
<222> (4)..(13)
<223> At least one residue mutated or absent

<400> 199
tttcattcca atggggtgac ttg 24

<210> 200
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (5)..(14)
<223> At least one residue mutated or absent

<400> 200
ttttcattcc aatggggtga cttt 24

<210> 201
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(15)
<223> At least one residue mutated or absent

<400> 201
cttttcattc caatggggtg acttt 25

<210> 202
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (5)..(14)
<223> At least one residue mutated or absent

<400> 202
ttttcattcc aatgactttg cttc 24

<210> 203
<211> 23
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

120

<220>
<221> misc_feature
<222> (4)..(8)
<223> At least one residue mutated or absent

<400> 203
tttcattcca atggggtgac ttt

23

<210> 204
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (5)..(9)
<223> At least one residue mutated or absent

<400> 204
ttttcattcg ggtgacttt

19

<210> 205
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(8)
<223> At least one residue mutated or absent

<400> 205
tttcattcgg gtgactttg

19

<210> 206
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (5)..(9)
<223> At least one residue mutated or absent

<400> 206
attccaatgg ggtgacttt

19

<210> 207
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature

121

<222> (4)..(8)
<223> At least one residue mutated or absent

<400> 207
ttccaatggg gtgactttg 19

<210> 208
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (5)..(14)
<223> At least one residue mutated or absent

<400> 208
ttttcattcc aatggggtga cttt 24

<210> 209
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(13)
<223> At least one residue mutated or absent

<400> 209
tttcattcca atggggtgac ttg 24

<210> 210
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(8)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (14)..(18)
<223> At least one residue mutated or absent

<400> 210
tttcattcca atggggtgac ttg 24

<210> 211
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

122

<220>
<221> misc_feature
<222> (5)..(9)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (15)..(19)
<223> At least one residue mutated or absent

<400> 211
ttttcattcc aatggggtga cttt

24

<210> 212
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (16)..(20)
<223> At least one residue mutated or absent

<400> 212
cttttcattc caatggggtg actt

24

<210> 213
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (7)..(11)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (17)..(21)
<223> At least one residue mutated or absent

<400> 213
acttttcatt ccaatggggt gact

24

<210> 214
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(13)
<223> At least one residue mutated or absent

123

<400> 214
ttccaatggg gtgactttgc ttct 24

<210> 215
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (5)..(14)
<223> At least one residue mutated or absent

<400> 215
attccaatgg ggtgactttg cttc 24

<210> 216
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(15)
<223> At least one residue mutated or absent

<400> 216
cattccaatg ggggtgacttt gctt 24

<210> 217
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (7)..(16)
<223> At least one residue mutated or absent

<400> 217
tcattccaat ggggtgactt tgct 24

<210> 218
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (8)..(17)
<223> At least one residue mutated or absent

<400> 218

124

ttcattccaa tggggtgact ttgc

24

<210> 219
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (9)..(18)
 <223> At least one residue mutated or absent

<400> 219
 tttcattcca atggggtgac ttg

24

<210> 220
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (10)..(19)
 <223> At least one residue mutated or absent

<400> 220
 ttttcattcc aatggggtga cttt

24

<210> 221
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (11)..(20)
 <223> At least one residue mutated or absent

<400> 221
 cttttcattc caatggggtg actt

24

<210> 222
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (12)..(21)
 <223> At least one residue mutated or absent

<400> 222
 acttttcatt ccaatggggt gact

24

125

<210> 223
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(18)
 <223> At least one residue mutated or absent

<400> 223
 tttcattcca atggggtgac ttgcttct 29

<210> 224
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (5)..(19)
 <223> At least one residue mutated or absent

<400> 224
 ttttcattcc aatggggtga ctttcttc 29

<210> 225
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (6)..(20)
 <223> At least one residue mutated or absent

<400> 225
 cttttcattc caatggggtg actttgctt 29

<210> 226
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (7)..(21)
 <223> At least one residue mutated or absent

<400> 226
 acttttcatt ccaatggggt gactttgct 29

<210> 227

126

<211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (8)..(22)
 <223> At least one residue mutated or absent

<400> 227
 tacttttcat tccaatggg tgactttgc 29

<210> 228
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (9)..(23)
 <223> At least one residue mutated or absent

<400> 228
 atacttttca ttccaatggg gtgactttg 29

<210> 229
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (10)..(24)
 <223> At least one residue mutated or absent

<400> 229
 catacttttc attccaatgg ggtgacttt 29

<210> 230
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (11)..(25)
 <223> At least one residue mutated or absent

<400> 230
 tcatactttt cattccaatg ggtgactt 29

<210> 231
 <211> 29
 <212> DNA

127

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (12)..(26)

<223> At least one residue mutated or absent

<400> 231

ttcatacttt tcattccaat ggggtgact

29

<210> 232

<211> 26

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (4)..(8)

<223> At least one residue mutated or absent

<220>

<221> misc_feature

<222> (19)..(23)

<223> At least one residue mutated or absent

<400> 232

tttcattcca atggggtgac ttgct

26

<210> 233

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (6)..(10)

<223> At least one residue mutated or absent

<220>

<221> misc_feature

<222> (16)..(20)

<223> At least one residue mutated or absent

<400> 233

cttttcattc caatgacttt gctt

24

<210> 234

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (6)..(10)

<223> At least one residue mutated or absent

128

<220>
<221> misc_feature
<222> (16)..(20)
<223> At least one residue mutated or absent

<400> 234
cttttcattc gggtagcttt gctt

24

<210> 235
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (5)..(9)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (15)..(19)
<223> At least one residue mutated or absent

<400> 235
ttttcattcc aatgactttg ctcc

24

<210> 236
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (5)..(9)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (15)..(19)
<223> At least one residue mutated or absent

<400> 236
ttttcattcg ggtgactttg ctcc

24

<210> 237
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (5)..(9)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (15)..(19)
<223> At least one residue mutated or absent

129

<400> 237
attccaatgg ggtgactttg cttc 24

<210> 238
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(8)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (14)..(18)
<223> At least one residue mutated or absent

<400> 238
ttccaatggg gtgactttgc ttct 24

<210> 239
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (16)..(20)
<223> At least one residue mutated or absent

<400> 239
cattccaatg ggggtgacttt gctt 24

<210> 240
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (7)..(11)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (17)..(21)
<223> At least one residue mutated or absent

<400> 240
tcattccaat ggggtgactt tgct 24

130

<210> 241
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(13)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (19)..(23)
 <223> At least one residue mutated or absent

<400> 241
 ttctattcca atggggtgac ttgtctct 29

<210> 242
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (5)..(14)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (20)..(24)
 <223> At least one residue mutated or absent

<400> 242
 ttttcattcc aatggggtga ctttgcttc 29

<210> 243
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (6)..(15)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (21)..(25)
 <223> At least one residue mutated or absent

<400> 243
 cttttcattc caatggggtg actttgctt 29

<210> 244
 <211> 29
 <212> DNA
 <213> Artificial sequence

131

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(25)
<223> At least one residue mutated or absent

<400> 244
tcatactttt cattccaatg actttgctt 29

<210> 245
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (10)..(24)
<223> At least one residue mutated or absent

<400> 245
catacttttc attccaatga ctttgettc 29

<210> 246
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (9)..(23)
<223> At least one residue mutated or absent

<400> 246
atacttttca ttccaatgac tttgettct 29

<210> 247
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (8)..(22)
<223> At least one residue mutated or absent

<400> 247
tacttttcat tccaatgact ttgcttctg 29

<210> 248
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

132

<220>
<221> misc_feature
<222> (7)..(21)
<223> At least one residue mutated or absent

<400> 248
acttttcatt ccaatgactt tgcttctgg

29

<210> 249
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(8)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (14)..(23)
<223> At least one residue mutated or absent

<400> 249
tttcattcca atggggtgac ttgcttct

29

<210> 250
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (5)..(9)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (15)..(24)
<223> At least one residue mutated or absent

<400> 250
ttttcattcc aatggggtga ctttgcttc

29

<210> 251
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (16)..(25)

133

<223> At least one residue mutated or absent

<400> 251

cttttcattc caatggggtg actttgctt

29

<210> 252

<211> 29

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (7)..(11)

<223> At least one residue mutated or absent

<220>

<221> misc_feature

<222> (17)..(26)

<223> At least one residue mutated or absent

<400> 252

acttttcatt ccaatggggt gactttgct

29

<210> 253

<211> 29

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (12)..(26)

<223> At least one residue mutated or absent

<400> 253

ttcatacttt tcattcgggt gactttgct

29

<210> 254

<211> 29

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (11)..(25)

<223> At least one residue mutated or absent

<400> 254

tcatactttt cattcgggtg actttgctt

29

<210> 255

<211> 29

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

134

<220>
 <221> misc_feature
 <222> (10)..(24)
 <223> At least one residue mutated or absent

 <400> 255
 catacttttc attcgggtga ctttgccttc 29

 <210> 256
 <211> 29
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> Exemplary element X variant

 <220>
 <221> misc_feature
 <222> (9)..(23)
 <223> At least one residue mutated or absent

 <400> 256
 atacttttca ttcgggtgac tttgccttct 29

 <210> 257
 <211> 29
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> Exemplary element X variant

 <220>
 <221> misc_feature
 <222> (8)..(22)
 <223> At least one residue mutated or absent

 <400> 257
 tacttttcat tcgggtgact ttgccttctg 29

 <210> 258
 <211> 29
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> Exemplary element X variant

 <220>
 <221> misc_feature
 <222> (7)..(21)
 <223> At least one residue mutated or absent

 <400> 258
 acttttcatt cgggtgactt tgcttctgg 29

 <210> 259
 <211> 29
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> Exemplary element X variant

 <220>
 <221> misc_feature

135

<222> (12)..(26)
<223> At least one residue mutated or absent

<400> 259
acttttcatt ccaatggggt gactttgct 29

<210> 260
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(25)
<223> At least one residue mutated or absent

<400> 260
cttttcattc caatggggtg actttgctt 29

<210> 261
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (10)..(24)
<223> At least one residue mutated or absent

<400> 261
ttttcattcc aatggggtga ctttgcttc 29

<210> 262
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (9)..(23)
<223> At least one residue mutated or absent

<400> 262
tttcattcca atggggtgac ttgcttct 29

<210> 263
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (8)..(22)
<223> At least one residue mutated or absent

<400> 263
ttcattccaa tggggtgact ttgcttctg 29

<210> 264
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (7)..(21)
<223> At least one residue mutated or absent

<400> 264
tcattccaat ggggtgactt tgcttctgg 29

<210> 265
<211> 34
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (12)..(31)
<223> At least one residue mutated or absent

<400> 265
ttcatacttt tcattccaat ggggtgactt tgct 34

<210> 266
<211> 34
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(30)
<223> At least one residue mutated or absent

<400> 266
tcatactttt cattccaatg ggggtgacttt gctt 34

<210> 267
<211> 34
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (10)..(29)
<223> At least one residue mutated or absent

<400> 267

137

catacttttc attccaatgg ggtgactttg cttc

34

<210> 268
 <211> 34
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (9)..(28)
 <223> At least one residue mutated or absent

<400> 268
 atacttttca ttccaatggg gtgactttgc ttct

34

<210> 269
 <211> 34
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (8)..(27)
 <223> At least one residue mutated or absent

<400> 269
 tacttttcat tccaatgggg tgactttgct tctg

34

<210> 270
 <211> 34
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (7)..(26)
 <223> At least one residue mutated or absent

<400> 270
 acttttcatt ccaatggggg gactttgctt ctgg

34

<210> 271
 <211> 28
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(8)
 <223> At least one residue mutated or absent

<400> 271
 ttccattcca atgggggtgac ttgcttc

28

138

<210> 272
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (5)..(9)
<223> At least one residue mutated or absent

<400> 272
ttttcattcg ggtgactttg cttc

24

<210> 273
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (5)..(9)
<223> At least one residue mutated or absent

<400> 273
ttttcattcc aatgactttg cttc

24

<210> 274
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (5)..(9)
<223> At least one residue mutated or absent

<400> 274
ttttcattcc aatggggtgg cttc

24

<210> 275
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<400> 275
cttttcattc caatggggtg gcttc

25

<210> 276

139

<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (10)..(14)
<223> At least one residue mutated or absent

<400> 276
catacttttc attcgggtgg ctgc

24

<210> 277
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (10)..(14)
<223> At least one residue mutated or absent

<400> 277
catacttttc attcactttg ctgc

24

<210> 278
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (10)..(14)
<223> At least one residue mutated or absent

<400> 278
catacttttc attccaatgg ctgc

24

<210> 279
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (15)..(19)
<223> At least one residue mutated or absent

<400> 279
tacttcatac ttttcattcg ctgc

24

<210> 280
<211> 23
<212> DNA

140

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (4)..(8)

<223> At least one residue mutated or absent

<400> 280

ttccaatggg gtgactttgc ttc

23

<210> 281

<211> 19

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (4)..(8)

<223> At least one residue mutated or absent

<400> 281

ttccaatgac tttgcttct

19

<210> 282

<211> 19

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (4)..(8)

<223> At least one residue mutated or absent

<400> 282

ttccaatggg gtggcttct

19

<210> 283

<211> 19

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (9)..(13)

<223> At least one residue mutated or absent

<400> 283

tttcattcca atggcttct

19

<210> 284

<211> 19

<212> DNA

<213> Artificial sequence

141

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (10)..(14)
 <223> At least one residue mutated or absent

<400> 284
 ttttcattcc aatggcttc

19

<210> 285
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (5)..(9)
 <223> At least one residue mutated or absent

<400> 285
 attccaatgg ggtgactttg cttc

24

<210> 286
 <211> 20
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (5)..(9)
 <223> At least one residue mutated or absent

<400> 286
 attccaatga ctttgcttct

20

<210> 287
 <211> 20
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (5)..(9)
 <223> At least one residue mutated or absent

<400> 287
 attccaatgg ggtggcttct

20

<210> 288
 <211> 28
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

142

<220>
<221> misc_feature
<222> (4)..(13)
<223> At least one residue mutated or absent

<400> 288
tttcattcca atggggtgac ttgcttc

28

<210> 289
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (5)..(14)
<223> At least one residue mutated or absent

<400> 289
ttttcattcc aatgactttg cttc

24

<210> 290
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (5)..(14)
<223> At least one residue mutated or absent

<400> 290
ttttcattcc aatggggtgg cttc

24

<210> 291
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (10)..(19)
<223> At least one residue mutated or absent

<400> 291
catacttttc attccaatgg cttc

24

<210> 292
<211> 28
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

143

<220>
 <221> misc_feature
 <222> (4)..(13)
 <223> At least one residue mutated or absent

<400> 292
 tttcattcca atggggtgac ttgcttc 28

<210> 293
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (5)..(14)
 <223> At least one residue mutated or absent

<400> 293
 tttcattcc aatgactttg cttc 24

<210> 294
 <211> 28
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(8)
 <223> At least one residue mutated or absent

<400> 294
 tttcattcca atggggtgac ttgcttc 28

<210> 295
 <211> 23
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(8)
 <223> At least one residue mutated or absent

<400> 295
 tttcattcca atggggtggc ttc 23

<210> 296
 <211> 23
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature

144

<222> (4)..(8)
 <223> At least one residue mutated or absent

<400> 296
 ttctattcgg gtgactttgc ttc 23

<210> 297
 <211> 19
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(8)
 <223> At least one residue mutated or absent

<400> 297
 ttctattcgg gtggtttct 19

<210> 298
 <211> 19
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (5)..(9)
 <223> At least one residue mutated or absent

<400> 298
 ttttattcgg ggtggttct 19

<210> 299
 <211> 23
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(8)
 <223> At least one residue mutated or absent

<400> 299
 ttccaatggg gtgactttgc ttc 23

<210> 300
 <211> 19
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (5)..(9)
 <223> At least one residue mutated or absent

145

<400> 300
attccaatgg ggtggcttc 19

<210> 301
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(8)
<223> At least one residue mutated or absent

<400> 301
attcaatggg gtggcttct 19

<210> 302
<211> 28
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(13)
<223> At least one residue mutated or absent

<400> 302
tttcattcca atggggtgac ttgcttc 28

<210> 303
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (5)..(14)
<223> At least one residue mutated or absent

<400> 303
ttttcattcc aatggggtgg cttc 24

<210> 304
<211> 28
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(8)
<223> At least one residue mutated or absent

<400> 304

146

tttcattcca atgggggtgac ttgcttc

28

<210> 305
<211> 23
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(8)
<223> At least one residue mutated or absent

<400> 305
tttcattcgg gtgactttgc ttc

23

<210> 306
<211> 23
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(8)
<223> At least one residue mutated or absent

<400> 306
tttcattcca atgactttgc ttc

23

<210> 307
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (5)..(9)
<223> At least one residue mutated or absent

<400> 307
ttttcattca ctttgettc

19

<210> 308
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(8)
<223> At least one residue mutated or absent

<400> 308
tttcattcac ttgcttct

19

147

<210> 309
<211> 23
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(8)
<223> At least one residue mutated or absent

<400> 309
ttccaatggg gtgactttgc ttc 23

<210> 310
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(8)
<223> At least one residue mutated or absent

<400> 310
ttccaatgac tttgcttct 19

<210> 311
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (5)..(9)
<223> At least one residue mutated or absent

<400> 311
attccaatga ctttgcttc 19

<210> 312
<211> 28
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(13)
<223> At least one residue mutated or absent

<400> 312
tttcattcca atggggtgac tttgcttc 28

<210> 313

148

<211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (5)..(14)
 <223> At least one residue mutated or absent

<400> 313
 ttttcattcc aatgactttg cttc

24

<210> 314
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(13)
 <223> At least one residue mutated or absent

<400> 314
 ttttcattcca atgactttgc ttct

24

<210> 315
 <211> 28
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(8)
 <223> At least one residue mutated or absent

<400> 315
 ttttcattcca atggggtgac ttgcttc

28

<210> 316
 <211> 23
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(8)
 <223> At least one residue mutated or absent

<400> 316
 tttcattcgg gtgactttgc ttc

23

<210> 317
 <211> 23
 <212> DNA

149

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (4)..(8)

<223> At least one residue mutated or absent

<400> 317

ttccaatggg gtgactttgc ttc

23

<210> 318

<211> 28

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (4)..(13)

<223> At least one residue mutated or absent

<400> 318

tttcattcca atgggggtgac tttgcttc

28

<210> 319

<211> 28

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (4)..(8)

<223> At least one residue mutated or absent

<220>

<221> misc_feature

<222> (14)..(18)

<223> At least one residue mutated or absent

<400> 319

tttcattcca atgggggtgac tttgcttc

28

<210> 320

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (4)..(13)

<223> At least one residue mutated or absent

<400> 320

ttttcattcg ggtgactttg cttc

24

150

<210> 321
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (5)..(9)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (15)..(19)
<223> At least one residue mutated or absent

<400> 321
ttttcattcc aatggggtgg ctgc

24

<210> 322
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (10)..(19)
<223> At least one residue mutated or absent

<400> 322
catacttttc attcgggtgg ctgc

24

<210> 323
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(13)
<223> At least one residue mutated or absent

<400> 323
tttcattcgg gtgactttgc ttct

24

<210> 324
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(8)
<223> At least one residue mutated or absent

<220>

151

<221> misc_feature
 <222> (14)..(18)
 <223> At least one residue mutated or absent

<400> 324
 tttcattcca atggggtggc ttct 24

<210> 325
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (9)..(18)
 <223> At least one residue mutated or absent

<400> 325
 atacttttca ttcgggtggc ttct 24

<210> 326
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (8)..(17)
 <223> At least one residue mutated or absent

<400> 326
 tacttttcat tcgggtggct tctg 24

<210> 327
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (7)..(16)
 <223> At least one residue mutated or absent

<400> 327
 acttttcatt cgggtggctt ctgg 24

<210> 328
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(13)

152

<223> At least one residue mutated or absent

<400> 328

ttccaatggg gtgactttgc ttct

24

<210> 329

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (5)..(14)

<223> At least one residue mutated or absent

<400> 329

attccaatgg ggtgactttg ctct

24

<210> 330

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (10)..(19)

<223> At least one residue mutated or absent

<400> 330

ttttcattcc aatggggtgg ctct

24

<210> 331

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (9)..(18)

<223> At least one residue mutated or absent

<400> 331

tttcattcca atggggtggc ttct

24

<210> 332

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (8)..(17)

<223> At least one residue mutated or absent

153

<400> 332
 ttcatccaa tggggtggct tctg 24

<210> 333
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (7)..(16)
 <223> At least one residue mutated or absent

<400> 333
 tcattccaat ggggtgactt tgcttctgg 29

<210> 334
 <211> 28
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(18)
 <223> At least one residue mutated or absent

<400> 334
 tttcattcca atggggtgac ttgcttc 28

<210> 335
 <211> 30
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (5)..(19)
 <223> At least one residue mutated or absent

<400> 335
 ttttcattcc aatggggtga ctttgcttct 30

<210> 336
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (9)..(23)
 <223> At least one residue mutated or absent

<400> 336
 atacttttca ttccaatggg gtggcttct 29

154

<210> 337
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (10)..(24)
<223> At least one residue mutated or absent

<400> 337
catacttttc attccaatgg ggtggcttc

29

<210> 338
<211> 28
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(8)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (19)..(23)
<223> At least one residue mutated or absent

<400> 338
tttcattcca atggggtgac tttgcttc

28

<210> 339
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (5)..(9)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (15)..(19)
<223> At least one residue mutated or absent

<400> 339
ttttcattcc aatgactttg cttc

24

<210> 340
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

155

<220>
<221> misc_feature
<222> (5)..(9)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (15)..(19)
<223> At least one residue mutated or absent

<400> 340
ttttcattcg ggtgactttg cttc

24

<210> 341
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (10)..(19)
<223> At least one residue mutated or absent

<400> 341
catacttttc attcactttg cttc

24

<210> 342
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (9)..(18)
<223> At least one residue mutated or absent

<400> 342
atacttttca ttcactttgc ttct

24

<210> 343
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (8)..(17)
<223> At least one residue mutated or absent

<400> 343
tacttttcat tcactttgct tctg

24

<210> 344
<211> 24
<212> DNA
<213> Artificial sequence

156

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (7)..(16)
<223> At least one residue mutated or absent

<400> 344
acttttcatt cactttgctt ctgg

24

<210> 345
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(8)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (14)..(18)
<223> At least one residue mutated or absent

<400> 345
ttccaatggg gtgactttgc ttct

24

<210> 346
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (5)..(9)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (15)..(19)
<223> At least one residue mutated or absent

<400> 346
attccaatgg ggtgactttg cttc

24

<210> 347
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (9)..(18)
<223> At least one residue mutated or absent

<400> 347

157

tttcattcca atgactttgc ttct

24

<210> 348
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (10)..(19)
 <223> At least one residue mutated or absent

<400> 348
 ttttcattcc aatgactttg cttc

24

<210> 349
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (5)..(14)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (20)..(24)
 <223> At least one residue mutated or absent

<400> 349
 ttttcattcc aatggggtga ctttgcttc

29

<210> 350
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (4)..(13)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (19)..(23)
 <223> At least one residue mutated or absent

<400> 350
 ttttcattcca atggggtgac ttgcttct

29

<210> 351
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

158

<220>
<221> misc_feature
<222> (10)..(24)
<223> At least one residue mutated or absent

<400> 351
catacttttc attccaatga ctttgcttc

29

<210> 352
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (9)..(23)
<223> At least one residue mutated or absent

<400> 352
atacttttca ttccaatgac tttgcttct

29

<210> 353
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (8)..(22)
<223> At least one residue mutated or absent

<400> 353
tacttttcat tccaatgact ttgcttctg

29

<210> 354
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (7)..(21)
<223> At least one residue mutated or absent

<400> 354
acttttcatt ccaatgactt tgcttctgg

29

<210> 355
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

159

<220>
<221> misc_feature
<222> (5)..(9)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (15)..(24)
<223> At least one residue mutated or absent

<400> 355
ttttcattcc aatggggtga ctttgcttc

29

<210> 356
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (5)..(9)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (15)..(24)
<223> At least one residue mutated or absent

<400> 356
ttttcattcc aatggggtga ctttgcttc

29

<210> 357
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (4)..(18)
<223> At least one residue mutated or absent

<400> 357
tttcattcgg gtgactttgc ttct

24

<210> 358
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (10)..(24)
<223> At least one residue mutated or absent

<400> 358
catacttttc attcgggtga ctttgcttc

29

<210> 359

160

<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (9)..(23)
<223> At least one residue mutated or absent

<400> 359
atacttttca ttcgggtgac ttgcttct

29

<210> 360
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (8)..(22)
<223> At least one residue mutated or absent

<400> 360
tacttttcat tcgggtgact ttgcttctg

29

<210> 361
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (7)..(21)
<223> At least one residue mutated or absent

<400> 361
acttttcatt cggtgactt tgcttctgg

29

<210> 362
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (10)..(24)
<223> At least one residue mutated or absent

<400> 362
ttttcatgcc aatgggtga ctttgcttc

29

<210> 363
<211> 29
<212> DNA

161

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (9)..(23)

<223> At least one residue mutated or absent

<400> 363

tttcattcca atggggtgac ttgcttct

29

<210> 364

<211> 29

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (8)..(22)

<223> At least one residue mutated or absent

<400> 364

ttcattccaa tggggtgact ttgcttctg

29

<210> 365

<211> 29

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (7)..(21)

<223> At least one residue mutated or absent

<400> 365

tcattccaat ggggtgactt tgcttctg

29

<210> 366

<211> 34

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (7)..(26)

<223> At least one residue mutated or absent

<400> 366

acttttcatt ccaatggggt gactttgctt ctgg

34

<210> 367

<211> 34

<212> DNA

<213> Artificial sequence

162

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (8)..(27)
<223> At least one residue mutated or absent

<400> 367
tacttttcat tccaatgggg tgactttgct tctg 34

<210> 368
<211> 34
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (9)..(28)
<223> At least one residue mutated or absent

<400> 368
atacttttca ttccaatggg gtgactttgc ttct 34

<210> 369
<211> 34
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (10)..(29)
<223> At least one residue mutated or absent

<400> 369
catacttttc attccaatgg ggtgactttg cttc 34

<210> 370
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(15)
<223> At least one residue mutated or absent

<400> 370
cttttcattc caatggggtg acttt 25

<210> 371
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

163

<220>
<221> misc_feature
<222> (7)..(16)
<223> At least one residue mutated or absent

<400> 371
acttttcatt ccaatggggt gactt

25

<210> 372
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (8)..(17)
<223> At least one residue mutated or absent

<400> 372
tacttttcat tccaatgggg tgact

25

<210> 373
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (9)..(18)
<223> At least one residue mutated or absent

<400> 373
atacttttca ttccaatggg gtgac

25

<210> 374
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (10)..(19)
<223> At least one residue mutated or absent

<400> 374
catacttttc attccaatgg ggtga

25

<210> 375
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

164

<220>
<221> misc_feature
<222> (11)..(20)
<223> At least one residue mutated or absent

<400> 375
tcatactttt cattccaatg ggggtg

25

<210> 376
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (12)..(21)
<223> At least one residue mutated or absent

<400> 376
ttcatacttt tcattccaat ggggt

25

<210> 377
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (13)..(22)
<223> At least one residue mutated or absent

<400> 377
cttcatactt ttcatccaa tgggg

25

<210> 378
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (12)..(16)
<223> At least one residue mutated or absent

<400> 378
ttcatacttt tcattccaa

19

<210> 379
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature

165

<222> (11)..(15)
 <223> At least one residue mutated or absent

<400> 379
 tcataactttt cattccaat 19

<210> 380
 <211> 19
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (10)..(14)
 <223> At least one residue mutated or absent

<400> 380
 cataactttt^c attccaatg 19

<210> 381
 <211> 19
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (9)..(13)
 <223> At least one residue mutated or absent

<400> 381
 atacttttca ttccaatgg 19

<210> 382
 <211> 19
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (8)..(12)
 <223> At least one residue mutated or absent

<400> 382
 tacttttcat tccaatggg 19

<210> 383
 <211> 19
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (7)..(11)
 <223> At least one residue mutated or absent

<400> 383
acttttcatt ccaatgggg

19

<210> 384
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<400> 384
cttttcattc caatggggt

19

<210> 385
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<400> 385
cttttcattc caatggggtg

20

<210> 386
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (10)..(14)
<223> At least one residue mutated or absent

<400> 386
catacttttc attcgggtga

20

<210> 387
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (9)..(13)
<223> At least one residue mutated or absent

<400> 387

167

atacttttca ttcgggtgac

20

<210> 388
 <211> 20
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (8)..(12)
 <223> At least one residue mutated or absent

<400> 388
 tacttttcat tcgggtgact

20

<210> 389
 <211> 20
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (7)..(11)
 <223> At least one residue mutated or absent

<400> 389
 acttttcatt cgggtgactt

20

<210> 390
 <211> 20
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (6)..(10)
 <223> At least one residue mutated or absent

<400> 390
 cttttcattc ggggtgacttt

20

<210> 391
 <211> 20
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (11)..(15)
 <223> At least one residue mutated or absent

<400> 391
 cttttcattc caatggggtg

20

168

<210> 392
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (10)..(14)
<223> At least one residue mutated or absent

<400> 392
catacttttc aatggggtg 19

<210> 393
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (9)..(13)
<223> At least one residue mutated or absent

<400> 393
atacttttca atggggtga 19

<210> 394
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (8)..(12)
<223> At least one residue mutated or absent

<400> 394
tacttttcaa tggggtgac 19

<210> 395
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (7)..(11)
<223> At least one residue mutated or absent

<400> 395
acttttcaat ggggtgact 19

<210> 396

169

<211> 19
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (6)..(10)
 <223> At least one residue mutated or absent

<400> 396
 cttttcaatg gggtgactt

19

<210> 397
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (10)..(19)
 <223> At least one residue mutated or absent

<400> 397
 catacttttc attccaatgg ggtg

24

<210> 398
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (9)..(18)
 <223> At least one residue mutated or absent

<400> 398
 atacttttca ttccaatggg gtga

24

<210> 399
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (8)..(17)
 <223> At least one residue mutated or absent

<400> 399
 tacttttcat tccaatgggg tgac

24

<210> 400
 <211> 24
 <212> DNA

170

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (7)..(16)

<223> At least one residue mutated or absent

<400> 400

acttttcatt ccaatggggt gact

24

<210> 401

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (6)..(15)

<223> At least one residue mutated or absent

<400> 401

cttttcattc caatggggtg actt

24

<210> 402

<211> 25

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (6)..(10)

<223> At least one residue mutated or absent

<400> 402

cttttcattc caatggggtg acttt

25

<210> 403

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (6)..(10)

<223> At least one residue mutated or absent

<400> 403

cttttcattc caatgacttt

20

<210> 404

<211> 20

<212> DNA

<213> Artificial sequence

171

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (6)..(10)
 <223> At least one residue mutated or absent

<400> 404
 cttttcattc gggtgacttt 20

<210> 405
 <211> 19
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (10)..(14)
 <223> At least one residue mutated or absent

<400> 405
 cataacttttc attcacttt 19

<210> 406
 <211> 19
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (9)..(13)
 <223> At least one residue mutated or absent

<400> 406
 atactttttca ttcactttg 19

<210> 407
 <211> 19
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (8)..(12)
 <223> At least one residue mutated or absent

<400> 407
 tactttttcat tcactttgc 19

<210> 408
 <211> 19
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

172

<220>
<221> misc_feature
<222> (7)..(11)
<223> At least one residue mutated or absent

<400> 408
acttttcatt cactttgct

19

<210> 409
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<400> 409
cttttcattc actttgctt

19

<210> 410
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(15)
<223> At least one residue mutated or absent

<400> 410
cttttcattc caatggggtg acttt

25

<210> 411
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(15)
<223> At least one residue mutated or absent

<400> 411
cttttcattc caatgacttt

20

<210> 412
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

173

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<400> 412
cttttcaatg gggtgacttt

20

<210> 413
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (10)..(14)
<223> At least one residue mutated or absent

<400> 413
catacttttc aatgacttt

19

<210> 414
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (9)..(13)
<223> At least one residue mutated or absent

<400> 414
atacttttca atgactttg

19

<210> 415
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (8)..(12)
<223> At least one residue mutated or absent

<400> 415
tacttttcaa tgactttgc

19

<210> 416
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature

174

<222> (7)..(11)
 <223> At least one residue mutated or absent

<400> 416
 acttttcaat gactttgct 19

<210> 417
 <211> 19
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (6)..(10)
 <223> At least one residue mutated or absent

<400> 417
 cttttcaatg acttttgctt 19

<210> 418
 <211> 25
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (6)..(15)
 <223> At least one residue mutated or absent

<400> 418
 cttttcattc caatggggtg acttt 25

<210> 419
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (10)..(19)
 <223> At least one residue mutated or absent

<400> 419
 catacttttc attccaatga cttt 24

<210> 420
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (9)..(18)
 <223> At least one residue mutated or absent

175

<400> 420
atacttttca ttccaatgac ttg 24

<210> 421
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (8)..(17)
<223> At least one residue mutated or absent

<400> 421
tacttttcat tccaatgact ttgc 24

<210> 422
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (7)..(16)
<223> At least one residue mutated or absent

<400> 422
acttttcatt ccaatgactt tgct 24

<210> 423
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(15)
<223> At least one residue mutated or absent

<400> 423
cttttcattc caatgacttt gctt 24

<210> 424
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<400> 424

176

cttttcattc caatggggtg acttt

25

<210> 425

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (6)..(10)

<223> At least one residue mutated or absent

<400> 425

cttttcattc gggtagcttt

20

<210> 426

<211> 25

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (6)..(15)

<223> At least one residue mutated or absent

<400> 426

cttttcattc caatggggtg acttt

25

<210> 427

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (6)..(10)

<223> At least one residue mutated or absent

<220>

<221> misc_feature

<222> (16)..(20)

<223> At least one residue mutated or absent

<400> 427

cttttcattc caatggggtg actt

24

<210> 428

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (7)..(11)

177

<223> At least one residue mutated or absent

<220>

<221> misc_feature

<222> (17)..(21)

<223> At least one residue mutated or absent

<400> 428

acttttcatt ccaatggggt gact

24

<210> 429

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (12)..(21)

<223> At least one residue mutated or absent

<400> 429

ttcatacttt tcattcgggt gact

24

<210> 430

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (11)..(20)

<223> At least one residue mutated or absent

<400> 430

tcatactttt cattcgggtg actt

24

<210> 431

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (10)..(19)

<223> At least one residue mutated or absent

<400> 431

catacttttc attcgggtga cttt

24

<210> 432

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

178

<220>
<221> misc_feature
<222> (9)..(18)
<223> At least one residue mutated or absent

<400> 432
atacttttca ttcgggtgac ttg

24

<210> 433
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (8)..(17)
<223> At least one residue mutated or absent

<400> 433
tacttttcat tcgggtgact ttgc

24

<210> 434
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (7)..(16)
<223> At least one residue mutated or absent

<400> 434
acttttcatt cgggtgactt tgct

24

<210> 435
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(15)
<223> At least one residue mutated or absent

<400> 435
cttttcattc ggggtgacttt gctt

24

<210> 436
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature

179

<222> (11)..(20)
<223> At least one residue mutated or absent

<400> 436
cttttcattc caatggggtg actt 24

<210> 437
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (12)..(21)
<223> At least one residue mutated or absent

<400> 437
acttttcatt ccaatggggt gact 24

<210> 438
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (12)..(21)
<223> At least one residue mutated or absent

<400> 438
ttcatacttt tcaatggggt gact 24

<210> 439
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(20)
<223> At least one residue mutated or absent

<400> 439
tcatactttt caatggggtg actt 24

<210> 440
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (10)..(19)
<223> At least one residue mutated or absent

180

<400> 440
catactttttc aatggggtga cttt 24

<210> 441
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (9)..(18)
<223> At least one residue mutated or absent

<400> 441
atactttttca atggggtgac ttg 24

<210> 442
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (8)..(17)
<223> At least one residue mutated or absent

<400> 442
tactttttcaa tggggtgact ttgc 24

<210> 443
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (7)..(16)
<223> At least one residue mutated or absent

<400> 443
actttttcaat ggggtgactt tgct 24

<210> 444
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(15)
<223> At least one residue mutated or absent

<400> 444

181

cttttcaatg gggtgacttt gctt

24

<210> 445
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (12)..(26)
<223> At least one residue mutated or absent

<400> 445
ttcatacttt tcattccaat ggggtgact

29

<210> 446
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(25)
<223> At least one residue mutated or absent

<400> 446
tcatactttt cattccaatg ggggtgactt

29

<210> 447
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (10)..(24)
<223> At least one residue mutated or absent

<400> 447
catacttttc attccaatgg ggtgacttt

29

<210> 448
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (9)..(23)
<223> At least one residue mutated or absent

<400> 448
atacttttca ttccaatggg gtgactttg

29

182

<210> 449
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (8)..(22)
 <223> At least one residue mutated or absent

<400> 449
 tacttttcat tccaatgggg tgactttgc

29

<210> 450
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (7)..(21)
 <223> At least one residue mutated or absent

<400> 450
 acttttcatt ccaatggggt gactttgct

29

<210> 451
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (6)..(20)
 <223> At least one residue mutated or absent

<400> 451
 cttttcattc caatggggtg actttgctt

29

<210> 452
 <211> 28
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (6)..(10)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (21)..(25)
 <223> At least one residue mutated or absent

183

<400> 452
cttttcattc caatggggtg actttgct 28

<210> 453
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (16)..(20)
<223> At least one residue mutated or absent

<400> 453
cttttcattc gggtgacttt gctt 24

<210> 454
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (16)..(20)
<223> At least one residue mutated or absent

<400> 454
cttttcattc caatgacttt gctt 24

<210> 455
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(20)
<223> At least one residue mutated or absent

<400> 455
tcatactttt cattcacttt gctt 24

<210> 456
<211> 24
<212> DNA
<213> Artificial sequence

<220>

184

<223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (7)..(11)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (17)..(21)
 <223> At least one residue mutated or absent

<400> 456
 acttttcatt cgggtgactt tgct

24

<210> 457
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (7)..(11)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (17)..(21)
 <223> At least one residue mutated or absent

<400> 457
 acttttcatt ccaatgactt tgct

24

<210> 458
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (12)..(21)
 <223> At least one residue mutated or absent

<400> 458
 ttcatacttt tcattcactt tgct

24

<210> 459
 <211> 28
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (11)..(15)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature

185

<222> (21)..(25)
<223> At least one residue mutated or absent

<400> 459
cttttcattc caatggggtg actttgct

28

<210> 460
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (16)..(20)
<223> At least one residue mutated or absent

<400> 460
cttttcaatg gggtgacttt gctt

24

<210> 461
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(20)
<223> At least one residue mutated or absent

<400> 461
cttttcattc caatgacttt gctt

24

<210> 462
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(20)
<223> At least one residue mutated or absent

<400> 462
tcatactttt caatgacttt gctt

24

<210> 463
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

186

<220>
<221> misc_feature
<222> (7)..(11)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (17)..(21)
<223> At least one residue mutated or absent

<400> 463
acttttcaat ggggtgactt tgct

24

<210> 464
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (12)..(21)
<223> At least one residue mutated or absent

<400> 464
acttttcatt ccaatgactt tgct

24

<210> 465
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (12)..(21)
<223> At least one residue mutated or absent

<400> 465
ttcatacttt tcaatgactt tgct

24

<210> 466
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(15)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (21)..(25)
<223> At least one residue mutated or absent

<400> 466
cttttcattc caatggggtg actttgctt

29

187

<210> 467
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (7)..(16)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (22)..(26)
 <223> At least one residue mutated or absent

<400> 467
 acttttcatt ccaatggggt gactttgct

29

<210> 468
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (7)..(21)
 <223> At least one residue mutated or absent

<400> 468
 acttttcatt ccaatgactt tgcttctgg

29

<210> 469
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (6)..(20)
 <223> At least one residue mutated or absent

<400> 469
 cttttcattc caatgacttt gcttctgga

29

<210> 470
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (11)..(25)
 <223> At least one residue mutated or absent

<400> 470

188

tcataactttt cattccaatg acttttgctt

29

<210> 471
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (12)..(26)
<223> At least one residue mutated or absent

<400> 471
ttcataacttt tcattccaat gactttgct

29

<210> 472
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(25)
<223> At least one residue mutated or absent

<400> 472
cttttcattc caatggggtg acttttgctt

29

<210> 473
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (12)..(26)
<223> At least one residue mutated or absent

<400> 473
acttttcatt ccaatggggt gactttgct

29

<210> 474
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (7)..(21)
<223> At least one residue mutated or absent

<400> 474
acttttcaat ggggtgactt tgcttctgg

29

189

<210> 475
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(20)
<223> At least one residue mutated or absent

<400> 475
cttttcaatg gggtgacttt gcttctgga 29

<210> 476
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(25)
<223> At least one residue mutated or absent

<400> 476
tcatactttt caatgggggtg actttgctt 29

<210> 477
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (12)..(26)
<223> At least one residue mutated or absent

<400> 477
ttcatactttt tcaatgggggt gactttgct 29

<210> 478
<211> 34
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (7)..(26)
<223> At least one residue mutated or absent

<400> 478
acttttcatt ccaatgggggt gactttgctt ctgg 34

<210> 479

190

<211> 34
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (8)..(27)
<223> At least one residue mutated or absent

<400> 479
tacttttcat tccaatgggg tgactttgct tctg

34

<210> 480
<211> 34
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (9)..(28)
<223> At least one residue mutated or absent

<400> 480
atacttttca ttccaatggg gtgactttgc ttct

34

<210> 481
<211> 34
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (10)..(29)
<223> At least one residue mutated or absent

<400> 481
catacttttc attccaatgg ggtgactttg cttc

34

<210> 482
<211> 34
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(30)
<223> At least one residue mutated or absent

<400> 482
tcatactttt cattccaatg gggtgacttt gctt

34

<210> 483
<211> 34
<212> DNA

191

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (12)..(31)

<223> At least one residue mutated or absent

<400> 483

ttcatacttt tcattccaat ggggtgactt tgct

34

<210> 484

<211> 30

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (6)..(10)

<223> At least one residue mutated or absent

<400> 484

cttttcattc caatggggtg actttgcttc

30

<210> 485

<211> 25

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (6)..(10)

<223> At least one residue mutated or absent

<400> 485

cttttcattc gggtgacttt gcttc

25

<210> 486

<211> 25

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (6)..(10)

<223> At least one residue mutated or absent

<400> 486

cttttcattc caatgacttt gcttc

25

<210> 487

<211> 25

<212> DNA

<213> Artificial sequence

192

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<400> 487
cttttcattc caatggggtg gcttc

25

<210> 488
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<400> 488
cttttcattc actttgcttc

20

<210> 489
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<400> 489
cttttcattc caatggcttc

20

<210> 490
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<400> 490
cttttcattc ggggtggcttc

20

<210> 491
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

193

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<400> 491
cttttcattc gcttctgga

19

<210> 492
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (7)..(11)
<223> At least one residue mutated or absent

<400> 492
acttttcatt cgcttctgg

19

<210> 493
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (8)..(12)
<223> At least one residue mutated or absent

<400> 493
tacttttcat tcgcttctg

19

<210> 494
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (9)..(13)
<223> At least one residue mutated or absent

<400> 494
atacttttca ttcgcttct

19

<210> 495
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

194

<220>
<221> misc_feature
<222> (10)..(14)
<223> At least one residue mutated or absent

<400> 495
catacttttc attcgcttc

19

<210> 496
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<400> 496
cttttcaatg gggtgacttt gcttc

25

<210> 497
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(15)
<223> At least one residue mutated or absent

<400> 497
cttttcattc caatgacttt gcttc

25

<210> 498
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(15)
<223> At least one residue mutated or absent

<400> 498
cttttcattc caatggggtg gcttc

25

<210> 499
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature

195

<222> (6)..(10)
<223> At least one residue mutated or absent

<400> 499
cttttcaatg actttgcttc 20

<210> 500
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<400> 500
cttttcaatg ggttgcttc 20

<210> 501
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(15)
<223> At least one residue mutated or absent

<400> 501
cttttcattc caatggcttc 20

<210> 502
<211> 30
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(15)
<223> At least one residue mutated or absent

<400> 502
cttttcattc caatggggtg actttgcttc 30

<210> 503
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

196

<400> 503
cttttcaatg gcttctgga

19

<210> 504
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (67)..(11)
<223> At least one residue mutated or absent

<400> 504
acttttcaat ggcttctgg

19

<210> 505
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (8)..(12)
<223> At least one residue mutated or absent

<400> 505
tacttttcaa tggcttctg

19

<210> 506
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (9)..(13)
<223> At least one residue mutated or absent

<400> 506
atacttttca atggcttct

19

<210> 507
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (10)..(14)
<223> At least one residue mutated or absent

<400> 507

197

catacttttc aatggcttc

19

<210> 508
 <211> 30
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (6)..(15)
 <223> At least one residue mutated or absent

<400> 508
 cttttcattc caatgggggtg actttgcttc

30

<210> 509
 <211> 25
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (6)..(15)
 <223> At least one residue mutated or absent

<400> 509
 cttttcattc caatgacttt gcttc

25

<210> 510
 <211> 25
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (6)..(15)
 <223> At least one residue mutated or absent

<400> 510
 cttttcattc caatgggggtg gcttc

25

<210> 511
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (6)..(15)
 <223> At least one residue mutated or absent

<400> 511
 cttttcattc caatggcttc tgga

24

198

<210> 512
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (7)..(16)
<223> At least one residue mutated or absent

<400> 512
acttttcatt ccaatggctt ctgg 24

<210> 513
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (8)..(17)
<223> At least one residue mutated or absent

<400> 513
tacttttcat tccaatggct tctg 24

<210> 514
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (9)..(18)
<223> At least one residue mutated or absent

<400> 514
atacttttca ttccaatggc ttct 24

<210> 515
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (10)..(19)
<223> At least one residue mutated or absent

<400> 515
catacttttc attccaatgg cttc 24

<210> 516

199

<211> 30
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (6)..(10)
 <223> At least one residue mutated or absent

<400> 516
 cttttcattc caatggggtg actttgcttc

30

<210> 517
 <211> 25
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (6)..(10)
 <223> At least one residue mutated or absent

<400> 517
 cttttcattc gggtagcttt gcttc

25

<210> 518
 <211> 25
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (6)..(10)
 <223> At least one residue mutated or absent

<400> 518
 cttttcattc caatggggtg gcttc

25

<210> 519
 <211> 20
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (6)..(10)
 <223> At least one residue mutated or absent

<400> 519
 cttttcattc gggtagcttc

20

<210> 520
 <211> 30
 <212> DNA

200

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (11)..(15)

<223> At least one residue mutated or absent

<400> 520

cttttcattc caatggggtg actttgcttc

30

<210> 521

<211> 25

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (6)..(10)

<223> At least one residue mutated or absent

<400> 521

cttttcaatg gggtgacttt gcttc

25

<210> 522

<211> 25

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (11)..(15)

<223> At least one residue mutated or absent

<400> 522

cttttcattc caatggggtg gcttc

25

<210> 523

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (6)..(10)

<223> At least one residue mutated or absent

<400> 523

cttttcaatg gggtgcttc

20

<210> 524

<211> 30

<212> DNA

<213> Artificial sequence

201

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(15)
<223> At least one residue mutated or absent

<400> 524
cttttcattc caatgggggtg actttgcttc 30

<210> 525
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(15)
<223> At least one residue mutated or absent

<400> 525
cttttcattc caatgggggtg gcttc 25

<210> 526
<211> 30
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<400> 526
cttttcattc caatgggggtg actttgcttc 30

<210> 527
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<400> 527
cttttcattc gggtgacttt gcttc 25

<210> 528
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

202

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<400> 528
cttttcattc caatgacttt gcttc

25

<210> 529
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<400> 529
cttttcattc actttgcttc

20

<210> 530
<211> 30
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(15)
<223> At least one residue mutated or absent

<400> 530
cttttcattc caatggggtg actttgcttc

30

<210> 531
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<400> 531
cttttcaatg gggtagcttt gcttc

25

<210> 532
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

203

<220>
<221> misc_feature
<222> (11)..(15)
<223> At least one residue mutated or absent

<400> 532
cttttcattc caatgacttt gcttc

25

<210> 533
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<400> 533
cttttcaatg actttgcttc

20

<210> 534
<211> 30
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(15)
<223> At least one residue mutated or absent

<400> 534
cttttcattc caatggggtg actttgcttc

30

<210> 535
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(15)
<223> At least one residue mutated or absent

<400> 535
cttttcattc caatgacttt gcttc

25

<210> 536
<211> 30
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature

204

<222> (6)..(10)
<223> At least one residue mutated or absent

<400> 536
cttttcattc caatggggtg actttgcttc 30

<210> 537
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<400> 537
cttttcattc ggggtgacttt gcttc 25

<210> 538
<211> 30
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(15)
<223> At least one residue mutated or absent

<400> 538
cttttcattc caatggggtg actttgcttc 30

<210> 539
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<400> 539
cttttcaatg ggggtgacttt gcttc 25

<210> 540
<211> 30
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(15)
<223> At least one residue mutated or absent

205

<400> 540
cttttcattc caatggggtg actttgcttc 30

<210> 541
<211> 30
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (16)..(20)
<223> At least one residue mutated or absent

<400> 541
cttttcattc caatggggtg actttgcttc 30

<210> 542
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(15)
<223> At least one residue mutated or absent

<400> 542
cttttcattc gggtgacttt gcttc 25

<210> 543
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (16)..(20)
<223> At least one residue mutated or absent

<400> 543
cttttcattc caatggggtg gcttc 25

<210> 544
<211> 24
<212> DNA
<213> Artificial sequence

206

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (9)..(18)
<223> At least one residue mutated or absent

<400> 544
atacttttca ttcgggtggc ttct

24

<210> 545
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (8)..(17)
<223> At least one residue mutated or absent

<400> 545
tacttttcat tcgggtggct tctg

24

<210> 546
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (7)..(16)
<223> At least one residue mutated or absent

<400> 546
acttttcatt cgggtggctt ctgg

24

<210> 547
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(15)
<223> At least one residue mutated or absent

<400> 547
cttttcattc ggggtggctt tgga

24

<210> 548
<211> 30
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (11)..(20)
 <223> At least one residue mutated or absent

<400> 548
 cttttcattc caatggggtg actttgcttc

30

<210> 549
 <211> 25
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (6)..(15)
 <223> At least one residue mutated or absent

<400> 549
 cttttcaatg gggtgacttt gcttc

25

<210> 550
 <211> 25
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (11)..(20)
 <223> At least one residue mutated or absent

<400> 550
 cttttcattc caatggggtg gcttc

25

<210> 551
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (9)..(18)
 <223> At least one residue mutated or absent

<400> 551
 atacttttca atggggtggc ttct

24

<210> 552
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

208

<220>
<221> misc_feature
<222> (8)..(17)
<223> At least one residue mutated or absent

<400> 552
tacttttcaa tgggtggct tctg 24

<210> 553
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (7)..(16)
<223> At least one residue mutated or absent

<400> 553
acttttcaat ggggtggctt ctgg 24

<210> 554
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(15)
<223> At least one residue mutated or absent

<400> 554
cttttcaatg ggggtggcttc tgga 24

<210> 555
<211> 30
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(20)
<223> At least one residue mutated or absent

<400> 555
cttttcattc caatggggtg actttgcttc 30

<210> 556
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature

209

<222> (9)..(23)
<223> At least one residue mutated or absent

<400> 556
atacttttca ttccaatggg gtggcttct 29

<210> 557
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (8)..(22)
<223> At least one residue mutated or absent

<400> 557
tacttttcat tccaatgggg tggcttctg 29

<210> 558
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (7)..(21)
<223> At least one residue mutated or absent

<400> 558
acttttcatt ccaatggggg ggcttctgg 29

<210> 559
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(20)
<223> At least one residue mutated or absent

<400> 559
cttttcattc caatgggggt gcttctgga 29

<210> 560
<211> 30
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

210

<220>
 <221> misc_feature
 <222> (21)..(25)
 <223> At least one residue mutated or absent

<400> 560
 cttttcattc caatgggggtg actttgcttc 30

<210> 561
 <211> 25
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (6)..(10)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (16)..(20)
 <223> At least one residue mutated or absent

<400> 561
 cttttcattc ggggtgacttt gcttc 25

<210> 562
 <211> 25
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (6)..(10)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (16)..(20)
 <223> At least one residue mutated or absent

<400> 562
 cttttcattc caatgacttt gcttc 25

<210> 563
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (9)..(18)
 <223> At least one residue mutated or absent

<400> 563
 atacttttca ttcactttgc ttct 24

211

<210> 564
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (8)..(17)
<223> At least one residue mutated or absent

<400> 564
tacttttcat tcactttgct tctg

24

<210> 565
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (7)..(16)
<223> At least one residue mutated or absent

<400> 565
acttttcatt cactttgctt ctgg

24

<210> 566
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(15)
<223> At least one residue mutated or absent

<400> 566
cttttcattc actttgcttc tgga

24

<210> 567
<211> 30
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(15)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (21)..(25)
<223> At least one residue mutated or absent

<400> 567

212

cttttcattc caatggggtg actttgcttc

30

<210> 568

<211> 25

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (6)..(10)

<223> At least one residue mutated or absent

<220>

<221> misc_feature

<222> (16)..(20)

<223> At least one residue mutated or absent

<400> 568

cttttcaatg gggtgacttt gcttc

25

<210> 569

<211> 25

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (11)..(20)

<223> At least one residue mutated or absent

<400> 569

cttttcattc caatgacttt gcttc

25

<210> 570

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (9)..(18)

<223> At least one residue mutated or absent

<400> 570

atacttttca atgactttgc ttct

24

<210> 571

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (8)..(17)

213

<223> At least one residue mutated or absent

<400> 571

tacttttcaa tgactttgct tctg

24

<210> 572

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (7)..(16)

<223> At least one residue mutated or absent

<400> 572

acttttcaat gactttgctt ctgg

24

<210> 573

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (6)..(15)

<223> At least one residue mutated or absent

<400> 573

cttttcaatg actttgcttc tgga

24

<210> 574

<211> 30

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (6)..(15)

<223> At least one residue mutated or absent

<220>

<221> misc_feature

<222> (21)..(25)

<223> At least one residue mutated or absent

<400> 574

cttttcattc caatggggtg actttgcttc

30

<210> 575

<211> 29

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

214

<220>
<221> misc_feature
<222> (9)..(23)
<223> At least one residue mutated or absent

<400> 575
atacttttca ttccaatgac ttgcttct 29

<210> 576
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (8)..(22)
<223> At least one residue mutated or absent

<400> 576
tacttttcat tccaatgact ttgcttctg 29

<210> 577
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (7)..(21)
<223> At least one residue mutated or absent

<400> 577
acttttcatt ccaatgactt tgcttctgg 29

<210> 578
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(20)
<223> At least one residue mutated or absent

<400> 578
cttttcattc caatgacttt gcttctgga 29

<210> 579
<211> 30
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature

215

<222> (6)..(10)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (16)..(25)
 <223> At least one residue mutated or absent

<400> 579
 cttttcattc caatggggtg actttgcttc 30

<210> 580
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (9)..(23)
 <223> At least one residue mutated or absent

<400> 580
 atacttttca ttcgggtgac ttgcttct 29

<210> 581
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (8)..(22)
 <223> At least one residue mutated or absent

<400> 581
 tacttttcat tcgggtgact ttgcttctg 29

<210> 582
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (7)..(21)
 <223> At least one residue mutated or absent

<400> 582
 acttttcatt cgggtgactt tgcttctgg 29

<210> 583
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

216

<220>
 <221> misc_feature
 <222> (6)..(20)
 <223> At least one residue mutated or absent

<400> 583
 cttttcattc gggtgacttt gcttctgga

29

<210> 584
 <211> 30
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (11)..(25)
 <223> At least one residue mutated or absent

<400> 584
 cttttcattc caatgggggtg actttgcttc

30

<210> 585
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (9)..(23)
 <223> At least one residue mutated or absent

<400> 585
 atacttttca atgggggtgac ttgcttct

29

<210> 586
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (8)..(22)
 <223> At least one residue mutated or absent

<400> 586
 tacttttcaa tgggggtgact ttgcttctg

29

<210> 587
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>

217

<221> misc_feature
 <222> (7)..(21)
 <223> At least one residue mutated or absent

<400> 587
 acttttcaat ggggtgactt tgcttctgg 29

<210> 588
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (6)..(20)
 <223> At least one residue mutated or absent

<400> 588
 cttttcaatg ggggtgacttt gcttctgga 29

<210> 589
 <211> 34
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (9)..(28)
 <223> At least one residue mutated or absent

<400> 589
 atacttttca ttccaatggg gtgactttgc ttct 34

<210> 590
 <211> 34
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (8)..(27)
 <223> At least one residue mutated or absent

<400> 590
 tacttttcat tccaatgggg tgactttgct tctg 34

<210> 591
 <211> 34
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (7)..(26)

218

<223> At least one residue mutated or absent

<400> 591

acttttcatt ccaatggggt gactttgctt ctgg

34

<210> 592

<211> 34

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (6)..(25)

<223> At least one residue mutated or absent

<400> 592

cttttcattc caatggggtg actttgcttc tgga

34

<210> 593

<211> 30

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (16)..(25)

<223> At least one residue mutated or absent

<400> 593

cttttcattc caatggggtg actttgcttc

30

<210> 594

<211> 25

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (11)..(20)

<223> At least one residue mutated or absent

<400> 594

cttttcaatg gggtgacttt gcttc

25

<210> 595

<211> 25

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (11)..(20)

<223> At least one residue mutated or absent

219

<400> 595
cttttcattc gggtgacttt gcttc

25

<210> 596
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (6)..(15)
<223> At least one residue mutated or absent

<400> 596
cttttgggtg actttgcttc tgga

24

<210> 597
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (7)..(16)
<223> At least one residue mutated or absent

<400> 597
acttttgggt gactttgctt ctgg

24

<210> 598
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (8)..(17)
<223> At least one residue mutated or absent

<400> 598
tacttttggg tgactttgct tctg

24

<210> 599
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (9)..(18)
<223> At least one residue mutated or absent

<400> 599
atacttttgg gtgactttgc ttct

24

220

<210> 600
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (10)..(19)
 <223> At least one residue mutated or absent

<400> 600
 catacttttg ggtgactttg cttc

24

<210> 601
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (21)..(25)
 <223> At least one residue mutated or absent

<400> 601
 gtacttcata gggtagcttt gcttctgga

29

<210> 602
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (16)..(20)
 <223> At least one residue mutated or absent

<400> 602
 gtacttcata actttgcttc tgga

24

<210> 603
 <211> 19
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (11)..(15)
 <223> At least one residue mutated or absent

<400> 603
 gtacttcata gcttctgga

19

221

<210> 604
<211> 34
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (26)..(30)
<223> At least one residue mutated or absent

<400> 604
gtacttcata cttttgggtg actttgcttc tgga

34

<210> 605
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (21)..(25)
<223> At least one residue mutated or absent

<400> 605
gtacttcata cttttacttt gcttctgga

29

<210> 606
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (16)..(20)
<223> At least one residue mutated or absent

<400> 606
gtacttcata cttttgcttc tgga

24

<210> 607
<211> 34
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (26)..(30)
<223> At least one residue mutated or absent

<400> 607
gtacttcata cttttcattc actttgcttc tgga

34

<210> 608
<211> 29

222

<212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (21)..(25)
 <223> At least one residue mutated or absent

<400> 608
 gtacttcata cttttcattc gcttctgga

29

<210> 609
 <211> 34
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (26)..(30)
 <223> At least one residue mutated or absent

<400> 609
 gtacttcata cttttcattc caatggcttc tgga

34

<210> 610
 <211> 34
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (26)..(30)
 <223> At least one residue mutated or absent

<400> 610
 gtactctttt caatggggtg actttgcttc tgga

34

<210> 611
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (21)..(25)
 <223> At least one residue mutated or absent

<400> 611
 gtactctttt ggtgacttt gcttctgga

29

<210> 612
 <211> 24
 <212> DNA
 <213> Artificial sequence

223

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (16)..(20)
<223> At least one residue mutated or absent

<400> 612
gtactctttt actttgcttc tgga

24

<210> 613
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (11)..(15)
<223> At least one residue mutated or absent

<400> 613
gtactctttt gcttctgga

19

<210> 614
<211> 34
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (26)..(30)
<223> At least one residue mutated or absent

<400> 614
gtactctttt cattcgggtg actttgcttc tgga

34

<210> 615
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (21)..(25)
<223> At least one residue mutated or absent

<400> 615
gtactctttt cattcacttt gcttctgga

29

<210> 616
<211> 24
<212> DNA
<213> Artificial sequence

<220>

224

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (16)..(20)

<223> At least one residue mutated or absent

<400> 616

gtactctttt cattcgcttc tgga

24

<210> 617

<211> 34

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (26)..(30)

<223> At least one residue mutated or absent

<400> 617

gtactctttt cattccaatg actttgcttc tgga

34

<210> 618

<211> 29

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (21)..(25)

<223> At least one residue mutated or absent

<400> 618

gtactctttt cattccaatg gcttctgga

29

<210> 619

<211> 34

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (26)..(30)

<223> At least one residue mutated or absent

<400> 619

gtactctttt cattccaatg ggggtgcttc tgga

34

<210> 620

<211> 34

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

225

<220>
<221> misc_feature
<222> (26)..(30)
<223> At least one residue mutated or absent

<400> 620
gtacttcata cattcggtg actttgcttc tgga

34

<210> 621
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (21)..(25)
<223> At least one residue mutated or absent

<400> 621
gtacttcata cattcacttt gcttctgga

29

<210> 622
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (16)..(20)
<223> At least one residue mutated or absent

<400> 622
gtacttcata cattcgcttc tgga

24

<210> 623
<211> 34
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>
<221> misc_feature
<222> (26)..(30)
<223> At least one residue mutated or absent

<400> 623
gtacttcata cattccaatg actttgcttc tgga

34

<210> 624
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Exemplary element X variant

<220>

226

<221> misc_feature
 <222> (21)..(25)
 <223> At least one residue mutated or absent

<400> 624
 gtacttcata cattccaatg gcttctgga

29

<210> 625
 <211> 34
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (26)..(30)
 <223> At least one residue mutated or absent

<400> 625
 gtacttcata cattccaatg gggtggcttc tgga

34

<210> 626
 <211> 34
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (26)..(30)
 <223> At least one residue mutated or absent

<400> 626
 gtacttcata cttttcaatg actttgcttc tgga

34

<210> 627
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (21)..(25)
 <223> At least one residue mutated or absent

<400> 627
 gtacttcata cttttcaatg gcttctgga

29

<210> 628
 <211> 34
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Exemplary element X variant

<220>
 <221> misc_feature
 <222> (26)..(30)

227

<223> At least one residue mutated or absent

<400> 628

gtacttcata cttttcattc gggtaggcttc tgga

34

<210> 629

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (16)..(20)

<223> At least one residue mutated or absent

<400> 629

gtactctttt caatggcttc lgga

24

<210> 630

<211> 29

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (21)..(25)

<223> At least one residue mutated or absent

<400> 630

gtactctttt caatgggggtg gcttctgga

29

<210> 631

<211> 29

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (21)..(25)

<223> At least one residue mutated or absent

<400> 631

gtactctttt cattcacttt gcttctgga

29

<210> 632

<211> 29

<212> DNA

<213> Artificial sequence

<220>

<223> Exemplary element X variant

<220>

<221> misc_feature

<222> (21)..(25)

<223> At least one residue mutated or absent

228

<400> 632
 gtacttcata cattcgggtg gcttctgga 29

<210> 633
 <211> 44
 <212> DNA
 <213> Artificial sequence

<220>
 <223> PPE-1-derived regulatory element scheme

<220>
 <221> misc_feature
 <222> (36)..(40)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (36)..(40)
 <223> Mutated fragment (or variation of) can appear in multiple copies

<400> 633
 gtacttcata cttttcattc caatggggtg actttgcttc tgga 44

<210> 634
 <211> 35
 <212> DNA
 <213> Artificial sequence

<220>
 <223> PPE-1-derived regulatory element scheme

<400> 634
 gtacttcata cttttcattc caatggggtg acttt 35

<210> 635
 <211> 25
 <212> DNA
 <213> Artificial sequence

<220>
 <223> PPE-1-derived regulatory element scheme

<400> 635
 cattccaatg gggtagcttt gcttc 25

<210> 636
 <211> 29
 <212> DNA
 <213> Artificial sequence

<220>
 <223> PPE-1-derived regulatory element scheme

<400> 636
 cattccaatg gggtagcttt gcttctgga 29

<210> 637
 <211> 20
 <212> DNA
 <213> Artificial sequence

<220>
 <223> PPE-1-derived regulatory element scheme

<400> 637
 cattccaatg gggtagcttt 20

229

<210> 638
 <211> 14
 <212> DNA
 <213> Artificial sequence

<220>
 <223> PPE-1-derived regulatory element scheme

<400> 638
 actttgcttc tgga 14

<210> 639
 <211> 10
 <212> DNA
 <213> Artificial sequence

<220>
 <223> PPE-1-derived regulatory element scheme

<400> 639
 actttgcttc 10

<210> 640
 <211> 9
 <212> DNA
 <213> Artificial sequence

<220>
 <223> PPE-1-derived regulatory element scheme

<220>
 <221> misc_feature
 <222> (6)..(9)
 <223> One or more residues can be mutated or absent

<400> 640
 gcttctgga 9

<210> 641
 <211> 14
 <212> DNA
 <213> Artificial sequence

<220>
 <223> PPE-1-derived regulatory element scheme

<220>
 <221> misc_feature
 <222> (6)..(10)
 <223> At least one residue mutated or absent

<220>
 <221> misc_feature
 <222> (11)..(14)
 <223> One or more residues can be mutated or absent

<400> 641
 actttgcttc tgga 14

<210> 642
 <211> 10
 <212> DNA
 <213> Artificial sequence

<220>
 <223> PPE-1-derived regulatory element scheme

230

<220>
<221> misc_feature
<222> (6)..(10)
<223> At least one residue mutated or absent

<400> 642
actttgcttc 10

<210> 643
<211> 9
<212> DNA
<213> Artificial sequence

<220>
<223> PPE-1-derived regulatory element scheme

<220>
<221> misc_feature
<222> (1)..(5)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (6)..(9)
<223> One or more residues can be mutated or absent

<400> 643
gcttctgga 9

<210> 644
<211> 15
<212> DNA
<213> Artificial sequence

<220>
<223> PPE-1-derived regulatory element scheme

<220>
<221> misc_feature
<222> (11)..(15)
<223> At least one residue mutated or absent

<220>
<221> misc_feature
<222> (11)..(15)
<223> Mutated fragment (or variation of) can appear in multiple copies

<400> 644
cattccaatg gcttc 15